Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Liposomes

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424400000 - PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20110177160Amino acid lipids and uses thereof - This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.07-21-2011
20110177159CUSTOM-FORMULATED PHOSPHOLIPID MICROBUBBLES AND METHODS AND USES THEREOF - A phospholipid microbubble comprising a shell which comprises a plurality of polyunsaturated fatty acid (“PUFA”)-containing phospholipids, and a core of inert gas surrounded by the shell comprising the plurality of PUFA-containing phospholipids. The present invention also provides methods of delivering a prophylactically or therapeutically effective amount of PUFA to an area of disease or injury in a subject. The present invention also provides methods of preventing or treating a disease in a subject using a prophylactically or therapeutically effective amount of the aforementioned phospholipid microbubbles.07-21-2011
20110177158Liposomes Capable of Effectively Binding the Beta Amyloid Peptide - Novel liposomes are described which are capable of effectively binding beta amyloid peptide and are useful for the treatment, prevention and diagnosis of Alzheimer's disease. Binding ability is provided by the presence in the formulation of particular natural lipids identified by the Applicant. These comprise a constant component, made up of cholesterol and sphingomyelin, and an additional variable component, made up of selected lipids.07-21-2011
20110177157Compositions for Controlled Delivery of Pharmaceutically Active Compounds - Pharmaceutical compositions comprising (i) a dibasic amino acid ester or dibasic amino acid amide; (ii) a dicarboxylic acid; (iii) a pharmaceutically active compound or pharmaceutically acceptable salt thereof; and (iv) a pharmaceutically acceptable organic solvent. The pharmaceutical compositions form a depot when administered to an animal by injection that releases the pharmaceutically active compound over time.07-21-2011
20110177154Tubular nanostructure targeted to cell membrane - Devices, compositions, and methods are described which provide a tubular nanostructure or a composite tubular nanostructure targeted to a lipid bilayer membrane. The tubular nanostructure includes a hydrophobic surface region flanked by two hydrophilic surface regions. The tubular nanostructure is configured to interact with a lipid bilayer membrane and form a pore in the lipid bilayer membrane. The tubular nanostructure may be targeted by including at least one ligand configured to bind to one or more cognates on the lipid bilayer membrane of a target cell.07-21-2011
20080305157Encapsulation and separation of charged organic solutes inside catanionic vesicles - Catanionic vesicles including solute ion, methods for forming these, and methods of using these.12-11-2008
20090162425METHODS AND COMPOSITIONS FOR INHIBITING UNDESIRABLE CELLULAR PROLIFERATION BY TARGETED LIPOSOME DELIVERY OF ACTIVE AGENTS - Provided are methods for inhibiting undesirable proliferation of a tumor cell or a tumor in a subject including administering to the subject a composition that includes an effective amount of an active agent, wherein the active agent is entrapped by one or more liposomes, the active agent has activity in inhibiting undesirable proliferation of the tumor cell or the tumor, and the one or more liposomes include one or more targeting agents that preferentially or specifically bind to a binding molecule expressed by the tumor cell or the tumor, present on the tumor cell or the tumor, present in the tumor cell or the tumor, or combinations thereof. Also provided are compositions for treating tumors, particularly gliomas, in a subject in need thereof.06-25-2009
20110200667VETERINARY PHARMACEUTICAL FORMULACION THAT COMPRISES AN RNA RECOMBINANT PARTICLE THAT ENCODES FOR A CU/ZN SUPEROXIDE DISMUTASE PROTEIN OF RUMINANT PATHOGENIC BACTERIA AND AT LEAST ONE RNA ALPHAVIRUS BELONGING TO THE SEMLIKI FOREST VIRUS FAMILY - The technology is a veterinary pharmaceutical formulation of two vaccines, one from an RNA viral vector system constituted by an RNA recombinant particle that codifies for a Cu/Zn superoxide dismutase protein of 08-18-2011
20090274752COSMETIC AND DERMATOLOGICAL FORMULATIONS OF MNTF PEPTIDES - The disclosure is directed to methods and compositions that include MNTF peptides and their analogs for cosmetic and dermatological purposes.11-05-2009
20090123533Compositions and methods for cancer diagnosis and therapy - The miR15 and miR16 micro RNA genes are located at 13q14 within a 30 kb region of loss characteristic of cells from certain cancers, such as cells from chronic lymphocytic leukemia or prostate cancer. Chronic lymphocytic leukemia or prostate cancer can be diagnosed by detecting a reduction in miR15 or miR16 gene copy number, by determining miR15 or miR16 gene mutational status, or by detecting a reduction in the RNA transcribed from these genes. The miR15 or miR16 gene products can inhibit the neoplastic or tumorigenic growth of cancers such as chronic lymphocytic leukemia or prostate cancer cells when administered to subjects suffering from these diseases.05-14-2009
20090123532OLIGONUCLEIC ACID-BEARING COMPOSITE AND PHARMACEUTICAL COMPOSITION CONTAINING THE COMPOSITE - The present invention provides a complex, which comprises a cationic liposome comprising 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglycerol and a phospholipid as main ingredients, and an oligo nucleic acid which is carried on the liposome. Also, the present invention provides a pharmaceutical composition containing the complex to be used for treating or preventing diseases caused by a target molecule of the oligo nucleic acid (target DNA, target RNA, target protein) since it is possible to administer the complex in vivo and to put the complex into practical use as a medicament because the complex can exhibit pharmacological efficacy in vivo.05-14-2009
20090123531GLUTATHIONE-BASED DELIVERY SYSTEM - A delivery system is provided. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative.05-14-2009
20090123530Liposome Drug Delivery - This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal tract after oral administration.05-14-2009
20090123529NUCLEIC ACID IMMUNOLOGICAL COMPOSITION FOR HUMAN METAPNEUMOVIRUS - There is provided an immunological composition that comprises a nucleic acid vector which includes a promoter region operably linked to a coding sequence encoding the human metapneumovirus F antigen or the human metapneumovirus G antigen. The immunological composition is useful for administering to an individual to elicit an immune response to human metapneumovirus in the individual and for the generation of diagnostic reagents for hMPV.05-14-2009
20090208563Method for delivering genes - Methods of delivering transgenes to target cells using plasmids comprising viral inverted terminal repeat (ITR) sequences are described. Such plasmids are capable of directing sustained transgene expression in target cells in rats provided that at least one adeno-associated virus (AAV) ITR sequence is present in the plasmid, regardless of whether that ITR is located upstream or downstream of the transgene. In a particular embodiment, plasmids comprising one or more AAV ITR sequence and an IL-10 transgene are shown to be effective in sustained reversal of pain in an animal model of neuropathic pain.08-20-2009
20110206757NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF - The present invention provides novel n-alkenyl glycosides and glycoconjugates, n-alkyl glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycoconjugates as disclosed herein.08-25-2011
20110206755METHODS AND PRODUCTS FOR MANIPULATING UNCOUPLING PROTEIN EXPRESSION - The invention is based in part on the discovery that uncoupling proteins (UCPs) are expressed in the plasma membrane of rapidly dividing cells but not of growth arrested, chemotherapy resistant cells. It has also been found according to the invention that UCP is expressed in the lysosomal membrane under certain metabolic conditions. Thus the invention is methods, products, screening assays and kits relating to the manipulation of UCP expression within cellular and intracellular membranes.08-25-2011
20100119593LIPOSOME AND METHOD FOR PRODUCING THE SAME - A liposome including a neutral lipid membrane, a positively charged polymer, and a surface active polymer is provided. The neutral lipid membrane is formed as a hollow sphere, the positively charged polymer is dispersed on the neutral lipid membrane by non-covalent bonding, and the surface active polymer is dispersed on the neutral lipid membrane by non-covalent bonding. The liposome can stably adsorb various amounts of biomaterials by non-covalent bonding.05-13-2010
20100119592CYTARABINE FOR TREATMENT OF GLIOMA - Provided are methods and compositions for the treatment of a subject with glioma. An exemplary method can comprise administering cytarabine to the subject. For example, DepoCyt® can be administered to the subject. An exemplary composition can comprise cytarabine. For example the composition can comprise DepoCyt®.05-13-2010
20090202618Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases - The present invention is related to recombinant constructs encoding active fragments of HSP60 which are effective in treating T cell-mediated inflammatory autoimmune diseases by DNA vaccines. The HSP60 fragments of the present invention are identified by their ability to react with T cells isolated from an animal vaccinated with DNA constructs encoding HSP70 to induce Th2/3 T-cell responses.08-13-2009
20090196918Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions - Provided is a liposome comprising a hydrophobic lactone drug and a cyclodextrin, wherein the liposome has an intraliposomal pH and cyclodextrin concentration such that upon administration of the liposome to a subject, the liposome exhibits a uniform release profile of the hydrophobic lactone drug. Also provided is a method of administering a hydrophobic lactone drug to a subject in need thereof. The method comprises administering a liposome to the subject in need, wherein the liposome comprises the hydrophobic lactone drug and a cyclodextrin. The liposome has an intraliposomal pH and cyclodextrin concentration such that upon administration of the liposome to the subject, the liposome exhibits a uniform release profile of the hydrophobic lactone drug.08-06-2009
20090196917Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions - Disclosed herein is a liposomal formulation that comprises a liposome and a liquid carrier. In the liposomal formulation, the liposome comprises a hydrophobic lactone drug and has an intraliposomal metal ion concentration higher than the metal ion concentration of the liquid carrier. Also disclosed herein is a method for active loading of a hydrophobic lactone drug into a liposome. The method includes preparing a liposome in the presence of a metal salt solution, an acid form of a counterion of the metal salt being membrane permeable, such that the liposome preparation contains entrapped metal ion. The method further includes forming a liposome with high intraliposomal pH by separating extravesicular metal salt solution from the liposome by exposing the liposome to a metal salt-free solution, resulting in diffusion of the acid form of the counterion out of the liposome and formation of an intraliposomal pH higher than that of the metal salt-free solution. The method also includes exposing the liposome with high intraliposomal pH to an isoosmolal solution containing a hydrophobic lactone drug, the isoosmolal solution having a pH lower than the intraliposomal pH, such that the hydrophobic lactone drug accumulates in the liposome predominantly in its ring-opened form.08-06-2009
20090196915COMPOSITION AND METHODS OF MAKING AND USING INFLUENZA PROTEINS - The invention provides compositions of influenza proteins, such as matrix and nucleoprotein, that are presented to an individual's immune system as multimeric displays to induce an immune response. The compositions are optionally associated with any type of immunomodulatory compound (IMC) comprising an immunostimulatory sequences (ISS). The invention further provides compositions of influenza matrix and nucleoproteins that can induce cellular and/or humoral immune response. The invention also provides methods of making and using these compositions, e.g., as a vaccine, for ameliorating symptoms associated with infection with influenza virus or for reducing the risk of infection with influenza virus.08-06-2009
20090196914LIPOSOMAL L-CARNITINE - The present invention provides liposomal L-carnitine formulations and methods for the treatment of intermittent claudication. The formulation is optimized with respect to L-carnitine transport through skin in vitro. Preferably, the formulation is a topical cream for the administration of the drug directly on the muscle group that is most affected by the poor local blood flow.08-06-2009
20090196913Anti-Alpha-V Immunoliposome Composition, Methods, and Uses - An immunoliposome composition targeted to the alpha-V-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha-V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or a the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.08-06-2009
20090196912Pyridinylamines - Described are pyridinylamines and pharmaceutically acceptable salts thereof, the use of these pyridinylamines for the prophylaxis and/or treatment of various diseases such as infectious diseases, including opportunistic infections, prion diseases immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as pharmaceutical compositions containing at least one pyridinylamine and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the pyridinylamines are disclosed.08-06-2009
20120171282GINKGO BILOBA EXTRACT WITH A STANDARDISED GINKGO FLAVONE GLYCOSIDES CONTENT DEPRIVED OF THE PAF-ANTAGONIST TERPENIC FRACTION, AND COMPOSITIONS CONTAINING IT, FOR THE PREVENTION AND TREATMENT OF CIRCULATORY, COGNITIVE, GERIATRIC AND SENSORY DISORDERS - Disclosed is a 07-05-2012
20100266677NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE - The present invention relates to homo- and hetero-dimer compounds formed by a disulfide, sulfinyl thio, or olefin bond between two monomers. A method of making a homo- or hetero-dimer compound is also disclosed. The present invention also relates to monomer compounds capable of forming homo- or hetero-dimer compounds, as well as oligomers formed via linkage of one or more dimers. Also disclosed are methods of inhibiting the activity of target RNA molecules, particularly those having a secondary structure that include a stem or stem-loop formation. Dimer compounds capable of inhibiting the activity of an HIV-I RNA frameshifting stem-loop and a (CUG)n expanded repeat stem-loop are disclosed, as are methods of treating diseases associated with these target RNA molecules. The dimer compounds can also be used for selectively detecting presence of the target RNA molecule in a sample.10-21-2010
20100062053CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1):03-11-2010
20090035364PARA-SUBSTITUTED 2-ALKOXYPHENOL COMPOUNDS - Para-substituted 2-alkoxyphenols having cooling properties of formula (I) wherein R02-05-2009
20090291133METHODS AND COMPOSTIONS FOR ENHANCING TRANSDERMAL DRUG DELIVERY - Methods and compositions for enhancing transdermal delivery of a bioactive agent. The method contains the step of applying to a skin tissue an effective amount of a composition comprising: (a) a drug vehicle; (b) a bioactive agent encapsulated within the drug vehicle; (c) a plurality of proteolytic enzyme molecules conjugated onto the surface of the drug vehicle; and (d) a pharmaceutically acceptable carrier, for a period of time effective to deliver the bioactive agent across the skin tissue at a desired dosage.11-26-2009
20090060989NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY - The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the other system component with such activity being typically a surfactant. In contrast, the remaining amongst said at least three amphipatic components typically forms a stable lipid membrane on it's own. An essential characteristics of the resulting, relatively large, aggregates is an improved ability to penetrate pores, in a semi-permeable barrier, at least 30%, and often much smaller than the average diameter of the complex aggregate. This enables said aggregates to mediate NSAID transport through semi-permeable barriers including mammalian skin. As a result of the skin penetration by NSAID loaded large aggregates, the drug delivered transcutaneously with such carriers gets deeper into the tissue than the corresponding NSAID from a solution on the skin surface. This is believed to be due to the special ability of suitable large carriers to bypass the local sink of blood capillaries at the epidermal-dermal junction in the skin. The carrier-mediated delivery of locally applied NSAIDs thus allows therapy of deep tissues under the drug administration site, which is medically highly desirable.03-05-2009
20090191262USE OF COMPOUNDS OF FORMULA A-R-XO PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF FOR PRODUCING A PHARMACEUTICALLY PREPARATIONS - The invention relates to a compound of formula A-R-X or pharmaceutically acceptable salts thereof which can be used for producing a pharmaceutical preparation suitable for preventing or treating cancerous diseases, pathological consequences of alcohol abuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases, hepatic insulin resistance in diabetes mellitus, hepatic damage in Wilson's disease and sideroses and/or ischaemic reperfusion damage, as an antidote against environmental toxins and medicament intoxication in order to extend the resistance time of medicaments in organisms, or for combating toxic side effects in the administration of chemotherapeutics. In the formula R is an aliphatic or aromatic C07-30-2009
20090208565STABILIZED EXENDIN-4 COMPOUNDS - The present invention discloses compositions comprising a stabilized Exendin-4 (1-39) and related compounds. The invention describes stabilized Exendin-4 agonists that include at least one modified amino acid residue particularly at positions Gln13, Met14, Trp25, or Asn28 of the Exendin-4 (1-39) molecule. Disclosed are preferred modifications of deaminated, hydrolyzed, oxidized, or isomerized reaction products of the specified amino acid residues corresponding to the same positions in the Exendin-4 (1-39) molecule. The invention also relates to methods of making and using the stabilized Exendin compounds, such as for the treatment of diabetes.08-20-2009
20100028419MEMBRANE(S) AND USES THEREOF - There is provided at least one agent delivery vehicle comprising at least one membrane of cubic structure or derivable from a membrane of cubic structure, methods for preparing them, and their use for transport of at least one foreign agent. In particular, the agent delivery vehicle may be in the form of at least one organelle, agent delivery particle and/or liposome. The invention further provides kits and methods of treatment using the agent delivery vehicle(s).02-04-2010
20100151006CANCER THERAPY SENSITIZER - The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of cancer therapy resistance, as well as ex vivo and in vivo therapy of cancer.06-17-2010
20100151005TARGETED CARRIERS FOR INTRACELLULAR DRUG DELIVERY - The invention provides a method for delivering a cargo molecule into a cell using a targeted DNA-based carrier (e.g., DNA dendrimer). Compositions and kits useful in the practice of the methods are also provided.06-17-2010
20100151004MODULATION OF DRUG SENSITIVITY - Methods for the treatment of disorders, including cancer, are described which include administering to a subject a DNA methylation inhibitor and an antineoplastic agent. Compositions containing a DNA methylation inhibitor and an antineoplastic agent, which are useful in treating disorders including cancer, are also described. Additionally, methods useful for developing a prognosis for or diagnosing a subject's development of resistance to treatment with a chemotherapeutic agent are described.06-17-2010
20100080843Natural and synthetic sulfur and selenium analogs and polymer conjugated forms thereof for the modulation of angiogenesis - The present invention relates to inhibiting angiogenesis with sulfur- or selenium-containing compounds, and polymeric forms thereof, in mammals including animals and humans. Sulfur- or selenium-containing compounds, and polymeric forms thereof, can be used alone or in combination with standard therapies to inhibit angiogenesis-mediated disorders. The present invention also relates to the combined use of sulfur- or selenium-containing compounds, and polymeric forms thereof, with other anti-angiogenesis agents, with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer, and with laser, photodynamic therapy for ocular-related disorders such as diabetic retinopathy or age-related macular degeneration.04-01-2010
20100151003EGFR BINDING PEPTIDES AND USES THEREOF - Short oligopeptides are provided which are capable of binding to the epidermal growth factor receptor on the surface of human tumor cells. Methods for using the peptides as targeting moieties in more complex compositions, such as conjugates of cytoxins, and/or structures, such as liposomal structures, for the purposes of drug delivery are also provided.06-17-2010
20100151001ETHYNYLATED HETERODINUCLEOSIDE PHOSPHATE ANALOGS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF - The invention relates to novel ethynylated heterodinucleoside phosphate analogs, the production thereof, substances containing at least one of said compounds, and the use thereof for the treatment of cancer and infectious diseases.06-17-2010
20110195114TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS - A delivery vehicle for topical pharmaceutical formulations that include a C2 to C4 alkanol, a polyalcohol, and a monoalkyl ether of diethylene glycol present in relative amounts sufficient to provide permeation enhancement of an active agent through mammalian dermal or mucosal surfaces. Preferably, the delivery vehicle as well as the formulations that contain it are substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters in order to avoid potential undesirable odor and irritation effects caused by such compounds during use of the formulation. Without these additives, use of the formulations is facilitated and patient compliance is greater08-11-2011
20110195113VIRUS-LIKE PARTICLES COMPRISING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR ENHANCED CROSS REACTIVITY - The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.08-11-2011
20110195112USE OF PLANT-DERIVED RECOMBINANT GROWTH FACTORS IN SKIN CARE - Cosmetic and therapeutic compositions for skin care, containing a transgenic plant extract containing a growth factor, or a growth factor purified from transgenic plants, or a mixture of growth factors derived from transgenic plants as extracts or in purified form, for use in topical therapeutic and/or cosmetic applications. Importantly, this invention makes safer growth factors available for use for cosmetic and topical treatment. These growth factors do not carry the risk of unwanted contaminants and transmissible agents that can result from animals or animal cell based expression systems, and the recombinant growth factors that plant expression systems provide are post-translationally modified proteins.08-11-2011
20110195111AQUEOUS COMPOSITIONS AND METHODS - A method of forming an aqueous composition effective to produce an agent-specific effect on an agent-responsive chemical or biological system, when the composition is added to the system, is disclosed. The composition is formed by exposing an aqueous medium to a low-frequency, time-domain signal derived from the agent, until the aqueous medium acquires a detectable agent activity. Exemplary compositions are formed by exposure to a paclitaxel signal or a signal derived from a therapeutic oligonucleotide, such as GAPDH antisense RNA and PCSK9 antisense RNA. Also disclosed are methods for confirming the activity of the composition, and for preparing and testing the activity of the compositions.08-11-2011
20110195110UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER - Pyrazole urea compounds, pharmaceutical compositions which contain them and methods for treating cancer using them.08-11-2011
20100150999THERAPY OF CANCER BASED ON TARGETING ADAPTIVE, INNATE AND/OR REGULATORY COMPONENT OF THE IMMUNE RESPONSE - The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises: (i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds; (ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally; (iii) an adjuvant component suitable for activating the innate immune response in a patient.06-17-2010
20090191264EPOTHILONE COMPOSITIONS - This invention provides liposomal compositions comprising an epothilone.07-30-2009
20090191263COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF HIF-1 ALPHA - RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.07-30-2009
20090191260AEROSOL AND USE THEREOF - The invention relates to an aerosol, in which a phase containing a solid substance is dispersed into a gaseous dispersant. The aim of the invention is to achieve a particularly effective anti-inflammatory action for the treatment of respiratory diseases. According to the invention, a depot is contained in the dispersed phase, said depot releasing silver ions when it comes into contact with water.07-30-2009
20100150998VACCINES FOR MALARIA - The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. In particular it relates to an immunogenic protein particle comprising the following monomers: 06-17-2010
20100068260Methods, Compositions and Device for Directed and Controlled Heating and Release of Agents - A composition coupled to an agent with a cleavable linker is provided. Specifically, the composition is used for releasing the agent through a temperature-sensitive mechanism at a targeted location in a subject with heat. It is advantageous to applications where there is a need to accurately deploy an agent in a targeted location to reduce adverse side effects or increase efficacy of the agent. A device and method for providing heat at the targeted location in the subject is also provided. The device and method allows release of the agents in a targeted manner and prevents overheating of the targeted location or the tissue surrounding the targeted location. It is advantageous to applications where there is a need to accurately control the temperature in a targeted location in a biological body, for instance, to deploy an agent in the targeted location.03-18-2010
20100150997TREATMENT OF ARTHRITIS - A method for treating and/or inhibiting arthritis is provided. The method includes administering an effective amount of a composition including a parathyroid hormone and a pharmaceutically acceptable carrier or salt to a subject with arthritis. Additionally, a method for inhibiting and/or rescuing terminal differentiation of cells is also provided.06-17-2010
20100158994Nanoparticles for Delivery of Therapeutic Agents Using Ultrasound and Associated Methods - The present invention relates to lipid based nanoparticles or liposomes that are sensitive to ultrasonic energy, compositions containing these particles, methods for delivering one or more active agents using the particles, and methods for preparing the particles. The nanoparticles and liposomes encapsulate active agents such as chemotoxins, genes, virus vectors, proteins, peptides, antisense oligonucleotides, carbohydrates, and stem cells. The particles contain an aqueous core, at least one active agent located within the aqueous core, and a lipid bilayer or membrane that encapsulates the active agent within the aqueous core. The lipid bilayer may comprise a primary phospholipid and a lysolipid that preferably have different acyl chain lengths, making the lipid bilayer sensitive to ultrasound. Ultrasound may be used to track the particles as they move throughout the body. When the ultrasonic energy reaches a certain pressure, the lipid bilayer will break apart, releasing the active agent.06-24-2010
20100158992PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS - There is disclosed a method for treating or preventing fungal infections comprising the administration of at least one glucan synthase inhibitor of a formula as described above in the specification or a pharmaceutically acceptable salt thereof; also claimed are methods of preparing pharmaceutical compositions comprising a compound as described above in the specification and a carrier, method of treating or preventing fungal infections comprising administration of combinations of glucan synthase inhibitor of a formula as described above in the specification and other antifungal agents, and method of treating or preventing fungal infections comprising administration of pharmaceutical compositions prepared according to a method described above in the specification, and a method of preparing a kit in a single package of the above described pharmaceutical composition and other antifungal agents.06-24-2010
20100047335MICROVESICLES DERIVED FROM RECOMBINANT YEAST HAVING HAEMOSTATIC ACTIVITIES AND USES THEREOF - Tissue factor-bearing yeast derived microvesicles comprising a yeast membrane and a tissue factor protein, or a fragment thereof, or a tissue factor protein or a fragment thereof fused to another peptide as a fusion protein having pro-coagulant activity are disclosed. Said products can be used as pro-coagulant agents in the treatment of hemorrhages in a subject.02-25-2010
20090010999Complex Particles and Coated Complex Particles - The present invention provides, for example, a method of inhibiting aggregation of complex particles in which a drug is adhered to lead particles, characterized by containing a lipid derivative or a fatty acid derivative of one or more substance(s) selected from sugars, peptides, nucleic acids and water-soluble polymers or a surfactant in the lead particles. Further, it provides, for example, a method of producing the complex particles in which a nucleic acid as a drug or a drug is adhered to lead particles, comprising the step of dispersing or dissolving the nucleic acid as a drug or the drug and an adhesion-competitive agent so as to be contained in a liquid in which the lead particles containing a lipid derivative or a fatty acid derivative of one or more substance(s) selected from sugars, peptides, nucleic acids and water-soluble polymers or a surfactant are dispersed, thereby allowing the nucleic acid as a drug or the drug and the adhesion-competitive agent adhered to the lead particles.01-08-2009
20100062052PEPTIDE-BASED COMPOUNDS AS NEW INHIBITORS OF METALLOECTOPEPTIDASES, COMPOSITIONS COMPRISING SAID COMPOUNDS AND THEIR PHARMACEUTICAL AND COSMETIC USES - The invention relates to a compound that inhibits a metallo-ectopeptidase, selected in the group consisting of x-aa2-aa1-z, x-aa3-aa2-aa1-z, x-aa4-aa3-aa2-aa1-z and x-aa5-aa4-aa3-aa2-aa1-z, wherein: aa1 and aa4, independently from each other, represent an arginine amino acid, an histidine amino acid, an asparagine amino acid or a lysine amino acid, aa2 represents a serine amino acid, a glycine amino acid, a threonine amino acid or an alanine amino acid, aa3 represents a phenylalanine amino acid, a leucine amino acid, an isoleucine amino acid, a tyrosine amino acid or a tryptophan amino acid, aa5 represents a glutamine amino acid, a glutamic acid amino acid, an asparagines amino-acid or a lysine amino acid, x and z, independently from each other, represent: —H; —OH1 SH; —a halogen atom, —an amino group, —an alkyl, haloalkyl or heteroalkyl group containing from 1 to 30 carbon atoms, linear or branched, —an alkenyl or alkynyl group containing from 2 to 30 carbon atoms, linear or branched, —a cycloalkyl, cycloakenyl, cycloalkynyl or an heterocyclic group containing from 3 to 30 carbon atoms, linear or branched, —one or more aryl or heteroaryl groups containing from 3 to 10 carbon atoms per cycle, —a alkoxy, thioalkyl, sulfonylalkyl, aminoalkyl containing from 1 to 30 carbon atoms, linear or branched, —one or more heterocyclic group, containing from 5 to 10 carbon atoms per cycle, said groups being optionally substituted by one or more halogen atoms, alkyl groups, hydroxy groups, alkoxy groups, aryloxy groups, acyloxy groups, carbamoyloxy groups, carboxy groups, mercapto groups, alkylthio groups, acylthio groups, arylthio groups, aryl groups, heterocyclic groups, heteroaryl groups or amino groups.03-11-2010
20090104255Liposome Drug Delivery of Polycyclic, Aromatic, Antioxidant or Anti-Inflammatory Compounds - This invention comprises pharmaceutical compositions for administering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver polycyclic, aromatic, antioxidant or anti-inflammatory compounds to the gastrointestinal tract after oral administration.04-23-2009
20100047332Treatments for burns using thyroid hormone compound in a human - A topical preparation for treating first and second degree burns includes TriAc. The topical preparation preferably includes less than 10 mg of TriAc per 100 ml of pharmaceutical excipient base. In another embodiment, a topical preparation includes TriAc for decreasing cellulite. In this embodiment, the topical preparation is preferably applied only before exercise. In a preferred embodiment, the preparation is applied only intermittently, preferably no more than three times a week, or in amounts sufficient to not downregulate receptor number and become inefficacious.02-25-2010
20080286352Liposome Compositions - A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes and/or liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components. After a desired liposome biodistribution is achieved, the affinity agent binds to the target surface and helps internalize the liposomes.11-20-2008
20100119595Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents - The pharmaceutical and/or cosmetic compositions for treatment of obesity and/or overweight contain an effective amount of a fatty-acid monoester of a 2 hydroxy derivative estrogen and a fatty acid wherein the estrogen is preferably a 2 hydroxy derivative of estrone, diethylstilbestrol, estriol, estradiol or ethinyl estradiol and the fatty acid is selected from the group consisting of the fatty acid oleic acid, arachadonic, palmitic, palmitoleic, linoleic, linolenic, cis 13 docosenoic acid, and the fatty acid, cis 15 tetracosenoic acid eicosenoic acid, especially cis 11 eicosenoic, although cis 5, cis 8, and cis 13 eicosenoic acid are also effective. The C-22 fatty acid monoester of estrogen, cis to 13 docosenoic acid (Erucic acid), and the C-24 fatty acid monoester of estrogen, cis 15 tetracosenoic acid (Nervonic acid) are also effective and are included in this disclosure. In addition, synthesized combination molecules formed when a monounsaturated fatty acid of 20 carbon atoms or more is joined via an ester, ether, or amide bond to either a steroid or any molecule containing a perhydrocyclopentanophenanthrene nucleus or perhydrocyclopentanophenanthrene nucleus derivative are also included in this invention. The fatty-acid monoesters mimic the function of estrone monooleate, as a signal that informs the brain of the size of fat tissue mass. In preferred pharmaceutical and/or cosmetic compositions for intravenous injection the monoester is incorporated in a lipidic suspension, prepared from lipoproteins or from liposome components, such as soy oil and egg phospholipids. When administered to rats with a 15% of total adipose tissue, they produce weight reduction of about 10%, by a new and unexpected mechanism. They are useful for the treatment of obesity and/or overweight in mammals, with the advantages of high efficacy and low toxicity.05-13-2010
20100119589LIPOSOMAL COMPOSITION OF ANTIOXIDANTS FOR INHALATIONS CARRIED OUT DURING LUNG AND UPPER RESPIRATORY TRACT DISEASES - The invention relates to medicine and pharmacology, in particular to liposomal compositions of antioxidants suitable for inhalations in lung and upper respiratory tract diseases. The present composition of antioxidants for inhalation in lung and upper respiratory tract diseases represents an emulsion of phospholipids in form of liposomes with an average particle size of 0.2-0.4 μm, in the membrane of which the flavonoid dihydroquercetin and wheat germ oil are introduced. The latter contains the hydrophobic antioxidants tocopherols (TP) (vitamin E) and carotenoids. The aqueous phase of the emulsion contains sodium chloride, the water-soluble antioxidants ascorbic acid (vitamin C), N-acetyl-L-cysteine and sodium benzoate. The composition of antioxidants is selected in order to provide the possibility of administering the individual vitamins in minimum doses, and to ensure that the content of active, not oxidized form of the antioxidants is not reduced during storage.05-13-2010
20100119591USE OF LIPID CONTAINING PARTICLES COMPRISING QUILLAJA SAPONINS FOR THE TREATMENT OF CANCER - The present invention relates to the use of lipid containing particles, such as liposomes, iscom and/or iscom matrix and posintros, comprising at least one lipid and at least one saponin for the preparation of a pharmaceutical for the treatment of cancer. The saponins are preferably from 05-13-2010
20100062050MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS - This invention relates to a peptide or polypeptide (a) which is esterified or thio-esterified (i) at the carboxylate of the C-terminus with a guanidinium alkanol, a guanidinium alkanethiol, a PEG substituted with a guanidinium group and having a free hydroxyl group, or a PEG substituted with a guanidinium group and a sulthydryl group; (ii) at a side-chain carboxylate of one or more Asp or GIu residues, if present, with a guanidinium alkanol, a guanidinium alkanethiol, a PEG substituted with a guanidinium group and having a free hydroxyl group, or a PEG substituted with a guanidinium group and a sulfhydryl group; (iii) at a hydroxyl group of one or more Ser, Thr or Tyr residues, if present, with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group; (iv) at a sulthydryl group of one or more Cys residues, if present, with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group; and/or (v) at the N-terminus with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group, wherein said N-terminus is previously amidated with an alpha- or beta-hydroxy acid, and wherein the ester is formed between the hydroxy group of said alpha- or beta-hydroxy acid and the carboxylic group of said guanidinium alkanoic acid or said PEG substituted with a guanidinium group and a carboxyl group; and/or (b) which contains one or more disulfides, the disulfide being formed between the sulthydryl group of a Cys reside, if present, and a guanidinium alkanethiol or a PEG substituted with a guanidinium group and a sulthydryl group.03-11-2010
20100074946PROCESS FOR PREPARING PURIFIED NUCLEIC ACID AND THE USE THEREOF - The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether)03-25-2010
20100074945MUTATED RAS PEPTIDES FOR GENERATION OF CD8+ CYTOTOXIC T LYMPHOCYTES - Mutant ras oncogene peptides may induce specific anti-ras cellular immune responses in vaccinated patients. Moreover, a human CD803-25-2010
20120244211Compositions And Methods For Treatment Of The Side-Effects Associated With Administration Of Cancer Chemotherapeutic Agents - A composition and method for the treatment of the side-effects associated with the administration of cancer chemotherapeutic agents involves the oral ingestion of a slow release capsule containing adenine and orotate. The administration of a protein pump inhibitor decreases systemic absorption of orotate and the administration of allopurinol decreases the formation of 2,8-dihydroxy adenine from adenine. In an alternative embodiment, cationic liposomes contain purine/pyrimidine precursors. The cationic liposomes bind to the cells lining the mucosa of the intestinal tract and then the contents of the cationic liposome are then taken up in the interior of the cells to prevent the metabolism of the cancer treatment drug 5-FU into a toxic species.09-27-2012
20120244210COMPOSITION FOR SUPPRESSING EXPRESSION OF TARGET GENE - The present invention provides a composition that comprises a lipidparticle encapsulating a double-stranded nucleic acid molecule, 09-27-2012
20120244208COSMETIC SKIN CARE METHODS AND COMPOSITIONS - This invention relates to a topical cosmetic skin care method and composition. The method and composition is for treating facial skin to cause contraction and tightening of the facial skin, by effecting contraction of the collagen of the skin using an active agent/s that induces fibroblast contraction of the extra cellular matrix of the skin. A preferred active agent is a beta-2-adrenergic receptor (beta2AR) inhibitor.09-27-2012
20120244207Methods For Increasing Efficacy of Lipid Formulated siRNA - This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that lowers LDL receptor levels.09-27-2012
20120244206DUAL ACTION, INHALED FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE - Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.09-27-2012
20120183604Treatment of Triple Receptor Negative Breast Cancer - The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of “triple receptor negative” breast cancer.07-19-2012
20120183603INHIBITORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO - The present invention makes availables assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein or aberrant activation of a hedgehog signal transduction pathway, e.g., which involve the use of a steroidal alkaloid or other small molecule.07-19-2012
20120183602LIPID FORMULATION - The invention features a cationic lipid of formula I,07-19-2012
20120183601Compositions And Methods For Regulation Of Tumor Necrosis Factor-Alpha - The present invention relates to compositions and methods relating to an interleukin18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression.07-19-2012
20120183600NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS - The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.07-19-2012
20120183599Pharmaceutical Composition - The present invention is related to methods and pharmaceutical compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to pharmaceutical composition comprising an antigenic peptide, particularly an antigenic phospho-peptide mimicking a major pathological phospho-epitope of protein tau, for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease.07-19-2012
20120183598HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITIONS - A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.07-19-2012
20120183597Method of inducing neutralizing antibodies to human immunodeficiency virus - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.07-19-2012
20120183596Encapsulation of Plasmid DNA (Lipogenes) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes - A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid molecules and fusogenic/NLS peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or NLS at their one end. The encapsulated molecules display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or negatively-charged drugs with other anti-neoplastic drugs (the positively-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value. Also of therapeutic value in cancer eradication are combinations of encapsulated the plasmids, oligonucleotides or negatively-charged drugs with HSV-tk plus encapsulated ganciclovir.07-19-2012
20100055166NOVEL METHOD AND COMPOSITIONS - The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants.03-04-2010
20130034597ORALLY BIOAVAILABLE PEPTIDE DRUG COMPOSITIONS AND METHODS THEREOF - The present invention provides orally bioavailable peptide drug compositions including a cyclic peptide and an orally compatible absorption enhancer, as well as methods for providing increased oral bioavailability of peptide drugs.02-07-2013
20130034599SYNTHETIC NANOSTRUCTURES INCLUDING NUCLEIC ACIDS AND/OR OTHER ENTITIES - Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.02-07-2013
20130034598INHIBITORS OF AKT/PKB WITH ANTI-TUMOR ACTIVITY - The subject invention concerns materials and methods for inhibiting the Akt/PKB pathway. In one embodiment, a compound of the invention inhibits kinase activity and/or phosphorylation levels of Akt proteins. The subject invention also concerns methods for inhibiting or killing a cancer cell or other cell in which expression of an Akt protein is elevated or constitutively active, comprising contacting the cell with an effective amount of a compound of formula I. The subject invention also concerns methods for treating cancer or a tumor in a person or animal comprising administering an effective amount of a compound of formula I to the person or animal.02-07-2013
20130084328METHYLATED CODING AND NON-CODING RNA GENES AS DIAGNOSTIC AND THERAPEUTIC TOOLS FOR HUMAN MELANOMA - Provided herein are methods for the diagnosis and treatment of human melanoma and prediction of early disease genesis to metastasis by assessing CpG island methylation or expression level of epigenetically regulated differentially expressed coding or non-coding genes. Methods of treatment of human melanoma by modifying or regulating the same pathways are also provided.04-04-2013
20130084329COMPOSITIONS FOR EXTERNAL APPLICATION, CONTAINING ADENOSYLCOBALAMIN FOR IMPROVEMENT OF SKIN DISEASES - The present invention relates to a composition for external application for improving a skin disease (e.g. psoriasis). The composition contains adenosylcobalamin (coenzyme B12), optionally in admixture with other cobalamins. The composition can be present in the form of liposomal preparations, which are made of a phospholipid and cholesterol.04-04-2013
20130084326LIPOSOMES FOR THE ORAL DELIVERY OF THERAPEUTIC AGENTS - The invention relates to liposomes having membranes composed of amphipathic molecules and long chain lipids in ratios that are proportionately higher in amphipathic molecules. Such ratios enhance the enzymatic breakdown of the inventive liposomes thereby improving the bioavailabity of encapsulated substances for oral delivery. Compositions of liposomes and methods of their use and manufacture are within the scope of the invention.04-04-2013
20130084331Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors - A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.04-04-2013
20130084327POLYNUCLEOTIDE ENCODING A TRIM-CYP POLYPEPTIDE, COMPOSITIONS THEREOF, AND METHODS OF USING SAME - The invention provides an isolated nucleic acid encoding a TRIM-cyclophilin A fusion sequence encoding a TRIMcyp fusion protein which is active as an anti-viral agent, and in particular an anti-HIV-1 agent. The invention provides for a nucleic acid encoding a polypeptide having both TRIM activity and cyclophilin activity. The invention provides for an isolated polynucleotide encoding a TRIM-cyclophilin fusion protein, or variants thereof retaining the TRIM and cyclophilin activities. The invention provides for compositions thereof, antibodies that specifically bind thereto, and vectors and host cells comprising the nucleic acid or polypeptide. In addition, the invention provides for methods for treating or preventing viral infection, or reducing viral load in a subject comprising administering the nucleic acid, polypeptide, vector, or composition to the subject in an amount effective to treat or prevent the viral infection.04-04-2013
20130084330COMPOSITION FOR THE TREATMENT OF ARTHRITIS CONTAINING A DIBENZO-P-DIOXIN DERIVATIVE AS THE ACTIVE INGREDIENT - Disclosed is a composition for treating arthritis containing a dibenzo-p-dioxin derivative as an active ingredient. This dibenzo-p-dioxin derivative is very effective in inhibiting NF-kB and AP-1 activity, alleviates the symptoms of degenerative arthritis and rheumatoid arthritis without irritating the skin or causing side effects, and can continue to exhibit improvement effects for a considerable period of time after discontinuation of treatment. Additionally, when the dibenzo-p-dioxin derivative is contained in liposomes, the composition of the invention exhibits much greater effects on treating arthritis by absorption through skin, and thus is useful for the treatment of degenerative arthritis and rheumatoid arthritis.04-04-2013
20130078301METHODS FOR STIMULATING GROWTH AND PREVENTING LOSS OF HUMAN HAIR - A method for stimulating hair growth includes providing a topical composition including a purified oil extract from 03-28-2013
20130078302Protein C Zymogen and Methods of Use Thereof to Prevent Cancer Metastases - Compositions and methods useful for the inhibition of cancer metastasis are disclosed.03-28-2013
20090175930Composition Suppressing The Expression of Target Gene in Eyeball and Medicament For Treating of Disease in Eyeball - There is provided a composition comprising an RNA-encapsulated liposome, the RNA comprising a sequence being of 15 to 30 contiguous nucleotides of mRNA of a target gene associated with a disease in an eyeball, and a sequence complementary to the sequence, wherein the liposome is capable of reaching an eyeball, and the like. The liposome in which an RNA is encapsulated is, for example, a liposome composing a complex particle comprising a lead particle and the RNA as constituent components, the lead particle comprising a cationic lipid, and a bilayer lipid membrane for coating the complex particle. The bilayer lipid membrane is a bilayer lipid membrane comprising a neutral lipid, and a lipid derivative, a fatty acid derivative or an aliphatic hydrocarbon derivative of a water-soluble substance as constituent components.07-09-2009
20130039974ANTI-MUC1 ANTIBODIES FOR CANCER DIAGNOSTICS - The present invention is directed to antibodies binding to the MUC1 cytoplasmic domain and methods of using such antibodies to treat, diagnose, detect and monitor cancers that express the MUC1 antigen.02-14-2013
20130039977PHARMACEUTICAL COMPOSITION, A METHOD OF PREPARING IT AND A METHOD OF TREATMENT BY USE THEREOF - Pharmaceutically acceptable liposome-encapsulated busulphan formulations for parenteral administration are provided, as well as such formulations furthermore comprising glutathione and/or at least one glutathione precursor and a process for manufacture of the preparations. The formulations are stable, have improved biodistribution and significantly reduced side effects over those produced by oral administration or parenteral administration of free drug. The formulations are useful as part of stem cell and/or bone marrow transplant conditioning regimens. A method of treatment of a mammal by use of such formulations.02-14-2013
20130039976Sodium channel blocker for treatment of loss of superficial sensitivity - The invention concerns a sodium channel blocker for the treatment of a reduction or loss of superficial sensitivity or sense of touch of a human being or another mammal.02-14-2013
20130039975Liposomes Containing Prostaglandin E1 (PGE1), Formulations Containing Them and Their Use - Unilamellar liposomes comprising PGE1 and/or PGE1-α-cyclodextrin combined with carnitine, in which there are hydrophilic polymers on the external surface of the liposomes are described.02-14-2013
20130039973Viral Immunogenic Compositions - Disclosed herein are immunogenic compositions for producing immediate and sustained immunity to infectious viral and bacteriological pathogens. A univalent immunogenic composition is disclosed comprising an isolated antigen and a polynucleotide formulated into a nanoparticle or liposome. Furthermore, multivalent immunogenic compositions are disclosed comprising multiple univalent immunogenic compositions. Also disclosed, are methods of inducing protective or therapeutic immune responses in individuals comprising administering one or more univalent immunogenic compositions.02-14-2013
20130039972COMPOSITIONS AND METHODS OF USE OF TARGETING PEPTIDES AGAINST PLACENTA AND ADIPOSE TISSUES - The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity. An exemplary placental receptor is FcRn/β02-14-2013
20130039971COMPOSITIONS AND METHODS FOR INHIBITION OF VEGF - Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.02-14-2013
20130039970Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics - Processes and compositions for liposomal delivery of therapeuticals prepared by contacting an aqueous solution of an active agent with a solution of liposome-forming components containing one or more DILA2 amino acid compounds or lipids in organic solvent to form an impinging stream. A protocol including flow rates, pH, and an incubation period are used to control formation of liposomal components for therapeutic applications. The impinging stream may be collected and incubated to prepare a liposomal formulation which encapsulates the active agent. The composition can be quenched with buffer and filtered by tangential flow and diafiltration and other means for finishing as a pharmaceutical composition.02-14-2013
20130039969Method And Composition For Treating Rhinitis - There is provided pharmaceutical compositions for the treatment of rhinitis by, for example, nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutical acceptable aqueous carrier. The compositions are preferably homogeneous in their nature.02-14-2013
20100098750PHARMACEUTICAL COMPOSITION COMPRISING PHENYLAMIDINE DERIVATIVE AND METHOD OF USING THE PHARMACEUTICAL COMPOSITION IN COMBINATION WITH ANTIFUNGAL AGENT - A pharmaceutical composition comprising a phenylamidine derivative or a salt thereof, represented by a general formula,04-22-2010
20100112042Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics - Processes and compositions for liposomal delivery of therapeuticals prepared by contacting an aqueous solution of an active agent with a solution of liposome-forming components containing one or more DILA2 amino acid compounds or lipids in organic solvent to form an impinging stream. A protocol including flow rates, pH, and an incubation period are used to control formation of liposomal components for therapeutic applications. The impinging stream may be collected and incubated to prepare a liposomal formulation which encapsulates the active agent. The composition can be quenched with buffer and filtered by tangential flow and diafiltration and other means for finishing as a pharmaceutical composition. An efficiency for delivering a drug cargo is provided. Compositions can include a liposome containing one or more carrier particles, each carrier particle having an active agent and a peptide, wherein the ratio of the mass of the peptide plus the mass of the liposome to the mass of the active agent is less than about 15.05-06-2010
20100112041Endoxifen Compositions And Methods - The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, Z- and E-guggulsterones, phospholipids, fatty acids, vitamin D, and vitamin E. The present invention also provides methods of preparing endoxifen. The present invention provides methods for treating and preventing breast cancer and other breast related diseases by administrating novel formulations or compositions comprising a therapeutically effective amount of endoxifen.05-06-2010
20100112040Preparation of Heavy Metal-Containing Nano-Liposomes and their Uses in Medical Therapy - Heavy metal-containing nano-liposome particles and their use in treating, for example, immune-related disorders, such as, cancer and inflammatory conditions, and metal deficiency-related diseases are described. The particles also can be used in diagnostic methods. The particles can contain gold, platinum or iron.05-06-2010
20100112039METHODS OF TREATING OVARIAN CANCER - Disclosed are methods of treating ovarian cancer (e.g., epithelial ovarian cancer) using lonafarnib, a taxane (e.g., paclitaxel or docetaxel) and a platinum coordinator complex (e.g., carboplatin, cisplatin or oxaliplatin). Also disclosed are methods of treating ovarian cancer (e.g. epithelial ovarian cancer) using lonafarnib, paclitaxel and carboplatin. Also disclosed are methods of treating ovarian cancer using lonafarnib in combination with a liposomal doxorubicin.05-06-2010
20100112038METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOEITIC GROWTH FACTORS - The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.05-06-2010
20100323002INHIBITION OF MELANOGENESIS AND MELANOMA METASTASIS WITH P-AMINO BENZOIC ACID (PABA) - The present invention relates to the inhibition of melanogenesis with para-aminobenzoic acid (PABA) and its use in treating melanotic cancer.12-23-2010
20100323000METHOD AND PROCESS FOR PREPARING CARDIOLIPIN - The invention provides novel methods for preparing cardiolipin and cardiolipin analogs having varying fatty acid chain lengths, particularly 1,1′,2,2′-tetramyristoyl cardiolipin. The methods comprise reacting a starting compound, such as a 1,2-O-sn-diacylglycerol and a 2-protected glycerol, with a phosphoramidite reagent to produce a protected cardiolipin, which is deprotected to prepare cardiolipin. The cardiolipin and cardiolipin analogs may be prepared in the presence of an activator, such as pyridinium trifluororacetate. The methods of the present invention are used to prepare cardiolipin and cardiolipin analogs in large quantities. The cardiolipin prepared by the present methods can be incorporated into liposomes which can also include active agents such as hydrophobic or hydrophilic drugs. Such liposomes can be used to treat diseases or in diagnostic and/or analytical assays.12-23-2010
20090155350CHLAMYDIA ANTIGENS AND PROTEIN VACCINE - The present invention provides vaccines for immunizing a host, including humans, against disease caused by infection by a strain of 06-18-2009
20090155349METHODS OF TREATING INFLUENZA VIRAL INFECTIONS - Methods are described for treating an influenza viral infection or associated diseases, disorders or mechanisms in a subject, comprising administering to the subject a therapeutically effective amount of a catecholic butane of the general formula (I) or a pharmaceutically acceptable salt thereof:06-18-2009
20090155348Detoxified Recombinant Botulinum Neurotoxin - The present invention relates to the isolation of polypeptides derived from the 06-18-2009
20090155347Cosmetic Composition for Stimulating the Synthesis of Proteins of the Basement Membrane - Cosmetic composition which can be applied topically, comprising at least one compound of the general formula (I) in which R06-18-2009
20090155346PREPARATION OF POWDERS CONTAINING COLLOIDAL PARTICLES - The invention discloses a method for preparing a powder from an aqueous liquid which comprises colloidal particles. The method is based on the use of dense-phase extraction media, i.e. near-critical or supercritical fluids. The powder obtained through the method can be reconstituted with an appropriate aqueous liquid to yield a colloidal dispersion. The method is particularly useful for drying and stabilising aqueous colloidal dispersions comprising an active compound, such as a drug substance.06-18-2009
20090155345METHODS FOR AFFECTING LIPOSOME COMPOSITION ULTRASOUND IRRADIATION - The present invention provides methods for loading of agents and substances into per-formed liposomes, preferably a suspension of pre-formed liposomes as well as to methods for the controlled quantum (step-wise) release of agents and substances from liposomes. One of the principle features of the methods of the invention is to expose the liposomes to ultrasound irradiation having predefined parameters, resulting in an increase in permeability of the liposomes, thereby permitting, respectively, the loading and/or release of agents and substances into and/or from the liposomes.06-18-2009
20100104633TOPICAL TERBINAFINE FORMULATIONS AND METHODS OF ADMINISTERING SAME FOR THE TREATMENT OF FUNGAL INFECTIONS - The present invention relates to topical antifungal formulations terbinafine or a pharmaceutically acceptable salt thereof, a lipid, and a surfactant, and uses thereof for the treatment of skin and nail fungal infections.04-29-2010
20100104632Drug Having Regulatory Cell Ligand Contained in Liposome - A liposome containing a regulatory cell ligand such as α-galactosyl ceramide or β-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.04-29-2010
20100104630WATER SOLUBLE STATIN MICROSTRUCTURES AND METHOD OF PREPARATION - A method of preparing a water soluble microstructure includes the steps of providing a saturated solution of a payload with poor water solubility, providing a solution of helper molecules, and combining the saturated solution of the payload with the solution of helper molecules. The combined saturated solution of the payload with the solution of helper molecules is mixed with an aqueous solution to form a water soluble microstructure. The water soluble microstructure includes the helper molecules forming an outside portion of the microstructure, and the payload having poor water solubility contained within the outside portion and forming an inside portion of the microstructure.04-29-2010
20100104629CATIONIC LIPIDS AND USES THEREOF - Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.04-29-2010
20100104623AGENT FOR ENHANCING THE RESISTANCE OF LIPOSOME AGAINST BIOLOGICAL COMPONENT, AND LIPOSOME MODIFIED WITH THE AGENT - It is intended to provide a positively charged liposome, particularly having a polyarginine peptide on a surface thereof, which is capable of increasing the resistance to a negatively charged biological component such as a protein in the blood and maintaining a high ability to deliver a substance even in the blood. An agent for enhancing the resistance of liposome against biological component comprising a peptide having at least one of the following characteristics (a) and (b) as an active ingredient: 04-29-2010
20100104622Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents - A carrier system for the delivery of therapeutic and/or diagnostic agents is described. The carrier system is comprised of ligands and a biodegradable polycation for complexing polyanionic molecules such as RNAi, said polycation forming a coating on the outer surface of anionic or neutral liposomes. Also disclosed is a method for using the composition to deliver to target cells and enhance cell membrane penetration of therapeutic and/or diagnostic agents.04-29-2010
20100104625BIODEGRADABLE COMPOSITIONS AND MATERIALS - The present invention provides compounds of Formula I, materials comprising one or more compounds of Formula I and one or more biologically active agents, pharmaceutical compositions comprising an inventive material and a pharmaceutically acceptable excipient, methods of making compounds of Formula I, methods of making inventive materials, and methods of using pharmaceutical compositions comprising an inventive material and a pharmaceutically acceptable excipient.04-29-2010
20100104631METHOD OF TREATMENT FOR BLADDER DYSFUNCTION - Liposomes are used for intravesical drug delivery, especially delivery of botulinum toxin (BoNT) to help improve lower urinary tract symptoms by decreasing bladder irritation and frequency. The system uses a lower and safer dose of BoNT with lower risk of urinary retention. A simple instillation of liposome-BoNT as a liquid formulation into the bladder, in a typical volume of 30-60 ml, will achieve efficacy similar to that currently achieved with cystscopic needle injection of BoNT. The dose may be lower than that done by injection, thereby causing significantly less risk of urinary retention. Liposome-BoNT can protect the BoNT from bladder and urine breakdown. Liposome-BoNT instillation is more comfortable for the patients and allows many more doctors' offices to offer this form of treatment that would otherwise be restricted to doctors skilled and certified in cystoscopic BoNT injection.04-29-2010
20100104628 METHOD OF TREATING NEUROBLASTOMA - The present invention relates, in general, to neuroblastoma and, in particular, to a method of treating neuroblastoma tumors, including refractory neuroblastoma tumors. The invention also relates to compounds and compositions suitable for use in such a method.04-29-2010
20090130193Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intraperitoneally - One aspect of the invention relates to methods of treating cancer in a patient comprising administering intraperitoneally to a patient in need thereof a cancer treating effective amount of a composition comprising a lipid-complexed platinum compound wherein the concentration of the platinum compound of the lipid-complexed platinum compound composition is greater than about 1.2 mg/ml. Another aspect of the invention relates to lipid-complexed platinum compound compositions where the concentration of the platinum compound is greater than about 1.2 mg/ml.05-21-2009
20100040676POLYCISTRONIC HIV VECTOR CONSTRUCTS - The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these vectors and sequences along with methods of using these vectors and sequences are also disclosed.02-18-2010
20100040675COMPOSITIONS AND METHODS FOR PROMOTING OR INHIBITING ANGIOGENESIS - Compounds, compositions and methods for promoting or inhibiting angiogenesis, and screening methods for identifying compounds are disclosed. The compounds bind to F1 ATP synthase, particularly to the alpha and/or beta subunits of F1 ATP synthase. When bound to these subunits, they can function as angiostatin agonists, antagonists, partial agonists, inverse agonists, or allosteric modulators. When the compounds mimic or enhance the activity of angiostatin, they inhibit angiogenesis. When the compounds inhibit the ability of angiostatin to bind F1 ATP synthase and are either inactive at inhibiting angiogenesis or directly promote angiogenesis, or if they inhibit the activity of angiostatin, they promote angiogenesis. The compounds can be, for example, antibodies, antibody fragments, enzymes, peptides, nucleic acids such as oligonucleotides, or small molecules. The antibodies can be monoclonal, humanized, or polyclonal antibodies. The compounds can be conjugated to or combined with various cytotoxic agents and/or labeled compounds. Methods for promoting angiogenesis can be used to introduce vasculature to areas in a patient that can benefit from such increased vasculature. Methods for inhibiting angiogenesis can be used to treat disorders mediated by angiogenesis, for example, tumors, autoimmune disorders such as rheumatoid arthritis, and the like.02-18-2010
20090324700METHODS AND COMPOSITIONS FOR THE INHIBITION OF CATHEPSINS - Methods and compositions for modulating cell death by contacting a cell with an Spi2A polypeptide or an Spi2A polypeptide equivalent are disclosed. In addition, methods of treating a subject by providing the subject a composition that includes an Spi2A polypeptide or an Spi2A polypeptide equivalent are disclosed. The Spi2A polypeptide and Spi2A polypeptide equivalent can be delivered to the subject using gene therapy techniques. The subject can be a patient with a disease associated with an abnormal rate of cell death, such as septic shock or myocardial infarction. Also disclosed are methods of preparing and storing donor granulocytes, involving contacting the donor granulocytes with an Spi2A polypeptide or an Spi2A polypeptide equivalent.12-31-2009
20130045271STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARING THE SAME - The present invention is directed to steroid hormone delivery systems and methods of preparing the same. In particular, the steroid hormone delivery systems provided include a primary construct having one or more hydrophobic steroid hormone esters in the form of a liposome, a lipid particle, a micelle, an emulsion or a niosome which is then formulated into a secondary construct for administration. Exemplary secondary constructs include a film for sublingual or buccal administration.02-21-2013
20130045270METHOD OF USE OF STABILIZED GROWTH FACTOR IN SKIN CARE - Dermatologic compositions for therapeutic use, containing a growth factor, or a growth factor purified from transgenic plants, or animal, bacterial, yeast or insect cells, or a mixture of growth factors in purified form, for treatment of various dermatological conditions and diseases. The pharmaceutical compositions are suitable for treatment of sensitive and challenged skin due to conditions and illnesses such as challenged skin due to systemic lupus erythematosus, Lichen simplex chronicus, blepharitis and blepharokeratoconjuctivitis. The skin compositions are also useful for use in combination with agents to treat anti-fungal infections such as Clotrimazole, Terbinafine, Miconazole, Ketoconazole, Amorolfine and Econazole.02-21-2013
20130045272AGENT FOR TREATING MYELOFIBROSIS - Disclosed is a substance delivery carrier for an extracellular-matrix-producing cell in the bone marrow, which comprises a retinoid. Also disclosed in an agent for treating myelofibrosis by utilizing a substance capable of regulating the activity or proliferation of an extracellular-matrix-producing cell in the bone marrow.02-21-2013
20100092547COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS - A method for prophylaxis and/or treatment of mucositis comprising the steps of providing a therapeutically effective amount of a composition comprising either (1) at least one compound selected from the group consisting of 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; or (2) a cytokinin compound; and administering the composition to a subject in need of such treatment. Also provided are pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione and/or a cytokinin compound and use of these compositions in the preparation of a medicament for the treatment and/or prophylaxis of mucositis. The cytokinin compound may be selected from, but is not limited to N04-15-2010
20130028966Broad Spectrum Antiviral and Antiparasitic Agents - The invention provides compounds represented by the formulae: (I) and (II) where the compounds are useful in treating, for example, viral and/or parasitic infections. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds.01-31-2013
20130028967THERAPEUTIC AGENT FOR PULMONARY FIBROSIS - Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for pulmonary fibrosis, which utilized the carrier; and a preparation kit of the therapeutic agent.01-31-2013
20130028961PHARMACEUTICAL COMPOSITIONS, COMPRISING A COMBINATION OF SELECT CARRIERS, VITAMINS, TANNINS AND FLAVONOIDS AS ANTIGEN-SPECIFIC IMMUNO-MODULATORS - The present invention provides adjuvant compositions that are capable of modulating the immune response in a subject, including enhancing or suppressing the immune response. These adjuvant compositions may also be used to enhance or suppress the immunogenicity of antigens by enhancing or suppressing antigen-presentation activity, enhancing or suppressing innate immune responses through activation or suppression of, e.g., natural killer cells, and/or direct activation of subsets of B and/or T cells. Also provided are methods of making the adjuvant compositions as well as methods of using the adjuvant compositions. In certain embodiments, the compositions comprise combinations of the following: a pharmaceutically acceptable carrier, a flavonoid, a tannin and a vitamin. The compositions may further comprise an antigen.01-31-2013
20130028964NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION - Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that target human cyclophilin A (CyPA) to inhibit Hepatitis C (HCV) infection. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.01-31-2013
20130028962Triggered Cargo Release from Nanoparticle Stabilized Liposomes - Control of the fusion activity of liposomes by adsorbing biocompatible nanoparticles to the outer surface of phospholipid liposomes is disclosed. The biocompatible nanoparticles effectively prevent liposomes from fusing with one another. Release of cargo from the liposome is accomplished via trigger mechanisms that include pH triggers, pore forming toxing triggers and photosensitive triggers. Dermal drug delivery to treat a variety of skin diseases such as acne vulgaris and staph infections is contemplated.01-31-2013
20130028965NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION - Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C (HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or as pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with known delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.01-31-2013
20130028963Forming an Artificial Cell with controlled membrane composition, asymmetry, and contents - The present invention provides a vesicle having a unilamellar bilayer including a lipid and a second bilayer component selected from a membrane protein or a functionalized lipid. The vesicle also includes a component encapsulated by the unilamellar bilayer, wherein the encapsulated component includes a protein, a peptide, an enzyme, an oligonucleotide, or a polynucleotide. Also included are methods of making the vesicles of the present invention.01-31-2013
20130028956METHOD FOR PREVENTING OR TREATING MEMORY IMPAIRMENT AND PHARMACEUTICAL COMPOSITIONS USEFUL THEREFORE - In a first aspect, the present invention relates to a method for prevention or treating memory impairment and/or a neurodegenerative condition, disorder or disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound targeting a miRNA or any precursor, or targeting the activity of said miRNA or any precursor thereof. In particular, the present invention relates to a method wherein the targeted miRNA is miR-34. Moreover, the present invention relates to a method for improving memory functionality in a subject suffering from memory loss, said method comprises the reduction or reducing the level of miR-34 levels or precursor molecule levels in brain tissue of said subject administering to the subject a therapeutically effective amount of a compound targeting miR-34 or any precursor thereof.01-31-2013
20130028960LIPID-BASED COMPOSITIONS OF ANTIINFECTIVES FOR TREATING PULMONARY INFECTIONS AND METHODS OF USE THEREOF - A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.01-31-2013
20130028959Liposomes for Preventing the Spread of HIV - Formulations for preventing the sexual transmission of the HIV virus are provided. In one embodiment, the formulations contain un-conjugated liposomes whose physicochemical properties allow binding to the HIV virus. The liposomes are made up of natural or synthetic lipids, alone or in combination. Preferably, the liposomes are made entirely of cardiolipin. In other embodiments the liposomes are modified to contain Hgands which bind HIV. The method for preventing the sexual transmission of the HIV virus includes self-administration of a formulation containing an effective amount of liposomes which bind to the HIV virus to the surface of a mucosal membrane prior to intercourse.01-31-2013
20130028958BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO - The present invention is directed at β-carbolines, preferred 9-alkyl-β-carbolines (01-31-2013
20130028957PHARMACEUTICAL COMPOSITION FOR TREATING CANCER - The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.01-31-2013
20130028955SUSTAINED RELEASE ORAL MATRIX AND METHODS OF MAKING THEREOF - A solid dosage form suitable for forming a tablet for the containment and delivery of medicament is provided wherein the matrix forming material is a pressure sensitive adhesive, present in the amount from about 0.1 to about 40 weight %, based on the total weight of the composition. The dosage form is comprised of the medicament and a water-insoluble polymer silicone pressure sensitive adhesive and allows release of the medicament in a controlled fashion depending on simple parameters such as weight percent of the polymer silicone adhesive. A sustained release dosage form is provided for delivery of medicament wherein the release rate of medicament does not depend on the dissolution medium of the pH. Another aspect of invention is formation of solid tablets of poorly compressible material and the method for making the solid composition. The dosage form for this invention s particularly suitable for oral dosage forms.01-31-2013
20080279918Liposome And Method For Injecting Substance To Cell Using This Liposome - It is intended to efficiently inject into a target cell, a substance charged within a liposome. The present inventors have found that connexin synthesized within a liposome is introduced as connexon having a gap junction function into the liposome membrane. Specifically, the liposome according to the present invention is a liposome in which connexon composed of connexin synthesized by an in-vitro protein synthesis system is incorporated in a state of having a gap junction function.11-13-2008
20100068261METHODS AND COMPOSITIONS FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES - The present invention comprises compositions and methods for making monoclonal antibodies. The present invention further comprises vectors that replicate the immune system components, particularly an antigen-presenting cell (APC) element of the immune synapse. Additionally, the present invention may further comprise synthetic T-cells.03-18-2010
20100068259NATURAL PRODUCT INHIBITORS OF 3DG - Compositions are disclosed which have as a component thereof an inhibitor of the enzymatic production of 3-deoxyglucosone (3DG) from fructoselysine and/or an inactivator of 3DG, and which are useful for the treatment or prophylaxis of a condition or disease state that is alleviated by inhibiting such 3DG production. Methods of using such compositions, e.g., for improving the appearance, texture and/or elasticity of aging skin, are also disclosed.03-18-2010
20080311184METHOD FOR DEVELOPING, TESTING, AND USING ASSOCIATES OF MACROMOLECULES AND COMPLEX AGGREGATES FOR IMPROVED PAYLOAD AND CONTROLLABLE DE/ASSOCIATION RATES - This invention describes the principles and procedures suitable for developing, testing, manufacturing, and using combinations of various amphipatic, if necessary modified, macromolecules (such as polypeptides, proteins, etc.) or other chain molecules (such as suitable, e.g. partly hydrophobised, polynucleotides or polysaccharides) with the aggregates which comprise a mixture of polar and/or charged amphipats and form extended surfaces that can be freely suspended or supported. The described methods can be utilised for the optimisation of aggregates that, after association with chain molecules exerting some activity or a useful function, are suitable for the application in vitro or in vivo, for example, in the fields of drug delivery, diagnostics or bio/catalysis. As special examples, mixtures of vesicular droplets consisting of lipids loaded (associated) with insulin, interferon, interleukin, nerve growth factor, calcitonin, and an immunoglobulin, etc., are described.12-18-2008
20130089601METHOD FOR TREATING ATHEROSCLEROSIS - The invention provides a method for treating atherosclerosis in a subject in need thereof, including administering an effective amount of microRNA-195 to the subject in need thereof. The microRNA-195 may be packaged in a pharmaceutically acceptable carrier. Moreover, the pharmaceutically acceptable carrier may includes a liposome, lipid particle or viral vector.04-11-2013
20130089599NANO-ENCAPSULATED THERAPEUTICS FOR CONTROLLED TREATMENT OF INFECTION AND OTHER DISEASES - This invention relates to a method to provide immediate, direct and controlled time release of an effective amount of therapeutics to a wound site for a prolonged period. The pharmaceutical formulation comprising a plurality of nanoparticles, said nanoparticles encapsulating a therapeutically effective amount of one or more antibacterial agents, and an application of the formulation to an implant before surgery provide for extended release of said antibacterial agents.04-11-2013
20130089597MicroRNA-130a,b as a Tumor Suppressor and Sensitizing Agent for Chemotherapy - The present invention provides a method of improving a therapeutic response to a cancer treatment, in a subject, the method comprising administering an effective amount of an agent that enhances the expression of microRNA-130 or an agent that mimics the effects of microRNA-130. Further provided is a method of treating a cancer in a subject in need of such treatment comprising the step of administering an effective amount of a microRNA-130 or an agent that enhances the expression of microRNA-130.04-11-2013
20130089598METHOD OF TREATING PULMONARY DISORDERS WITH LIPOSOMAL AMIKACIN FORMULATIONS - Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period.04-11-2013
20130089596COMPOSITIONS AND METHODS OF MAKING AND USING INFLUENZA PROTEINS - The invention provides compositions of influenza proteins, such as matrix and nucleoprotein, that are presented to an individual's immune system as multimeric displays to induce an immune response. The compositions are optionally associated with any type of immunomodulatory compound (IMC) comprising an immunostimulatory sequences (ISS). The invention further provides compositions of influenza matrix and nucleoproteins that can induce cellular and/or humoral immune response. The invention also provides methods of making and using these compositions, e.g., as a vaccine, for ameliorating symptoms associated with infection with influenza virus or for reducing the risk of infection with influenza virus.04-11-2013
20090252786Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor - The present invention relates to a method of preventing or treating in a subject a disorder characterized in a reduced GABA receptor function by administering to the subject a therapeutically effective amount of a pharmacologically active blood serum product obtainable by a method comprising electrostimulation of a non-human animal, withdrawal of blood from said animal isolation of serum from said blood, and gamma irradiation of said serum.10-08-2009
20130089600CANNABINOID FORMULATIONS - The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications.04-11-2013
20100136098AVIAN INFLUENZA VACCINE - The present invention provides an avian influenza vaccine containing a peptide-bound liposome wherein; 06-03-2010
20090324701COMPOSITIONS CONTAINING (S)-BETHANECHOL AND THEIR USE IN THE TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, GLUCOSE INTOLERANCE AND RELATED DISORDERS - The present invention provides pharmaceutical compositions comprising (S)-bethanechol or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier and optionally at least one diabetes drug. The use of said composition in the treatment of insulin resistance, type 2 diabetes, impaired glucose tolerance and related disorders is also provided. The invention also provides for a kit comprising the pharmaceutical compositions and instructions for its use.12-31-2009
20100266679CRYSTALLINE MODIFICATIONS OF N-ALPHA-(2,4,6-TRIISOPROPYLPHENYLSULFONYL)-3-HYDROXYAMIDINO- (L)- PHENYLALANINE 4-ETHOXYCARBONYLPIPERAZIDE AND/OR SALTS THEREOF - The present invention relates to novel crystalline modifications of N-α-(2,4,6-triisopropylphenyl-sulfonyl)-3-hydroxyamidino-(L)-phenylalanine 4-ethoxy-carbonylpiperazide and/or salts thereof, which can be used as pharmaceutical agents, and to pharmaceutical compositions and pharmaceutical uses comprising these novel crystalline modifications.10-21-2010
20110002978ENZYME PRODRUG CANCER THERAPY SELECTIVELY TARGETED TO TUMOR CELLS OR TUMOR VASCULATURE AND METHODS OF PRODUCTION AND USE THEREOF - Conjugates for use in an enzyme prodrug cancer therapy treatment are provided.01-06-2011
20090304783COMPOSITIONS AND METHODS FOR TREATING BACTERIA - The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications.12-10-2009
20090304782Topical Ibuprofen Formulation - The present invention relates to a liposomal liquid pharmaceutical composition comprising ibuprofen, at least one phospholipid, at least one C12-10-2009
20090304781MASTER GENE OF ARTERIOGENESIS - The present invention relates to a pharmaceutical composition comprising (a) a polynucleotide comprising or consisting of a nucleotide sequence encoding a polypeptide with the amino acid sequence as set forth in SEQ ID NO: 2; (b) a polynucleotide comprising or consisting of a nucleotide sequence which is a fragment of a nucleotide sequence encoding the polypeptide with the amino acid sequence as set forth in SEQ ID NO: 2, wherein the polypeptide encoded by said polynucleotide has arteriogenic activity; (c) a polynucleotide comprising or consisting of a nucleotide sequence encoding a polypeptide, wherein said polypeptide exhibits at least 70% sequence identity with the sequence of the polypeptide encoded by the polynucleotide of (a) or (b) over the entire length, and wherein said polypeptide has arteriogenic activity; and/or (d) a polypeptide encoded by the polynucleotide of any one of (a) to (c).12-10-2009
20090041837Aptamers utilized as targeting agents for pharmaceutical compounds used in the treatment of cancer and other diseases - This invention describes a method whereby selected aptamers are used as a carrier compound to deliver drug nanoparticles and/or drug liposomes to the tumor or disease site. These aptamers have the propensity to localize in areas of tissue necrosis. Many tumors have areas of necrosis that can be targeted using aptamer coated drug nanoparticles and/or aptamer coated drug liposomes. Similarly many infectious diseases and autoimmune diseases have areas of inflammation and/or areas of necrosis and can also be targeted using aptamer coated drug nanoparticles and/or aptamer coated drug liposomes.02-12-2009
20090041835METHOD OF INHIBITING LEAKAGE OF DRUG ENCAPSULATED IN LIPOSOMES - The present invention provides a method of inhibiting the leakage of a drug encapsulated in liposomes, which comprises satisfying at least two requirements selected from the group consisting of the following three requirements: using at least two lipid bilayers of the liposomes, controlling the average particle size of the liposomes to 120 nm or more, and using lipid having a phase transition temperature higher than in vivo temperature as lipid constituting the liposomes. Also, the present invention provides a liposome preparation which is stable in vivo and satisfies at least two requirements selected from the group consisting of the following three requirements: the number of lipid bilayers of the liposomes is at least two, the liposomes have an average particle size of 120 nm or more, and lipid constituting the liposomes has a phase transition temperature higher than in vivo temperature.02-12-2009
20090041834Compositions and methods for treating lymphoma - This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.02-12-2009
20110008422SYSTEM FOR DELIVERY OF PROTEIN IN INSOLUBLE FIBRILLAR OR AGGREGATE FORM - A pharmaceutical composition containing a therapeutic protein which is particularly amenable to oral administration by providing stability in the gastrointestinal tract. Insoluble fibrils or aggregates of the therapeutic protein in the pharmaceutical composition are encapsulated in a lipidated glycosaminoglycan particle, coated with a multi-layer of lipids and lipid-glycosaminoglycan conjugates, or present as unencapsulated and uncoated insoluble fibrils or aggregates.01-13-2011
20130071470Fenugreek Seed Extract to Lower Blood Cholesterol - A method of lowering blood cholesterol in a non-diabetic patient by at least 30% is described. The method involves orally administering for 30 consecutive days a fenugreek seed extract composition. Various methods of preparation and various formulations are described. Physiologically effective pharmaceutical compositions and beverages containing fenugreek seed extracts and other active components are also disclosed.03-21-2013
20130071469Lipid-Based Compositions of Antiinfectives for Treating Pulmonary Infections and Methods of Use Thereof - A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.03-21-2013
20130071468Lipid-Based Compositions of Antiinfectives for Treating Pulmonary Infections and Methods of Use Thereof - A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.03-21-2013
20130071467RETINOID-LIPOSOMES FOR TREATING FIBROSIS - What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 expression, including fibrosis.03-21-2013
20130071471PHARMACEUTICAL COMPOSITION FOR TREATING ATOPIC DERMATITIS - A method of treating mild atopic dermatitis patients by locally administering an external composition containing adenosylcobalamin as an active ingredient is provided. The composition can effectively treat mild atopic dermatitis patients without side effects.03-21-2013
20130071466METHODS AND COMPOSITIONS FOR TREATING GASTRIC DISORDERS - Improved efficacy in treatment of gastric disorders with botulinum toxin is obtained using liposomal encapsulated botulinum formulations for topical administration of the botulinum toxin. The liposomes are typically administered in a physiologically acceptable carrier such as saline or phosphate buffered saline by application onto the surface of the tissue within into the gastrointestinal (GI) tract in need of treatment. Preferably, the formulation is applied via a roller, sponge or nozzle that is attached to an endoscope.03-21-2013
20130164365FORMULATIONS FOR TREATMENT WITH GLUCOSINOLATES - The application relates to topical formulations comprising a phase II enzyme inducer precursor and an activating agent. Methods for producing and using the topical formulations are also provided.06-27-2013
20090092666Vaccines with enhanced immune response and methods for their preparation - The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in eliciting the production of antibodies that recognize epitopes of native proteins.04-09-2009
20090092665OPHTHALMIC COMPOSITIONS COMPRISING CALCINEURIN INHIBITORS OR mTOR INHIBITORS - The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles.04-09-2009
20090092663Tumor-targeted drug delivery systems and uses thereof - The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems. In particular, the delivery systems of the present invention are capable of accumulating a higher amount of therapeutic agent in a tumor, or in the vicinity of a tumor cell or tumor-supporting cell, resulting in exposure of the tumor cell and tumor-associated endothelial cell to therapeutic levels of the agent for a longer period of time as compared to other delivery systems. The present invention also describes pharmaceutical compositions comprising the delivery systems of the present invention. The present invention further relates to a tumor treatment comprising an increased amount of therapeutic agent delivered by the system of the present invention as compared to other delivery systems. The delivery systems and pharmaceutical compositions can be administered to a subject, preferably a human, alone or in combination, sequentially or simultaneously, with other prophylactic or therapeutic agents and/or anti-cancer treatments.04-09-2009
20090092661LIPOSOME COMPOSITIONS FOR IN VIVO ADMINISTRATION OF BORONIC ACID COMPOUNDS - Liposome formulations for administration of a boronic acid compound are described. The liposomes are comprised of a phospholipid having two acyl chains with between 20-22 carbon atoms in each chain and a boronic acid compound entrapped in the liposomes. In a preferred embodiment, the boronic acid compound is in the form of a complex with meglumine.04-09-2009
20130058997VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.03-07-2013
20130058998ENCAPSULATED N-ACETYLMANNOSAMINE OR N-ACETYLNEURAMINIC ACID TO INCREASE SIALYLATION - A method for treating a disorder characterized by hyposialylation in a subject that includes administering to the subject an effective amount of (i) a composition comprising N-acetylmannosamine, or a derivative thereof, encapsulated within a liposome, or (ii) a composition comprising N-acetylneuraminic acid, or a derivative thereof, encapsulated within a liposome, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammonium-propane and cholesterol.03-07-2013
20130058994LIPOSOMES CONTAINING OLIGOPEPTIDE FRAGMENTS OF MYELIN BASIC PROTEIN, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR TREATMENT OF MULTIPLE SCLEROSIS - The present invention provides compositions and methods for the treatment of multiple sclerosis. Among others, the invention provides compositions of immunodominant peptides of myelin basic protein encapsulated in mannosylated liposomes. In a specific embodiment, the compositions comprise mylein basic protein (MBP) peptides MBP(46-62), MBP(124-139), and MBP(147-170).03-07-2013
20130058996LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF - This method provides a method for delivering shRNA targeting TS in vivo. In addition, the following is provided: an antitumor agent, which comprises short hairpin RNA (shRNA) capable of inhibiting expression of thymidylate synthase by RNAi action and a PEG-modified cationic liposome, wherein the shRNA is bound to the surface of the PEG-modified cationic liposome and has an overhang comprising at least two nucleotides at the 3′ end.03-07-2013
20130058995Composition and method for weight reduction - Disclosed is a composition and method for facilitating weight loss in individuals. The composition is a physiologically effective amount of the herbal substance 03-07-2013
20130058992GENE EXPRESSION SIGNATURES ASSOCIATED WITH RESPONSE TO IMATINIB MESYLATE IN GASTROINTESTINAL STROMAL TUMORS AND USE THEREOF FOR PREDICTING PATIENT RESPONSE TO THERAPY AND IDENTIFICATION OF AGENTS WHICH HAVE EFFICACY FOR THE TREATMENT OF CANCER - Compositions and methods are disclosed for identifying agents useful for the treatment of malignancy, particularly GISTs which are resistant to imatinib mesylate (IM). In a preferred embodiment, agents which sensitize cancer cells to IM are provided.03-07-2013
20130058993METHODS AND COMPOSITIONS FOR ENHANCING WOUND HEALING USING CAR PEPTIDES - Disclosed are compositions and methods useful for treating wounded, injured, and inflamed tissue. The compositions and methods are based on peptide sequences, such as CAR peptides and truncated CAR peptides, that are selectively targeted to wounded tissue and are internalized by a cell, penetrate tissue, or both. The disclosed peptides promote and enhance wound healing.03-07-2013
20110038922COMPOUNDS FOR TREATING OR PREVENTING AMINE OXIDASE RELATED DISEASES OR DISORDERS - This invention relates to small interfering RNAs (siRNAs) that down regulates the expression of vascular adhesion protein 1 (VAP-1) for prevention or treatment of a disease or disorder that benefits from the inhibition or down regulation of VAP-1. Pharmaceutical compositions comprising said siRNAs in combination with pharmaceutically acceptable carriers are also included. Furthermore, the invention concerns expression vectors comprising nucleic acids encoding the siRNA duplexes or the antisense strands of said duplexes in a manner which allows expression of said siRNA duplexes or antisense strands within a mammalian cell. Pharmaceutical compositions comprising said expression vectors in combination with pharmaceutically acceptable carriers are also included.02-17-2011
20100291193Immunogenic compositions comprising progastrin and uses thereof - The present invention is drawn to immunotherapeutic methods to treat tumors/cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents that target the progastrin receptor, annexin II, or both. Such a composition may be administered in combination with chemotherapy or to an individual who had been previously subjected to chemotherapy or radiation therapy. The cancers that may be treated using such a composition may include but are not limited to colon cancer, breast cancer, lung cancer or pancreatic cancer.11-18-2010
20110014276SYNERGISTIC ANTIMICROBIAL PREPARATIONS CONTAINING CHLORITE AND HYDROGEN PEROXIDE - An anti-microbial preservative for use in ophthalmic and dermatologic products. The preservative includes from about 0.005 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.05 wt. % peroxy compound. Additionally, the preservative does not generate chlorine dioxide within the pH range of 5.0-8.8. Also included are an antimicrobial ophthalmic and dermatologic compositions for direct application onto an eye or skin of a living being including from about 0.005 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.05 wt. % peroxy compound. Also included are methods for treating dryness of the eyes and skin disorders (e.g., wounds, burns, infections, ulcerations, psoriasis, etc.) and for disinfecting and cleansing contact lenses while in place upon an eye by applying the composition to the eye or to the contact lens.01-20-2011
20110014275COMPOSITIONS AND METHODS FOR INHIBITING OR INDUCING ADIPOGENESIS - This invention relates generally to compositions and methods which utilization nuclear receptors for regulating adipogenesis in cells. Specifically, the invention is directed to compositions which regulate transcription factor PPARγ, and enhance or inhibit the transcription of genes responsible for directing cell differentiation towards a pathway of adipogenesis. More specifically, disclosed herein is a novel polypeptide coactivator of PPARγ, and fragments thereof, which possess coactivator or corepressor activity. Also related are nucleotide sequences which express these polypeptides. Also disclosed is an interfering RNA that may be used to inhibit adipogenesis.01-20-2011
20110014274VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.01-20-2011
20110014273Method of Treating BCC - A method of treating chronic infection with 01-20-2011
20110014272Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria - The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of 01-20-2011
20110014271Substituted Aniline Derivatives - The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections.01-20-2011
20110014270PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION INJURY AND RELATED CONDITIONS - Disclosed are Lipids, Annexin, and Lipid-Annexin Complexes for Use in the Prevention and/or Treatment of Ischemia-Reperfusion injury and reperfusion injury associated with a variety of diseases and conditions. Also disclosed are therapeutic targets and compositions for the prevention and treatment of ischemia-reperfusion injury and diseases and conditions associated with ischemia-reperfusion injury.01-20-2011
20120308642INHIBITING HEPATITIS C VIRAL REPLICATION WITH SIRNA COMBINATIONS - Compositions are disclosed of combinations of small interfering RNAs (siRNA) that can inhibit the replication of hepatitis C virus (HCV) in liver cells, along with methods of co-administering the siRNAs to subjects. Further, methods are disclosed for improving the delivery of nucleic acids to the liver.12-06-2012
20110064790ADAPTABLE MODIFIED VIRUS VECTOR TO DELIVER RIBOSOMAL RIBONUCLEIC ACID AS A MEDICAL TREATMENT DEVICE TO MANAGE DIABETES MELLITUS AND OTHER PROTEIN DEFICIENT DISEASES - Diabetes mellitus is a disease of elevated blood glucose, often directly related to a deficiency in insulin production or insulin receptor production. The innovative strategy of treatment described here utilizes modified viruses and virus-like vehicles to act as a transport mechanism to deliver ribosomal RNA molecules to target cells in the body. Delivering to the Beta cells in the body the ribosomal RNA needed to assist ribosomes with the construction of insulin or insulin receptors will lead to enhanced production of biologically active insulin or insulin receptors by Beta cells as necessary, which will lead to correcting deficiencies in insulin or insulin receptors, the result of which will help properly regulate blood glucose levels throughout the body utilizing innate cellular regulatory mechanisms.03-17-2011
20120189688CARRIER COMPONENT AND FABRICATION METHOD THEREOF - The present invention provides a carrier component. The carrier component includes a carrier core body including a dispersive object and a dualistic self-assembly material for encapsulating the dispersive object, wherein the dualistic self-assembly material has an electric charge; and a first shell layer having an electric charge opposite to the electric charge of the dualistic self-assembly material, and coating the carrier core body, and thus avoids inactivation of a medicine, eliminates medicine leakage and reduces medicine releasing. The present invention further provides a method for forming a carrier component.07-26-2012
20090280164THERAPY FOR HUMAN CANCERS USING CISPLATIN AND OTHER DRUGS OR GENES ENCAPSULATED INTO LIPOSOMES - A method for encapsulating cisplatin and other positively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers is disclosed. The liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans. The encapsulated cisplatin has a high therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the encapsulated cisplatin with encapsulated doxorubicin or with other antineoplastic drugs are claimed to be of therapeutic value. Also of therapeutic value in cancer eradication are claimed to be combinations of encapsulated cisplatin with a number of anticancer genes including but not limited to p53, IL-2, IL-12, angiostatin, and oncostatin encapsulated into liposomes as well as combinations of encapsulated cisplatin with HSV-tk plus encapsulated ganciclovir.11-12-2009
20090269395USE OF PROTOBERBERINES AS AN ACTIVE SUBSTANCE REGULATING THE PILOSEBACEOUS UNIT - The present invention relates to cosmetic use, by topic application on the skin of at least one protoberberine, with exception of berberine, or a vegetable extract containing it, as an active substance reducing activity of the pilosebaceous unit, preferably inhibiting activity of the pilosebaceous unit. In particular, the invention relates to cosmetic use of at least one protoberberine, with exception of berberine, or a vegetable extract containing it, as an agent reducing, preferably inhibiting the growth of hairs of the face and/or the body, and/or seborrheic activity of the sebaceous glands. The invention also relates to a cosmetic composition comprising in a dermatologically acceptable carrier, at least one protoberberine, with exception of berberine, or a vegetable extract containing protoberberines, as an active substance, which reduces, preferably inhibits the skin's pilosebaceous unit activity.10-29-2009
20090269397TARGETED AND HIGH DENSITY DRUG LOADED POLYMERIC MATERIALS - Polymeric delivery devices have been developed which combine high loading/high density of molecules to be delivered with the option of targeting. As used herein, “high density” refers to microparticles having a high density of ligands or coupling agents, which is in the range of 1000-10,000,000, more preferably between 10,000 and 1,000,000 ligands per square micron of microparticle surface area. A general method for incorporating molecules into the surface of biocompatible polymers using materials with an HLB of less than 10, more preferably less than 5, such as fatty acids, has been developed. Because of its ease, generality and flexibility, this method has widespread utility in modifying the surface of polymeric materials for applications in drug delivery and tissue engineering, as well other fields. Targeted polymeric microparticles have also been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, bone repair or regeneration materials, and other applications where the microparticles are retained at the site of application or implantation. Another preferred application is in the use of microparticles to deliver anti-proliferative agents to the lining of blood vessels following angioplasty, transplantation or bypass surgery to prevent or decrease restenosis, and in cancer therapy. In still another application, the microparticles are used to treat or prevent macular degeneration when administered to the eye, where agents such as complement inhibitors are administered.10-29-2009
20120225117PROCESS FOR PRODUCTION OF W/O/W EMULSION, PROCESS FOR PRODUCTION OF LIPOSOME EMPLOYING THE PROCESS, AND POROUS MEMBRANE FOR USE IN THE PROCESSES - The present invention provides a liposome production process which enables production of a liposome that has a nano-size particle diameter and a high water-soluble drug encapsulation rate. The process for producing a W1/O/W2 emulsion of the present invention includes the steps of (1) emulsifying an organic solvent (O) that is a volatile organic solvent, an aqueous solvent (W1) and a mixed lipid component (F1) to give a W1/O emulsion; and (2) dispersing the W1/O emulsion produced in step (1) in an aqueous solvent (W2) by use of a porous membrane, to give a W1/O/W2 emulsion, wherein the porous membrane has been surface-treated with a hydrophilic drug so as to allow its surface to have a water contact angle of 0 to 42° in the air.09-06-2012
20120225116BIODEGRADABLE POLYPHOSPHAZENES CONTAINING PYRROLIDONE SIDE GROUPS - Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.09-06-2012
20120225115Methods and Compositions for Improved Deliver, Expression or Activity of RNA Interference Agents - The present disclosure provides methods and compositions for enhanced delivery of siRNA or miRNA, into the interior of multilayered tissues, and into the cytoplasm or nucleus of cells of a tissue. Such methods and compositions yield tumor-selective and intracellular delivery of RNAi agents and allow for RNAi-mediated activity such as knock-down of the target genes and associated products. The current disclosure further provides methods and compositions for improving the intracellular bioavailability of nucleotide agents.09-06-2012
20120225114Modifying Macrophage Phenotype for Treatment of Disease - The present invention provides compositions and methods for modulating one or more phenotypes of a macrophage-related cell, e.g., a macrophage. The invention further provides methods of treating disease by modulating macrophage phenotype. Representative phenotypes include pro-inflammatory, anti-inflammatory, immunogenic, tolerogenic, tissue-destructive, tissue restorative, cytotoxic, migratory, bone-resorbing, pro-angiogenic, anti-angiogenic, suppressor, antigen presentation, or phagocytic. Representative diseases include atherosclerosis, arthritis, and multiple sclerosis.09-06-2012
20120225113METHOD FOR TREATING TUBERCULOSIS - Disclosed is a method for treating a symptom of 09-06-2012
20100203109Methods and Compositions for Treating Melanoma08-12-2010
20130064881COMPOSITIONS AND METHODS FOR TREATING PROSTATE CANCER - Compositions and methods to interfere with Androgen Receptor (AR) action based on bifunctional shRNA, targeting the AR and/or expression of SRC derived peptides are disclosed herein.03-14-2013
20130064882Compositions and Methods for the Prevention of Cancer in High Risk Patients - This relates to the prevention of cancer initiation. More specifically, the invention provides compositions and methods useful for altering the genetic signature in breast tissue, said alteration being correlated with a reduced risk for the development of breast cancer.03-14-2013
20130164370NOVEL FORMULATION OF PEGYLATED-LIPOSOME ENCAPSULATED GLYCOPEPTIDE ANTIBIOTICS - This invention is directed to a novel method of treating an individual suffering from a bacterial infection, such as bacterial infections of various tissues or organs of an individual. In general, the method of treatment involves administering to an individual a pharmaceutical formulation that comprises a liposome-encapsulated antimicrobial agent, wherein polyethylene glycol (PEG) molecules are covalently attached to the surface of the liposomes.06-27-2013
20130164367TREATMENT OF NEURODEGENERATIVE DISEASE WITH CREB-BINDING PROTEIN - The present invention relates to improving cognition and treating of neurodegenerative disease using CREB-binding protein. The protein may be delivered to the brain by an expression vector, in particular a lentiviral vector.06-27-2013
20130064880ADMINISTRATION REGIME FOR N-HYDROXY-4-BENZAMIDE - N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I):03-14-2013
20130064879Compositions and Methods for Inhibiting Viral Replication - The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.03-14-2013
20130064883LIPID-BASED COMPOSITIONS OF ANTIINFECTIVES FOR TREATING PULMONARY INFECTIONS AND METHODS OF USE THEREOF - A system for treating or providing prophylaxis against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.03-14-2013
20080317839AMINO ACID LIPIDS AND USES THEREOF - This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.12-25-2008
20120195958Implantable devices - The present invention relates to implantable devices, which are coated or coatable with liposomes. The present invention further relates to liposomes encapsulating nucleic acids termed lipoplexes, to methods for the manufacture and coating of such implantable devices, and to the use of such implantable devices to improve treatment of patients with coronary artery disease or other vascular diseases and cancers.08-02-2012
20110020437OLIGOPEPTIDIC COMPOUNDS AND USES THEREOF - The present invention provides an oligopeptidic compound comprising a PCNA interacting motif, or a nucleic acid molecule comprising a sequence encoding said oligopeptidic compound, for use in therapy, wherein the PCNA interacting motif is X01-27-2011
20110020436TOPICAL APPLICATION OF MELATONIN DIRECTLY OR IN LIPOSOMES FOR THE AMELIORATION OF ITCHING AND HISTAMINE AND NON-HISTAMINE RELATED INFLAMMATORY SKIN CHANGES - The invention is a topical therapeutically effective amount of melatonin encapsulated in a liposome applied topically to an area of skin affected by immunologic response, radiation treatment induced dermatitis, acne, insect bite or other irritant stimulus such as sunburn in order to reduce itching. The invention also proposes a topical therapeutically effective amount of melatonin and reduced glutathione encapsulated in a liposome applied topically to an area of skin for relief of those afflictions.01-27-2011
20110020435STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF - The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of insulin or an analog thereof.01-27-2011
20110020434NANOPARTICLE ARSENIC-PLATINUM COMPOSITIONS - The present invention relates to nanoparticle encapsulated arsenic and platinum compositions and methods of use thereof. In particular, the present invention provides co-encapsulation of active forms of arsenic and platinum drugs into liposomes, and methods of using such compositions for the diagnosis and treatment of cancer.01-27-2011
20110020433COMPOSITIONS FOR DELIVERY OF CARGO SUCH AS DRUGS PROTEINS AND/OR GENETIC MATERIALS - Compositions and methods for delivery of cargo molecules to a patient or subject in need thereof include a proteoliposome carrier vehicle that incorporates an RLIP76 protein and contains the cargo molecule. The vehicle effectively delivers the cargo molecule systemically throughout the tissues of the body including into the central nervous system.01-27-2011
20110020432COMPOSITIONS AND METHODS OF USE FOR POST-RADIATION PROTECTION - The present disclosure is directed to methods of administering RL1P76 or an active fragment thereof more than 24 hours after radiation exposure, wherein administration is effective for the protection and treatment of mammals exposed to radiation. In addition, compositions are disclosed including RLIP76 and other radioprotective agents, for example antioxidants.01-27-2011
20110020431ANTITUMOR EFFECT OF MUTANT BIK - The present invention regards mutant forms of Bik that comprise anti-cell proliferation and/or pro-apoptotic activities. In particular embodiments, the Bik polypeptides comprise a substitution at Thr33 and Ser35 and, in some embodiments, phosphorylation at these sites is inhibited. In more particular embodiments, these forms are useful for cancer therapy, particularly when administered in combination with liposomes. In embodiments wherein a mutant Bik polynucleotide is administered for cancer therapy, the polynucleotide may be regulated in a tissue-specific manner.01-27-2011
20110020427Method Of Treating Malignant Solid Tumors Using Transcatheter Arterial Chemoembolization (TACE) - This invention is directed to methods of treating solid tumor cancers, particularly refractory cancers by administration of two pluralities of microparticles, one comprising drug-carrying microparticles sized to lodge at the tumor preferably in the capillary bed of the tumor and the other comprising non-drug-carrying microparticles sized to lodge in the arterial system servicing the tumor so as to embolize the tumor.01-27-2011
20090238865LIPID NANOCAPSULES, PREPARATION PROCESS AND USE AS MEDICINE - The invention concerns nanocapsules, in particular with an average size less than 50 nm, consisting of an essentially lipid core liquid or semiliquid at room temperature, coated with an essentially lipid film solid at room temperature having a thickness of 2-10 nm. The invention also concerns a method for preparing same which consists in producing a reverse phase of an aqueous emulsion brought about by several temperature raising and lowering cycles. Said lipid nanocapsules are particularly designed for producing a medicine.09-24-2009
20090238864DNA VACCINES ENCODING HEAT SHOCK PROTEINS - The present invention is related to a method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 60 (HSP60), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences, and wherein the disease is other than insulin dependent diabetes mellitus (IDDM), thereby treating the disease.09-24-2009
20090238863LIPOSOME COMPOSITION FOR INDUCTION OF IMMUNITY - It is an object of the present invention to provide a liposome composition which is able to allow the MHC class I and class II molecules of antigen-presenting cells to efficiently present an antigen substance. The present invention provides a liposome composition, which comprises an oligosaccharide-coated liposome and an antigen substance and is used to cause the MHC class I and class II molecules of an antigen-presenting cell to present an antigen peptide.09-24-2009
20090232883METHOD OF SEPARATING VESICLE, PROCESS FOR PRODUCING MEDICINAL PREPARATION, AND METHOD OF EVALUATION - A method of separating vesicles whose membrane has been modified with a hydrophilic polymer (polyethylene glycol, etc.). In the method, vesicles (liposome, etc.) differing in the degree of membrane modification are separated by ion-exchange chromatography using a concentration gradient in which the ionic intensity of an eluent is changed with time. Also provided are: a process for producing vesicles purified so as to have a desired degree of modification with a hydrophilic polymer which comprises utilizing the separation method in the step of purifying vesicles; a method of evaluating a medicinal vesicle preparation containing a drug therein, the method comprising using the separation method; and vesicles in which the membrane has been modified with a hydrophilic polymer and which include no vesicle having a degree of membrane modification less than 0.5 mol %.09-17-2009
20090232880Analogue Compounds Of Archaebacterial Membrane Lipids And Liposomal Compounds Integrating Such Compounds - The invention relates to a compound of general formula (I): where =0 or 1, Z=O, S or CH09-17-2009
20090232881Enhanced Delivery of Skin Benefit Agents - Pro-vesicles for enhanced delivery of skin benefit agents through formation of vesicular phases in the presence of water in topically applied cosmetic products, said pro-vesicles comprising: (i) the benefit agent to be delivered; (ii) a phospholipid; (iii) a mono-, di- or tri-ester of glycerol; (iv) a straight or branched chain propyl or butyl ester of C09-17-2009
20090232882PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER - Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.09-17-2009
20090148505Novel Antiproliferative Factor and Methods of Use - A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.06-11-2009
20090047340LIPOSOMAL REDUCED GLUTATHIONE AND 1-ARGININE, INCLUDING WITH OTHER INGREDIENT(S), CAPABLE OF MULTIPATH ADMINISTRATION FOR REVERSAL AND PREVENTION OF OBESITY AND FOR MITOCHONDRIAL BIOGENESIS - The invention enables management of mammalian disease related to decreased energy production in the mitochondria, the powerhouse of the cell. The invention uses the combination of liposomal reduced glutathione and l-arginine to increase the ability weight loss in individuals with excess weight. The mechanism of weight loss appears to be related to improving the inefficient production of energy by the respiratory transport chain of mitochondria, the function of which are influenced positively by the availability of antioxidant nitric oxide in a non-oxidized environment. This invention enables weight loss in individuals who's inability to lose weight is related to inefficiency of the biochemical pathways facilitating mitochondrial function and energy production. The pathways related to inability to lose weight are also related to the phenomenon of the inability to metabolize fats, which results in insulin resistance and diabetes. The invention is useful for the management of the metabolic syndrome. The metabolic syndrome is actually a group of metabolic factors associated with an increased risk of vascular disease problems. The invention is also useful for the resolution of fatigue that accompanies both weight gain and illnesses. The ability of the invention to increase the production of the biochemical agmatine in the central nervous system as well generally in the body is part of the benefit of the combination of liposomal reduced glutathione and l-arginine. In addition, the biochemical pathways stimulated by this invention can have a beneficial effect in individuals suffering from a variety of infectious diseases.02-19-2009
20090047339Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof - The present invention relates to polynucleotides encoding immunogenic HIV type C Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Gag- and/or Env-containing proteins are also described.02-19-2009
20090092662LIPOSOME FORMULATIONS OF BORONIC ACID COMPOUNDS - A liposome composition comprised of liposomes having a peptide boronic acid proteasome inhibitor compound entrapped in the liposomes is described. More specifically, liposomes having a compound of Formula I or II entrapped in the interior aqueous compartment are loaded with a peptide boronic acid compound, to form a boronate ester compound inside the liposomal aqueous compartment. In one embodiment, the liposomes have an outer coating of hydrophilic polymer chains and are used to treat a solid tumor in a subject.04-09-2009
20100008976Medical Use of N-Phenylpropenoyl-Amino Acid Derivatives and Related Compounds - The invention relates to compounds having the general structural formula (formula I) for use in a diagnostic method or a method for treatment of the human or animal body by surgery or therapy.01-14-2010
20130164364LIPOSOME TARGETING COMPOUNDS AND RELATED USES - The present invention provides liposome targeting compounds for targeting cells expressing sialic acid binding Ig-like lectin (Siglec). The liposome compounds typically comprise a binding moiety that is a glycan ligand of the Siglec on the target cell. The liposome compounds also incorporate or encapsulate a biological agent (e.g., an antigen or a therapeutic agent) that can be delivered to the target cell to modulate or kill the target cell. The invention also provides methods of using the liposome targeting compounds for targeted delivery of antigen and for modulating immune cells or immune responses.06-27-2013
20120114746Immunostimulatory Compositions Comprising Liposome-Encapsulated Oligonucleotides and Epitopes - The present invention relates to a composition for enhancing an immune response, an epitope having immunogenicity, screening and preparing method thereof, a antibody to peptide antigen and screening and preparing method thereof. The composition of the present invention may be effectively used for preventing or treating diverse immune-deficiency diseases such as cancer, influenza virus, hepatitis C virus and RSV (respiratory syncytial virus) by enhancing immune responses.05-10-2012
20120114745METHOD FOR TREATING OR AMELIORATING MUCOCUTANEOUS OR OCULAR TOXICITIES - A method for treating or ameliorating mucocutaneous, ocular toxicities, or side effects induced by blocking cellular growth and survival signal transduction pathways. The method comprises administering to a subject in need thereof an effective amount of a histone deacetylase inhibitor and a pharmaceutically acceptable carrier, salt or solvate thereof, wherein the cell growth and survival signal transduction pathways are blocked by an antibody targeted therapy agent, antibody fragment, targeted small-molecule chemical compound, low-molecular-weight tyrosine kinase inhibitor, peptide mimetic, anti-sense oligonucleotide (DNA and/or RNA), or ribozyme.05-10-2012
20120114744COMPOSITIONS AND METHODS TO TREAT MUSCULAR & CARDIOVASCULAR DISORDERS - The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2.05-10-2012
20120114743TRANSDERMAL RICINOLEIC ACID COMPOSITIONS - Transdermal compositions containing castor oil are described. The compositions comprise ricinoleic acid and a transdermal vehicle with optional additional agents. One optional additional agent is an adrenergic drug which may cause the ricinoleic acid to penetrate the skin more deeply and have a longer lasting effect. The compositions can be used for treating a variety of ailments traditionally treated with castor oil or castor oil packs, without the mess and inconvenience of using castor oil packs.05-10-2012
20120114742Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof - Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.05-10-2012
20120114741TOPICAL THERAPY FOR THE TREATMENT OF MIGRANES, MUSCLE SPRAINS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS - The invention is directed to topical formulations and methods of treating a migraines and/or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations thereof, pharmaceutically acceptable salt thereof, prodrugs thereof or derivative thereof.05-10-2012
20120114740SUSTAINED RELEASE FORMULATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG - Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.05-10-2012
20120114739PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS - The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.05-10-2012
20090028931Liposomal compositions for parenteral delivery of agents - The invention provides methods and compositions for loading an agent, such as econazole, onto a liposome for parental delivery. The loading of the agent into a liposome comprises combining the agent with a micelle-forming compound to form a micelle including the agent, where the agent is releasable from the micelle-forming compound, and adding the micelle to the liposome, where the micelle combines with the liposome such that the agent is loaded into the liposome to form a loaded liposome. The methods are suitable for the loading of poorly soluble agents onto liposome.01-29-2009
20090011005Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions - Pharmaceutical compositions containing nanomaterials useful for treating restenotic lesions, which comprise nanomaterials containing one or more antiproliferative agents for treatment of intra-stent restenotic lesions by means of a local infusion, providing the increase in adhesion, penetration, and diffusion of the nanomaterials that contain the antiproliferative active agent in the tissue responsible for the neointimal hyperplasia, are described.01-08-2009
20090011003Composition for Suppressing Expression of Target Gene - The present invention has its object to provide a composition for suppressing the expression of a target gene and the like, and provides a composition, comprising an RNA-encapsulated liposome which comprises complex particles comprising as constituent components a lead particle and an RNA comprising a sequence consisting of 15 to 30 contiguous nucleotides of a target gene mRNA and a sequence complementary to the sequence, and a lipid membrane for coating the complex particles, wherein constituent components of the lipid membrane can be solved in a polar organic solvent, and wherein the polar organic solvent can be contained in a liquid at such a concentration that the constituent components of the lipid membrane are dispersible and the complex particles are dispersible, and the like.01-08-2009
20090011001Manufacturing process for liposomal preparations - The present invention provides a manufacturing process for liposomal preparations comprising water-insoluble or hydrophobic active principals. In accordance with one aspect of the inventive method, at least one active principal and lipid fraction are dissolved in an organic solvent. This solution is then subjected to reduced pressure (vacuum) in a container with or with out inert packing to remove the organic solvent, thereby forming a puffy cake comprising the active principal or principals and lipid fraction. This puffy cake is then mixed with an aqueous solution, under controlled conditions suitable to form a bulk liposomal preparation. Because the active principal is imbedded in the lipid bilayer, removal of the aqueous solution is optional.01-08-2009
20090011000Inhibitors of Infection - Fusion inhibitor peptides are provided comprising a sequence derived from an HR2 domain. In preferred embodiments, the peptides are capable of oligomerization. Also provided are nucleic acids encoding the peptides, vectors comprising the nucleic acids and host cells transformed with the vectors. The peptides may be used as medicaments. Also provided are methods for expressing a protein comprising one or more transmembrane domain(s) in an expression system. The methods comprise fusing a sequence encoding an 18-mer peptide, or a functional equivalent thereof, to a gene encoding the protein and expressing the resultant gene-fusion product in an expression system.01-08-2009
20090004260MEDICAMENT COMPRISING HGF GENE - The present invention relates to a method for treating insufficiency of peripheral circulation or peripheral angiostenosis in a subject for which HGF is effective, comprising administering to the area affected by the insufficiency of peripheral circulation or peripheral angiostenosis a therapeutically effective amount of an expression vector containing a constitutive promoter operably linked to a HGF coding sequence, whereby the HGF is expressed, promoting the growth of vascular endothelial cells but not vascular smooth muscle cells.01-01-2009
20080299184Anticancer agent - It is an object of the present invention to provide a cancer-suppressing agent comprising a novel cancer-suppressing gene based on the discovery of such cancer-suppressing gene. The present invention provides A cancer-suppressing agent which comprises PCDH20 gene or a homologous gene thereof.12-04-2008
20120237591MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES - Drug derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drug derivatized with a weak-base moiety that facilitates active loading of the drug through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drug to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drug derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drugs.09-20-2012
20120237590CURCUMIN COMBINATION WITH ANTI-TYPE 2 DIABETIC DRUGS FOR PREVENTION AND TREATMENT OF DISEASE SEQUELAE, DRUG-RELATED ADVERSE REACTIONS, AND IMPROVED GLYCEMIC CONTROL - Compositions and methods for treating type 2 diabetes and its sequelae by intravenous or subcutaneous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly one or more anti-diabetic agents to human subjects are disclosed herein. The composition of the present invention may be used to: (i) treat patients with diabetes in advanced stages with evidence of any or all encephalopathy, retinopathy, nephropathy, pancreatitis or neoplasias; (ii) treat patients with diabetic disease status without symptomatic or pathologic evidence of associated sequelae but requiring better glycemic control than that offered by standard of care anti-diabetic; and (iii) patients with objective signs or symptoms of sequelae from diabetes of anti-diabetic drugs. One three-drug combination of the present invention includes a slow release PLGA-curcumin and an oral gliptin (DPP-4)-inhibitor or any incretin-mimetic and metformin.09-20-2012
20120237589AMPHOTERIC LIPOSOMES COMPRISING IMINO LIPIDS - The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are imino moieties that are essentially charged under physiological conditions, and their use for serum resistant transfection of cells.09-20-2012
20120237588METHODS OF IMPROVING CARDIAC FUNCTION AND ATTENUATING AND/OR PREVENTING CARDIAC REMODELING WITH HSP20 - Methods of improving cardiac function and/or methods for attenuating and/or prevention cardiac remodeling in an individual's heart comprising administering to an individual an effective amount of Heat-Shock Protein Hsp20 or an agent that increase the levels of and/or the activity of Hsp20 are provided.09-20-2012
20120237587COMBINATION PREPARATION INCLUDING A CORTICOSTEROID AND EXOSOMES - The present invention relates to pharmaceutical compositions for a combination therapy with a corticosteroid and exosomes. By means of the combination therapy diseases such as osteoarthritis, arthritis and/or degenerative spinal diseases can be treated.09-20-2012
20120269882Brain Delivery of Insulin to Treat Systemic Inflammation - Methods and composition for the treatment of systemic inflammation, such as bacterial or viral sepsis, are described. Methods of treating systemic inflammation comprise delivery of insulin to the brain, for example by intracranial or intranasal administration. Insulin delivery systems and brain-targeted insulin compositions and polypeptides are also provided.10-25-2012
20080241233TARGETED DELIVERY AND EXPRESSION OF PROCOAGULANT HEMOSTATIC ACTIVITY - A platelet substitute consisting of large unilamellar lipid vesicles that contain phosphatidylserine or another procoagulant (clot-promoting) phospholipid, a protein that has binding affinity for collagen or other component of the vessel wall that becomes exposed upon vessel injury, and/or a phospholipid scramblase, has been developed. This platelet substitute provides a means for selectively delivering procoagulant phospholipids and/or fatty acids to the site of vessel injury through targeted adherence to collagen or other component exposed upon vessel injury. These are particularly effective due to the combination of targeting procoagulant vesicles to a site of injury, and triggered exposure of phosphatidylserine (PS) on the surface.10-02-2008
20110033523USE OF MICROVESICLES (MVS) DERIVED FROM STEM CELLS FOR PREPARING A MEDICAMENT FOR ENDO/EPITHELLAL REGENERATION OF DAMAGED OR INJURED TISSUES OR ORGANS, AND RELATED IN VITRO AND IN VIVO METHODS - The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD1 33+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).02-10-2011
20090155344PREPARATION AND APPLICATION OF BIODEGRADABLE-MATERIAL-MADE MICROSPHERE VASCULAR EMBOLUS CONTAINING LIPOSOME-ENCAPSULATED CYTOKINES - The present invention discloses preparation and application of a kind of biodegradable-material-made microsphere vascular embolus that contains liposome-encapsulated cytokines. The present invention is technologically characterized by encapsulation of liposome-wrapped immunocytokines such as IL-2, TNF and interferon by sodium polysaccharide or gelatin, which is extracted from natural alga and is good at biodegradability and biocompatibility. Owing to the encapsulation procedures, cytokine microspheres can take shape measuring 50-75 μm, 75-150 μm, 100-200 μm, 200-300 μm, 200-450 μm, 100-300 μm, 300-500 μm, 500-700 μm, and 700-900 μm. The microsphere preparations are good targeting medication for embolism treatment and immunochemotherapy of animals loaded with human hepatocarcinoma and cervical cancer, as well as human suffering from late-stage or recurrent liver cancer, renal tumors, bladder cancer, colon carcinoma and rectal cancer.06-18-2009
20080226707WNT compositions and methods of use thereof - Methods and compositions are provided for the therapeutic use of Wnt proteins, where the Wnt protein is inserted in the non-aqueous phase of a lipid structure. In some embodiments the Wnt protein is presented in its active conformation on an outer liposome membrane or micelle. Pharmaceutical compositions of the present invention can be administered to an animal for therapeutic purposes. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain conditions it is desirable to provide Wnt activity for short periods of time, and an effective dose will be administered over a defined, short period of time.09-18-2008
20110250259Method of treating and preventing breast diseases and breast cancer with medicated formula - Breast cancer is a common cancer in women. Early diagnosis and treatments are vital for better outcomes. This formula consists of a liquid anti-disease anti-cancer formula that can be delivered to the source where breast cancer begins.10-13-2011
20110117184Compositions for mucosal delivery of agents - Compositions and methods for mucosal delivery of agents are provided. The compositions are intended for administration to mucosal surface, such as oral, gastrointestinal and nasal mucosa. The compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.05-19-2011
20110064793INHIBITORS OF HIV REPLICATION AND METHOD OF TREATMENT OF HIV INFECTIONS - The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.03-17-2011
20090053297COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN-LIPID COMPLEXES - The present invention provides compositions and methods for reducing the immunogenicity and increasing the circulating half-life of therapeutic proteins such as Factor VIII. The compositions comprise lipidic structures such as liposomes, micelles and cochleates comprising a negatively charged lipid and polyethylene glycol derivatized phosphatidyl ethanolamine.02-26-2009
20110129527RAB3B FOR THE TREATMENT AND PREVENTION OF PARKINSON'S DISEASE - The invention features methods and compositions for the treatment and prevention of Parkinson's Disease.06-02-2011
20130164369TELODENDRIMER NANODISCS WITHOUT APOLIPOPROTEIN - The present invention provides a nanodisc without a membrane scaffold protein. The nanodisc includes a telodendrimer and a lipid; the nanodisc does not include a membrane scaffold protein. The telodendrimer has the general formula PEG-L-D-(R)06-27-2013
20130164368HEPAROSAN POLYMERS AND METHODS OF MAKING AND USING SAME FOR THE ENHANCEMENT OF THERAPEUTICS - Compositions, methods, and systems are disclosed for the development and use of heparosan, a natural polymer related to heparin, as a new therapeutic modifying agent or vehicle which can modulate drug cargo pharmacokinetics and behavior within a mammalian patient.06-27-2013
20100233251Vaccine Nanotechnology - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at least one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.09-16-2010
20090104256Methods of Treating Pulmonary Disorders with Liposomal Amikacin Formulations - Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period.04-23-2009
20100310637COMPOSITION AND METHOD FOR THE TREATMENT OR PREVENTION OF GLAUCOMA AND OCULAR HYPERTENSION - This invention relates to compositions and methods for lowering intraocular pressure and treatment and/or prevention of glaucoma and ocular hypertension. The invention provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin peptide and other products of protein/gene engineered modifications of insulin for the lowering of intraocular pressure. The invention also provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin and other products of protein/gene engineered modifications of insulin for increasing the success of glaucoma surgical procedures. The invention further provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin and other products of protein/gene engineered modifications of insulin for neuroprotection of retinal ganglion cells.12-09-2010
20100158993Topical Gel Compositions - Topical alcoholic gel compositions are disclosed that are useful for delivering therapeutic levels of an NSAID to target in and below the skin. The compositions comprise a topically active drug, an alcoholic solvent, a polymeric thickener, and optionally a keratolytic agent. In one embodiment, excellent viscosity for dermal application is attained without the need of a step for neutralizing the pH of the composition. Alcoholic and alcohol-free topical compositions comprising an NSAID prodrug are also disclosed. The compositions are particularly useful for the treatment of pseudofolliculitis barbae.06-24-2010
20110142917COMPOSITIONS AND METHODS FOR TREATMENT OF EAR DISORDERS - The present invention relates to pharmaceutical compositions useful for topical, non-invasive delivery of an oligonucleotide to the ear and to methods for the treatment of an ear disorder, including hearing loss arising from chemical-induced ototoxicity, acoustic trauma and presbycusis; and microbial infections. The method comprises topically administering to the ear of a subject in need thereof a pharmaceutical composition comprising an inhibitory oligonucleotide, a permeability enhancer and a pharmaceutically acceptable carrier, wherein the oligonucleotide reduces or inhibits expression of a gene associated with the ear disorder in the subject.06-16-2011
20110142923OPHTHALMIC PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEOANGIOGENIC PATHOLOGIES OF THE EYE - The present invention relates to ophthalmic pharmaceutical compositions comprising Sorafenib, its derivatives or active metabolites, for the treatment and prevention of ocular neoangiogenic pathologies.06-16-2011
20110142919Cytotoxic T-Lymphocyte-Inducing Immunogens for Prevention, Treatment and Diagnosis of Cancer - The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as ovarian carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against cancer.06-16-2011
20110142918ANTI-ANGIOGENIC COMPOSITIONS AND THERAPEUTIC APPLICATIONS THEREOF - There is described the use of the Human herpesvirus type 6 (HHV-6) U94 gene and its product, the protein Rep, expression vectors and pharmaceutical compositions suitable for the delivery of the U94 gene or the protein encoded therefrom to the therapeutic sites, to inhibit angiogenic and lymphangiogenic processes in a subject in need thereof.06-16-2011
20110142911HIV epitopes and pharmaceutical composition containing same - The invention concerns a peptide comprising an epitope consisting of a sequence of amino acids selected among SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, and having a length not more than 24 amino acids.06-16-2011
201001897735-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.07-29-2010
20110280933EPICATECHIN COMPOSITIONS AND METHODS - Provided herein are methods and compositions for treating a subject who has pulmonary damage or an injury caused by or who is at risk for an injury caused by an anti-vesicant agent. The compositions comprise cacao extracts that include a mixture of epicatechin and one or more epicatechin oligomers and a pharmaceutically acceptable carrier. Also provided are methods for fermenting cacao to enhance epicatechin and antioxidant content.11-17-2011
20110280934Increased Expression of Specific Antigens - The response of immunotherapy in the treatment of cancer is enhanced by use of an oligonucleotide in a dose effective to induce at least one of endogenous production of cytokines, and the regulation of the expression of one or more of the cell surface antigens (FIG. 11-17-2011
20110280935VIRAL AND NON-VIRAL VECTORS AS VEHICLES FOR DELIVERING TRANSGENES FOR TREATING BONE PATHOLOGIES - The present invention relates to a method for treating bone pathologies comprising delivering a viral or non-viral delivery vehicle comprising genetic information (e.g. a transgene) encoding a therapeutic osteoinductive factor to target cells in vivo enabling the cells to produce the osteoinductive factor at the site of the bone pathology. The delivery is achieved by a simplified method which does not require cumbersome ex vivo techniques or additional matrix or scaffolding agents. Such viral and non-viral delivery vehicles of the present invention are derived from the following nonlimiting examples: adenoviruses, adeno-associated viruses, retroviruses, herpes simplex viruses, liposomes, and plasmids. The osteoinductive factors include, but are not limited to, growth factors, cytokines, growth factor inhibitors and cytokine inhibitors.11-17-2011
20110280932SUSTAINED RELEASE FORMULATION OF METHOTREXATE AS A DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD) AND AN ANTI-CANCER AGENT - Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a C11-17-2011
20110280931MATRIX METALLOPROTEINASE INHIBITOR - Compounds of FIG. 11-17-2011
20110280930PRODUCTS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE - The present invention provides products which comprise (i) a support and (ii) a BCR-binding antigen attached to the support. The products are capable of BCR-mediated internalization. The products are useful in the induction or augmentation of immune responses, and methods and uses of the products are provided. The present invention also provides methods of delivering an agent preferentially to dendritic cells versus B cells in a population of cells comprising both dendritic and B cells, which methods comprise (i) attaching the agent to a support and (ii) contacting the population of cells with the agent attached to the support, wherein the population of cells comprise B cells and dendritic cells.11-17-2011
20110117180VEGETARIAN MICROCAPSULES - Disclosed are microcapsules with shells that are not animal by-products and methods for preparing and using such microcapsules.05-19-2011
20090117177Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents - Described are methods and compositions for treating tumors, such as drug-sensitive tumors, inoperable tumors, poorly vascularized tumors, and multidrug resistant tumors, by intravenous or direct intratumoral injection of compositions comprising microemulsions and polymeric micelle-encapsulated biologically active agents. The methods and compositions also include microemulsions converting into microbubbles in situ upon injection. The methods disclosed optionally including applying a micelle disruption method such as ultrasound. Also disclosed are methodologies of imaging administration of agents in tissues using streams of microemulsions which create microbubbles in situ upon injection. The methods and compositions also include enhancement of tumor treatment through use of microemulsions which create microbubbles in situ, upon injection, as cavitation nuclei. The methods and compositions are also useful in enhancing intracellular drug delivery.05-07-2009
20110070296TOPICAL COMPOSITIONS AND METHODS FOR UTILIZING PEPTIDES CONTAINING LIPID-MODIFIED CYSTEINE-CONTAINING PEPTIDES - Described are compositions for topical application to keratinous tissues or substrates such as skin, or mucosal surfaces. The composition may be used to treat a skin condition or disease. The composition comprises at least one polypeptide and/or lipidated peptide and a carrier.03-24-2011
20100330155METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA - The present invention relates to chemically modified, linked double-stranded (ds)RNA compositions comprising two or more double-stranded (ds) oligoribonucleotides linked by at least one linking moiety and methods of formulating and delivering such compositions to modulate gene expression through target-specific RNA co-interference (RNAco-i). The compositions of the invention may optionally comprise a conjugation or a complex with one or more small molecule drugs, protein therapeutics, or other dsRNA molecules. The present invention is directed at the methods of production for, methods of use of, and therapeutic utilities for RNAi co-interference therapy utilizing the compositions of the invention.12-30-2010
20090148507Chimeric polypeptides containing chemokine domains - This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof.06-11-2009
20100172963MEDICINAL AGENT FOR TREATING PATIENTS SUFFERING FROM DISEASES CAUSED BY THE MONOAMINOOXIDASE EXCESSIVE ACTIVITY AND A METHOD FOR TREATING PATIENTS SUFFERING - The invention relates to the chemical and pharmaceutical industry and to medicine, in particular, to medicinal agents based on a mixture of natural oligomers of isoprenol (Ropren), which inhibits monoamine oxidase (MAO) activity; and to a method for treatment of patients suffering from diseases associated with the excessive activity of monoamine oxidase.07-08-2010
20110081409SELECTIVE INHIBITORS OF HISTONE DEACETYLASE - Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.04-07-2011
20100330156PHENAZINE DERIVATIVES AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.12-30-2010
20100291192Detoxification method for lipopolysaccharide (LPS) or lipid A of gram-negative bacteria - The invention relates to a method of detoxifying a lipopolysaccharide (LPS) or a lipid A from a Gram-negative bacterium, which comprises mixing the LPS or the lipid A with a cationic lipid so as to form a complex in which the LPS or the lipid A is associated with the cationic lipid. According to the conventional preparation modes, the cationic lipid with the co-lipid, if this latter is present, get(s) structured into complexes i.a. liposomes. When preparing lipidic complexes, the addition of LPS or Lipid A leads to an association of this latter with the cationic lipid and as a result, the LPS or lipid A is substantially detoxified. The LPS or lipid A detoxified by the complexes, e.g. when incorporated into liposomes, can be used as vaccinal antigen or as adjuvant.11-18-2010
20090169610Liposome Preparation - The present invention provides cancer treatment preparations of excellent targetability. The sugar chain-modified liposomes of the present invention, which contain an aromatase inhibitor, anti-androgenic agent, lyase inhibitor, GnRH agonist, GnRH antagonist, anti-angiogenic agent, tyrosine kinase inhibitor, serine-threonine kinase inhibitor, antibody having an anticancer activity, ansamitocin, capecitabine, celmoleukin, docetaxel hydrate, gemcitabine hydrochloride, oxaliplatin, prednisolone, tegafur-uracil mixtures, zinostatin stimalamer or arsenic trioxide may be used as cancer treatment preparations having an excellent targetability.07-02-2009
20100266680Treatment of Cancer Using TLR3 Agonists - The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells.10-21-2010
20100266678CHOLESTEROL LEVEL LOWERING LIPOSOMES - Provided are methods of reducing cellular cholesterol levels using lipid particles that are capable of cellular entry. Such lipid particles may be used for treating or preventing a disease or condition that is caused by or associated with an increased cellular cholesterol level and for treating or preventing a disease or condition, that is caused by or associated with a virus, that relies on cellular cholesterol for its replication.10-21-2010
20110081403HISTONE OCTAMERS FOR INCREASED NUCLEIC ACID TRANSFER - The present invention provides reconstituted histone octamers with multiple modifications (e.g. acetylation of all histones and trimethylation of histone H3K4) assembled onto plasmids for increased transcription post-transfection using our unique bi-lamellar invaginated liposomes (BIVs) to more effectively recruit the transcriptional machinery of human cancer cells post-transfection and substantially increase the production of therapeutic gene products.04-07-2011
20100266673COMPOSITIONS AND METHODS FOR THE DELIVERY OF NITRIC OXIDE - H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or 010-21-2010
20100266674L-ODDC PRODRUGS FOR CANCER - The main drawback in the use of most nucleoside anticancer agents originates from their hydrophilic nature, of which property requires a high and frequent dosage for an intravenous administration. Unlike other nucleoside anti-tumor agents, troxacitabine appears to predominantly enter tumor cells by passive diffusion rather then by using nucleoside transporters, although this may be model dependent. Accordingly, in the present work, a small library of twenty troxacitabine prodrugs has been synthesized using a parallel approach in order to evaluate the relationship between the lipophilicity of the prodrugs and their antitumor activity. Biological evaluation of the prodrugs on two non-small cell lung cancer cell lines (A549 and SW1573) and in pancreatic cell lines clearly showed better antitumor activity than that of troxacitabine, with IC10-21-2010
20100266672VACCINES - The present invention provides a vaccine composition comprising the B subunit of Shiga toxin or an immunologically functional equivalent thereof which is able to bind the Gb3 receptor, complexed with at least one first antigen, and further comprising at least one second antigen (which may be the same or different as the first antigen) and an adjuvant.10-21-2010
20090324703Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders - Curcuminoid formulations having enhanced bioavailability are provided and comprise a curcuminoid, antioxidant, glucuronidation inhibitor, and water-soluble, pharmaceutically acceptable inhibitor. A method of treating Alzheimer's and other age-related diseases by administering such a composition is also provided.12-31-2009
20100239655TAURINE-BASED COMPOSITIONS AND THERAPEUTIC METHODS - Taurine and derivatives thereof may be used in conjunction with agents that activate or up-regulate the Taurine Transporter so as to enhance hydration of the skin and repair the skin bather, prevent apoptosis and oxidative damage in the skin, and heal or prevent photo-induced skin damage. The presence of biogenic taurine or taurine derivatives in tissues and/or body fluids can be used as a biomarker for tissue trauma. Detection and/or quantification of such biogenic taurine or derivatives form the basis for an assay for determining the presence and/or extent of tissue damage.09-23-2010
20110091527COMPOSITIONS AND METHODS FOR REDUCING SCAR FORMATION IN WOUND HEALING - The invention pertains to a method of reducing scar formation during wound healing by administering a phosphatidylserine-binding compound, in particular an annexin, to a subject in need thereof. The healing wound may be a skin damage, but it may also be a myocardium e.g. which is at risk of suffering or is recovering from a heart failure.04-21-2011
20100003317COMPOSITIONS AND METHODS FOR MEDIATING RNAI IN VIVO - This invention relates to new formulated lipid particles (FLiPs) comprising at least one of a single or double stranded oligonucleotide, where the oligonucleotide has been conjugated to a lipophile and at least one of an emulsion or liposome to which the conjugated oligonucleotide has been aggregated, admixed or associated. These particles have surprisingly been shown to effectively deliver oligonucleotides to heart, lung and muscle where they effect gene silencing.01-07-2010
20110300206VACCINES AGAINST CHLAMYDIAL INFECTION - The present invention relates to compositions comprising proteins or polynucleotides of 12-08-2011
20110091526Parasite Vaccine - Compositions and methods for the development and use of a vaccine that includes one or more FusM antigens in a carrier adapted to trigger a FusM-specific immune response in the human blood stream are disclosed herein.04-21-2011
20110081405Zeolite Formulation And Use Thereof For The Prevention And Therapy Of Diseases Caused By Infections With Herpes Simplex Virus Type 1 And Type 2 - Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2.04-07-2011
20130022666METHODS AND COMPOSITIONS FOR TRANSFER OF MITOCHONDRIA INTO MAMMALIAN CELLS - Disclosed are compositions comprising a lipid carrier and a mitochondria. Also disclosed are methods of delivering exogenous mitochondria to a cell and methods of treating or reversing progression of a disorder associated mitochondrial dysfunction in a mammalian subject in need thereof01-24-2013
20130022665CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS - Here described are compounds of formula I:01-24-2013
20110318409FRACTIONS OF WHEAT GERM FERMENT - The invention concerns wheat germ ferment, its biologically active fractions, the process for their production, the pharmaceutical preparations containing them and their uses.12-29-2011
20120003301TISSUE MARKINGS AND METHODS FOR REVERSIBLY MARKING TISSUE EMPLOYING THE SAME - Provided are methods of applying a tissue marking to a tissue and rendering said tissue marking colorless when desired, comprising implanting into the tissue an amount of the tissue marking in sufficient quantity to form a detectable marking, said tissue marking comprising at least one colored compound comprising a thermally activatable fragmentation group and at least one infrared absorbing compound, wherein the at least one colored compound is capable of being rendered colorless by unimolecular fragmentation of the thermally activatable fragmentation group when the tissue marking is non-imagewise exposed by a source of infrared radiation and applying sufficient infrared radiation to a sufficient amount of the tissue marking to render the tissue marking colorless when desired.01-05-2012
20120156281Meningococcal Vaccine Based on Lipooligosaccharide (LOS) and Neisseria Meningitidis Protein - The invention relates to a vaccine against 06-21-2012
20110300205SELF REPLICATING RNA MOLECULES AND USES THEREOF - This application discloses self-replicating RNA molecules that contain modified nucleotides, compositions that contain the self-replicating RNA molecules, and methods for using the self-replicating RNA molecules, for example, to raise an immune response.12-08-2011
20100021533NUTRITIONAL SUPPLEMENT FOR THE PREVENTION OF CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE, DIABETES, AND REGULATION AND REDUCTION OF BLOOD SUGAR AND INSULIN RESISTANCE - A synergistic mixture (which may be utilized as a food or a drink or a supplement or a drug or a cosmetic or a hygienic product) that is formulated and is capable of improving a person's well being, lowering the risks of cardiovascular and/or Alzheimer's diseases and/or lowering blood sugar using natural and synthetic ingredients. Numerous ratios may be formulated for aroma, color, flavor, flow (viscosity), taste and uniformity. Moreover, ingredients for sugar substitutes, natural preservatives, nano-dispersion, nano-emulsion, nano-encapsulation of ingredients and apparatus for personalized nutrition are also described herein.01-28-2010
20110274746Therapeutic Liposomes and Methods For Producing and Using the Same - The present invention provides therapeutic liposomes and methods for producing and using the same. In particular, therapeutic liposomes of the invention comprise phospholipids comprising C11-10-2011
20100239656EGFR/NEDD9/TGF-BETA INTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS - Compositions and methods for the treatment and diagnosis of cancer are disclosed.09-23-2010
20100189774FORMATION OF PROTEOLIPOSOMES CONTAINING MEMBRANE PROTEINS BY MEANS OF AN ACELLULAR PROTEIN SYNTHESIS SYSTEM - This invention concerns a process for obtaining proteoliposomes containing membrane proteins. This process is characterized by lipid vesicles being incubated in the reaction medium of an in vitro cell-free protein transcription/translation system.07-29-2010
20090202622VIROSOME-LIKE VESICLES COMPRISING GP41-DERIVED ANTIGENS - The present invention relates to a virosome-like vesicle comprising at least a gp41-derived antigen or an analogue thereof, said gp41-derived antigen being located to the external surface of and/or encapsulated inside said vesicle and being in a convenient configuration for conferring said virosome-like vesicle with an ability to induce an immune response against a gp41 protein or a human immunodeficiency virus (HIV).08-13-2009
20110287088MODULATION OF OLFML-3 MEDIATED ANGIOGENESIS - The present invention relates to nucleic acids and antibodies against Olfml-3 and Olfml-3 protein function in angiogenesis. Angiogenesis-related conditions, such as cancer or wound healing, can be treated by the composition comprising the Olfml-3 antagonists or agonists, respectively.11-24-2011
20110287090Compositions and Methods for Inhibiting Expression of a Mutant Gene - The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a second strand of the dsRNA complementary or substantially complementary to the first strand. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.11-24-2011
20110287086Regeneration of Pancreatic Islets and Reversal of Diabetes by Islet Transcription Factor Genes Delivered in Vivo - The present invention includes compositions and methods for regenerating glucose-responsive cells by ultrasound-targeted microbubble destruction in the pancreas, wherein the composition comprises a pre-assembled liposome-nucleic acid complex in contact with in and about a microbubble, wherein the pre-assembled liposome-nucleic acid complex comprises a NeuroD gene under the control of the promoter, wherein disruption of the microbubble in the pancreas at a target site delivers the nucleic acid into pancreas cells at the location of the ultrasound disruption, wherein cells that incorporate the nucleic acid express insulin in response to high blood glucose levels.11-24-2011
20110287084METHOD FOR REDUCING BODY FAT AND INCREASING LEAN BODY MASS BY REDUCING STEAROYL-COA DESATURASE 1 ACTIVITY - It is disclosed here that inhibiting the activity of the enzyme stearoyl-CoA desaturase (SCD1) in an animal causes the animal to have less body fat and greater lean body mass. The lower of SCD1 activity level can be accomplished by inhibiting activity of the enzyme or lowering levels of active enzyme in the subject.11-24-2011
20110287085LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER - The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.11-24-2011
20090280163High-Efficiency Fusogenic Vesicles, Methods of Producing Them, and Pharmaceutical Compositions Containing Them - The present invention relates to novel fusogenic vesicles as highly efficient and versatile encapsulation systems for delivering a substance of choice, such as nucleic acids, proteins, peptides, antigens, pharmaceutical drugs and cosmetic agents to cells and tissues.11-12-2009
20110097393Skin Patches and Sustained-Release Formulations Comprising Lofexidine for Transdermal and Oral Delivery - This invention relates to a sustained release oral and transdermal pharmaceutical formulations and delivery systems comprising lofexidine. The invention is also directed to methods of treatment comprising administering lofexidine in a sustained release manner. Such methods can involve administration of the lofexidine containing compositions described herein. Compositions of lofexidine formulated for sustained release delivery are provided. Also provided are methods for the treatment of opiate addicts, migraine, neuropathic pain, and other therapeutic indications related to lofexidine. The methods may provide treatment for a variety of conditions amenable to amelioration by lofexidine administration. The methods utilize lofexidine compositions formulated for transdermal and sustained release oral delivery for administration of lofexidine in an amount effective for the treatment of the drug indications.04-28-2011
20110293709PEPTIDE TYROSINASE INHIBITORS AND USES THEREOF - Disclosed are peptides which inhibit the enzymatic activity of tyrosinase as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Methods of skin treatment are also provided, the methods further including use of a peptide characterized by the amino acid sequence SFLLRN (SEQ ID NO: 1).12-01-2011
20110293708PROCESS FOR PREPARING PURIFIED NUCLEIC ACID AND THE USE THEREOF - The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether)12-01-2011
20090092664POLYMER-METAL CHELATOR CONJUGATES AND USES THEREOF - The present invention provides prodrugs comprising a polymer conjugated to a metal chelator via a disulfide bond. For example, D-penicillamine may be conjugated to a polymer (e.g., gelatin, chitosan, polyglutamic acid) via a linker, such as SPDP. Thus, the cellular delivery and pharmacokinetics of D-penicillamine can be substantially improved. Methods for the treatment of cancer using compositions of the present invention are also disclosed.04-09-2009
20100015218COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALLY ACTIVE MOLECULES - The present invention relates to novel compositions and methods for potentiating the activity of biologically active molecules in conjunction with one or more delivery vehicles and one or more carrier molecules. Specifically, the invention features the use of a carrier molecule in combination with a delivery vehicle and a biologically active molecule of interest to potentiate the activity of the biologically active molecule. The carrier molecule can be biologically inert, inactive, or attenuated; or can alternately be biologically active in the same or different manner than the biologically active molecule of interest. Specifically, the invention features novel particle forming delivery agents including cationic lipids, microparticles, and nanoparticles that are useful for delivering various biologically active molecules to cells in conjunction with a carrier molecule. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity in a subject or organism that are delivered intracellularly in conjunction with a carrier molecule. In various embodiments, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver biologically active molecules, such as antibodies (e.g., monoclonal, chimeric, humanized etc.), cholesterol, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, allozymes, aptamers, decoys and analogs thereof, and small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules, to relevant cells and/or tissues, such as in a subject or organism, in conjunction with one or more carrier molecules. Such novel cationic lipids, microparticles, nanoparticles and transfection agents that are used in conjunction with one or more carrier molecules are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject or organism.01-21-2010
20100330165USE OF CHEMOTHERAPEUTIC AGENTS - The use of chemotherapeutic agents for the preparation of a medicament for the topical and/or local treatment of diseases caused by bacteria and/or for prophylaxis in humans or animals.12-30-2010
20110165229Compositions and Methods for Treatment - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.07-07-2011
20110165228Compositions and Methods for Treatment - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.07-07-2011
20130216614IMMUNOGENIC COMPOSITIONS AND METHODS FOR TREATING NUEROLOGIC DISORDERS - The present invention relates to methods and compositions for preventing and reducing amyloid deposition in a subject by administering to the subject a composition containing aTLR4 agonist free of endotoxin, where the composition does not contain beta amyloid.08-22-2013
20130216612TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS - The invention relates to methods of targeted drug delivery of antiviral compounds, including, chemical agents (like nucleoside analogs or protease inhibitors) and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of antiviral compounds to intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (CNS), into and across the blood-brain barrier, by targeting to internalizing uptake receptors present on these cells, tissues and organs. Thereto, the antiviral compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to ligands that facilitate the specific binding to and internalization by these receptors.08-22-2013
20130216609Controlled Release Antimicrobial Compositions and Methods for the Treatment of Otic Disorders - Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).08-22-2013
20130216605MICRO-RNAS MODULATING IMMUNITY AND INFLAMMATION - MicroRNAs are shown to be up- and/or down-regulated in inflammation and immune cells using a mouse model of asthma and regulatory T cells as source of RNA, respectively. Modulating the expression of these microRNAs can be effective in redirecting inflammation and immunity and hence, can be beneficial as biomarkers or as therapeutic agents against diverse human immunologic and inflammatory diseases.08-22-2013
20130216604POLYPEPTIDE FOR INHIBITING METASTASIS, USES THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - A polypeptide for inhibiting, treating or diagnosing metastasis and an use thereof are disclosed, wherein the polypeptide is a polypeptide, a derivative polypeptide, or a mutated polypeptide of a fibronectin-binding domain of dipeptidyl peptidase IV. In addition, a pharmaceutical composition treating or diagnosing metastasis is also disclosed, which comprises the aforementioned polypeptide, and a pharmaceutically acceptable carrier.08-22-2013
20110293706NANOSHELLS ON POLYMERS - Nano-constructscomprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.12-01-2011
20110293703AMINOALCOHOL LIPIDOIDS AND USES THEREOF - Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.12-01-2011
20110293695Amphoteric liposomes - Amphoteric liposomes are proposed, which comprise positive and negative membrane-based or membrane-forming charge carriers as well as the use of these liposomes.12-01-2011
20100203115ORGANIC-INORGANIC HYBRID MATERIAL FOR THE STORAGE AND RELEASE OF ACTIVE PRINCIPLES - This invention relates to a hybrid material composed of organic-inorganic particles, characterised in that said particles have a diameter of between 10 and 800 nm, and it is structured in two portions: 08-12-2010
20110293707USE OF THE CATHELICIDIN LL-37 AND DERIVATIVES THEREOF FOR WOUND HEALING - Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.12-01-2011
20110293705METHODS AND COMPOSITIONS FOR LOCALIZED AGENT DELIVERY - The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.12-01-2011
20110293702Compounds and Methods for the Treatment of Inflammatory Diseases of the CNS - Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated or at least alleviated, by the administration of an oligonucleotide in a dose effective to inhibit or reduce the influx of mononuclear and/or autoaggressive cells to the central nervous system. The oligonucleotide can be used alone, or in combination with other treatment strategies.12-01-2011
20110293701MULTIVALENT SYNTHETIC NANOCARRIER VACCINES - The invention relates, at least in part, to compositions comprising populations of synthetic nanocarriers that comprise different sets of antigens as well as related methods.12-01-2011
20110293700NANOCARRIER COMPOSITIONS WITH UNCOUPLED ADJUVANT - Disclosed are synthetic nanocarrier compositions with separate adjuvant compositions as well as related methods.12-01-2011
20110293699HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING - The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.12-01-2011
20110293698Reagents and Methods for Treating Cancer - This invention describes a genetic system for targeting the EVI1 gene in mammalian cells. The EVI1 gene is an oncogenic transcription factor that, when expressed, accelerates cell division and inhibits death of cells. Nucleotide sequences that block the expression of EVI1 and drug delivery systems for them are described. These nucleotide sequences cause a block in cell growth and division and trigger death of mammalian cells, including lung and ovarian cancer cells.12-01-2011
20110293696COMPOSITIONS AND METHODS FOR TREATING BRUISES - A composition for the treatment of bruising is disclosed. The composition can include an antioxidant, one or more citrus flavanoids, as active agents along with a pharmaceutically acceptable excipient or filler. The compositions are nutriceutical formulations having the capacity to reduce the number of bruises that occur over time and that reduce the healing time of bruises. The compositions are preferably in tablet form for oral consumption one or more times per day. A method of reducing bruising is also disclosed in which a patient in need of a treatment for bruising or at risk of developing bruises is identified. The composition can then be administered orally to the patient.12-01-2011
20110293693QUANTUM UNIT OF INHERITANCE VECTOR THERAPY - The innovative treatment strategy described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver quantum genes to specific type of cells in the body. Utilizing probes on the exterior of the transport device, transport device locate specific target cell types in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery device inserts its payload of quantum genes into the target cell type. By delivering quantum genes to specific type of cells, genes can be activated or inactivated in those specific type of cells. These medically therapeutic quantum genes are intended to improve cell function or the longevity of cells or neutralize harmful cells that pose a hazard to the general health of the body.12-01-2011
20100303897NOVEL ADDL RECEPTOR POLYPEPTIDES, POLYNUCLEOTIDES AND HOST CELLS FOR RECOMBINANT PRODUCTION - This invention provides a novel receptor expressed on neuronal cells in a developmentally-specific manner. Accordingly, this invention provides the amino acid sequences of selected portions of the receptor and polynucleotides encoding these portions as well as antibodies that bind to the polypeptide portions of the receptor. Compositions and methods for using the compositions are also provided.12-02-2010
20110038926Method of producing a cationic liposomal preparation comprising a lipophilic compound - A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.02-17-2011
20110293697HIV-1 Immunogenic Compositions - The present invention encompasses vaccine and/or immunogenic compositions against HIV and their methods of use for the prevention and/or treatment of HIV infection and/or AIDS. The vaccine and/or immunogenic compositions may contain an isolated HIV protein or fragment thereof, an adjuvant comprising a Toll like receptor (TLR) 4 ligand, in combination with a saponin.12-01-2011
20090068254MULTIVALENT LIPOSOMAL VACCINE COMPOSITIONS COMPRISING POLYSACCHARIDE ANTIGENS AND A PROTEIN ADJUVANT - A multivalent liposomal composition, preferably a vaccine, comprises liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigens of several serotypes and T-cell dependent protein carrier, such as tetanus toxoid. The invention is of use in the production of vaccines against 03-12-2009
20090110719Polyamine modified particles - A particle composition comprising a graft copolymer formed from a biocompatible polymer and a plurality of polyamine moieties, wherein the polyamine moieties are bound to the biocompatible polymer, and a combinatorial delivery polymer comprising a plurality of particles that comprises a graft copolymer formed from a biocompatible polymer and a plurality of polyamine moieties, wherein the polyamine moieties are bound to the biocompatible polymer, a plurality of nucleic acids electrostatically loaded onto the particles, a plurality of chemokine molecules, and a biodegradable polymer network, in which the loaded particles and chemokine molecules may be entrapped, are disclosed. Also disclosed is a method for treating a subject comprising administering a therapeutically effective dose of a pharmaceutical composition, the pharmaceutical composition comprising a particle composition that comprises a graft copolymer formed from a biocompatible polymer and a plurality of polyamine moieties, wherein the polyamine moieties are bound to the biocompatible polymer.04-30-2009
20100330160Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6 - The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by 12-30-2010
20100255077METHODS OF TREATING INTESTINAL DISEASES AND INFLAMMATORY CONDITIONS RELATED TO HIV-AIDS - Provided herein are methods of treating intestinal diseases or inflammatory conditions, including HIV-AIDS, in which oxidative stress is a triggering or exacerbating factor by administering GVT to a patient suffering from the condition such that the condition is treated.10-07-2010
20100203114MICELLE ENCAPSULATION OF THERAPEUTIC AGENTS - The invention provides 17 AAG encapsulated in micelle particles. The micelles can be comprised of safe poly(ethylene glycol)-block-poly(lactic acid) (PEG-PLA). A significant advantage of PEG-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO. Additionally, PEG-PLA micelles are easier to handle than DMSO and they do not possess foul odors, which is a problem associated with 17-AAG formulations currently in clinical trials. The invention also provides methods of preparing active agents encapsulated micelles and therapeutic methods of using the micelles and their corresponding formulations, such as for the inhibition of Hsp 90, and/or for the treatment of cancer.08-12-2010
20110293694QUANTUM UNIT OF INHERITANCE VECTOR THERAPY METHOD - The innovative treatment method described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver quantum genes to specific type of cells in the body. Utilizing probes on the exterior of the transport device, transport device locate specific target cell types in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery device inserts its payload of quantum genes into the target cell type. By delivering quantum genes to specific type of cells, genes can be activated or inactivated in those specific type of cells. This method of delivering medically therapeutic quantum genes to specific cells is intended to improve cell function or extend the longevity of cells or neutralize harmful cells that pose a hazard to the body.12-01-2011
20090068255USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE - The application of matrix metalloproteinase (MMP) inhibitors to the skin inhibits the degradation of proteins found in the skin including collagen, elastin, and other basement membrane and extracellular matrix protein. MMP inhibitors may be used in both cosmetic compositions and pharmaceutical compositions for application to skin. MMP inhibitors are formulated with a cosmetically suitable vehicle or pharmaceutically acceptable excipient for application to the skin as creams, lotions, ointments, solutions, face masks, etc. As cosmetics, the inventive MMP inhibitor compositions are applied to the skin to prevent or reduce the appearance of wrinkles, pigmentation changes, loss of elasticity, or other effects associated with aging or sun damage. As pharmaceuticals, the inventive MMP inhibitor compositions may also be applied to the skin to treat or prevent a skin disease (e.g., proliferative disease, inflammatory disease).03-12-2009
20100272790Methods of Treating Skin - A topical composition comprising a lipoic acid, a carnitine, and a carnosine in a suitable vehicle for topical application and a method for treating skin is provided. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles and loss of elasticity. Preferred components include R-lipoic acid or R-dihydrolipoic acid, acetyl-l-carnitine, and l-carnosine.10-28-2010
20090148506LIPOSOMAL FORMULATIONS COMPRISING SECONDARY AND TERTIARY AMINES AND METHODS FOR PREPARING THEREOF - Provided herein are liposomal compositions comprising a therapeutic agent having a protonatable amino group and a secondary or tertiary amine, and methods for encapsulating such therapeutic agents. In one aspect, the present invention relates to liposomal formulations comprising irinotecan in a triethanolamine solution, and optionally comprising copper gluconate, and methods for preparing the same.06-11-2009
20090220587Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands - A receptor ligand is conjugated to a lipid-soluble moiety, thereby allowing effective delivery of the peptide ligand to a target cell in the form of a liposome complex. The ligand brings the liposome in proximity to the target cell, facilitating the fusion of the liposome with an endosome of the cellular target to release the payload into the cytoplasm. The liposome itself packages drugs or other therapeutics that are delivered to the interior of the cell upon fusion of the liposome.09-03-2009
20110200664LIPOSOMAL STRUCTURES FORMING ISOMETRIC AGGLOMERATES, ESPECIALLY BATH BEADS, THE PRODUCTION AND USE THEREOF - The present invention relates to isometric agglomerates of an essentially spherically shaped form, especially bath beads, and the cosmetic, therapeutic and hygienic use thereof. The invention is especially concerned with agglomerates on the basis of carriers of natural origin such as collagen, gelatine, starch, cellulose or urea, which comprise both lipids and vesicle forming agents as well as emulsifying components and optionally additives, without impairing the stability or activity thereof. The agglomerates when contacting water, especially in a bathing, will form liposomal mono- up to multi-layer structures thereby enabling an improved transport of active compounds. This will result in an improved balneological/or therapeutic action as well as a caring effect in the sense of a reconstruction of the skin barrier function.08-18-2011
20100129429INHIBITION OF AUTOPHAGY GENES IN CANCER CHEMOTHERAPY - There is provided compositions and methods for improving the therapeutic efficacy of various cancer treatments, for example endocrine therapy, chemotherapy or radiation therapy, by inhibiting the expression of one or more genes involved in the cellular autophagy response. The compositions include compositions comprising an siRNA directed against an Atg gene and may be used to inhibit expression of an Atg gene in a cell currently undergoing cancer therapy, or to treat, inhibit or prevent cancer in a subject in combination with a cancer therapy.05-27-2010
20110189264Group of Nucleic Acid Fragments for Prevention of HIV Infection or AIDS and the Usage Thereof - The invention provides a group of nucleic acid fragments, shown in the sequence listing, for prevention of HIV infection or AIDS and the usage thereof. In the invention, a series of RNA fragments, which are highly homogenous to all the published HIV gene sequences, were obtained by homology compare. The double-stranded RNA (dsRNA) derived from these fragments can effectively inhibit the expression of the HIV genes. The RNA transcribed by plasmid, also can suppress the expression of the HIV in the cell. After the adenovirus or associated virus which carry DNA corresponding above RNA infect the cell, the transcription dsRNA can inhibit the expression of the HIV genes.08-04-2011
20100203113WNT SIGNALLING INHIBITORS, AND METHODS FOR MAKING AND USING THEM - The invention provides dBHD-based compositions and dBHD analog compositions, and pharmaceutical compositions comprising them, e.g., in the form of liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these dBHD analogs are used to inhibit a dysfunctional stem cell and/or a cancer (tumor) stem cell.08-12-2010
20120269886THERAPEUTIC AGENT FOR PULMONARY FIBROSIS - Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for pulmonary fibrosis, which utilized the carrier; and a preparation kit of the therapeutic agent.10-25-2012
20100086584VACCINE COMPOSITIONS OF M2e, HA0 AND BM2 MULTIPLE ANTIGENIC PEPTIDES - The present disclosure generally relates to a composition comprising one or more peptides selected from influenza virus antigenic peptides M204-08-2010
20100136100Removal promoters and inhibitor for apoptosis cells in vivo - The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor.06-03-2010
20100034874LIPOSOME ENCAPSULATING AMMINE-PLATINUM COMPLEX AT HIGH CONCENTRATION, AND METHOD FOR PRODUCTION OF THE LIPOSOME - The present invention provides a method of producing a liposome encapsulating an ammine platinum complex. The method includes A) providing a water-soluble ammine platinum complex, platinum complex raw materials or the combination thereof; B) providing a liposome, liposome raw materials or the combination; and C) preparing a mixture of the water-soluble ammine platinum complex, platinum complex raw materials or the combination thereof and the liposome, liposome raw materials or the combination thereof and subjecting it to a liposome-forming/maintaining condition, wherein the salt of the platinum complex forms when the liposome is in a water-soluble form.02-11-2010
20090028932VACCINE FORMULATIONS FOR LEISHMANIA - The present invention involves the use of 01-29-2009
20100034873TRANSDERMAL RICINOLEIC ACID COMPOSITIONS - Transdermal compositions containing castor oil are described. The compositions comprise ricinoleic acid and a transdermal vehicle with optional additional agents. One optional additional agent is an adrenergic drug which may cause the ricinoleic acid to penetrate the skin more deeply and have a longer lasting effect. The compositions can be used for treating a variety of ailments traditionally treated with castor oil or castor oil packs, without the mess and inconvenience of using castor oil packs.02-11-2010
20110217366IMMUNOPOTENTIATING COMPOSITION - The present invention provides an immunopotentiating composition which comprises an antigen or antigen-inducing substance, and a carrier comprising a biocompatible material for effectively increasing an immune response derived from an antigen. The present invention further provides a method of producing an antibody by administering said immunopotentiating composition to a mammal or bird, thereby modulating the immune response in said mammal or bird and recovering the antibody produced.09-08-2011
20110217367MEANS FOR INHIBITING THE EXPRESSION OF ORC-1 - The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ ID NO: 1, whereby the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 1755 to 1763 of SEQ ID NO: 1; from nucleotide positions 1904 to 1912 of SEQ. ID. No.1; from nucleotide positions 1905 to 1913 of SEQ ID NO: 1; from nucleotide positions 2548 to 2556 of SEQ ID NO: 1; whereby the first stretch is additionally at least partially complementary to a region preceding the 5′ end of the nucleotide core sequence and/or to a region following the 3′ end of the nucleotide core sequence.09-08-2011
20110217365Compositions and Methods for Gene Silencing - Compositions and methods for modulating the expression of a protein of interest are provided.09-08-2011
20110217364CONJUGATED SURAMIN AMINO COMPOUNDS FOR MEDICAL CONDITIONS - A modification of pharmacokinetics of suramin by use of amino compounds in modification of lipophilicity and protein binding characteristics for tackling the physico-chemical properties of suramin that gives it poor distribution in the body; formulating the resulting product in a form that leads to targeting body fluids like the lymphatic system when administered in a specific way; and determining the route of administration that maximizes targeting with a view to reducing the dosage so as to limit toxicity, hence increase tolerance by patient.09-08-2011
20110217363TWO-STEP TARGETED TUMOR THERAPY WITH PRODRUG ENCAPSULATED IN NANOCARRIER - A two-step targeted tumor therapeutic method is described comprising nanocarrier with prodrug encapsulated thereto and prodrug activating enzyme. The enzyme is either encapsulated in nanocarrier, or not encapsulated, or synthesized in the tumor. With the method, the prodrug released from the nanocarrier is activated by the enzyme mainly in the tumor.09-08-2011
20110217362Group of Nucleic Acid Fragments for Prevention of HIV Infection or AIDS and the Usage Thereof - The invention provides a group of nucleic acid fragments, shown in the sequence listing, for prevention of HIV infection or AIDS and the usage thereof. In the invention, a series of RNA fragments, which are highly homogenous to all the published HIV gene sequences, were obtained by homology compare. The double-stranded RNA (dsRNA) derived from these fragments can effectively inhibit the expression of the HIV genes. The RNA transcribed by plasmid, also can suppress the expression of the HIV in the cell. After the adenovirus or associated virus which carry DNA corresponding above RNA infect the cell, the transcription dsRNA can inhibit the expression of the HIV genes.09-08-2011
20110038925INTRAVENOUS FORMULATIONS OF NEUROKININ-1 ANTAGONISTS - Pharmaceutical compositions for intravenous administration comprising the compound of Formula I02-17-2011
20090081281Photosensitizer Formulation for Topical Applications - Highly flexible penetrating liposomal carrier systems are formulated with enhanced skin penetration properties. These specialized formulations of highly flexible penetrating liposomal delivery systems comprise one or more phospholipids, lysophosphatides and hydrophobic photosensitizer. This new formulations can squeeze liposomal particles through intercellular regions of stratum corneum as intact structures, and, in this way, deliver encapsulated photosensitizer to the epidermis, dermis, hypodermis and surroundings. The penetrating liposomal formulation provides therapeutically effective amounts of the hydrophobic photosensitizer through topical application with better skin penetration thus improving drug targeting and the efficacy of photodynamic therapy (PDT).03-26-2009
20090191259Efficient liposomal encapsulation - The present invention concerns a method for preparing liposomes, said method comprising the following steps: (I) mixing at least one liposome-forming lipid, a water-miscible organic solvent and aqueous medium Y to form a gel or liquid containing gel particles without sonication; and thereafter (II) (a) mixing the gel or liquid containing gel particles with aqueous medium Z1 to directly form the liposomes; (b) (i) mixing the gel or liquid containing gel particles with aqueous medium Z1 to form a curd or curdy substance; and (ii) mixing the curd or curdy substance with aqueous medium Z2 to directly form the liposomes; or (c) (i) cooling the gel or liquid containing gel particles to form a waxy substance; and (ii) mixing the waxy substance with aqueous medium Z1 to directly form the liposomes; wherein aqueous media Y, Z1 and Z2 are the same or different.07-30-2009
20090098195Influenza virus infection suppressor - The present invention is directed to providing influenza virus infection suppressors which contain a sialylgalactose-binding peptide, for example, a ganglioside GM3-binding peptide, as an active ingredient. Specifically, the invention provides influenza virus infection suppressors which contain the sialylgalactose-binding peptide of the following (a) or (b): (a) a peptide having the amino acid sequence of SEQ ID NO. 1 or 2; (b) a peptide having an amino acid sequence in which one or several nucleotides are deleted, substituted, or added, from/to the amino acid sequence of SEQ ID NO. 1 or 2, and having sialylgalactose-binding activity.04-16-2009
20110262525METHODS OF TREATMENT - This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application.10-27-2011
20110262528PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF BONE TISSUE RESORPTION OF VARIOUS ETIOLOGY - The invention relates to medicine and pharmacology, and represents a pharmaceutical composition for the treatment of bone resorption of various etiology comprising, as the biologically active ingredient, liposomes with biphosphonates in gel dosage form suitable for transdermal delivery of biphosphonates and effective local therapy. Using this composition, methods for the prevention and treatment of osteoporosis, Paget's disease, patoplogical fractures associated with oncological diseases, and some other pathological processes associated with bone resorption and reparation are proposed.10-27-2011
20090186073Design of Delivery Vehicle Based On Rolling Model - Objects of the present invention are to provide a method for designing an optimum delivery preparation with the use of a convenient experiment and/or assay and to search for the thus produced delivery vehicle. The present invention provides a method for producing a delivery vehicle for achieving the delivery of a desired substance to a desired site, which comprises the steps of: 07-23-2009
20090317458Fluid-jet pens configured for making modulated release bioactive agents - The present invention is drawn to methods of preparing a bioactive agent-containing emulsion for delivery to a biological system. This method can comprise the step of jetting a bioactive agent and a first fluid medium from a fluid-jet pen into a second fluid medium to form a bioactive agent-containing emulsion, wherein the second fluid comprises a continuous phase of the emulsion. Alternatively, a method of preparing a bioactive agent-containing liposome can comprise jetting a lipid-containing composition and a bioactive agent from a fluid-jet pen into a medium to form a bioactive agent-containing liposome carried by the medium. The present invention is also drawn to fluid-jet pens and systems configured for making liposome- and emulsion-containing biological agents.12-24-2009
20100272786VACCINE - The invention relates to a replication deficient simian adenoviral vector C7 encoding a protein comprising CS protein from 10-28-2010
20090136565Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R - This invention provides a method for regulating migration of neuronal progenitor cells in the nervous system of a mammal. The method comprises providing a mammal with TNR, a biologically active fragment of TNR, or a TNR agonist in an amount sufficient to direct migration of the neuronal progenitor cells. The invention provides a method of treating neurological diseases by replenishing diseased, damaged, or destroyed neural cells in the central nervous system or in the peripheral nervous system.05-28-2009
20090148509ENCAPSULATION AND DEAGGREGATION OF POLYENE ANTIBIOTICS USING POLY(ETHYLENE GLYCOL)-PHOSPHOLIPID MICELLES - Amphotericin B (or other hydrophobic compound) is encapsulated in a deaggregated form in micelles of monomethoxy poly(ethylene glycol)-phospholipid (as specifically exemplified, the phospholipid is 1,2 di-stearoyl-sn-glycero-3-phosphatidyl ethanolamine) formed by solvent evaporation. Advantageously, the hydration of the dried drug-polymer film is carried at between about 25° C. and about 80° C. The micelles can be reconstituted with the Amphotericin B (or other hydrophobic compound) in a deaggregated state and safely used in therapy for fungal infections of humans or animals, especially for systemic fungal infections, or other desired application. The polyene micellar formulations described herein are reduced in toxicity as compared with those polyene formulations in which there is significant occurrence of aggregated polyenes.06-11-2009
20110129525MUCOSAL MEMBRANE RECEPTOR AND USES THEREOF - The invention is based on the identification of aminopeptidase N (APN) as the receptor for F4 fimbriae of enterotoxigenic 06-02-2011
20090148510GPCR crystalization method using an antibody - An antibody that specifically binds a three dimensional epitope on the IC3 loop of a GPCR is provided. The antibody may be employed in a method that comprises: contacting a GPCR with a monovalent version of the antibody binding conditions to form a complex; and crystallizing the complex.06-11-2009
20100266676NANOCAPSULES WITH A LIQUID LIPID CORE CHARGED WITH WATER-SOLUBLE OR WATER-DISPERSIBLE ACTIVE AGENTS - The invention relates to nanocapsules with a liquid lipidic core and a solid lipidic shell, the lipidic core being loaded with at least one water-soluble or water-dispersible ingredient, said ingredient being present in the form of a reverse micellar system.10-21-2010
20080268032Stabilizing Alkylglycoside Compositions and Methods Thereof - The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.10-30-2008
20080268031 Therapeutic Treatment of Dermatologic Skin Disorders - L-retinol AGP complex is incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of cosmetic and dermatologic disorders are described as follows. In particular, 1-retinol AGP complex is combined with liposomes to increase the penetration of the 1-retinol AGP complex into the skin, to provide hydration of the skin during treatment, to reduce irritation of the skin during the application of the 1-retinol AGP complex, for use as a chemical skin peel and other embodiments and uses.10-30-2008
20110171290INHIBITION OF ANGIOGENESIS AND TUMOR METASTASIS - The present invention relates to an anti L1-CAM antibody for use in a method for the treatment of a disease in a patient which can be treated by inhibition of angiogenesis, wherein the administration of said anti L1-CAM antibody results in the inhibition of angiogenesis and/or tumor metastasis.07-14-2011
20100278906MOISTURIZING ANTIMICROBIAL COMPOSITION - An antimicrobial moisturizing composition includes benzethonium chloride or benzalkonium chloride, a non-benzyl cationic surfactant, and an aqueous carrier. The composition of the present invention provides a significant and unexpected reduction of irritation, inflammation, dryness and/or redness, all issues associated with known alcohol-based skin disinfectants. In particular, the present invention provides a stable, aesthetically-pleasing, long-lasting, and moisturizing antimicrobial composition that is substantially free of ethanol, polysorbates, and anionic compounds that are known to inhibit the activity of benzethonium chloride or benzalkonium chloride.11-04-2010
20100124566Protection against and treatment of ionizing radiation - Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposome. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds, and prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds. In addition, RalBP1 is effective for the protection and treatment of mammals against the effects of ionizing radiation.05-20-2010
20100119587SOLID LIPIDIC PARTICLES AS PHARMACEUTICALLY ACCEPTABLE FILLERS OR CARRIERS FOR INHALATION - The present invention relates to new compositions of (active) solid lipidic particles (SLP), e.g. for inhalation, and their use as carriers or as fillers in pharmaceutical compositions. It also relates new formulations obtained by mixing a SLP composition of the invention and a (micronized) active compound. It further relates to a method for fabricating said compositions of (active) solid lipidic particles.05-13-2010
20100015214Novel Trans-Adjuvant System - The present invention relates to a novel adjuvant system that generates an efficient immune response against antigens of various origins while reducing the risk of toxic side effects attendant to the use of known adjuvants. The novel adjuvant of the present invention comprises virosomes and allows antigenic molecules to be bound to or encapsulated in a variety of delivery vehicles which are easier to prepare for virosomes.01-21-2010
20120141578COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES - Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein.06-07-2012
20100086585Antinuclear antibody utilized as a targeting agent for pharmaceutical compounds used in the treatment of cancer and other diseases - This invention describes a method whereby autoimmune antinuclear antibodies are used as a targeting agent to deliver drug nanoparticles or drug liposomes to the tumor or disease site. The antinuclear antibodies have the propensity to localize in areas of tissue necrosis where dead cells have released their nuclear material into the extracellular environment. Many tumors have areas of necrosis that can be targeted using antinuclear antibody coated drug nanoparticles or liposomes. Similarly, many infectious diseases have areas of necrosis and can also be targeted using antinuclear antibody coated drug nanoparticles or liposomes. Similarly, many immune disorders such as rheumatoid arthritis and osteoarthritis have areas of inflammation where there is cell death, and these inflammatory sites can also be targeted using antinuclear antibody coated drug nanoparticles or liposomes.04-08-2010
20100129428SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL - The instant invention is drawn to a hepatocyte targeted composition comprising interferon associated with a lipid construct comprising amphipathic lipid molecules and receptor binding molecule. The composition can comprise a mixture of free interferon and interferon associated with the complex. The composition can be modified to protect interferon and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading interferon into the composition and recycling various components of the composition and methods of treating individuals infected with the hepatitis C and other hepatitis viruses.05-27-2010
20120282327PHOSPHATE-CONTAINING NANOPARTICLE DELIVERY VEHICLE - A phosphate-containing nanoparticle delivery vehicle includes nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.11-08-2012
20100285113ENHANCED STABILITY OF INVERSE THERMAL GELLING COMPOSITE HYDROGELS - The present invention relates to a composite hydrogel comprising a blend of an aqueous solution of an anionic polysaccharide or a derivative thereof, such as hyaluronan (also commonly referred to as hyaluronic acid) or a derivative thereof and an aqueous solution of methylcellulose or another water soluble cellulose derivative thereof, having dispersed polymeric particles, such as polymeric hydrophobic particles therein selected from micro particles and nanoparticles, and wherein the stability of the hydrogel is enhanced relative to the stability of the hydrogel alone. The polymeric particles may contain at least one therapeutic agent, in which case each therapeutic agent exhibits a linear sustained release rate that can be tuned or altered by selecting the appropriate polymer formulation of the micro particles and/or nanoparticles. The composite may be injectable, and in the absence of a therapeutic agent may be used as a bulking agent for reconstructive and cosmetic surgery or may act as a platform for subsequent delivery of therapeutic agents.11-11-2010
20090053291FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS - The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or derivative thereof; or (c) an HIV Nef protein or derivative thereof linked to an HIV Tat protein or derivative thereof and a fusion partner. The invention further provides for a nucleic acid encoding such a protein and a host cell, such as 02-26-2009
20100119594NOURIN AND NOURIN ANTAGONISTS - The present invention provides compositions and methods for identifying, monitoring, and/or treating tissue inflammation caused by diseases or injury. Inflammatory mediators from the Nourin family are provided as diagnostic markers to detect or monitor a disease or injury that results in inflammation. In addition, the Nourin family antagonist, Nourexin-4 is provided as a therapy to treat diseases or injury. Further, cyclocreatine is provided as an inhibitor of Nourin formation, which can be used as a therapy to treat injury and inflammation.05-13-2010
20100119590Method of drug loading in liposomes by gradient - A method for encapsulation of pharmaceutical agents (e.g., antineoplastic agents) in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes can be made by a process that loads the drug by an active mechanism using a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%. Drug:lipid ratios employed are higher than for older traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. After loading, residual acid is quenched with a quenching agent that is base permeable at low temperatures. The residual aciditiy is thus reduced and chemical stability (e.g. against hydrolysis) is enhanced. The stability of both the liposome and the pharmaceutical agent is thus maintained, prior to administration. The pH gradient is, however, present when the liposome is administered in vivo because the quenching agent rapidly exits the liposome.05-13-2010
20100086583LIPID-ANALOGOUS PHOSPHORIC TRIESTERS - The present invention relates to novel phosphoric triesters which comprise apolar lipid structures.04-08-2010
20120087973siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES - The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.04-12-2012
20120121692COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER - Disclosed herein are compounds suitable for use as antitumor agents, methods for treating cancer wherein the disclosed compounds are used in making a medicament for the treatment of cancer, methods for treating a tumor comprising, administering to a subject a composition comprising one or more of the disclosed cytotoxic agents, and methods for preparing the disclosed antitumor agents.05-17-2012
20090087478Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them - The invention provides antibodies with superior therapeutic efficacy and related methods of engineering such antibodies to increase their stability and resistance to proteases, e.g., in the digestive tract. Protease cleavage motifs are identified and subsequently modified to reduce or eliminate cleavage at that site. Methods of employing these orally deliverable antibodies as therapeutic compositions, particularly against gastrointestinal pathogens are also provided herein. In one aspect, the invention provides combinations of monoclonal antibodies, e.g., “synthetic polyclonals,” that work synergistically to neutralize bacterial toxins, particularly enteric bacterial toxins such as 04-02-2009
20100098749METHODS FOR JOINT LUBRICATION AND CARTILAGE WEAR PREVENTION MAKING USE OF GLYCEROPHOSPHOLIPIDS - The present invention concerns methods of joint lubrication and/or prevention of cartilage wear making use of liposomes having membranes with at least one phospholipid (PL) of the group consisting of a glycerophospholipid (GPL) having two, being the same or different, C04-22-2010
20100098748Arg-Gly-Asp (RGD) Sequence Containing Cyclic Peptide and Its Active Targeting Liposomes - The present invention relates to the field of pharmaceutics and clinical pharmacy, involving the preparation method and application of a cyclic peptide containing Argnine-Glycine-Aspartate sequence and its active targeting liposomes. The cyclic peptide described here meets the requirement for ligand in that it forms ring by amide linkage with stable sterical structure, it shows low propensity to degrade, and it carries an active hydrosulfide group which is easy to modify carriers. The artificially synthesized peptide, which has a small molecular weight and low propensity to cause immune response, can be used as the ligand to bind with the integrin on the surface of HSC. The active targeting liposome established with the cyclic peptide realized cell-targeted therapy of experimental hepatic fibrosis via receptor-mediated pathway. The invention can target RGD cyclic peptide-labeled interferon-loaded liposomes to the fibrotic liver and its good efficacy in the treatment of hepatic fibrosis has been proven by experiments in rats in vitro and in vivo.04-22-2010
20090092660Methods and compositions for needleless delivery of particles - Methods and compositions for needleless delivery of particles to the bloodstream of a subject are provided herein. In one aspect, the invention provides a delivery construct, comprising a receptor binding domain, a transcytosis domain, a particle to be delivered to a subject, and, optionally, a cleavable linker. In other aspects, the invention provides compositions comprising delivery constructs of the invention, kits comprising delivery constructs of the invention, and methods of using delivery constructs of the invention.04-09-2009
20100080845Cosmetic Methods And Compositions For Repairing Human Skin - The present invention relates to methods and compositions for repairing adverse effects of the environment, daily stress, sun exposure, or pre-mature aging on human skin, comprising applying to the skin, prior to a period of bodily rest, a topical composition that contains resveratrol or a derivative thereof and at least one DNA repair enzyme.04-01-2010
20100080844METHOD TO ENHANCE AN IMMUNE RESPONSE OF NUCLEIC ACID VACCINATION - A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The composition provides an improved immune response compared to mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein.04-01-2010
20090081283TUMOR THERAPY WITH NON-VIRAL-BASED HIGH AFFINITIY LAMININ RECEPTOR-TARGETED VECTORS - The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis.03-26-2009
20120294933Use of PVP-Iodine Liposomes for Treatment of Acne - The invention concerns a method for the production of a pharmaceutical preparation for the treatment of acne forms that is characterized in, that the preparation comprises at least one antiseptic compound associated with a particular carrier.11-22-2012
20120107392USE OF HUPERZINE FOR DISORDERS - Methods and compositions containing huperzine are used to prevent and alleviate seizures. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of orthostatic hypotension.05-03-2012
20120107390FELINE INFECTIOUS PERITONITIS VACCINE - FIP vaccines were provided that use an N protein with a specific structure, or a fragment thereof, as an antigen. Preferred antigens of this invention are N proteins derived from a specific type I virus strain (KU-2). Vaccines comprising such an N protein confer preventive effects against a wide range of FIPVs. In addition, the N proteins are very safe because they do not comprise epitopes that enhance infection. Furthermore, preventive effects can be accomplished against type I viruses, which actually cause 70% or more of FIP.05-03-2012
20090169609PQS AND ITS CONJUGATES AS ADJUVANTS AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS - The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.07-02-2009
20090169614METHODS OF SUPPRESSING MICROGLIAL ACTIVATION AND SYSTEMIC INFLAMMATORY RESPONSES - Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or reduces microglial activation are described. ApoE receptor binding peptides that may be used in the methods of the invention are also described, as are methods of using such peptides to treat peripheral inflammatory conditions such as sepsis. Also described are methods of screening compounds for the ability to suppress or reduce microglial activation.07-02-2009
20090263471Controlled Release Pharmaceutical Composition of Venlafaxine Hydrochloride, and Process for Preparation Thereof - Herein is described a controlled release pharmaceutical composition of venlafaxine hydrochloride, an effective antidepressant, comprising an inert core; on which the active principle is uniformly layered, that in turn is coated with a layer comprising a hardening agent and a lipophilic agent; the process for the preparation of said pharmaceutical composition is also described.10-22-2009
20090263472ENDOTHELIN RECEPTOR ANTAGONIST DERIVATIVES - Endothelin receptor antagonist nitroderivatives of general formula (I):10-22-2009
20090263473Nanoliposome Using Esterified Lecithin And Method For Preparing The Same, And Composition For Preventing Or Treating Skin Diseases Comprising The Same - The present invention relates to a nanoliposome comprising a liposome membrane containing esterified lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane; a method for preparing the same; and a composition for preventing or treating skin diseases, comprising the same. The nanoliposome according to the present invention has long-term stability and uniformity, and so can be used to prepare a composition for skin having excellent moisturizing and penetrating properties, such as cosmetics, medicament for treating skin diseases, or the like. In particular, the present composition for preventing or treating skin diseases comprises epidermal growth factor included in the nanoliposome, thereby showing an excellent effect of stimulating skin-penetration and good pharmaceutical stability. Also, the esterified lecithin used in preparing liposome can provide effects of softening skin and stimulating skin-penetration, thereby enhancing the penetration of epidermal growth factor and natural extract into skin, as well as additional moisturizing effect which is advantageous in treating skin diseases. Further, since the present composition comprises nanoliposome prepared by containing esterified lecithin in liposome membrane, the conventional problems of heating and dispersing active ingredients at high temperature (70° C. or more), low stability and uniformity, or the like can be solved.10-22-2009
20090263474Methods for Treating Autoimmune Diseases in a Subject and In Vitro Diagnostic Assays - The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and a Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk for developing an autoimmune disease, and kits for use, inter alia, with the assay.10-22-2009
20090263470Vaccine Compositions Comprising Virosomes and a Saponin Adjuvant - This invention provides virosome preparations from an enveloped virus, in particular from influenza virus, containing from said virus, and a saponin adjuvant. In particular the invention provides a virosome preparation from influenza virus an influenza antigen a QS21, optionally with a sterol. The invention also provides vaccine compositions containing said virosome preparations, methods of preparing said virosome preparations and vaccine containing them.10-22-2009
20090162423Formulations for cosmetic and wound care treatments with photosensitizes as fluorescent markers - Photoactive materials, such as photosensitizers, are used as fluorescent markers for in vivo detection of the distribution of the injected filler material during cosmetic treatments. In one preferred embodiment, liposomal formulated temoporfin is used, as the photoactive component, in very small concentrations along with fillers for cosmetic and wound healing applications. Fillers, which can be used in the invention, include collagen, hyaluronic acids and other synthetic or natural products which are generally used in wound healing, scar reduction and other such medical applications. In a preferred embodiment, the formulated photosensitizer is coupled to the filler so that tracking is possible over longer periods of time A liposomal formulated photosensitizer is injected with the fillers into the treatment area, and is irradiated with laser light shortly after injection. The emitted fluorescence is measured by a special non-invasive device. Thereby it is possible to monitor the injection site and the distribution of the injected solution around the injection site. When irradiated with laser or other light source, the fluorescence of the photosensitizer is detected using a fluorescence detector, which permits tracking the filler at injection site and in the injection volume.06-25-2009
20100098753PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR CARDIAC INFARCTION - The present invention relates to a novel preventive and/or therapeutic drug for myocardial infarction.04-22-2010
20100098752Materials and Methods for Delivering Antioxidants into the Skin - Compositions and methods for administering one or more antioxidants to a human subject have been developed. The antioxidant-containing lipid vesicles of the invention provide a delivery system for antioxidants which can be applied topically to the skin.04-22-2010
20090098197CANCER VACCINE COMPRISING A CANCER ANTIGEN BASED ON THE PRODUCT OF A TUMOR SUPPRESSOR GENE WT1 AND A CATIONIC LIPOSOME - A cancer vaccine comprising a cancer antigen which comprises, as an active ingredient, the product of a tumor suppressor gene WT1, a partial peptide or a modified version thereof, and a cationic liposome.04-16-2009
20090202627METHODS AND COMPOSITIONS FOR DISEASES ASSOCIATED WITH AMYLOIDOSIS - The present invention generally relates to the detection, treatment or prevention of disease states. Specifically, the present invention relates to the detection, treatment or prevention of amyloidosis or amyloid-associated diseases. The present invention further comprises methods and compositions comprising therapeutic vaccines, antisera and molecular constructs, comprising expression vectors and fusion proteins encoded therein.08-13-2009
20090202620POLYMER-STABILIZED LIPOSOMAL COMPOSITIONS AND METHODS OF USE - The invention provides liposomal particle compositions, which incorporate a lipophilic biodegradable polymer, such as amino acid-containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU), throughout the particles to stabilize the composition for in vivo delivery in of an incorporated biologic agent. For oral delivery, a biologic, such as insulin, is conjugated directly to the polymer. Lipids in the particle are selected to further stabilize the composition during fabrication and digestion, providing sustained delivery of the biologic with native activity. Methods of making and using the invention compositions to administer the biologic agent in vivo are also included.08-13-2009
20090202621CELL-SURFACE DECORATION WITH ACTIVE AGENTS - A lipid vesicle comprising a functionalized lipid comprising a tether moiety having binding affinity for a ligand portion of an active agent and the active agent are provided. Methods of decorating endothelial cells, tissues, and organs with active agents utilizing the disclosed lipid vesicles are also provided.08-13-2009
20100098751Novel Use Of An Extract Of Common Mallow As An Hydrating Agent, And Cosmetic Composition Containing It - The present invention relates to a novel use of an extract of common mallow for restoring, maintaining or reinforcing the state of moisturization of the skin; to a cosmetic composition containing it, and also to cosmetic care methods using said composition.04-22-2010
20090274754DUAL ACTION, INHALED FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE - Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.11-05-2009
20090142391Conjugated RNAi Therapeutics - A method for modulating at least one pharmacokinetic property of a drug which degrades mRNA upon administration to a host by an siRNA mechanism is provided. In a further embodiment of this invention, a bifunctional compound comprising an siRNA and a recruiter moiety are provided. The recruiter moiety may be lipophilic and may enable the siRNA to cross cell membranes and then targets an endogenous, intracellular protein to allow better distribution of the therapeutic into the cell and therefore, higher efficacy.06-04-2009
20080317837PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.12-25-2008
20110171287Use of Oligonucleotides with Modified Bases as Antiviral Agents - The present invention relates to the use of oligonucleotides having modified nucleobases to inhibit gene expression and/or replication of viruses in a subject. The modified nucleobases may be mercapto-modified bases or hydroxy-modified nucleobases. It is contemplated that the oligonucleotides further comprise a nuclease complex which enhances anti-viral activity of the oligonucleotides.07-14-2011
20110171288TOPICAL COMPOSITIONS AND METHODS FOR WHITENING SKIN - Methods and compositions for whitening or brightening skin comprising at least one whitening active contained in association structures.07-14-2011
20090285883Identification of gastrointestinal, pancreatic and cancer stem cell markers and methods of use thereof - DCAMKL-1 has been identified as a biomarker for stem cells, as well as cancer stem cells. Methods of detecting the presence of at least one stem cell, methods of isolating stem cells, and methods of inhibiting growth of cancer cells utilizing DCAMKL-1 are disclosed herein.11-19-2009
20130216611THERAPEUTIC AGENT FOR FIBROID LUNG - Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent.08-22-2013
20090291130Physiologically Active Polypeptide- or Protein-Encapsulating Polymer Micelles, and Method for Production of the Same - The invention provides a physiologically active polypeptide- or protein-encapsulating polymer micelle composition derived from a block copolymer comprising hydrophilic segments and hydrophobic segments.11-26-2009
20080206318Therapeutic compositions that alter the immune response - The invention is therapeutic methods and compositions that alter the immunogenicity of the host.08-28-2008
20080206319Hexosylceramides as Adjuvants and Their Uses in Pharmaceutical Compositions - The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.08-28-2008
20110171291PATHOLOGICALLY-ACTIVATED THERAPEUTICS - Disclosed are methods and compositions for identifying, producing, and using pathologically-activated targeting compounds. Pathologically-activated compounds are compound that only have an effect, or have a disproportionate effect, on a target molecule when a pathological condition exists.07-14-2011
20090274753PH-SENSITIVE POLYMERIC MICELLES FOR DRUG DELIVERY - Mixed micelles containing poly(L-histidine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers exhibiting multidrug resistance. Targeting ligands, such as folate, can also be attached to the mixed micelles for enhancing drug delivery into cells. Methods of treating a warm-blooded animal with such a drug are disclosed.11-05-2009
20080311185Deregulated Genes and/or Processes in Inflammatory Arthritis - The invention provides means and methods for determining whether a sample is derived from an individual suffering from inflammatory arthritis or from an individual at risk of suffering there from, said method comprising measuring in said sample the level of expression of at least one gene product of a gene of table A, table B or and comparing said expression level with a reference value. Further provided is a non-human animal model comprising an altered expression of a gene of table A, table B or when compared to a reference non-human animal, and use of this model as or in an arthritis model. Further provided is an in vitro assay for screening compounds for effect on a phenotype of synovial fibroblasts. The synovial fibroblast are preferably derived from a human or non-human animal suffering from inflammatory arthritis.12-18-2008
20080311183Novel Inhibitors of Pyruvate Kinase as Therapeutic Agents for Cancer - The present invention relates to compounds for the inhibition of pyruvate kinase and ATP production which are capable of inhibiting cancer cells proliferation.12-18-2008
20090274751Growth Factor Sensitive Vesicle - A generally spherical growth factor sensitive vesicle bearing growth factor receptors (11-05-2009
20090274750Therapeutic Treatment of Dermatologic Skin Disorders - Willowherb derivatives are incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of cosmetic and dermatologic disorders. In particular, willowherb derivates are combined with liposomes to increase the penetration of the willowherb derivates into the skin, to provide hydration of the skin during treatment.11-05-2009
20090274749Topical Application for Minimizing Melanin Production - Tyrosinase inhibitors are incorporated with liposomes in therapeutic compositions for topical application to hyperpigmentation. In particular, combinations of tyrosinase inhibitors are combined with liposomes to increase the penetration of the tyrosinase inhibitors into the deep epidermis skin layers and to provide hydration of the skin during treatment.11-05-2009
20090280166FERRITIN AS A THERAPEUTIC TARGET IN ABNORMAL CELLS - Compositions for treatment of iron related diseases comprise an inhibitor of ferritin. An inhibitor of ferritin is active to reduce the level of H ferritin protein in a cell and/or to reduce the activity of H ferritin in a cell. Compositions providing cytoprotection, regulation of iron, increasing longevity and viability of cells are described.11-12-2009
20090280165COMPOUNDS THAT BIND ALPHA5BETA1 INTEGRIN AND METHODS OF USE - The present invention provides biologically active compounds that bind an αsβi integrin. Also included in the present invention are methods for using such biologically active compounds.11-12-2009
20090104260COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ICAM-1 - RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy and other complications arising from type I diabetes, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.04-23-2009
20090104259COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ANGIOGENESIS - RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.04-23-2009
20090104254Controlled Release Hydrogels - Formulations and methods for their preparation including a hydrogel including a crosslinked matrix comprising a polymer, and a one or more liposomes containing a therapeutic agent.04-23-2009
20090285878Compositions and methods for stabilizing liposomal drug formulations - The present invention is directed to liposomal compositions comprising a camptothecin, which are optimized to reduce camptothecin degradation and/or precipitation of camptothecin degradation products in the external medium. The invention further provides improved methods of formulating liposomal camptothecins, kits comprising liposome-encapsulated camptothecins, and methods of using the same to treat a variety of diseases and disorders, including cancer.11-19-2009
20090285882Stabilized Liposome Compositions and Related Methods of Use - Liposome compositions and related methods of preparation which can comprise one or a plurality of biopolymer components.11-19-2009
20090285879Malaria prime/boost vaccines - Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from 11-19-2009
20110076324Use of Histamine H4 antagonist for the treatment of post-operative adhesions - The present invention includes methods for the inhibition of post-operative adhesion formation between tissue surfaces in a body cavity having been subjected to a surgical procedure, which methods involve administering a histamine H4 receptor antagonist, systemically, directly to tissue surfaces in the body cavity, or both, and to delivery vehicles and compositions suitable for use for local, non-systemic administration of a drug to the body and directly to tissue within a body cavity having been subjected to a surgical procedure.03-31-2011
20110171292PEPTIDE COMPOSITIONS AND METHODS OF USE - The present invention provides isolated peptides with at least two cysteine residues capable of forming one or more disulfide bonds. Pharmaceutical compositions comprising the isolated peptides of the present invention are also provided. The invention also provides methods for inhibiting, preventing or improving the pathological or clinical manifestations of cancer or an inflammatory disease or disorder in a subject, comprising administering a peptide of the invention.07-14-2011
20110171289COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS - The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.07-14-2011
20110076323VACCINE FOR ALZHEIMER'S DISEASE - Compositions and methods for prevention and treatment of Alzheimer's disease utilize a combination of amyloid-beta protein or a fragment thereof and a heat shock protein or a fragment thereof.03-31-2011
20090291131SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA - The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and/or modifying PLK-1 interfering RNA having immunostimulatory properties. Methods for sensitizing a cell such as a cancer cell to the effects of a chemotherapy drug comprising sequentially delivering PLK-1 interfering RNA followed by the chemotherapy drug are also provided.11-26-2009
20120269884Vaccine for Modulating Between T1 and T2 Immune Responses - The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.10-25-2012
20110076322Amphoteric liposomes - A serum-stable mixture of lipids capable of encapsulating an active agent to form a liposome, said mixture comprising phosphatidylcholine and phosphatidylethanolamine in a ratio in the range of about 0.5 to about 8. The mixture may also include pH sensitive anionic and cationic amphiphiles, such that the mixture is amphoteric, being negatively charged or neutral at pH 7.4 and positively charged at pH 4. Amphoteric liposomes comprising such a mixture may be used for encapsulating nucleic acid therapeutics, such as oligonucleotides and DNA plasmids. The drug/lipid ratio may be adjusted to target the liposomes to particular organs or other sites in the body.03-31-2011
20100291190Topical Composition For Anti-Aging Skin Treatment Using Dual DNA Repair Mechanism and Method of Use - A topical composition for anti-aging treatment of the skin includes water soluble extract of 11-18-2010
20090169613TARGETING OF TUMOR STEM CELLS THROUGH SELECTIVE SILENCING OF BORIS EXPRESSION - The present invention provides compositions useful for the treatment of cancer that inhibit tumor stem cells through suppression of an activity or the expression of BORIS. The compositions target tumor stem cells through molecules that are specific to tumor stem cells. Specifically, the invention provides immunoliposomes specific to tumor stem cells that include nucleic acid compositions capable of eliciting the process of RNA interference of BORIS expression. Also provided are immunoliposomes specific to tumor stem cells that include anti-BORIS ribozymes, antisense oligonucleotides, decoy oligonucleotides or small molecule inhibitors. Methods of manufacturing, delivering, and use of such compositions in the treatment of cancer are also provided.07-02-2009
20100129435Methods and compositions for treatment of ocular neovascularization and neural injury - Methods and compositions for the treatment of ocular neovascularization and macular degeneration. The invention includes combining photodynamic therapy with administration of a neuroprotectant and a neovascularization inhibitor.05-27-2010
20100129438Methods and Compositions for the Treatment and Prevention of HIV Infection Using TRIM5ALPHA - The invention provides novel TRIM polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length TRIM proteins, the invention further provides isolated TRIM fusion proteins, antigenic peptides and anti-TRIM antibodies. The invention also provides TRIM nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an TRIM gene has been introduced or disrupted. The present invention also provides methods and compositions for the diagnosis and treatment of viral infection and/or replication, e.g., HIV infection. The invention further provides methods for identifying a compound capable of treating or preventing viral infection and/or replication, e.g., HIV infection and AIDS. In addition, the invention provides a method for treating a subject having a viral infection and/or replication, e.g., HIV infection using the modulators of the invention.05-27-2010
20100129434COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCORMYCOSIS AND OTHER FUNGAL DISEASES - The invention provides a composition including at least one iron chelating compound and at least one antifungal agent. The composition can include the iron chelating compounds deferiprone or deferasirox. An antifungal agent included in the composition can include a polyene antifungal agent, an azole antifungal agent or an echinocandin antifungal agent. The invention also provides a method of treating or preventing a fungal condition. The method includes administering to an individual having, or susceptible to having, a fungal condition a therapeutically effective amount of at least one iron chelating compound for a sufficient time to reduce the severity of a fungal condition, wherein the iron chelating compound comprises a non-siderophore or non-xenosiderophore relative to the fungal condition. A method of treating or preventing a fungal condition provided by the invention also can include administering to an individual having, or susceptible of having, a fungal condition a therapeutically effective amount of at least one iron chelating compound and at least one antifungal agent. Provided further by the invention is a method including prophylactic administration of the at least one iron chelating compound or at least one iron chelating compound and at least one antifungal agent prior to onset of the fungal condition.05-27-2010
20080279916Liposome Preparation - A liposome preparation is provided. This liposome preparation is capable of stably encapsulating a drug which is unstable under an acidic condition, and such stable encapsulation is realized without detracting the effect realized by the modification of the membrane by a hydrophilic macromolecule such as stability in blood. More specifically, the liposome preparation comprises a unilamellar vesicle formed from a lipid bilayer comprising a phospholipid as its main membrane component, and an interior aqueous phase of the vesicle at a pH of up to 5. The liposome has a drug loaded therein, and the vesicle is modified with a hydrophilic macromolecule only on its exterior surface.11-13-2008
20110200666UV PROTECTION AGENT FOR THE SKIN OR HAIR HAVING A UV FILTER SUBSTANCE ENCAPSULATED IN A VESICULAR CARRIER SYSTEMu - To provide a UV protection agent for topical application to the skin or hair with a very high UV filter substance concentration and good adhesion to skin and hair in accordance with the invention there is proposed a UV protection agent having at least one UV filter substrate encapsulated in a vesicle carrier system, wherein the UV protection agent is characterised in that the at least one UV filter substance encapsulated in the vesicular carrier system is soluble in oil and the vesicular carrier system comprises vesicles which are made up of hydrophobised polysaccharides and are of a particle size of between 10 and 1000 nm and have a positive surface charge with a zeta potential in the range of between 1 and 150 mV. In addition there is proposed the use of such a UV protection agent in suitable cosmetic and/or pharmaceutical formulations.08-18-2011
20110200665Novel Thermosensitive Liposomes Containing Therapeutic Agents - A thermosensitive liposome for the delivery of active agents and a composition thereof are disclosed, wherein the liposome comprises at least one phosphatidylcholine, at least one phosphatidylglycerol and at least one lysolipid, and the gel to liquid phase transition temperature of said liposome is from 39 0° C. to 45° C.08-18-2011
20100285109TRUNCATED SECRETORY ASPARTYL PROTEINASE 2 - The present invention relates to a truncated form of the secretory aspartyl proteinase 2 (Sap2), as well as to nucleic acid molecules encoding same. This truncated Sap2 polypeptide (tSap2) is surprisingly stable and devoid of enzymatic activity but retains full immunogenicity upon intravaginal administration and confers full protection against intravaginal challenge by the 11-11-2010
20100104626METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE - The invention relates to a method for diagnosing a kidney disease state. The method comprises the steps of administering to a patient a composition comprising a conjugate or complex of the general formula V-L-D where the group V comprises a vitamin receptor binding ligand that binds to kidney proximal tubule cells and the group D comprises a diagnostic marker, and diagnosing the kidney disease state. The invention also relates to a method for treating a kidney disease state. The method comprises the steps of administering to a patient suffering from the disease state an effective amount of a composition comprising a conjugate or complex of the general formula V-L-D where the group V comprises a vitamin receptor binding ligand that binds to kidney proximal tubule cells and the group D comprises an antigen, a cytotoxin, or a cell growth inhibitor, and eliminating the disease state.04-29-2010
20100062054LIPOBEADS AND THEIR PRODUCTION - Lipobeads (liposome-encapsulated hydrogels) combine properties of hydrogels and liposomes to create systems that are sensitive to environmental conditions and respond to changes in those conditions in a fast time scale. Lipobeads may be produced by polymerizing anchored or unanchored hydrogels within liposomes or by mixing anchored or unanchored hydrogels with liposomes. Giant lipobeads may be produced by shrinking unanchored nanogels in lipobeads and fusing the resulting lipobead aggregates, long-term aging of anchored or unanchored lipobeads, or mixing anchored or unanchored aggregated nanogels with liposomes. Poly(acrylamide), poly(N-isopropylacrylamide), and poly(N-isopropylacrylamide-co-1-vinylimidazole) lipobeads were produced and characterized.03-11-2010
20100062051COMPOSITION FOR TREATMENT OF CERVIX CANCER - The present invention relates to a composition for the treatment of cervix cancer, more precisely a composition for the treatment of cervix cancer comprising the first active part containing human papilloma virus (referred as “HPV” hereinafter) specific siRNA as an active ingredient and the second active part containing an anticancer agent as an active ingredient. The composition for the treatment of cancer of the present invention has better anticancer effect than the single therapy of the HPV specific siRNA or the anticancer agent, and has an advantage of reducing side effects by using the anticancer agent at a low concentration.03-11-2010
20100062049AQUEOUS FORMULATION FOR SELECTIVE TARGETING AND DELIVERING GENE TO CANCER CELLS - The present invention relates to a cationic lipid based aqueous formulation comprising cationic lipid, dexamethasone and a neutral co-lipid, wherein the said formulation is useful for selective targeting and delivering gene to glucocorticoid receptor expressing cancer cells. Glucorticoid receptors (GR) express in various normal and cancer cells. A lot of ligand activated physiological functions are known involving GR but its role in cancer progression (if any) is not clearly understood. Synthetic GR antagonist, dexamethasone (Dex) finds use as anti-inflammatory drug and is known to induce apoptosis in cancer cells. This Dex is included in a cationic lipid-based formulation as a co-lipid to deliver to and express genes specifically in cancer cells possibly through expressed GR. Gene delivery to cancer cells is independent of the gene construct, and tumor cell line. Normal transformed cells expressing GR but with no cancer lineage show much smaller level of transfection. The composition of the formulation is optimized. The formulation may have particular application to the enhanced delivery of anticancer genetic constructs to cancer, with the synergistic effect of Dex in inducing apoptosis as such.03-11-2010
20100104624COMBINATION THERAPY USING PHOSPHODIESTERASE INHIBITORS - Described here are compositions and methods for treating side-effects of vasodilator therapy. The compositions may include both a vasodilator and a side-effect alleviating agent in a single dosage form. Alternatively, the vasodilator and side-effect alleviating agent may be formulated separately, each in its own dosage form. The compositions may be packaged as kits for use with various medical conditions.04-29-2010
20110268791POROUS NANOPARTICLE SUPPORTED LIPID BILAYER NANOSTRUCTURES - Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components, for example, drugs, can be loaded in and released from the porous particle core of the protocell(s) and then delivered within the bioactive cell.11-03-2011
20090169611Gel-Formulations of Hydrophobic Photosensitizers for Mucosal Applications - The present invention relates to improved methods of formulations of hydrophobic photosensitizers, and their precursors, for mucosal administration. The formulation of the invention comprises of hydrophobic photosensitizers which have been incorporated into suitably sized liposomes. Additionally, these formulations include the incorporation of PS-loaded liposomes into a copolymer matrix. The liposome of the present invention allows the hydrophobic photosensitizers to be incorporated into the thermogel matrix and thus promoting intimate contact between the formulation and the mucosal layer for enhanced drug absorption.07-02-2009
20090169612Systemic Immune Activation Method Using Nucleic Acid-Lipid Complexes - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method.07-02-2009
20090169615Collagen Formulations for Improved Skin Care - Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.07-02-2009
20090169607Pharmaceutical Compositions Comprising Cyclosporin - The invention relates to liquid pharmaceutical compositions containing: a) a therapeutically effective dose of a cyclosporin; b) an aqueous carrier liquid; c) a first solubilizing substance selected among the group of phospholipids; and d) a second solubilizing substance selected among the group of non-ionic surfactants. Preferably, the cyclosporin is liposome solubilized. The inventive composition is suitable for oral, parenteral, nasal, mucosal, topical, and particularly pulmonary application in the form of an aerosol.07-02-2009
20080241232Use of green porphyrins to treat neovasculature in the eye - Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.10-02-2008
20110206758Vaccine Compositions Comprising a Saponin Adjuvant - The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of 08-25-2011
20100129432MICROORGANISM-KILLING COMBINATION - The invention is directed to a microorganism-killing combination comprising a photosensitizer in an amount effective to kill microorganisms in a photodynamic process and a chitosan in an amount effective to enhance the microorganism-killing effect of the photosensitizer in the photodynamic process. The invention also provides the methods of administering the synergistic bacteria-killing combination to kill bacteria or treat infection.05-27-2010
20100129431IDEBENONE COMPOSITION FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The invention describes the use of an injectable form of Idebenone to induce protect from neuronal damage, improve recovery after brain trauma; stroke, intoxication, neurodegenerative diseases, memory loss or neuropathology associated with neuroinflammation or infection damage and to restore cognitive function, suppress disorientation, alcoholic and drug abuse associated syndromes and other signs of neuronal damage.05-27-2010
20100129436SUBTANCES FOR THE PROTECTION OF CELLS AND/OR TISSUES - The invention relates to substances that are suitable for protecting cells and/or tissues.05-27-2010
20100129430LIPOSOME DRUG CARRIERS WITH PH-SENSITIVITY - Using liposomes to deliver bioactive agents to cancer or tumor cells and compositions of specific lipids that form liposomes to deliver a biologically active agent. A liposome composition for delivering of a biologically active agent, comprising liposomes comprising at a least first rigid lipid and a second rigid lipid each having a head group and a hydrophobic tail; a polyethyleneglycol-linked lipid having a side chain matching at least a portion of the first or the second lipid; and an entrapped biologically active agent. The first lipid can be a zwitterionic lipid and the second lipid can have a titratable head group. The composition can be adapted to release the entrapped at a certain pH.05-27-2010
20100209491METHOD FOR ENHANCING SERUM STABILITY AND LOWERING IMMUNE RESPONSE OF SIRNA DOWN-REGULATING GENE EXPRESSION OF HBV OR HCV - A method for enhancing the serum stability and lowering the immunostimulatory property of a small interfering ribonucleic acid (siRNA) which mediates RNA interference (RNAi) against a viral gene expression of hepatitis B virus (HBV) or hepatitis C virus (HCV) is provided.08-19-2010
20100209488PROTEIN KINASE MODULATING COMPOUNDS AND METHODS FOR MAKING AND USING THEM - The invention provides compositions, e.g., small molecules, that disrupt the activity of protein kinases, including constitutively activated protein kinases, such as kinases constitutively activated through mutations, and kinases in their native inactivated state, and methods for making and using them. In one aspect, compositions of the invention bind a protein kinase in its inactive conformation involving the conserved asparagine-phenylalanine-glycine residue motif, or “Asp-Phe-Gly” or “DFG” motif, of the activation loop in the allosteric binding site. The small molecule protein kinase inhibitors of the invention comprise or are derivatives or analogs of oxadiazoles, thiadiazoles, oxazoles, thiazoles, arylamides, quinolones, pyrazoles, pyrazolones, imides, pyrolles, imidazoles and/or triazoles.08-19-2010
20090169608TOPICALLY APPLICABLE COMPOSITION FOR USE AS A SKIN BLEACHING AGENT - Topical composition for use especially as a skin lightener, characterized in that it contains an effective amount of at least one compound of general formula (I) or a mixture of such compounds and/or an acid addition salt thereof:07-02-2009
20080274173HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.11-06-2008
20100209487NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF - The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.08-19-2010
20100209486Method of enhancing CoenzymeQ10 levels in mammals - The invention relates to a method of enriching the CoEnzyme Q08-19-2010
20100203112COMPOSITION OF CATIONIC PHOSPHOLIPID NANOPARTICLES FOR EFFECTIVE DELIVERY OF NUCLEIC ACIDS - The present invention provides a cationic phospholipid liposome composition comprising 1,2-dioleoyl-sn-glycero-S-ethylphosphocholine (EDOPC), 3β-[N—(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-cholesterol) and 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhPE), a liposome-nucleic acid complex which is capable of forming a complex therewith, and a pharmaceutical composition comprising the same. The cationic phospholipid liposome of the present invention is highly effective for intracellular delivery of nucleic acids and reduction of cytotoxicity, as compared to conventional liposome products. Therefore, the present invention can be useful for gene therapy via intracellular delivery of a desired material to target cells.08-12-2010
20120294932Prostate Carcinogenesis Predictor - A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-ι and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-ι, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-ι levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-ι. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-ι. The compound can be a small interfering RNA (siRNA) molecule.11-22-2012
20120294934TRANSDERMAL COMPOSITIONS FOR ANTICHOLINERGIC AGENTS - The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for administering such formulations to a person in need thereof while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics.11-22-2012
20120294930COMBINATION OF KINASE INHIBITORS AND USES THEREOF - The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.11-22-2012
20080279922Releasable linkage and compositions containing same - A conjugate comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-, hydroxy- or carboxyl-containing ligand is described. The resulting conjugate is capable of releasing the parent amine, hydroxy, or carboxyl-containing compound via thiol-mediated cleavage. The system allows for delivery of various amino-, hydroxy-, or carboxy-containing drugs in the form of their thiolytically cleavable macromolecular conjugates.11-13-2008
20080279926Vaccine Compositions Comprising a Saponin Adjuvant - An immunogenic composition in a dose volume suitable for human use comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of 11-13-2008
20080279925Method(s) of preventing, arresting, reversing and treatment of atherosclerosis - A method of preventing, arresting, reversing and treatment of atherosclerosis by enhancing the activities of Δ11-13-2008
20080279921Gel-formulations of hydrophobic photosensitizers for mucosal applications - The present invention relates to improved methods of formulations of hydrophobic photosensitizers, and their precursors, for mucosal administration. The formulation of the invention comprises of hydrophobic photosensitizers which have been incorporated into suitably sized liposomes. Additionally, these formulations include the incorporation of PS-loaded liposomes into a copolymer matrix. The liposome of the present invention allows the hydrophobic photosensitizers to be incorporated into the thermogel matrix and thus promoting intimate contact between the formulation and the mucosal layer for enhanced drug absorption.11-13-2008
20080279919LIPOSOMES FOR PROTECTION AGAINST TOXIC COMPOUNDS - Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposome. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds and prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds.11-13-2008
20080279917Bisbenzamidines for the Treatment of Pneumonia - A method of combating infectious agents, such as 11-13-2008
20100203111G-SUBSTRATE FOR THE TREATMENT AND PREVENTION OF PARKINSON'S DISEASE - The invention features methods and compositions for the treatment and prevention of Parkinson's Disease.08-12-2010
20080286350Formulation of Multivalent Antibody Constructs and Use of Same for Cancer Therapy - The invention relates to the formation of multivalent antibody constructs for testing and therapeutic purposes. In one embodiment the constructs consist of antibodies or antibody fragments conjugated to liposomes. The constructs are employed in a cell-based in vitro assay for comparing the therapeutic activity of antibodies or antibody fragments in multivalent form to the same antibodies or fragments in bivalent, free form. The assay is useful for identifying antibodies having potential in vivo activity. Selected antibodies may then be tested in an animal model of a disease state, such as cancer or an autoimmune disorder. Co-delivery of antibodies and chemotherapeutics may also be investigated. In accordance with the invention, a significant enhancement in the activity of antibodies such as trastuzumab and rituximab was observed when these antibodies were presented in the multivalent liposomal form. Key cell survival signaling molecules were down-regulated upon treatment with the multivalent liposomal antibody construct. The invention demonstrates the potential of liposome technology to enhance the therapeutic effect of antibodies via a mechanism that modulates cell survival, likely through clustering of target/antibody complex.11-20-2008
20080286351Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof - The invention provides synthetic methods for PEGylated cardiolipins with varying linkers. The methods can be employed to prepare PEGylated cardiolipin with different fatty acid and/or alkyl chain length with or without unsaturation. The PEGylated cardiolipin, prepared by the present methods, can be incorporated into liposomes that can also include active agents such as hydrophilic or hydrophobic drugs for the treatment of human and animal diseases. In addition, the PEGylated cardiolipin can be incorporated into liposomes that include compounds for therapeutic and diagnostic imaging. The use of such liposomes with PEGylated cardiolipin prolongs the period of liposomal circulation without disrupting the lipid bilayer.11-20-2008
20080292689METHOD FOR INHIBITING FREE RADICALS - A method for inhibiting free radical is provided. The method includes administering to a subject an effective amount of an herbal composition including 11-27-2008
20080292687Methods of Treating Cancer and Other Conditions or Disease States Using Lfmau and Ldt - The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states: Where X is H or F; R11-27-2008
20080292688Liposome and preparation method of the same - The present invention relates to a composition and a method for preparing a liposome, the liposome including a lipid bilayer and an aqueous core contains a hydrophobic or a hydrophilic drug and a component—Vitamin E derivative (d-α tocopheryl polyethylene glycol 1000 succinate; TPGS). TPGS is able to increase the encapsulation efficiency of drug in liposome as well as to enhance the stability of drug in liposomes. Such liposome is capable to increase the skin permeation of drugs. The preparation method comprises the following steps: (1) adding the drug to a Vitamin E derivative solution to form a mixture; and (2) adding at least one phosphatidyl choline to the mixture, after hydration from either sonication or homogenization.11-27-2008
20080305156Echogenic Vehicle for Clinical Delivery of Plasminogen Activator and Other Fibrin-Binding Therapeutics to Thrombi - We disclose a composition comprising an echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, and a thrombolytic compound trapped by the ELIP. We also disclose a method of treating a medical condition in a patient characterized by a thrombus in the patient's vasculature, comprising administering to the patient the composition in an amount effective to reduce the size of the thrombus.12-11-2008
20100278903PROPHYLACTIC AND IMMUNOMODULATORY COMPOSITIONS AND USES - Provided is use of a sphingosine compound, or a derivative of a sphingosine compound, in the manufacture of a vaccine effective in the treatment and prevention of an infectious disease and treatment and/or prevention of an autoimmune disease. Also provided is use of a sphingosine compound, or a derivative of a sphingosine compound, in the manufacture of an immunomodulation medicament effective in the prevention of infectious disease and treatment and/or prevention of an autoimmune disease.11-04-2010
20080220056Treatment for liver disease - The present invention is based on the finding that the artificial induction of hepatic stellate cell (HSC) apoptosis in vivo can promote the resolution of liver fibrosis. Thus, the present invention provides methods for treating liver disease in a subject involving administration of an inducer of apoptosis which is capable of selectively inducing hepatic stellate cell apoptosis in the liver of the subject or of an agent which is capable of giving rise to such an inducer in the subject. In addition, the invention provides methods for treating liver fibrosis in a subject comprising the selective delivery of an inducer of apoptosis specifically to the hepatic stellate cells of the subject or of an agent which is capable of giving rise to an inducer of hepatic stellate cell apoptosis.09-11-2008
20100291189METHOD FOR PRODUCING A MEMBRANE PROTEIN - A method is provided for producing a membrane protein folded to its native structure or active structure in a lipid disc or a liposome. The method comprises: (a) preparing a reaction solution for cell-free protein synthesis containing a polynucleotide encoding a membrane protein, a steroidal detergent, and a phospholipid, wherein the steroidal detergent is contained at a concentration higher than its critical micelle concentration; (b) decreasing the concentration of said steroidal detergent in the reaction solution; and (c) synthesizing the membrane protein simultaneously with formation of a lipid disk or liposome into which the synthesized membrane protein is integrated.11-18-2010
20110008417IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR - This invention discloses compositions that consist essentially of a Gag polypeptide or at least one portion thereof, and optionally antigen-presenting cells or their precursors, for treating or preventing lentiviral infections including the treatment or prevention of related acquired immunodeficiency diseases. In certain embodiments, the compositions consist essentially of a plurality of overlapping and/or non-overlapping peptides derived from a single Gag polypeptide or from different Gag polypeptides.01-13-2011
20080311181Serum-Stable Amphoteric Liposomes - The invention relates to amphoteric liposomal formulations which are provided with great serum stability and are suitable for the intracellular delivery of oligonucleotides.12-18-2008
20110206759CCR7 LIGAND DELIVERY AND CO-DELIVERY IN IMMUNOTHERAPY - Chemokines may be administered to a patient for immunotolerization. Chemokines include CCL19 and CCL21. Materials and methods for accomplishing tolerization and described.08-25-2011
20120294929METHOD OF DIAGNOSING AND TREATING CANCER USING B-CATENIN SPLICE VARIANTS - The invention relates to method and compositions for treating and diagnosing cancer, in particular β-catenin related cancers. In general, the methods include administering RNAi constructs. The invention further relates to methods of identifying CTNNB1 related cancer therapeutics.11-22-2012
20080206317Ternary Non-Lamellar Lipid Compositions - The present invention provides a particulate composition including; a) at least 50 % of at least one structure forming amphiphile, b) 0 to 40% of at least one structure swelling amphiphile, and c) 2 to 20% of at least one dispersion stabilising polymeric amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and wherein the composition comprises non-lamellar particles or forms non-lamellar particles when contacted with an aqueous fluid. Where component b) is 0% then component a) comprises at least two structure forming amphiphiles. The invention also provides pharmaceutical compositions of the compositions and kits containing the compositions for establishing a pharmaceutical formulation of an active agent.08-28-2008
20100209494Liposomes and Uses Thereof - The invention relates to the field of molecular medicine and pharmacology. More specifically, it relates to liposomes and their use as delivery vehicle for therapeutic compounds. Provided is a liposome comprising at least one lipid bilayer enclosing an interior compartment, wherein said lipid bilayer comprises at least one synthetic pyridinium-derived amphiphile, for instance a Saint-molecule.08-19-2010
20100209493HLA-A2 Tumor Associated Antigen Peptides and Compositions - A peptide or composition comprising at least one HLA-A2 epi tope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.08-19-2010
20100209492Targeted Liposomal Drug Delivery System - A metal targeting complex which associates with a charged liposomal structure is provided. The metal targeting complex provides the targetability of the liposomal construct to the desired receptor sites of a warm-blooded host for therapy or diagnostic use.08-19-2010
20080279920Compositions For Treating Respiratory Viral Infections and Their Use - The invention provides siRNA compositions that interfere with viral replication in respiratory viral infections, including respiratory syncytial virus and avian influenza A, including the H5N1 strain. The invention further provides uses of the siRNA compositions to inhibit expression of viral genes in respiratory virus-infected cells, and to uses in the treatment of respiratory virus infections in a subject. Generally the invention provides polynucleotide that includes a first nucleotide sequence of 15 to 30 bases that targets the genome of a respiratory syncytial virus or an influenza A virus, a complement thereof, a double stranded polynucleotide or a hairpin polynucleotide. Additionally the invention provides vectors, cells and pharmaceutical compositions containing siRNA sequences.11-13-2008
20100143452POLYPHENOL CONTAINING COMPOSITIONS - The present invention relates to liposomal compositions comprising polyphenol in the interior of a colloidal carrier, and especially to the use of such compositions in the treatment of cancer or in the inhibition of cancer growth and in the treatment of inflammatory and autoimmune conditions. More specifically, the invention relates to a method for targeting a polyphenol to tumor tissue, or to sites in the body requiring anti-inflammatory activity or activity against autoimmune conditions. Furthermore, the present invention describes a method of post-loading a polyphenol derivate such as caffeic acid into a liposome.06-10-2010
20100143456MODEL MEMBRANE SYSTEMS - The present invention relates generally to modifying biological and/or synthetic membranes or liposomes, or combinations thereof, for the purpose of altering immunity, or for the targeting of drugs and other agents to a specific cell type or tissue when administered in vivo to achieve a therapeutic effect. Modification of the membranes is achieved by incorporation and/or attachment of metal chelating groups, thereby allowing engraftment of one or more targeting molecules possessing a metal affinity tag, and a targeting of the engrafted membranes to specific cell types or tissues in vivo. The invention, thus, provides a means of modifying the properties of biological and/or synthetic membranes and liposomes for the purpose of altering or enhancing immunity when used as vaccines, or for the targeting of encapsulated/incorporated drugs or other agents to a specific cell type or tissue when administered in vivo, to achieve a therapeutic effect or response, or for modifying a physiological response or biological function.06-10-2010
20100143450DEVELOPMENT OF ASTHMA THERAPY WITH rAAV-mediated AMCase shRNA - The invention provides small interfering RNA (siRNA) and their carriers that could treat asthma in mammalian through inhibiting acidic mammalian chitinase (AMCase) gene expression. The invention further provides a composition comprising siRNA of the present invention and a carrier. The invention also provides a method for treating asthma of a subject.06-10-2010
20080268030Gene therapy for diabetic ischemic disease - It is possible to stimulate the angiogenesis of an ischemic site declined by diabetes and to recuperate ischemic disease by administering HGF (hepatocyte growth factor) gene to the diabetic ischemic.10-30-2008
20080268033BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES - The present invention relates to a phenothiazinium compound of Formula (I):10-30-2008
20100136101COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF HIF-1 ALPHA - RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.06-03-2010
20090087480PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION - A pharmaceutical composition containing one or more antifungal agents selected from an arylamidine derivative represented by the general formula:04-02-2009
20110206760ANGIOPOIETIN DERIVED PEPTIDES - Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.08-25-2011
20110268789USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS - This invention relates to methods and compositions for the treatment, management or prevention of injuries to one or more of the organs of the body, such as the brain, heart, lung, kidneys, liver, and gastrointestinal tract, of humans or other mammals caused by one or more anticancer agents. The methods of this invention consist of the administration of an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP/VIP receptors, including all of their various isoforms. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents useful for the treatment, management or prevention of injuries to the organs of the body of humans or other mammals undergoing cancer chemotherapy. Combination therapy with one or more PACAP-like compounds plus one or more anticancer agents can be used in the treatment of hematological cancers.11-03-2011
20100143458GLUTAMIC ACID DECARBOXYLASE (GAD) BASED DELIVERY SYSTEM - The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the hippocampus, subthalamic nucleus of the basal ganglia, mesaphilia and thalamus.06-10-2010
20100143454Flavivirus NS5A Proteins For the Treatment of HIV - GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a -GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.06-10-2010
20090053294Anti Mineralocorticoid Therapy of Infection - Antimineralocorticoid compounds are disclosed for use in the prophylaxis and therapy of viral infections, especially the retroviral infection by HIV. These compounds can be administered alone or in combination with conventional anti-viral agents or anti-sense mineralocorticoid Steroid ReceptorNA or DNA mutants of heat shock proteins.02-26-2009
20110206756DITHIOCARBAMATE METAL CHELATES AND METHODS OF MAKING AND USING THEREOF - Described herein are compositions useful in anticancer treatment and prevention. The compositions are composed of (a) a dithiocarbamate metal chelate and (b) an amphiphile, wherein the amount of amphiphile is sufficient to produce a liposome or micelle. Methods for using the compositions in anticancer treatment and prevention are also described herein.08-25-2011
20110142922STABILIZED COMPOSITION AND METHOD FOR DERMATOLOGICAL TREATMENT - A stabilized, topical composition for the treatment of acne and other dermatological conditions comprises a liposomal formulation of a retinoid and an antibiotic in which the retinoid is disposed in the lipid phase of the formulation, and the antibiotic is disposed in the aqueous phase so as to be isolated from the retinoid. Lincosamides, such as clindamycin, are one group of antibiotics which may be used in the composition. Tretinoin is one preferred retinoid. Also disclosed are methods for making the compositions and methods for using the composition.06-16-2011
20110142921NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION - Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C (HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or as pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with known delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.06-16-2011
20110142920TREATMENT OF LENGTH DEPENDENT NEUROPATHY - Compositions, and methods of use thereof, are provided for the treatment of painful neuropathy by local or topical delivery of compounds that interact with α-adrenergic receptors, especially an alpha06-16-2011
20090220583Method and composition for treating inflammatory disorders - There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.09-03-2009
20110142916Adjuvants for Use in Vaccination - A compound of formula (I) for use as an adjuvant in vaccination; wherein R is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 50 carbon atoms; R06-16-2011
20110142914INHALABLE COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY - The present disclosure provides methods and compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent. In embodiments the compositions may be introduced by inhalation.06-16-2011
20120070491CASB7439 CONSTRUCTS - The present disclosure relates to compounds and methods for increasing the recombinant production of CASB7439 polypeptides, and for methods of utilizing the same.03-22-2012
20120070490ANTI-TRYPANOSOMAL PEPTIDES AND USES THEREOF - The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid protozoan with hydrophobic signal sequence peptides and compositions including such hydrophobic signal sequence peptides.03-22-2012
20120070489COMBINATION THERAPY FOR TREATMENT OF FIV INFECTION - The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and another nucleoside analog, such as, for example, 3TC to the animal. In another embodiment, cats are given an effective dose(s) of AZT, 3TC, and a retroviral protease inhibitor.03-22-2012
20120070488METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.03-22-2012
20120070487ALKYLSACCHARIDE COMPOSITIONS WITH NUTRACEUTICALS - The present invention provides nutraceutical compositions with enhanced oral bioavailability. The compositions of the present invention include one or more alkylsaccharides admixed with one or more nutraceutical.03-22-2012
20120070486METHODS AND COMPOSITIONS RELATED TO PREFOLDIN AND ITS REGULATION - The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides methods for the delivery of a siNA (e.g., a siRNA) to a cell to modulate expression of a PFDN 1-6. These methods may be used to treat a disease, such as cancer.03-22-2012
20090087479Orally bioavailable lipid-based constructs - The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetucic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.04-02-2009
20090130192CLASS III SLRP AGONISTS FOR THE REDUCTION OF BLOOD VESSEL FORMATION - The invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the inhibition of blood vessel formation. In addition the invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the prevention and/or treatment of conditions characterised by excessive activity and/or migration of monocytes and/or macrophages. Suitable agents may include class III SLRPs such as opticin. Methods of treatment using agents able to promote class III SLRP activity are also provided.05-21-2009
20090186077THERMO-RESPONSIVE MATERIALS - The invention is directed to, inter alia, injectable materials, which comprise a a zero-length cross-linking agent encapsulated in a thermo-responsive liposome dispersed in a polymer solution where the polymer and cross-linking agent are segregated at a first temperature, and non-segregated at a second temperature, and the material is injectable at the first temperature. The invention is directed to, inter alia, processes for producing the material and use of the material for tissue repair and regeneration and controlled delivery of an agent are also described.07-23-2009
20090136563Method for Coating Particle with Lipid Film - A method for coating an object, i.e. a particle, with two sheets of lipid film having a space formed there between. In the method for coating a particle having a positive electrostatic-charging property with two sheets of lipid film, the particle having a positive electrostatic-charging property is brought into contact with a plurality of SUV type liposomes having a negative electrostatic-charging property to form a complex having a negative electrostatic-charging property containing the particle having a positive electrostatic-charging property and the SUV type liposomes having a negative electrostatic-charging property coupled electrostatically with the particle having a positive electrostatic-charging property, and then the complex having a negative electrostatic-charging property is treated with cation.05-28-2009
20090136564MICELLES - The present invention provides micelles, solutions comprising micelles, methods for preparing micelles, and methods for delivering micelles to patients. The micelles have fixed, preselected hydrodynamic diameters and are formed from basic or acidic amphiphilic compounds.05-28-2009
20090136566THERAPEUTIC TRITERPENOIDS - The present invention relates generally to compositions that can be obtained by extraction of birch bark, methods of using such compositions (e.g., methods of medical use, cosmetic use and/or pharmaceutical use), food products and methods of manufacturing such compounds. The compositions are triterpenes, triterpene alcohols, or derivatives of triterpene alcohols.05-28-2009
20120244213METHODS FOR THE TREATMENT OF SPEECH IMPEDIMENTS - The present invention relates to methods of treating for treating stuttering or other speech impediments that are not related to psychiatric disorders or autism using oxytocin or its analogs.09-27-2012
20090186074LIPID VESICLES DERIVED FROM OLIVE OIL FATTY ACIDS - Novel lipid vesicle compositions comprising lipids derived from olive oil fatty acids known as olivates, methods of their preparation, and methods of their use in cosmetics, food, dermatologics, and pharmaceuticals.07-23-2009
20090186078TREATMENT OF TRIPLE RECEPTOR NEGATIVE BREAST CANCER - The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of ‘triple receptor negative’ breast cancer.07-23-2009
20090186075Composition - The present invention provides the use of a composition comprising an antigen recognizing molecule or fragment thereof and a lipid-based carrier for blocking an interaction between a ligand and a receptor.07-23-2009
20080317838Liposomal Vaccine Compositions Comprising a Polysaccharide Antigen and a Protein Adjuvant - A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against 12-25-2008
20080317836Topical compositions for anti-aging skin treatment - This invention discloses anti-aging skin treatment compositions and methods that utilize plant-based copper and zinc antioxidant complexes.12-25-2008
20130216606LIPOSOMAL FORMULATION FOR OCULAR DRUG DELIVERY - The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2μπι. The present invention is also directed to a pharmaceutical comprising the liposomal formulation and a method of producing the liposomal formulation for ocular drug delivery. Additionally, the present invention is directed to a method of treating or preventing an ocular disease, comprising administering the liposomal formulation or the pharmaceutical composition to a subject in need thereof.08-22-2013
20130216610BIPHASIC LIPID-VESICLE COMPOSITION AND METHOD FOR TREATING CERVICAL DYSPLASIA BY INTRAVAGINAL DELIVERY - A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks.08-22-2013
20090053300MONOCLONAL ANTIBODY, GENE ENCODING THE ANTIBODY, HYBRIDOMA, PHARMACEUTICAL COMPOSITION, AND DIAGNOSTIC REAGENT - Disclosed is a monoclonal antibody which has a heavy chain variable region containing amino acid sequences depicted in SEQ ID NOs:74, 76 and 78 and a light chain variable region containing amino acid sequences depicted in SEQ ID NOs:80, 82 and 84. The monoclonal antibody can be used as a cancer therapeutic agent which acts selectively on a cancer tissue of non-small lung cancer, pancreatic cancer, gastric cancer or the like.02-26-2009
20090053298COMPOSITIONS AND METHODS FOR INHIBITING CAR GENE EXPRESSION BY RNA INTERFERENCE - The present invention provides short interfering ribonucleic acid (siRNA), compositions and methods for inhibiting the CAR gene expression simply and rapidly, which can be used for evaluating toxicity of a chemical substance.02-26-2009
20090053293Nano Anticancer Micelles of Vinca Alkaloids Entrapped in Polyethylene Glycolylated Phospholipids - The present invention provides a nano-micellar preparation containing vinca alkaloids antitumor agent for intravenous injection, which cincludes a therapeutically effective amount of vinca alkaloids antitumor agent (vinblastine, vincristine, vindesine and vinorelbine), a phosphatide derivatized with polyethylene glycol, together with pharmaceutically acceptable adjuvants. The preparation is prepared by encapsulating the medicament with a nano-micelle to obtain the nano-micellar preparation containing vinca alkaloids antitumor agent for injection. The vinca alkaloids antitumor agent and the phosphatide derivatized with polyethylene glycol form a nano-micelle with a highly uniform particle size. In the micelle, the hydrophobic core of encapsulated medicament is surrounded by polyethylene glycol molecules to form a hydrophilic protective layer, so that the medicament is prevented from contacting with the enzymes and other protein molecules in blood and being recognized and phagocytozed by reticuloendothelial system in body, and the circulation time in vivo of the micelle is prolonged.02-26-2009
20090017107NOVEL COMPOSITION TO INCREASE LIBIDO - The present invention relates to a composition for increasing testosterone physiological levels comprising a sufficient amount of at least two ketosteroid derivatives of testosterone metabolism in association with a liposomal carrier bound to a saliva-absorbing carrier, wherein said increase in testosterone levels increases libido.01-15-2009
20090208562Vaccine Composition Comprising a Fibronectin Binding Protein or a Fibronectin Binding Peptide - The present invention relates to a composition comprising at least one fibronectin binding protein, and/or at least one a truncated fibronectin binding protein and/or at least one fibronectin binding peptide, all comprising at least one fibronectin binding domain; and at least one Iscom matrixcomplex and/or liposome and/or at least one lipid and at least one saponin, whereby the at least one lipid and the at least one saponin may be in complex, solution or suspension. Further, it regards use thereof for the production of a vaccine against a micro organism that comprises at least one one fibronectin binding domain. It also regards a kit of parts comprising at least two compartments, wherein one compartment comprises at least one truncated fibronectin binding protein and/or a fibronectin binding peptide, that comprises at least one fibronectin binding domain, and another compartment comprises an instruction for use and/or an Iscom matrixcomplex and/or an iscom complex and or a liposome. Further it relates to a method for vaccination of an individual.08-20-2009
20090208564Compositions of asymmetric interfering RNA and uses thereof - The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5′-overhang, 3′-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.08-20-2009
20130122080PHARMACEUTICAL COMPOSITION CAPABLE OF IMMUNO-REGULATION OR ENHANCEMENT OF IMMUNE RESPONSE - A pharmaceutical composition of immuno-regulation or enhancement of immune response is disclosed, which includes a liposome and an immuno-regulating molecule or an antigenic molecule. The liposome, the immuno-regulating molecule or the antigenic molecule needs no genetic or chemical modification. The immuno-regulating molecule or the antigenic molecule is spontaneously adsorbed by the liposome. Thus, the formed pharmaceutical composition can be used for immuno-regulation or enhancement of immune responses.05-16-2013
20130122082Methods And Compositions For The Treatment And Prevention Of Aging-Associated Conditions - The present disclosure provides novel compositions and therapeutics and their methods of use. In particular, it relates to novel compositions and therapeutics expressing the Cisd2 gene and increasing Cisd2 protein activity as well as methods of using the compositions and therapeutics for treating or preventing aging-associated conditions.05-16-2013
20130122083DNA VACCINES ENCODING HEAT SHOCK PROTEINS - A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease.05-16-2013
20090324704PHOSPHATE DIESTER AMIDES - The present invention relates to lipid-analogous phosphoric acid compounds and in particular phosphoric triesters, phosphoric diester amides and phosphoric diesters. These are preferably cationic phospholipids preferably having at least one free hydroxyl group.12-31-2009
20090324705PHYTONUTRIENT COMPOSITIONS FOR TOPICAL USE - Topical anti-oxidant liposomal phytonutrient formulations and methods for their use such as the treatment of skin inflammation and skin-lightening applications.12-31-2009
20090324706Nanostructures Suitable for Sequestering Cholesterol and Other Molecules - Articles, compositions, kits, and methods relating to nanostructures, including those that can sequester molecules such as cholesterol, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanoparticle core may be surrounded by a shell including a material, such as a lipid bilayer, that can interact with cholesterol and/or other lipids. In some embodiments, the structures, when introduced into a subject, can sequester cholesterol and/or other lipids and remove them from circulation. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions, especially those associated with abnormal lipid levels.12-31-2009
20090324702NOVEL VIRAL VECTOR - The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza; and methods for preventing and treating infectious diseases such as malaria and influenza. More specifically, the invention provides a recombinant transfer vector capable of expressing a foreign gene fused to a virus gene under the control of a dual promoter; a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient; and methods for preventing and treating infectious diseases such as malaria and influenza comprising administrating the recombinant baculovirus to patients.12-31-2009
20090324708COMPOUND HAVING INHIBITORY ACTIVITY ON A RHO-GTPASE CELL PROTEIN, A PROCESS FOR OBTAINING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF AND A METHOD FOR THE TREATMENT OF RHO-GTPASE CELL PROTEIN-MEDIATED CONDITION - The present invention relates to a compound having inhibitory activity on a Rho-GTPase cell protein, the compound having the formula I (Formula I) wherein A is selected from N and N—H, R12-31-2009
20090324707METHOD FOR SYNTHESIZING CONFORMATIONALLY CONSTRAINED PEPTIDES, PEPTIDOMIMETICS AND THE USE THEREOF AS SYNTHETIC VACCINES - The present invention relates to methods for synthesizing conformationally constrained peptides and cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link. This cross-link is formed between the side chain of an amino acid residue or analog and a (2S, 4S)4-functionalized proline residue. The invention further relates to the use of (2S, 4S)-4-functionalized proline residues as building units in the synthesis of such peptidomimetics and to the use thereof as antigens, alone or in combination with suitable immunopotentiating delivery systems, for example immunopotentiating reconstituted influenza virosomes to elicit an immune response in a mammal. Moreover, the invention also relates to pharmaceutical compositions containing the same.12-31-2009
20110223239SPERMICIDAL AND VIRUCIDAL PROPERTIES OF VARIOUS FORMS OF SOPHOROLIPIDS - A method for inactivating spermatozoa, neutralizing or inactivating a virus, and neutralizing or inactivating HIV using sophorolipids having spermicidal and/or antiviral properties produced by synthesizing the sophorolipid by fermentation of 09-15-2011
20110223238Bisbenzamidines for the Treatment of Pneumonia - A method of combating infectious agents, such as 09-15-2011
20110142912NON-SPECIFIC IMMUNOSTIMULATING AGENTS - The present invention relates to the use of a lipid vesicle for the preparation of a medicament. The invention further relates to a method of treating and/or preventing a disease or disorder involving administering such a lipid vesicle to an animal in need thereof.06-16-2011
20090238862Methods and Compositions for Seprase Inactivation - The present invention relates to isolated nucleic acids encoding short hairpin RNAs that interfere with seprase mRNA expression, vector and host cells for expressing seprase mRNA interfering short hairpin RNAs, and methods of therapeutic use of the same for preventing further tumor invasation and metastasis.09-24-2009
20090053292Moraxella catarrhalis protein, nucleic acid sequence and uses thereof - The invention discloses the 02-26-2009
20090053302CANCER TREATMENTS - The present invention relates to liposome comprising encapsulated oxaliplatin and methods for making encapsulated oxaliplatin. The invention also relates to liposomes comprising oxaliplatin and another anticancer drug. The liposomes of the invention are useful in cancer treatments.02-26-2009
20110229560NLRC5 AS A TARGET FOR IMMUNE THERAPY - The present invention concerns the enhancement of immune response to microbial infection and/or inflammation-associated disease through at least partial inhibition of NLRC5. The inhibition may be of any suitable means, although in particular cases it is via siRNA agents. In specific embodiments, a particular domain of NLRC5 is targeted by the siRNA.09-22-2011
20110229557METHODS FOR TREATING EYE DISORDERS - The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at 5 least one siRNA which down regulates expression of a target gene associated with loss of the retinal ganglion cell, thereby inhibiting loss of the retinal ganglion cell in the subject. The methods of the invention also relate to the use of chemically modified siRNA compounds possessing structural motifs which down-regulate the expression of human genes expressed in retinal tissue in the mammalian eye.09-22-2011
20090074852LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM - The present invention is related to a lipid composition contained in and/or containing a carrier comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is optionally removable from the lipid composition under in vivo conditions, whereby the lipid composition containing carrier has an osmolarity of about 50 to 600 mosmole/kg, preferably about 250-350 mosmole/kg, and more preferably about 280 to 320 mosmole/kg, and/or whereby liposomes formed by the first lipid component and/or one or both of the helper lipid and the shielding compound in the carrier have a particle size of about 20 to 200 nm, preferably about 30 to 100 nm, and more preferably about 40 to 80 mm.03-19-2009
20090087482Temperature-Sensitive Liposomal Formulation - A liposome contains an active agent and has a gel-phase lipid bilayer membrane comprising phospholipid and a surface active agent. The phospholipids are the primary lipid source for the lipid bilayer membrane and the surface active agent is contained in the bilayer membrane in an amount sufficient to increase the percentage of active agent released at the phase transition temperature of the lipid bilayer, compared to that which would occur in the absence of the surface active agent. The surface active agent is present in the lipid bilayer membrane so as to not destabilize the membrane in the gel phase.04-02-2009
20090081280COMPOSITIONS AND METHODS FOR MODULATING HEMOSTASIS - Novel thrombin/prothrombin protease/zymogen variants which have anticoagulation activity and methods of use thereof are disclosed.03-26-2009
20110229559Drug Release From Nanoparticle-Coated Capsules - Methods of producing a controlled release formulation for an active substance are disclosed, wherein the methods involve dispersing a discontinuous phase comprising an active substance into a continuous phase so as to form a two-phase liquid system comprising droplets of said discontinuous phase, and allowing nanoparticles provided to the two-phase liquid system to congregate at the phase interface to thereby coat the surface of the droplets in at least one layer of said nanoparticles. The methods utilise a concentration of a suitable electrolyte which enhances the nanoparticle congregation such that the coating of nanoparticles on the surface of the droplets presents a semi-permeable barrier to the active substance, or otherwise utilise a amount of the active substance that is greater than the solubility limit of that active substance in the discontinous phase. Formulations comprising vitamin A (retinol) as the active substance for dermal delivery are specifically exemplified.09-22-2011
20110229558AGENT FOR TREATING MYELOFIBROSIS - Disclosed is a substance delivery carrier for an extracellular matrix-producing cell in the bone marrow, which comprises a retinoid. Also disclosed is an agent for treating myelofibrosis by utilizing a substance capable of regulating the activity or proliferation of an extracellular matrix-producing cell in the bone marrow.09-22-2011
20110229556LIPID-COATED POLYMER PARTICLES FOR IMMUNE STIMULATION - The invention provides delivery systems comprised of lipid coated polymer core particles, as well as compositions, methods of synthesis, and methods of use thereof. The particles can be used to carry antigen and adjuvant, resulting in enhanced immune responses.09-22-2011
20110229555INTRAVENOUS CURCUMIN AND DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE AND STRESS DISORDERS - Liposomal formulations and polymer conjugates of curcumin, curcumin analogues and derivatives thereof for parenteral administration are disclosed herein. The formulations are effective in the treatment of progressive supranuclear palsy, Alzheimer's disease (AD), Parkinson's disease (PD), Tauopathies or stress disorders including Post Traumatic Stress Disorder (PTSD). Curcumin crosses the blood brain barrier, localizes in the hippocampus and striata, prevents stress-induced neuronal cell damage, and stimulates neurogenesis and remediation of damaged neural circuits.09-22-2011
20110229553Plant Extract with Pharmacological Profile for Treating or Preventing Diseases, Dysfunctions and Disorders of the Central Nervous System, Neurodegenerative Disorders and Sequel from Vascular Dementia - Plant extracts for pharmaceutical compositions as acetylcholinesterase inhibitors useful as neuroprotectors, to manage depressive states and cognitive deficits of diverse etiologies, and for the treatment of neurodegenerative conditions, such as Alzheimer's and Parkinson's diseases, and the sequel from ischemic events.09-22-2011
20110229552NOVEL mRNA SPLICE VARIANT OF THE DOUBLECORTIN-LIKE KINASE GENE AND ITS USE IN DIAGNOSIS AND THERAPY OF CANCERS OF NEUROECTODERMAL ORIGIN - The present invention relates to novel nucleic acid and protein molecules and their use in cancer therapy and diagnosis.09-22-2011
20090191261Antibody fragment-targeted immunoliposomes for systemic gene delivery - Nucleic acid-immunoliposome compositions useful as therapeutic agents are disclosed. These compositions preferably comprise (i) cationic liposomes, (ii) a single chain antibody fragment which binds to a transferrin receptor, and (iii) a nucleic acid encoding a wild type p53. These compositions target cells which express transferrin receptors, e.g., cancer cells. These compositions can be used therapeutically to treat persons or animals who have cancer, e.g., head and neck cancer, breast cancer or prostate cancer.07-30-2009
20090081282PHARMACEUTICAL COMPOSITION FOR TREATING CANCER - The present invention provides a small interfering RNA (siRNA) that is capable of inhibiting intracellular expression of Wnt1 through complementary binding to a Wnt1 transcript (mRNA transcript) base sequence and a pharmaceutical composition for treating cancer comprising the same. siRNA of the present invention which is complementary to a base sequence of a Wnt1 transcript (mRNA) provides apoptotic cancer cell death due to inhibition of expression of Wnt1 commonly expressed in cancer cells, by RNA-mediated interference (RNAi). Therefore, the composition of the present invention comprising the same can be used as an excellent anticancer drug.03-26-2009
20090004258Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field - Thermosensitive liposomes encapsulating paramagnetic iron oxide nanoparticles are used as a drug controlled release system. Paramagnetic iron oxide nanoparticles are used to generate heat by applying alternative magnetic field to cause leakage of drugs in the liposomes.01-01-2009
20090004259METHODS OF PREPARING A THERAPEUTIC FORMULATION COMPRISING GALECTIN-INDUCED TOLEROGENIC DENDRITIC CELLS - In spite of their pivotal role in orchestrating immunity, dendritic cells (DCs) may be licensed by immunosuppressive signals to become tolerogenic. Here we show that ligation of cell surface glyco-receptors by Galectin-1, an endogenous glycan-binding protein, can drive the differentiation of regulatory DCs with tolerogenic potential in vivo. Galectin-1-differentiated DCs acquired a tolerogenic phenotype characterized by IL-27-dependent, STAT3-mediated and CD45RB01-01-2009
20090196916Liposome-mediated ligation - Chemoselective ligation of hydrophobic reactants in a lipid phase.08-06-2009
20090220589TREATMENT, DIAGNOSTIC, AND METHOD FOR DISCOVERING ANTAGONIST USING SPARC SPECIFIC MIRNAS - miRNAs that regulate human SPARC and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, ds miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA.09-03-2009
20090220588Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity - The compositions and methods of the present invention relate to the co-delivery of a molecule and a polypeptide to cells to improve the therapeutic efficacy of the molecules. In one embodiment of the invention, the invention may improve delivery of growth factors by co-delivering these growth factors with their receptors and co-receptors, such as syndecans. Co-delivery of growth factors with syndecans, for example, may protect growth factors from proteolysis, enhance their activity, and target the growth factors to the cell surface to facilitate growth factor signaling. This novel approach to growth factor therapy could be extended to other systems and growth factors enabling the enhancement of multiple signaling pathways to achieve a desired therapeutic outcome.09-03-2009
20090220585Biological Active Blood Serum Fraction S-1-10, Methods for Producing It and Uses Thereof - The present invention relates to a method for preparing a biological active fraction of blood serum, the biological active fraction (S-1-10) and a pharmaceutical composition comprising said fraction as well as uses thereof in the treatment of various diseases and conditions, in particular seizures, cardiovascular diseases and proliferative diseases.09-03-2009
20090252784Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same - Compositions for inhibiting RNA binding proteins, as well as methods of producing and using the same, are disclosed herein.10-08-2009
20090220581METHODS OF REDUCING INFLAMMATION AND MUCUS HYPERSECRETION - Methods and compounds for decreasing MARCKS-related inflammation and MARCKS-related mucus hypersecretion or decreasing MARCKS-related inflammation in a subject by the administration of a N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein or a peptide fragment thereof are disclosed.09-03-2009
20090220584Amphoteric Liposome Formulation - The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides DNAi oligonucleotides sequestered by amphoteric liposomes for the treatment of cancer.09-03-2009
20090220582METHOD OF CANCER TREATMENT USING SIRNA SILENCING - The present invention is a method for the treatment of cancer involving tumor derived immunosuppression in a subject. The method comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions.09-03-2009
20080260812Therapeutic Medicine Containing Monoclonal Antibody Against Folate Receptor Beta (Fr-Beta) - An objective of the present invention is to provide a therapeutic agent for treating rheumatoid arthritis, juvenile rheumatoid arthritis, macrophage activation syndrome, septicemia, and FR-β expressing leukemia, which induces apoptosis in activated macrophages and folate receptor beta (FR-β) expressing leukemia cells to specifically destroy these cells. An FR-β monoclonal antibody of the present invention is preferably an IgG-type monoclonal antibody which specifically reacts with a human-type FR-β antigen and is produced from a clone resulting from immunization with an FR-β expressing B300-19 cell. The FR-β monoclonal antibody of the present invention specifically reacts with the FR-β antigen of activated macrophages and FR-β expressing leukemia cells and a therapeutic agent of the present invention contains an FR-β antibody immunotoxin which causes apoptosis in activated macrophages and FR-β expressing leukemia cells, as an active ingredient. Further, suitable administration form for the therapeutic agent of the present invention includes intravenous injection as well as joint injection in the case of therapeutic agents for rheumatoid arthritis and juvenile arthritis.10-23-2008
20090258064COMPOSITIONS OF UCP INHIBITORS, FAS ANTIBODY, A FATTY ACID METABOLISM INHIBITOR AND/OR A GLUCOSE METABOLISM INHIBITOR - Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an antibody against UCP and/or Fas antigen with an oxirane carboxylic acid, represented by etomoxir, and/or with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.10-15-2009
20100003315Method and Composition for the Treatment of Skin Conditions - The present invention relates to artificial seawater and its use to treat a variety of skin conditions, when that sea water has more magnesium in it than in naturally occurring seawater. The treatment of acne would healing and the like can be improved with the product of the present invention and with treatments thereof.01-07-2010
20100015217Enhancing Pulmonary Host Defense via Administration of Granulocyte-Macrophage Colony Stimulating Factor - The present invention provides methods for enhancing pulmonary host defense in a subject by administering via inhalation an effective amount of granulocyte-macrophage colony stimulating factor or a functional homologue thereof. Methods of the present invention are useful in alleviating symptoms and/or treating pulmonary diseases or conditions including, but not limited to lung cancer, 01-21-2010
20090252785ENDOPLASMIC RETICULUM TARGETING LIPOSOMES - Provided are compositions that include lipid particles, such as liposomes, that can fuse with the ER membrane of a cell. The lipid particles can also deliver a cargo, such as a therapeutic or an imaging agent, encapsulated inside the particles inside the ER lumen of the cell. The compositions can be useful for treating and/or preventing diseases or conditions caused by or associated with a virus, such as viral infections, including HIV and HCV infections.10-08-2009
20090252783MEANS FOR INHIBITING THE EXPRESSION OF CD31 - The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ ID NO: 1, whereby the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 1277 to 1295 of SEQ ID NO: 1; from nucleotide positions 2140 to 2158 of SEQ ID NO:1; from nucleotide positions 2391 to 2409 of SEQ ID NO: 1; and whereby the first stretch is additionally at least partially complementary to a region preceding the 5′ end of the nucleotide core sequence and/or to a region following the 3′ end of the nucleotide core sequence.10-08-2009
20100151008Preparations and Methods for Textile and or Fiber Surface Finishing, Surface Finished Articles Prepared Thereby, and Uses Therefor - The invention relates to the use of liposomes, particularly liposomes based on soybean oil lecithins, for finishing textiles and fibers, a key aspect of the invention being that, besides a fiber-care effect, skin-friendly substances are transferred by liposome-finished fibers or textiles to the skin from those fibers or textiles.06-17-2010
20120195960POST-EXPOSURE THERAPY OF INFLUENZA A INFECTIONS - Poly ICLC or liposome-encapsulated Poly ICLC (LE Poly ICLC) in combination with antisense oligonucleotides (AS) act synergistically in post-exposure prophylaxis or therapy of influenza infections, especially H5N1 virus infections.08-02-2012
20120195962Multiepitope Vaccine for Her2/Neu-Associated Cancers - The present invention includes fusion peptides comprising fragments of the cancer-related protein Her2/neu, methods of preparing such fusion peptides, virosomes comprising such fusion peptides, and uses of such fusion peptides or virosomes for the prevention, treatment or amelioration of a cancer characterized by expression or over-expression of the Her2/neu protein.08-02-2012
20120195961Use of Spinosyns and Spinosyn Compositions Against Disease Caused By Protozoans, Viral Infections and Cancer - The present invention relates to the use of spinosyns and spinosyn compositions as pharmaceuticals and methods for treatment—including prevention—of protozoan infections and/or disorders relating to a protozoan infection, such as malaria and 08-02-2012
20120195959METHOD FOR TREATING DISEASE OR DISORDER OF ADULT CENTRAL NERVOUS SYSTEM ASSOCIATED WITH TISSUE SHRINKAGE OR ATROPHY BY ADMINISTRATION OF INSULIN - The present invention provides a use of an insulin for manufacture of a medicament for treating or preventing a disorder or disease of a central nervous system of an adult individual, wherein the disorder or disease is associated with tissue shrinkage or atrophy. Also provided are methods of treating such disorder or disease using a pharmaceutically effective amount of an insulin or composition that enhances the activity of endogenous insulin.08-02-2012
20100178325AMPHIPHILIC NUCLEOTIDE COCHLEATE COMPOSITIONS AND METHODS OF USING THE SAME - The present invention is directed to cochleate compositions that include a nucleotide that is associated with a positively charged amphiphile. The present invention also includes methods for making and using the compositions provided herein.07-15-2010
20100233250VACCINE - The present invention provides a vaccine or immunogenic composition comprising: an immunogenic SARS coronavirus S (spike) polypeptide, or a fragment or variant thereof; and an adjuvant comprising a lipopolysaccharide, a saponin and a liposome.09-16-2010
20080317840COMPOSITIONS AND METHODS FOR POLYMER-CAGED LIPOSOMES - The present invention provides liposomal compositions and methods of using such compositions in vitro and in vivo. In particular, the present invention provides stable, polymer-caged liposomes comprising a pH responsive delivery mechanism for delivery of nucleic acids, peptides, small molecules, drugs, etc. in vitro and in vivo.12-25-2008
20100015212IMMUNOGENIC BACTERIAL VESICLES WITH OUTER MEMBRANE PROTEINS - Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity of MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.01-21-2010
20100151000COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES - This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the NF-κB signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases.06-17-2010
20100151007COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF VEGF - Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Such compositions and methods further involve siRNA capable of selectively targeting angiogenic VEGF isoforms while selectively sparing anti-angiogenic isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.06-17-2010
20100260830Liposomal Formulations of Tocopheryl Amides - Formulations of N-chroman dicarboxylic acid derivatives and their bioisosteres in liposomal systems. Lyophilized liposomal dosage forms of N-chromans, are found to be stable, to achieve therapeutically meaningful plasma levels on administration to a mammalian host, and to demonstrate selective pro-apoptotic oncolytic properties in vivo. Advantageously, these formulations overcome the systemic toxicity that characterized their administration by other dosage forms.10-14-2010
20100178330ASYMMETRIC LIPOSOMES AND USES IN MEDICAL FIELD THEREOF - The invention concerns new asymmetric liposomes and uses thereof in medical field to transport lipids involved in antimicrobial or antiviral response, particularly at level of pulmonary target cells.07-15-2010
20100178329LIPOSOME COMPOSITION - The invention relates to a liposomal composition, containing a citrus type (Aurantioideae) essential oil of pharmaceutical grade 0.5-5.0 part by weight; lavender oil of pharmaceutical grade 0.5-5.0 part by weight; vitamin E 0.1-1.5 part by weight; vitamin A 0.1-1.5 part by weight; castor oil ethoxylated 1.0-6.0 part by weight; a phospholipid 0.1-1.0 part by weight; distilled water 15-30 part by weight; ethanol 96% 65-75 part by weight. The composition can be used for treatment of wounded, burned, frozen, infected skin surfaces.07-15-2010
20100178328COMBINATION THERAPY FOR OVARIAN CANCER - The present invention provides a method to treat ovarian cancer by the administration of effective amounts of picoplatin and pegylated liposomal doxorubicin.07-15-2010
20120195957NOVEL NANOPARTICLE FORMULATIONS FOR SKIN DELIVERY - Methods and formulations for treating a condition of the skin by delivering therapeutic formulations to the skin that translocates active substances across the stratum corneum barrier to a targeted skin tissue. The methods and formulations comprise active substances encapsulated within surface modified nanostructured lipid carrier nanoparticles.08-02-2012
20090053296METHODS AND COMPOSITIONS RELATING TO HPV-ASSOCIATED PRE-CANCEROUS AND CANCEROUS GROWTHS, INCLUDING CIN - The present invention concerns the use of E6 and/or E7 peptides from human papilloma virus (HPV) to evaluate a cell-mediated response in a patient infected with HPV to determine the prognosis for that patient with respect to the development or recurrence of pre-cancerous or cancerous growths, including cervical intraepithelial neoplasia (CIN).02-26-2009
20090117178PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.05-07-2009
20090117179siDNA against Influenza Virus - Silencing of Influenza virus RNA can be achieved by siDNA. These are oligodeoxynucleotides having an antisense-strand homologous to the viral RNA and a second strand, partially complementary to the antisense-strand. The two strands are preferentially linked by a linker (eg 4 thymidines). Triple-helix formation with the target RNA is a preferred effect. The siDNA is superior to siRNA because it acts earlier, is easier taken up by the cell, the formation of RNA-DNA hybrids is preferred over double-stranded DNA or double-stranded RNA, which forms as tertiary structures in RNA genomes. Also the induction of interferon is less likely. siDNA is easier to synthesize and it is more stable. It can be combined with siRNA.05-07-2009
20100189775PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL KIT FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA - The present invention provides pharmaceutical compositions for the treatment of hepatocellular carcinoma (HCC) comprising Notch3 inhibitors and a chemotherapeutic agent, methods for the preparation of said compositions and a medical treatment comprising the administration of said pharmaceutical compositions in patients in need thereof.07-29-2010
20090246268LIPOSOMAL, RING-OPENED CAMPTOTHECINS WITH PROLONGED, SITE-SPECIFIC DELIVERY OF ACTIVE DRUG TO SOLID TUMORS - A method for preparing a stable dispersion of a camptothecin, camptothecin prodrug, or analog thereof for administration to a patient in need thereof includes preparing a solution of the camptothecin, wherein the solution has a pH which places substantially an entirety of that camptothecin in a carboxylate form. The camptothecin may be a neutral camptothecin. The solution is next loaded into a liposome including at least one lipid, which may be a phospholipid. An intraliposomal pH is maintained which preserves substantially an entirety of the camptothecin in the carboxylate form. The liposomal dispersion is administered to an individual in need thereof, whereby the liposomes accumulate at and permeate into tumor tissue and an active, lactone form camptothecin is released in situ at the tumor site. Compositions formulated in accordance with the described method for treatment of a cancer in an animal in need thereof are provided also.10-01-2009
20110104262Topical Combinations Comprising an Antimycotic Agent and an Antiviral Agent - There is provided a pharmaceutical composition comprising an antimycotic agent and an antiviral agent, useful for prophylaxis and/or treatment of an associated infection and/or disease and a method of manufacturing thereof.05-05-2011
20100183705PHOSPHOLIPID-ANALOGOUS COMPOUNDS - Phospholipid-analogous compounds of the general formula (I)07-22-2010
20100183707METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION - A method for treating latent HIV infection is disclosed. The method includes administering to a subject in need of such treatment an effective amount of an anti-IκBα agent, an anti-IκBε agent or both; and administering to the subject an effective amount of an antiviral agent. A pharmaceutical composition for treating latent HIV infection is also disclosed.07-22-2010
20100260829Sustained Release of Antiinfectives - Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 μm. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.10-14-2010
20100196450TARGETING PAX2 FOR THE INDUCTION OF DEFBI-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.08-05-2010
20100189777FUNCTIONALIZED NANOCOMPARTMENTS WITH A TRANSPORT SYSTEM - The invention is directed to vesicles comprising at least one transmembrane triggered transport system for controlled transmembrane efflux and/or influx.07-29-2010
20100189776ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY - The present invention relates to isolated or purified or partially purified peptide derived molecules having the following general formula (S1): X-[(Pro)07-29-2010
20100189771FIXED RATIO DRUG COMBINATION TREATMENTS FOR SOLID TUMORS - Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors.07-29-2010
20100260831NON-PEGYLATED LIPOSOMAL DOXORUBICIN TRIPLE COMBINATION THERAPY - The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.10-14-2010
20100260832COMBINATION THERAPY FOR OVARIAN CANCER - The present invention provides a method to treat ovarian cancer by the administration of effective amounts of picoplatin and doxorubicin.10-14-2010
20100166848LIPOSOMAL FORMULATIONS FOR TREATING CANCER - The invention provides a pharmaceutical composition comprising liposomes which coencapsulate 5-fluorouracil (5-FU) and 2′-deoxyinosine (d-Ino). In a preferred embodiment, the liposomes comprise phosphatidylcholine (PC), phosphatidyl-glycol (PG) and sterol, preferably in a molar ratio PC/PG/sterol of 20-80/10-60/15-60. The invention further provides a method for preparing liposomes which coencapsulate 5-fluorouracil (5-FU) and 2′-deoxyinosine (d-Ino), and the use thereof for the manufacture of a medicament for treating cancer in a patient.07-01-2010
20100215730Compositions for Nasal Administration of Phenothiazines - Provided herein are pharmaceutical compositions comprising phenothiazines or derivatives thereof that are formulated for nasal administration. Also provided herein are methods of utilizing the same.08-26-2010
20100015216METHODS AND MATERIALS FOR TREATING ACNE - Compositions and methods for the treatment of acne are based upon a first therapeutic agent which is one or more members selected from the group consisting of: salicylic acid, azelaic acid, adapalene, benzoyl peroxide, and antibiotics; and a second therapeutic agent which comprises a taurine species. The two agents may be present in a single preparation and applied to the skin simultaneously, or they may be present in two separate preparations and applied to the skin sequentially. The taurine species may comprise free taurine, taurine salts, taurine esters, taurine complexes, taurine conjugates and taurine precursors either singly or in combination. The composition may include a liposomal carrier. Further disclosed are specific preparations and methods used for the treatment of acne.01-21-2010
20110104256METHODS FOR TREATING OR PREVENTING COLORECTAL CANCER - The present invention provides, for example, methods for treating or preventing colorectal cancer with an anti-IGF1R antibody in association with sunitinib or a combination of leucovorin and 5-fluorouracil.05-05-2011
20120244212ENHANCED METHOD AND COMPOSITION FOR THE TREATMENT OF HIV+ TUBERCULOSIS PATIENTS WITH ANTI-RETROVIRAL DRUGS AND LIPOSOMAL ENCAPSULATION FOR DELIVERY OF REDUCED GLUTATHIONE - The invention is the use of a therapeutically effective amount of glutathione (reduced) in a liposome encapsulation for oral administration to improve symptoms of illnesses that are related to tuberculosis and HIV and more generally viruses and for the treatment and prevention of virus, particularly HHV-6 and EBV, which liposomal encapsulation of glutathione (reduced) is referred to as liposomal glutathione. The application references specifically reduced glutathione and its importance, and how to stabilize it effectively so it can be taken orally, and need not be refrigerated. New uses for tuberculosis are discussed. The combination is proposed of reduced glutathione and Highly Active Anti-Retroviral Therapy having at least one pharmaceutical composition selected from the group of Nucleoside/tide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), and Non-nucleoside Reverse Transcriptase Inhibitors (NnRTIs), and further anti-tuberculosis drugs.09-27-2012
20110236470GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS - The present invention relates to polypeptide fragments, including variants and analogs, of 09-29-2011
20100215731METHOD FOR IMPROVING CARTILAGE REPAIR AND/OR PREVENTING CARTILAGE DEGENERATION IN A JOINT - The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and/or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is preferably selected from the group consisting of agents that stimulate chondrogenic differentiation and/or cartilage matrix synthesis; agents that inhibit osteogenesis and/or hypertrophy, anti-inflammatory agents, agents that inhibit apoptosis of chondrocytes, agents that inhibit senescence of chondrocytes and agents that enhance lubrication of a joint.08-26-2010
20100215724Microcapsule Nanotube Devices for Targeted Delivery of Therapeutic Molecules - A nanotube device comprises a gel matrix that includes microcapsules and functionalized nanotubes, or other functionalized nanostructures incorporated into said gel matrix. Pharmaceutical compositions and methods of treatment comprising same. The pharmaceutical compositions of the present invention enable the specific and targeted delivery of therapeutic agents such as DNA molecules, peptides, including antibodies, drug molecules (e.g. small organic molecules), while offering sufficient resistance towards mucus layer of the intestine and high concentrations of enzymes and other molecules found in the blood stream and the GI tract.08-26-2010
20100183704dsRNA FOR TREATING VIRAL INFECTION - The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the CAD target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propagation of positive stranded RNA viruses in and between cells.07-22-2010
20100226969COMPOUNDS FOR INHIBITING PROTEIN AGGREGATION, AND METHODS FOR MAKING AND USING THEM - The invention provides compositions comprising protein aggregation inhibitors, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for preventing, reversing, slowing or inhibiting protein aggregation, e.g., for treating diseases that are characterized by protein aggregation—including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e.g., synuclein, beta-amyloid and/or tau protein aggregation. In one aspect, compositions and methods of this invention are used to treat, prevent or ameliorate (including slowing the progression of) Parkinson's disease, Alzheimer's Disease (AD), Lewy body disease (LBD) and Multiple system atrophy (MSA).09-09-2010
20090324709LIPOSOMAL FORMULATIONS - The invention relates to formulations of hydrophilic substances encapsulated in liposomes, to the method of encapsulation of the hydrophilic substances in the liposomes and the use of said formulations in the prevention and/or treatment of diseases and/or disorders in humans and animals.12-31-2009
20110059162TANNIN-CHITOSAN COMPOSITES - The invention provides a composition comprising a matrix of chitosan and a tannin wherein the chitosan is electrostatically bonded to the tannin to form a chitosan-tannin composite material. The chitosan can be partially or fully deacetylated, and the tannin can be a monomeric or an oligomeric proanthocyanidin or a hydrolysable tannin. The chitosan-tannin composite material can be a nanoparticle, a hydrogel film, a bio-foam, or a biogel, or the chitosan-tannin composite material can coat a liposome. The composite materials can be used for drug delivery, for antibacterial and/or antifungal applications, for tissue engineering applications, for wound healing applications, or they can be used as adjuvants for vaccination, including oral vaccinations. The invention also provides methods of preparing the composite materials and their various forms.03-10-2011
20110059161TARGETED DELIVERY USING TISSUE-SPECIFIC PEPTIDOMIMETIC LIGANDS - Compositions and methods for tissue-specific targeted delivery of therapeutic agents through the use of tissue-specific peptidomimetic ligands are disclosed herein. The ligand comprises a composition of formula A-scaffold-A′ and one or more hydrophobic anchors covalently linked to the scaffold. The A and A′ compounds linked to the scaffold comprise monovalent peptidomimetic compounds wherein each monovalent peptidomimetic compound is selected from the group consisting of fragments IKs, GKs, IDs, GSs, GTs, VSs, TKs, KTs, ARs, KIs, KEs, AEs, GRs, YSs, IRs, and morpholino.03-10-2011
20110059158CHARGED PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR USE - The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins.03-10-2011
20100239657COMPOSITE FOR LIVER-SPECIFIC DELIVERY AND RELEASE OF THERAPEUTIC NUCLEIC ACIDS OR DRUGS - The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents.09-23-2010
20100215729OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN - Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2′-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogues can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogues and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogues, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders.08-26-2010
20100255080Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment - Liposomal ALA pharmaceutical and cosmeceutical compositions, and methods of treatment are disclosed herein. In an embodiment, a Liposomal ALA composition of the present disclosure is used in for photodynamic therapy. In an embodiment, a photodynamic therapy system is disclosed that includes nanocorpuscles comprising 5-aminolevulinic acid in a scattering agent, wherein a concentration of the 5-aminolevulinic acid is from about 0.01% to about 10%; and a light source for activating the 5-aminolevulinic acid. In an embodiment, a photodynamic therapy method is disclosed that includes administering nanocorpuscles comprising 5-aminolevulinic acid to a target tissue in a patient; and activating the 5-aminolevulinic acid with a light source. In an embodiment, a kit is disclosed.10-07-2010
20100239650ISOTHIAZOLIN BIODELIVERY SYSTEMS - A biodelivery system has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks.09-23-2010
20100226973METHODS AND COMPOSITIONS FOR LIPOSOMAL FORMULATION OF ANTIGENS AND USES THEREOF - The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).09-09-2010
20100226967IMAGING AND THERAPEUTIC METHOD USING PROGENITOR CELLS - The invention relates to a method of treating or diagnosing a disease state worsened by progenitor cells. The method utilizes a composition comprising a conjugate or complex of the general formula09-09-2010
20100226974ANTIBODY RECOGNIZING ANTIGEN - The invention provides antibodies against a non-muscular myosin heavy chain type A or a mutant thereof, and F(ab′)09-09-2010
20100226970Cationic liposome delivery of taxanes to angiogenic blood vessels - Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are comprised of promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell.09-09-2010
20100226968Topical agent for muscle treatment - A topical liposomal base delivery agent for physiologically enhancing muscle efficiency and relaxation, which combines the physiological effects of guaifenesin, magnesium, and methylsulfonylmethane. The resulting physiological reaction reduces muscle and joint soreness in the host. The present invention is an improvement over existing methods that deliver magnesium to muscle tissue.09-09-2010
20100226971ULTRASOUND-ENHANCED INTRASCLERAL DELIVERY OF MACROMOLECULES - The present invention provides a novel system and method for transscleral delivery of therapeutic agents, including macromolecules, into a target site in intrascleral space using ultrasound. Advantageously, the present invention not only significantly enhances transscleral diffusivity of macromolecular therapeutic agents, but also causes little damages to ocular tissues and structure.09-09-2010
20100215727STABILIZED PICOPLATIN DOSAGE FORM - Methods for stabilizing aqueous solutions of picoplatin are provided. Such stable, preferably aseptic solutions are particularly useful for preparing unit dosages of picoplatin for oral or intravenous administration, preferably in combination with at least one additional non-platinum anti-cancer agent.08-26-2010
20100239649Tumor Suppressor Factor - The present invention relates to a tumour suppressor gene, termed HLS-5 and the amino acid sequence that it encodes. The present invention also relates to the use of HLS-5 in regulating cell growth.09-23-2010
20130216607ZWITTERIONIC LIPIDS - In various embodiments, the present invention provides zwitterionic lipids, encapsulants incorporating these zwitterionic lipids and such encapsulants encapsulating one or more bioactive agent. An exemplary bioactive agent is a nucleic acid. Also provided are pharmaceutical formulations of the encapsulants and methods of using such formulations to deliver a bioactive agent to a subject in treating or diagnosing disease in that subject.08-22-2013
20130216608Airway Administration of Angiogenesis Inhibitors - The present invention provides methods for the local pulmonary treatment of lung metastases and/or primary lung cancer, such as squamous lung cancer and/or small cell lung cancer, using local deposition of one or more agents capable of inhibiting angiogenesis and/or an agent that acts as an active anti-cancer agent and/or an active anti-metastatic agent. The agent capable of inhibiting angiogenesis and/or which acts as an active anti-cancer agent and/or an active anti-metastatic agent is administered to a patient with cancer as a treatment of said metastasis and/or cancer or to extend the lifespan for said cancer patient with reduced systemic side-effects compared to other treatment forms. The agent capable of inhibiting angiogenesis and/or which acts as an active anti-cancer agent and/or an active anti-metastatic agent is administered intratracheal, intrabronchial, intraalveolar or broncioalveolar. Administration for example via inhalation of an aerosol or as a dry powder and/or administered as a bronchoalveolar lavage (BAL) an effective amount of the agent.08-22-2013
20130216613CYTOMEGALOVIRUS GB ANTIGEN - The invention relates to a cytomegalovirus (CMV) gB polypeptide comprising at least a portion of a gB protein extracellular domain comprising a fusion loop 1 (FL1) domain and a fusion loop 2 (FL2) domain, wherein at least one of the FL1 and FL2 domains comprises at least one amino acid deletion or substitution.08-22-2013
20100239653PHARMACEUTICAL PREPARATIONS AND METHODS FOR INHIBITING TUMORS - The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.09-23-2010
20100239651NITRILOPROPIONAMIDE DELIVERY SYSTEMS - A biodelivery system has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks.09-23-2010
20100239652IMMUNOLIPOSOMES FOR TREATMENT OF CANCER - The present invention relates to immunoliposomes for multiple treatment of human patients suffering from cancer, particularly a cancer represented by a locally advanced or metastatic tumor and to compositions used in said method. The invention further relates to the use of immunoliposomes for the treatment of multi-drug resistance in cancer therapy.09-23-2010
20100239654VESICULAR PHOSPHOLIPID GELS COMPRISING PROTEINACEOUS SUBSTANCES - The present invention relates to a pharmaceutical composition for sustained release of a pharmaceutically active compound, the composition comprising a vesicular phospholipid gel. More particularly, the invention relates to a pharmaceutical composition comprising at least one proteinaceous substance as the pharmaceutically active compound in encapsulated form, the at least one proteinaceous substance being a biologically active protein, peptide or polypeptide. Furthermore, the present invention relates to a method for the production of said pharmaceutical composition comprising dual asymmetric centrifugation and to the use of said pharmaceutical composition for immunotherapy and/or for stimulating selective tissue regeneration in the treatment of surgical defects in the course of surgical interventions.09-23-2010
20100255081Method for treating symptoms of diabetes - The present invention provides a method for treating symptoms of diabetes in a diabetic subject which comprises administering to the subject a therapeutically effective amount of an agent which inhibits binding of advanced glycation endproducts to any receptor for advanced glycation endproducts so as to treat chronic symptoms of diabetes in the subject.10-07-2010
20100255078SERPIN DRUGS FOR TREATMENT OF VIRAL INFECTION AND METHOD OF USE THEREOF - The invention includes compositions comprising substantially purified serpin that are useful in methods for the treatment and prevention of HIV, HSV or HCV infection. The invention also includes methods for the treatment and prevention of HIV, HSV or HCV infection comprising contacting a composition of the invention with a human patient or treating HIV, HSV or HCV infection by introducing into a cell susceptible to HIV, HSV or HCV infection, a DNA molecule encoding a serpin.10-07-2010
20100255079Systems and methods for skin rejuvenation - Systems and methods for skin rejuvenation are disclosed herein. In an embodiment, a skin rejuvenation system includes a unit dose of a booster product that includes active ingredients of ferulic acid and phloretin; a unit dose of at least one exfoliating product that includes active ingredients of ferulic acid and phloretin in combination with fruit acids or alpha hydroxyacids; and a unit dose of a nano-additive product for enhancing penetration of the active ingredients. A method for skin rejuvenation includes applying topically, to a skin surface to be treated, a booster product including active ingredients of ferulic acid and phloretin; applying topically, to the skin surface, at least one exfoliating product including active ingredients of ferulic acid and phloretin in combination with one of fruit acids or alpha hydroxyacids; and applying topically, to the skin surface, a nano-additive product for enhancing penetration of the active ingredients.10-07-2010
20100255075CR-2 Binding Peptide P28 as Molecular Adjuvant for DNA Vaccines - The invention is an DNA vaccine and method of use thereof for modulating the immune response against the circumsporozoite protein (CSP) of malaria parasites, using the CR2 binding motifs of C3d, especially p28.10-07-2010
20100221319Compositions and Methods for Improved Skin Care - Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.09-02-2010
20120141579Cytotoxic T Lymphocyte Inducing Immunogens for Prevention Treatment and Diagnosis of Cancer - The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as lung carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against lung and other cancers.06-07-2012
20100143455Triazole antifungal agents - New triazole antifungal agents having C6S7 or S6C7 bridges are disclosed. These triazoles provide alternatives to existing antifungals in terms of formulation, bioavailability and activity.06-10-2010
20090202623GENE THERAPY FOR CANCER USING SMALL INTERFERING RNA SPECIFIC TO ANT2 AND A METHOD TO OVERCOME TOLERANCE TO ANTITUMOR AGENT - The present invention relates to a small interfering RNA (siRNA) suppressing the expression of adenine nucleotide trnaslocator 2 (ANT2) gene and an anticancer agent containing the same. Particularly, the invention relates to ANT2 siRNA comprising a sense sequence selected from the nucleotide sequences of ANT2 mRNA, a hairpin loop sequence and an antisense sequence binding complementarily to the said sense sequence and an anticancer agent containing the same. ANT2 siRNA of the present invention inhibits the expression of ANT2 gene, suggesting that it inhibits the growth of cancer cells exhibiting high level of ANT2. Therefore, ANT2 siRNA of the invention can be effectively used for gene therapy for cancer treatment and further prevents the anticancer effect from decreasing by anticancer drug resistance of cancer cells.08-13-2009
20100143451 Composition for Improving Skin Condition and Appearance - Disclosed is a cosmetic composition comprising prenylated isoflavonoid and a carrier, wherein the prenylated isoflavonoid is from about 0.0000001% to about 10%, preferably from 0.00001% to 1%, most preferably from 0.01% to 1%, by weight, based on the total weight of the composition. The active agent prenylated isoflavonoid induces a statistically significant upregulation of collagen 1A1 and elastin genes in normal human dermal fibroblasts. The composition is effective to stimulate the production of collagen and elastin and improve the appearance and condition of the skin.06-10-2010
20100143457Extended soluble PH20 polypeptides and uses thereof - Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof.06-10-2010
20100221317DYNAMIN MEDIATED DISEASES AND ASSOCIATED METHODS AND PRODUCTS - This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.09-02-2010
20100221315VESICULAR FORMULATIONS CONTAINING ORGANIC ACID PRODRUGS, PROCESS FOR THEIR PREPARATION - The present invention relates to vesicular formulations containing a prodrug, characterized for comprising the combination of a prodrug of weak organic acids having the following general formula: R09-02-2010
20100136099LIPOSOME FOR INDUCTION OF CELL-MEDIATED IMMUNITY - Disclosed is a liposome which includes an antigenic substance therein and has, on its surface, a peptide containing several contiguous arginine residues. The liposome enables an antigen-presenting cell to achieve the selective antigen presentation through an MHC Class-I molecule, and can induce a cell-mediated immunity specifically. The liposome can also induce the antigen presentation by a matured dendritic cell.06-03-2010
20100136097Systems for modulating inflammation - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.06-03-2010
20100136096Systems for modulating inflammation - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.06-03-2010
20100136094Systems for modulating inflammation - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.06-03-2010
20100203110Therapeutics for Cancer Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production - The present invention relates to methods of treating a cancerous tumor in a subject comprising administering to the subject an effective amount of 3-bromopyruvate. The 3-bromopyruvate may be administered intraarterially directly to a tumor as a continuous intraarterial infusion. The present invention also relates to methods for identifying agents that inhibit type II hexokinase activity.08-12-2010
20100129437TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS - The invention relates to methods of targeted drug delivery of antiviral compounds, including, chemical agents (like nucleoside analogs or protease inhibitors) and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of antiviral compounds to intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (CNS), into and across the blood-brain barrier, by targeting to internalizing uptake receptors present on these cells, tissues and organs. Thereto, the antiviral compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to ligands that facilitate the specific binding to and internalization by these receptors.05-27-2010
20100247621CODON MODIFIED IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - The present invention features immunogenic compositions comprising codon modified genes that encode viral proteins and/or glycoproteins or fragments. The immunogenic compositions of the invention are useful in various methods of treatment, such as preventing or treating viral infection. Also provided in the present invention are kits and instructions for use.09-30-2010
20120141577LINEAR EXPRESSION CASSETTE VACCINES - The disclosure relates to a linear expression cassette (LEC) as a nucleic acid based vector for producing a gene product of interest. Methods of preparing a disclosed LEC, as well as methods for its use to express a gene product in a subject, are also described. An LEC may be used in an animal or human subject to produce a therapeutic and/or immune response in the subject, such as an immunized state.06-07-2012
20120141576Treatment of Dermatologic Skin Disorders - Retinal and its derivatives are incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of cosmetic and dermatologic disorders are described as follows. In particular, retinal and its derivatives are combined with liposomes to increase the penetration of the retinal into the skin, to provide hydration of the skin during treatment, to reduce irritation of the skin during the application of the retinal, for use as a chemical skin peel and other embodiments and uses. The present invention includes utilizing retinol products, and particularly retinal in combination with liposomes each of these embodiments and uses separately as well as in combinations with one another.06-07-2012
20100112043TRANSPULMONARY LIPOSOME FOR CONTROLLING DRUG ARRIVAL - An object of the present invention is to provide a liposome which is excellent in intrapulmonary delivery controllability of drugs or genes and is suited for pulmonary administration.05-06-2010
20090041836Glycolipopeptide and uses thereof - A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.02-12-2009
20090074851CPG-PACKAGED LIPOSOMES - Liposomes are known to enhance the activity of K- (B-) type CpGs which trigger the production of IL-12. In the present invention, the surprising finding was made that liposomes also enhance the activity of D- (A-) type CpGs, leading to the production of IFNα in vivo. These findings are relevant for the humans situation, since IFNα rather than IL-12 is the key cytokine for the induction of Th1 responses and anti-viral protection in humans.03-19-2009
20090074853Vaccines with enhanced immune response and methods for their preparation - The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in eliciting the production of antibodies that recognize epitopes of native proteins.03-19-2009
20090074850USE OF A TOPICAL COMPOSITION CONTAINING EPIDERMAL GROWTH FACTOR (EGF) FOR DIABETIC FOOT AMPUTATION PREVENTION - The present invention is related to the use of topical formulations that contain epidermal growth factor encapsulated in or associated to deformable or conventional liposomes to be applied on the surface of and around chronic ischemic skin lesions. The formulations of the present invention, in contrast with the previous art, are useful because they provide a high bioavailability of EGF in the tissue deep below the lesions and for preventing diabetic foot amputation.03-19-2009
20090074848COMBINATION FORMULATIONS OF CYTIDINE ANALOGS AND PLATINUM AGENTS - Compositions which comprise delivery vehicles having stably associated therewith a cytidine analog and a platinum agent are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered.03-19-2009
20100221316Encapsulated Transfer Factor Compositions and Methods of Use - Methods for stress reduction comprising administering a transfer factor to an animal. The transfer factor can be combined with glucans, such as hybrid glucans and other components, to bring about stress reduction. The formulation is encapsulated when administered to adult ruminants.09-02-2010
20090285880DRIED RECONSTITUTED VESICLE FORMATION FOR PHARMACEUTICAL APPLICATION - The present invention relates to dried reconstituted vesicle (DRV) compositions and water based formulations thereof, which contain one or more therapeutic agents (e.g. hydrophilic protein). More particularly, it relates to DRVs comprising at least one lipid and a fusion promoting agent which after reconstitution form large multilamellar liposomes encapsulating an active agent in an aqueous phase.11-19-2009
20090280168CHLAMYDIA OMP ANTIGEN - The present invention provides purified and isolated polynucleotide molecules that encode 11-12-2009
20090280167ENHANCEMENT OF DRUG THERAPY BY MIRNA - This invention provides methods and compositions for screening of microRNA capable of modulating gene expression in the apoptotic pathway in the presence of HSP90 inhibitor. The use of miRNA for enhancing the activity of therapeutic agents not limited to HSP90 inhibitor is also disclosed. The diagnostic use of miRNA for predicting response to therapy not limited to therapeutic agents is also disclosed. A method for the identification and therapeutic application of small molecules which are modulators of these nucleic acids are also included in this application11-12-2009
20090246269IDENTIFICATION AND USE OF GPRC VARIANTS IN THE TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE - The invention relates genes that are deregulated in Parkinson's disease tissues and the corresponding proteins are identified. These genes and the corresponding proteins are suitable targets for the treatment of Parkinson's disease. Also, the invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention more specifically relates to new uses of compounds that activate the B2 bradykinin receptor, for treating neurodegeneration involving oxidative stress and, more particularly, Parkinson's disease. The invention also relates to corresponding methods of treatment, and can be used in human subjects for preventive or curative treatment, either alone or in combination with other active agents or treatments.10-01-2009
20090246267Carnitine Conjugates of Adamantanamines and Neramexane Derivatives as Dual Prodrugs for Various Uses - This invention concerns compounds of adamantanamines and neramexane, including their pharmaceutically-acceptable salts, diesterioisomers, and formulations for treating Alzheimer's related dementias, depression, AIDS related dementias, as antivirals, inflammatory diseases such as rheumatoid arthritis, and cerebral ischemia, hyperlipidemia, and diabetes.10-01-2009
20090246273Ketorolac Sublingual Spray for the Treatment of Pain - The present invention provides for compositions and methods for accelerating the rate of delivery of ketorolac to the systemic circulation by sublingual spray administration under the tongue to provide a rapid response in the treatment of pain, especially acute pain associated with postoperative pain and migraine headache. Compositions of ketorolac formulated for sublingual delivery as liquid spray are provided. Also provided are methods of treatment and management of pain.10-01-2009
20090148508METHODS OF COMPOSITIONS FOR THE TREATMENT OF OCULAR DISEASES - Methods and compositions for the treatment of ocular disease with a cyclin dependent kinase inhibitor are provided.06-11-2009
20080279927Non-Pegylated Long-Circulating Liposomes - The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.11-13-2008
20110177153 TARGETED NANOPARTICLE DRUG FOR MAGNETIC HYPERTHERMIA TREATMENT ON MALIGNANT TUMORS - The present invention relates to a targeted magnetic nanoparticle drug and the preparation method thereof. The targeted magnetic nanoparticle drug comprises an effector molecule and a guidance molecule in a weight ratio of 1:0.0001-0.20. The aforesaid effector molecule is a magnetic particle, with a particle size of not more than 1000 nm and a specific adsorption rate (SAR) of 10-7000 W/gFe. The aforesaid guidance molecule comprises an antibody, a ligand or a magnetic particle. The particle size of the aforesaid targeted drug is 2-1000 nm. The targeted magnetic nanoparticle drug is prepared by coupling a magnetic particle and a guidance molecule in a weight ratio of 1:0.0001-0.20 in water, organic or inorganic substance or the mixed solution thereof. The resultant targeted magnetic nanoparticle drug can realize targeted magnetic hyperthermia treatment and targeted magnetic thermoablation treatment and prevention on the tumors, and effectively kill the cancer cells, and cure the malignant tumors.07-21-2011
20080279923Use of Microtubule Stabilizing Compounds for the Treatment of Lesions of Cns Axons - The present invention provides a use of one or more microtubule stabilizing compounds for the preparation of a pharmaceutical composition for the treatment of lesions of CNS axons wherein the pharmaceutical composition is administered locally directly into the lesion or immediately adjacent thereto, whereby the one or more compound(s) is/are selected from the group consisting of taxanes, epothilones, laulimalides, sesquiterpene lactones, sarcodictyins, diterpenoids, peloruside A, discodermolide, dicoumarol, ferulenol, NSC12983, taccalonolide A, taccalonolide E, Rhazinilam, nordihydroguaiaretic acid (NDGA), GS-164, borneol esters, Synstab A, Tubercidin and FR182877 (WS9885B). Furthermore, the invention provides a method for the treatment of lesions of CNS axons the method comprising the step of administering to a patient in the need thereof a pharmaceutical composition comprising (i) one or more microtubule stabilizing compounds selected from the group consisting of taxanes, epothilones, laulimalides, sesquiterpene lactones, sarcodictyins, diterpenoids, peloruside A, discodermolide, dicoumarol, ferulenol, NSC12983, taccalonolide A, taccalonolide E, Rhazinilam, nordihydroguaiaretic acid (NDGA), GS-164,′ borneol esters, Synstab A, Tubercidin and FR182877 (WS9885B) and, optionally, (ii) further comprising suitable formulations of carrier, stabilizers and/or excipients, wherein the pharmaceutical composition is administered locally directly into the lesion or immediately adjacent thereto.11-13-2008
20110177155METHODS OF DELIVERY OF AGENTS TO LEUKOCYTES AND ENDOTHELIAL CELLS - The present invention generally relates to methods and compositions for the simultaneous delivery of at least one insoluble agent and at least one soluble agent to a cell. In particular the present invention relates to methods and compositions for the dual delivery of an insoluble agent and a soluble agent to a particular target cell, for example, a leukocyte or endothelial cell. In particular, methods and compositions for simultaneous delivery of a hydrophilic (i.e. soluble) agent and/or a hydrophobic (i.e. insoluble) agent to a leukocyte cell or endothelia cell are disclosed.07-21-2011
20110129526COMPOSITIONS AND METHODS FOR TREATING VASCULAR DISEASE - The use of tPA to treat hemorrhagic transformation, neurotoxicity has been limited to short treatment time windows because a high dose of tPA required to generate sufficient amounts of the enzyme plasmin for clot lysis. The present invention combines tPA with recombinant Annexin A2 resulting in thrombolysis without hemorrhagic transformation at delayed times after stroke. This embodiment allows the administration of a lower, non-neurotoxic, tPA dose. Our results suggest this novel combination for stroke therapy may greatly improve both efficacy and safety, and prolong tPA therapeutic time window.06-02-2011
20080274171Renin Inhibitors Nitroderivatives - Renin inhibitors nitroderivatives of formula (I):11-06-2008
20080274169Photosensitizer formulations for topical applications - Highly flexible penetrating liposomal carrier systems are formulated with enhanced skin penetration properties. These specialized formulations of highly flexible penetrating liposomal delivery systems comprise one or more phospholipids, lysophosphatides and hydrophobic photosensitizer. This new formulations can squeeze liposomal particles through intercellular regions of stratum corneum as intact structures, and, in this way, deliver encapsulated photosensitizer to the epidermis, dermis, hypodermis and surroundings. The penetrating liposomal formulation provides therapeutically effective amounts of the hydrophobic photosensitizer through topical application with better skin penetration thus improving drug targeting and the efficacy of photodynamic therapy (PDT).11-06-2008
20100297215COMPOSITIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY - Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents.11-25-2010
20100297216METHOD FOR ADMINISTRATION OF PEGYLATED LIPOSOMAL DOXORUBICIN - An embodiment of the present invention comprises a method of treating malignancies in a subject in need of treatment comprising administering to the subject a high loading dose of a pegylated liposomal doxorubicin (PLD) in an initial cycle, followed by a reduced dose in a second cycle, wherein the second cycle reduced dose is in the range of 20% to 50%, preferably 50%, of the initial loading dose, and thereafter one or more maintenance doses in further cycles. The interval between dose cycles is in the range of about three-to-four weeks, preferably about four weeks. The initial loading dose is in the range of between the maximum tolerated dose (MTD) and the recommended dose, preferably the MTD (for instance, in the range of about 70 mg/m2 to 50 mg/m2, preferably 60 mg/m2). The one or more maintenance doses are in the range of about 40 mg/m2 to 50 mg/m2, preferably 45 mg/m2).11-25-2010
20100297218TISSUE ADHESIVE COMPOSITIONS AND METHODS THEREOF - The present invention relates to composition and method for an adhesive composition. In particular, the present invention relates to a composition of an adhesive composition containing a protein component and an aldehyde component where the aldehyde component further comprises of a thickening agent. The adhesive composition is used for adhering to a tissue in various applications. The adhesive composition can be used for marking a location within the human body, such as a tumor.11-25-2010
20100297217ISOPRENOID COMPOUNDS, THEIR ISOLATION AND USE - There is provided an isoprenoid according to the general formula (I) wherein R11-25-2010
20100297219Methods and Compositions for Modifying Apolipoprotein B mRNA Editing - Products and methods for modifying apolipoprotein B mRNA editing in vivo, reducing serum LDL levels, and treating or preventing an atherogenic disease or disorder are disclosed. Such methods involve the use of a protein including APOBEC-1 or fragments thereof which can edit mRNA encoding apolipoprotein B. The protein including APOBEC-1 can be taken up by cells in the form of a delivery vehicle, such as a liposome or niosome, or directly as a chimeric protein which includes a first polypeptide that includes a protein transduction domain and a second polypeptide that includes APOBEC-1 or a fragment thereof which can edit mRNA encoding apolipoprotein B.11-25-2010
20100297214PERCOLATIVE DRYING FOR THE PREPARATION OF PARTICLES - The present invention relates to dry particles and methods of preparing the same, in particular to methods of producing dry particles comprising a thermally labile component such as a colloidal system or a thermally labile biopharmaceutical compound, to the use of such dry particles, and to pharmaceutical compositions comprising the same.11-25-2010
20110117189OPHTHALMIC COMPOSITIONS FOR TREATING PATHOLOGIES OF THE POSTERIOR SEGMENT OF THE EYE - New compositions for ophthalmic use for the prevention and therapy of pathologies of the posterior segment of the eye. These compositions utilize xanthan gum as an active principle carrier, and can be advantageously administered as liquid-gel eye drops on the surface of the eye and optionally used in combination with other therapies for the treatment of the same pathologies.05-19-2011
20110117187TOPICAL COMPOSITIONS AND METHODS FOR EPITHELIAL-RELATED CONDITIONS - The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditions05-19-2011
20110117183Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors - A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.05-19-2011
20110123601BIOFUNCTIONALIZED PHOSPHOLIPID-CAPPED MESOPOROUS SILICA NANOSHUTTLES FOR TARGETED DRUG DELIVERY - The present invention provides a multilayer vehicle, including a mesoporous silica core and a lipid bilayer coating thereon. Hydrophobic molecules are formed between the silica core and lipid layer. Additionally, methods and uses of the multilayer vehicle are also provided.05-26-2011
20100303894POX VIRIDAE TREATMENT - A vaccine composition for combating 12-02-2010
20100303893NOVEL COMPOUND FOR TREATMENT OF TUMOR - Specific modifying agent is coupled to an anti-tumor protein on a certain site. It conquers the disadvantages which include high antigenicity, short circulating half-life, nonuniform modified sites, inhomogeneous component, reduced activity and uncontrollable quality of the products prepared by non-specific modifying method. The anti-tumor protein coupled with specific modifying agent can be used for the treatment of tumor and for manufacturing an anti-tumor medicament.12-02-2010
20100310636STEARICALLY STABILIZED UNILAMILAR VESICLES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF - The present invention relates to modified formulations of recombinant human glycoprotein having an in-vivo biological activity to increase the production of reticulocytes and red blood cells. A stearically stabilized unilamillar vesicles (SSUV) containing the said biopharmaceutical composition and process for preparation thereof is provided. The pharmaceutical composition comprises a various lipids, covalently modified lipids with polyethylene glycol and or neutral detergent to form long circulating and tightly packed lipid vesicles, which reduced the reticulo-endothelial clearance of SSUV and cause the sustained released effect of encapsulated biopharmaceutical and recombinant human glycoprotein or an erythropoietin moiety. The scope of present invention also describes the process of encapsulation of biopharmaceutical into the SSUV driven by the pH gradient and also the buffer system to enhance the encapsulation efficiency, preventing the protein aggregation and or degradation.12-09-2010
20130136786LONG NON-CODING RNA SPRY4-IT1 AS A DIAGNOSTIC AND THERAPEUTIC AGENT - Provided herein are methods for the diagnosis of cancer by comparison of a quantification of long non-coding RNA SPRY4-IT1 with the same measurement taken in a reference sample from a healthy patient. Further provided herein are methods of anticipating the likelihood that such a disease will develop, and methods of treatment in the event of such development.05-30-2013
20130136787Liposomal Camptothecins and Uses Thereof - This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.05-30-2013
20130136788METHOD FOR TREATING PULMONARY DISORDERS WITH LIPOSOMAL AMIKACIN FORMULATIONS - Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period.05-30-2013
20130136790LIPOSOMES WITH IMPROVED DRUG RETENTION FOR TREATMENT OF CANCER - The present invention relates to the use of copper ions to achieve enhanced retention of a therapeutic agent within a liposome. The invention may be employed to more effectively deliver a liposomally encapsulated therapeutic agent to a target site in vitro and in vivo for anti-cancer or other therapy. The liposome may comprise an interior buffer solution containing the therapeutic agent, the solution having a pH less than 6.5 and most preferably approximating pH 3.5. At least some of the copper ions are retained within the interior solution. In a particular embodiment the therapeutic agent may be a chemotherapeutic drug, such as irinotecan. The invention may also comprise an ionophore to facilitate loading of drug into the liposome. In one particular embodiment the combination of the ionophore A23187 and encapsulated divalent copper (Cu2+) resulted in an irinotecan formulation that exhibited surprisingly improved drug retention attributes.05-30-2013
20100310635Compositions and Methods for Regulating T-Cell Activity - Methods, compositions and kits effective for modulating and immunomonitoring of Treg activity are provided. Therapeutic methods involving formation and uses of cleaved Foxp3 are disclosed, as well as screening assays for identifying agents effective for modulating Treg activity.12-09-2010
20100310645METHODS FOR INHIBITING TUMOR CELL PROLIFERATION - The subject invention concerns methods for inhibition of STAT biological functions using platinum complexes.12-09-2010
20100310638LIPOSOMES COMPRISING DURAMYCIN AND ANTI-VIRAL AGENTS - Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.12-09-2010
20100310646SELECTIVE EXOSITE INHIBITION OF PAPP-A ACTIVITY AGAINST IGFBP-4 - The present invention relates in one embodiment to PAPP-A exosite(s) interactors such as antibodies which bind to a region comprising LNR3 of PAPP-A and efficiently inhibit proteolysis of IGFBP-4, but not -5. The region comprising LNR3 represents a substrate binding exosite, which can be targeted for selective proteolytic inhibition. Accordingly, the present invention relates in one embodiment to differential inhibition of natural protease substrates by exosite targeting.12-09-2010
20100316696LIPOSOME PREPARATION BY SINGLE-PASS PROCESS - The present invention relates to a method of preparing liposomes in a single-pass mode. The method comprises the extusion of a solution or suspension through a porous device and subsequently passing said suspension or solution through a nozzle. Passing the suspension through said nozzle may result in an atomisation of the suspension or solution into droplets which might be employed in a subsequent spray-drying or spray-freezing process.12-16-2010
20090162427VACCINES USING NUCLEIC ACID-LIPID COMPLEXES - This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.06-25-2009
20110111015COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO EIMERIA - Vaccines comprising TRAP polypeptides and 05-12-2011
20100330164METHOD OF INCREASING TEAR PRODUCTION WITH PURINERGIC RECEPTOR AGONISTS - A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.12-30-2010
20090068253METHOD FOR THE TREATMENT OF INFECTION WITH HHV-6 VIRUS AND THE AMELIORATION OF SYMPTOMS RELATED TO VIRUS USING LIPOSOMAL ENCAPSULATION FOR DELIVERY OF REDUCED GLUTATHIONE - The invention is the use of a therapeutically effective amount of glutathione (reduced) in a liposome encapsulation for oral administration to improve symptoms of illnesses that are related to viruses and for the treatment and prevention of virus, particularly HHV-6 and EBV, which liposomal encapsulation of glutathione (reduced) is referred to as liposomal glutathione. The application references specifically reduced glutathione and its importance, and how to stabilize it effectively so it can be taken orally, and need not be refrigerated. New uses for tuberculosis, and asthma are discussed. The combination is proposed of reduced glutathione and Highly Active Anti-Retroviral Therapy having at least one pharmaceutical composition selected from the group of Nucleoside/tide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), and Non-nucleoside Reverse Transcriptase Inhibitors (NnRTIs).03-12-2009
20110008420SYNERGISTIC ANTIMICROBIAL PREPARATIONS CONTAINING CHLORITE AND HYDROGEN PEROXIDE - An anti-microbial preservative for use in ophthalmic and dermatologic products. The preservative includes from about 0.005 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.05 wt. % peroxy compound. Additionally, the preservative does not generate chlorine dioxide within the pH range of 5.0-8.8. Also included are an antimicrobial ophthalmic and dermatologic compositions for direct application onto an eye or skin of a living being including from about 0.005 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.05 wt. % peroxy compound. Also included are methods for treating dryness of the eyes and skin disorders (e.g., wounds, burns, infections, ulcerations, psoriasis, etc.) and for disinfecting and cleansing contact lenses while in place upon an eye by applying the composition to the eye or to the contact lens.01-13-2011
20110008414METHOD FOR SYNTHESIZING CONFORMATIONALLY CONSTRAINED PEPTIDES, PEPTIDOMIMETICS AND THE USE THEREOF AS SYNTHETIC VACCINES - The present invention relates to methods for synthesizing conformationally constrained peptides and cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link. This cross-link is formed between the side chain of an amino acid residue or analog and a (2S, 4S)4-functionalized proline residue. The invention further relates to the use of (2S, 4S)-4-functionalized proline residues as building units in the synthesis of such peptidomimetics and to the use thereof as antigens, alone or in combination with suitable immunopotentiating delivery systems, for example immunopotentiating reconstituted influenza virosomes to elicit an immune response in a mammal. Moreover, the invention also relates to pharmaceutical compositions containing the same.01-13-2011
20130164366Method and medicament for inhibiting the expression of a given gene - The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.06-27-2013
20110008419Vaccine Against Streptococcus Pneumoniae - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen from 01-13-2011
20110008415NOVEL LIPOPHILIC COMPOSITIONS AND USES THEREOF - New co-lipids for use in combination with lipophilic compounds as nucleic acid vectors, for preparing a nucleic acid vector composition, and methods for introducing in vitro or in vivo a nucleic acid of interest into host cells, including a step of contacting host cells these nucleic acid vector compositions. The nucleic acid vector compositions have the combination (i) of a nucleic acid, cationic, lipophilic vector with (ii) a co-lipid. These nucleic acid vector compositions, in some embodiments, are present in the form of unilamellar or multilamellar vesicles.01-13-2011
20110008418Compositions and Methods for the Treatment of Cancer - The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I01-13-2011
20110111016NON-DNA BASE-CONTAINING POLYNUCLEOTIDE COMPOSITIONS AND THEIR USE FOR THE MODULATION OF IMMUNE RESPONSES - The present invention provides compositions comprising synthetic non-DNA base-containing polynucleotide sequences of 3 to 30 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases, in combination with a pharmaceutically acceptable vehicle, particularly one or more adjuvant vehicle, and one or more antigen. The present invention relates to methods of administering these compositions for inducing or modulating an immune response in vitro or in vivo, and particularly for activating antigen presenting cells.05-12-2011
20100183706PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.07-22-2010
20090035359IMMUNOGENIC FRAGMENTS OF T-CELL RECEPTOR CONSTANT DOMAINS AND PEPTIDES DERIVED THEREFROM - The present invention is directed to an isolated T-Cell Receptor constant domain and to peptides derived therefrom and recombinant constructs encoding same, effective in therapy of T cell mediated inflammatory disease, autoimmunity and graft rejection. Therapeutic and prophylactic vaccine compositions and methods utilizing these proteins and peptides, DNA vaccines encoding same and T cell vaccines thereof are further provided.02-05-2009
20090035362Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss - The present invention includes methods and compositions useful for treating and preventing skin disorders, hair loss and other skin disorders. The compositions include an ARD enhancer in combination with a second compound or composition. In some embodiments the second compound is at least one of a bactericide, an antibiotic, an anti-microbial peptide, Vitamin A, a Vitamin A derivative, a retinoid, an anti-inflammatory compound, and anti-androgen compounds.02-05-2009
20090035361Composition for vaginal use - Compositions for vaginal use comprising lupulus (02-05-2009
20090035358PHOSPHATIDYL OLIGOGLYCEROLS - In order to form liposomes with a longer half-life in blood, use is made of defined compounds with the general formula (A)02-05-2009
20090035360LYOPHILISED ANTIGEN COMPOSITION - The present invention provides lyophilised compositions comprising an antigen and a Toll-like receptor (TLR) 9 agonist. Such compositions may be reconstituted into immunogenic compositions for use in vaccination with a carrier selected from the group of particulate carriers consisting of liposomes, mineral salts, emulsions, polymers and ISCOMs. Methods of making immunogenic compositions from the lyophilised compositions of the invention and use of the same in immunisation are also herein provided.02-05-2009
20110027348COMPOSITION AND METHOD INHIBITING INFLAMMATION - Composition and method for preventing, treating or attenuating inflammatory diseases by way of inhibiting lipid peroxidation and subsequent elementary inflammation through ensuring the presence of the following biologically active ingredients in the PMRS of cells involved in inflammation: i) at least one killed probiotic and ii) at least one omega 3 FA and iii) vitamin E and iv) ubiquinone by introducing a composition comprising any of the missing ingredients.02-03-2011
20110027346Lyase Enzymes, Nucleic Acids Encoding Them and Methods for Making and Using Them - This invention provides polypeptides having lyase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having ammonia lyase activity, e.g., phenylalanine ammonia lyase, tyrosine ammonia lyase and/or histidine ammonia lyase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.02-03-2011
20110027349POLYPEPTIDE VACCINE AND VACCINATION STRATEGY AGAINST MYCOBACTERIUM - A vaccine is provided wherein a polypeptide or combination of peptides from 02-03-2011
20110033522REAGENTS FOR INDUCING AN IMMUNE RESPONSE - The present disclosure relates to reagents (antigenic and/or immunogenic reagents) and kits that are useful in a variety of in vitro, in vivo, and ex vivo methods including, e.g., methods for inducing an immune response, or for generating an antibody, in a subject. The reagents described herein can be used in the treatment or prevention of HIV-1 infections. In addition, the disclosure provides methods and compositions useful for designing (or identifying) an agent that binds to an membrane proximal external region (MPER) of an HIV-1 gp160 polypeptide or an agent that inhibits the fusion of an HIV-1 particle to a cell.02-10-2011
20100172964VESICLE USEFUL FOR EXTERNAL PREPARATION FOR SKIN, AND EXTERNAL PREPARATION FOR SKIN COMPRISING THE VESICLE - Disclosed is a technique for allowing an active ingredient as an agent for improving or maintaining the dermal environment to reach a dermis. Specifically disclosed is a vesicle comprising the following components 1) to 3): 1) an α,ε-bis(γ-N—(C07-08-2010
20100172961Encapsulated Peptide Amphiphile Nanostructures - The present invention provides compositions and methods for creating encapsulated peptide amphiphilic nanostructures useful in treating diseases. In particular, the present invention provides compositions and methods for preparing peptide amphiphile nanostructures that are encapsulated in liposomes by the application of light, and using such compositions in treating diseases, such as cancer.07-08-2010
20110033521Molecules and Methods of Using Same for Treating MCP-1/CCR2 Associated Diseases - Molecules and compositions including same for the isolation of MCP-1 and treatment of CCR2/MCP-1 associated diseases.02-10-2011
20090047338Method to Treat Flavivirus Infection with siRNA - The present invention is directed to methods of treating flavivirus mediated diseases using siRNAs. The invention is based upon our findings in a mouse model that siRNAs directed against sequences conserved among multiple flaviviruses prevents and treats flavivirus infections. Accordingly, the present invention provides an isolated siRNA comprising a sense RNA and an antisense RNA strand or a single strand. The sense and the antisense RNA strands, or the single RNA strand, form an RNA duplex, and wherein the RNA strand comprises a nucleotide sequence identical to a target sequence of about 15 to about 30 contiguous nucleotides in flavivirus mRNA or mutant or variant thereof.02-19-2009
20090047335Anti-angiogenic peptides and methods of use thereof - Anti-angiogenic peptides that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. Such peptides may be used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR). Such peptides may also be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases and skin disorders.02-19-2009
20110212159VACCINES - The invention relates to use of an antigen derived from the circumsporozoite protein (CS) protein of 09-01-2011
20110244026DELIVERY OF MRNA FOR THE AUGMENTATION OF PROTEINS AND ENZYMES IN HUMAN GENETIC DISEASES - Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids. The compositions disclosed herein demonstrate a high transfection efficacy and are capable of ameliorating diseases associated with protein or enzyme deficiencies.10-06-2011
20110244030TOPICAL FOAMING COMPOSITON AND METHOD OF APPLICATION - There is provided a topical foaming composition for the uniform distribution of formulations without drizzle formation. In accordance with the present invention, the topical composition contains a foaming agent and a pharmaceutically acceptable topical carrier. In accordance with the present invention, the composition may contain at least one active agent incorporated into the topical foaming composition. In accordance with a method of the present invention, the composition is capable of forming a stable foam in the present of a gas and the foam produced therefrom is topically applied on a subject in need thereof.10-06-2011
20110244029COMPOSITION OF MATTER COMPRISING LIPOSOMES EMBEDDED IN A POLYMERIC MATRIX AND METHODS OF USING SAME - The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes. The present disclosure also provides a method of removal of non-encapsulated active agent from the composition of matter, a method of preparing said composition of matter, a pharmaceutical composition comprising said composition of matter, use of such composition of matter; a method of providing prolonged delivery of a active agent to a subject in need thereof by administering to said subject the composition of matter disclosed herein as well as a package comprising said composition of matter held within said aqueus medium and instructions for use thereof.10-06-2011
20110244028METHOD OF SOLUBILIZING BIOLOGICALLY ACTIVE COMPOUNDS - The invention describes a method of preparing lipid compositions by associating pH sensitive compounds which maybe weak acids, bases or amphoteric compounds with at least one ionisable or pH sensitive group and low water solubility into preformed and standardised lipid particles by pH manipulation. Drug association is carried out in situ by changing the pH of the aqueous medium to pH 6-8 wherein the compound spontaneously partitions into the lipid particles. Drug association may also be carried out by exploiting pH changes in the GI tract. The lipophilic compound is solubilised by the lipid particles and may be used as such for in-vitro and pharmacokinetic assessments or processed for oral, parenteral or topical therapy.10-06-2011
201102440272'-Fluoro-6'-Methylene Carbocyclic Nucleosides and Methods of Treating Viral Infections - The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.10-06-2011
20110244025MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY - The invention provides immunostimulatory compositions and methods for their use. In particular, the immunostimulatory compositions of the invention include RNA-like polymers that incorporate an immunostimulatory sequence motif and at least one chemical modification to confer improved stability against nuclease degradation and improved activity. Specific modifications involving phosphate linkages, nucleotide analogs, and combinations thereof are provided. Compositions of the invention optionally include an antigen and can be used to stimulate an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an to allergic condition, or asthma. Modified oligoribonucleotide analogs of the invention are believed to stimulate Toll-like receptors TLR7 and TLR8.10-06-2011
20110244024MICRORNA COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELOGENOUS LEUKEMIA - The invention provides methods, uses, kits and compositions comprising a therapeutically effective amount of the microRNA miR-223 for treating myelogenous leukemia in a subject in need of such treatment. The invention further comprises methods encompassing the use of miR-223 for promoting the differentiation of a leukemia stem cell that is resistant to a differentiating agent, and a method of screening for candidate compounds capable of treating a myeloid leukemia by comparison of the therapeutic activity of the candidate compound with the therapeutic activity of miR-233.10-06-2011
20110212168COMPOSITION FOR TARGETING DENDRITIC CELLS - The present disclosure relates to a composition for targeting dendritic cells. In particular, the present disclosure relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The disclosure further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.09-01-2011
20100136095Systems for modulating inflammation - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.06-03-2010
20120244209TUSC2 THERAPIES - A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.09-27-2012
20110129524THERAPEUTIC AGENT FOR CANCER, AND METHOD FOR TREATMENT OF CANCER - [Problems] To provide a technique which enables an effective antibody therapy for cancer which targets for FGFR1 without the need of using any effective antibody having high specificity and a potent cell-killing activity.06-02-2011
20110212163MAGNETIC HEATING FOR DRUG DELIVERY AND OTHER APPLICATIONS - The present invention generally relates to systems and methods for releasing a compound from an article using an external trigger, for example, magnetic fields. One aspect of the invention is generally directed to an article containing a magnetically-susceptible material. Exposure of the magnetically-susceptible material to a magnetic field, such as an oscillating magnetic field, may cause the magnetically-susceptible material to increase in temperature. This increase in temperature may be used, in some embodiments, to cause the release of a drug or other releasable material from the article. For instance, the drug may be contained in a heat-sensitive material in thermal communication with the magnetically-susceptible material, or the drug may be contained within an enclosure that is isolated, at least in part, by a heat-sensitive material in thermal communication with the magnetically-susceptible material. Other aspects of the invention are directed to systems and methods of making or using such articles, e.g., by implanting the article within a subject, methods of treatment involving such articles, kits including such articles, or the like.09-01-2011
20100221318NUCLEIC ACIDS FOR INHIBITING HAIRLESS PROTEIN EXPRESSION AND METHODS OF USE THEREOF - The present invention provides DNAzymes and ribozymes that specifically cleave Hairless protein mRNA. The present invention also provides antisense oligonucleotides that specifically inhibit translation of Hairless Protein mRNA. The present invention also provides various methods of inhibiting the expression of Hairless Protein. Finally the invention provides pharmaceutical compositions containing the instant DNAzymes, ribozymes and antisense oligonucleotides as active ingredients.09-02-2010
20110086088Compositions and methods for treatment of mammalian skin - Compositions useful for treatment of a wide range of skin disorders including: pre-cancerous lesions, keratotic lesions, superficial basal cell carcinomae; squamous cell carcinomae; malignant melanoma, and radiation-induced burns. In some embodiments the treatments comprise contacting human or other mammalian skin with a composition according to the disclosure. In other embodiments, administration of compositions provided is by injection. Some embodiments provide for preventive use of compositions provided towards preventing some forms of skin cancer and skin cancer-related disorders by repeated application to healthy-looking skin. Methods for providing the compositions are disclosed.04-14-2011
20110086089USE OF P27KIP1 FOR THE PREVENTION AND TREATMENT OF HEART FAILURE04-14-2011
20110086091STABLE CRYSTAL MODIFICATIONS OF DOPC - The invention relates to stable crystal modifications of (R,S)-, (R)- and (04-14-2011
20110086090Vectors Containing the Max Gene - The present invention refers to the construction of cloning vectors containing the max gene. Especially, the present invention refers to the introduction of cloning vectors containing the max gene in cells using transport vectors. In addition, the presence of cloning vectors containing the max gene in cells allows the differential expression of the max gene in the same cells. In addition, the present invention refers to a method of gene therapy in which the differential expression of the max gene has cytoprotective activity, especially neuroprotective activity, and is capable of application to medical and veterinary therapeutics of neurodegenerative conditions.04-14-2011
20100015213Compositions and Methods Using Same for Delivering Agents Into a Target Organ Protected by a Blood Barrier - A method of delivering a pharmaceutical agent into a target organ protected by a blood barrier is provided. The method comprising administering to a subject in need thereof an amount of liposomes which comprise the pharmaceutical agent, the amount and the liposomes are selected such that the liposomes accumulate in cells of an immune system of the subject to thereby generate liposome loaded immune cells, the liposome loaded immune cells become activated and cross the blood barrier, and an effective amount of the pharmaceutical agent is released from the liposomes in the target organ of the subject.01-21-2010
20090311313METHODS FOR TREATING TWEAK-RELATED CONDITIONS - The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.12-17-2009
20100015211Combination Approaches For Generating Immune Responses - The present invention relates to methods, polypeptides, and polynucleotides encoding immunogenic identical or analogous HIV polypeptides derived from the same or different strains within an HIV subtype and/or different subtypes. Uses of the polynucleotides and polypeptides in combination approaches for generating immune responses are also described. The combination approaches described herein induce broad and potent immune responses against diverse HIV strains from multiple strains within a given subtype and against diverse subtypes. Formulations of compositions for generating immune responses and methods of use for such compositions are also disclosed.01-21-2010
20110177156Sterol-Modified Amphiphilic Lipids - Disclosed are sterol-modified amphiphilic lipid compounds having two or more hydrophobic tails of which at least one is a sterol. Also disclosed are the processes for the synthesis of these compounds, compositions comprising such compounds, and the use of such compounds in delivery of an agent of interest, e.g., therapeutics, imaging agents, contrast materials for ultrasound applications, vaccines, biosensors, nutritional supplements and skin care products.07-21-2011
20100055165LIPOSOMAL GEL PHTHALOCYANINE PREPARATION FOR PHOTODYNAMIC THERAPY OF TUMORS AND ITS MANUFACTURING - Liposomal gel hydrophobic phthalocyanine (FCH) preparation for photodynamic therapy of tumors and other diseases is composed of lecithin liposomes or liposomes on the basis of other lipids, with incorporated curing drug, which can be chosen either from a group including hydrophobic hydroxyaluminum phthalocyanine, hydrophobic aluminum phthalocyanine, hydrophobic zinc phthalocyanine, hydrophobic silicone phthalocyanine, or organic silicone phthalocyanine, or hydrophobic phthalocyanine without the core metal; while resulting liposomes are mixed in ratios of 10:1 to 1:10 with a translucent gel, advantageously on the basis of carboxymethylcellulose. The added curing drug can be coated by glucose or other saccharides, by polyethylenglycol or other usable polymers, as lecithin or other lipids, or by sodium chloride or other salts usable in pharmacology. Liposomal gel hydrophobic phthalocyanine (FCH) preparation is manufactured on the following schema: Lecithin or other lipid of a pharmacological purity at concentration between 10 to 40 mg per ml of sterile isotonic solution is fluidised on a microfluidizer in particular chamber to the final particle size smaller than 1000 nm, in temperature higher than 0° C. and a pressure at 500 to 2000 Bar; then while stirring the curing drug or the treated curing drug is added in the ratio of 5:1 to 0.1:1 in relation to the lecithin or other lipid; the resulting suspension is again fludized on a microfludizer in particular smaller chamber to the final particle size smaller than 500 nanometer, with pressure at least 1000 to 2000 Bar, in temperature higher than 0° C.; the resulting suspension is then mixed with a translucent gel in ratios of 10:1 to 1:10; Alternatively, first lecithin or other lipid of a pharmacological purity at concentration between 10 to 40 mg per ml of sterile isotonic solution is microfludized on a microfluidizer in particular chamber to the final particle size smaller than 1000 nm, a pressure at least 1000 to 2000 Bar and temperature higher than 0° C.; Afterwards, in parallel the curing drug or the treated curing drug is separately microfluidized in amounts corresponding to the ratio of 5:1 to 0.1:1 in relation to the lecithin or other lipid in an equal volume of fluid, advantageously on the basis of sterile isotonic solution to the final particle size smaller than 1000 nanometer, and with pressure at 1000 to 2000 Bar; Afterwards both microfludized components are mixed together and again microfludized on a microfludizer in particular chamber with a pressure at 1000 to 2000 Bar and temperature higher than 0° C. to the final particle size maximum of 500 nanometer, the resulting suspension is fluidised on a microfluidizer in a particular smaller chamber with a pressure at least 1000 to 2000 Bar and temperature higher than 0° C. to the final particle size smaller then 500 nm, the resulting suspension is then mixed with a translucent gel in ratios of 10:1 to 1:10; Alternatively, Lecithin or other lipid in the pharmacological purity at the concentration of 10 to 40 mg per milliliter of sterile isotonic solution is first treated by extrusion across the filters with a size 10 to 500 nm together with the curing drug or the treated curing drug in the ratio of 5:1 to 0.1:1 related to the lecithin or other lipid; and the resulting suspension is again fluidised on a microfluidizer in a particular chamber with a pressure at least 1000 to 2000 Bar and temperature higher than 0° C. to the final particle size smaller then 500 nm, with a pressure at least 1000 to 2000 Bar and temperature higher than 0° C., the resulting suspension is mixed with a translucent pharmaceutical gel in a ratio of 10:1 to 1:10.03-04-2010
20100055169CATIONIC LIPIDS AND USES THEREOF - Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.03-04-2010
20100055167STEM CELL DELIVERY OF ANTI-NEOPLASTIC MEDICINE - The present disclosure provides a modified stem cell comprising a stem cell and at least one controlled-release vehicle, wherein the at least one controlled-release vehicle includes at least one anti-neoplastic agent and at least one targeting moiety, and wherein the modified stem cell is characterized by an ability to target one or more glioma cells. The disclosure also provides pharmaceutical compositions and methods of treating a glioma by administering a therapeutically effective amount of the modified stem cells.03-04-2010
20100062047Composition for Administration to Mammals or Human - The invention relates to a composition for administration to mammals or humans, which is used to destroy damaged, pathogenic cells, including empty liposomes, structural protein elements and specific binding elements that are selected as a function of the pathogenic micro-organism or cell to be destroyed. When administered to the patient, the composition acts in the manner of an effective effector agent which interacts with the membrane of the target cell or with the membrane of the micro-organism in order produce discharge ports which release the intracellular content to the extracellular medium.03-11-2010
20090028933COMPOSITIONS AND METHODS FOR TREATING LYMPHOMA - The present invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of leukemias, including acute lymphoblastic leukemia (ALL). These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, in combination with dexamethasone to a mammal with a leukemia.01-29-2009
20100178327ACTIVE INGREDIENT OF A MEDICINAL AGENT, A MEDICINAL AGENT, A PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEMENTIA SYNDROME PATIENTS - The invention relates to an area of the chemical-pharmaceutical industry and medicine, particularly to an agent for treatment of dementias, including Alzheimer's disease (AD), as well as to a method of treatment and pharmaceutical composition, which is effective for both treatment of dementias, including AD or dementias of Alzheimer type, and during manifestations of the first symptoms of memory disorder.07-15-2010
20110081408ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.04-07-2011
20110081406ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.04-07-2011
20110081402Cosmetic base comprising collagen-modified liposome and skin cosmetic containing the same - The affinity of collagen for the skin and its persistence on the skin are improved without destroying the triple helical structure inherent in collagen to thereby improve its ability to retain the moisture of the skin and increase the amount of bound water when such collagen is used as a skin cosmetic. The collagen can thereby exert its moisture retention effect more effectively. A cosmetic base includes an aqueous solution of a liposome that is surface-modified with water-soluble collagen having a triple helical structure.04-07-2011
20110097388Methods of Expressing Proteins with Disulfide Bridges - This invention relates to methods of expressing eukaryotic proteins in prokaryotic hosts, particularly eukaryotic proteins that require formation of disulfide bridges for biological activity. Various approaches are used including fusion to thioredoxin, cytoplasmic expression of disulfide isomerases, deficiencies in thioredoxin and/or glutathione reductases, deficiencies in proteases, and the like. The method is applicable to express monomeric and dimeric forms of the eukaryotic protein with biological activity such as monomeric and dimeric forms of a disintegrin or a disintegrin domain. Included are the vectors, host cells expressing the proteins, the expressed proteins and methods of using the proteins.04-28-2011
20090214639OMP P6 VACCINE FOR TREATING AND PREVENTING CHLAMYDIA INFECTION - The present invention provides a vaccine for immunization of a host, including humans, against disease caused by infection by a strain of 08-27-2009
20090214638LIPOSOME ENCAPSULATED POLY-ICLC METHOD TO PROPHYLACTICALLY TREAT AN AVIAN INFLUENZA VIRAL INFECTION - A method of treating an avian influenza viral infection using a poly ICLC formulation with improved therapeutic efficacy is disclosed. The poly ICLC is encapsulated within liposomes which provides a drug delivery system with slow sustained release characteristic and which has the ability to target the drug to sites of viral infection without causing systemic burden to normal tissues, thereby enhancing the immunological and biological activities of poly ICLC. This poly ICLC formulation has been found to be particularly effective in treating an avian influenza viral infection and in particular, an avian H08-27-2009
20090214637Novel Gene Therapy Approach For Treating The Metabolic Disorder Obesity - The present application relates to novel methods and compositions for treating metabolic disorders. Some aspects pertain to the use of gene therapy to treat diseases related to metabolic disorders, such as diabetes, obesity, high blood pressure, wasting syndrome, cachexia and atherogenic dyslipidemia. The present application also pertains to the use of vectors such as a recombinant adeno-associated virus (AAV) to deliver a at least a portion of a gene that can increase or decrease expression of a therapeutic protein of interest, e.g., in cells in a specific region of the brain associated with metabolic disorder. The present application also discloses the use of vectors such as a recombinant adeno-associated virus for the delivery of small interference RNA's (siRNAs) capable of decreasing expression of a deleterious protein involved in the disorder. Other related aspects, including compositions related to such methods, are also disclosed.08-27-2009
20090214636Imaging and Therapeutic Method Using Monocytes - The invention relates to a method of treating or diagnosing a disease state mediated by monocytes. The method utilizes a composition comprising a conjugate or complex of the general formula08-27-2009
20090214634COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLADDER CANCER - Compositions and methods for the treatment of bladder cancer include intravesical dosage forms of a neoplastic agent and a permeation enhancer. The neoplastic agent may be valrubicin. Pharmaceutical compositions include intravesical dosage forms of a neoplastic agent complexed liposomes. Tight junction openers may be used for the effective delivery of the neoplastic agent.08-27-2009
20090214632Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions - This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.08-27-2009
20090214631Process for the Preparation of Strontium Ranelate - A process for the preparation of strontium ranelate or a hydrate thereof is provided comprising (a) reacting a tetraester compound of Formula II: wherein R, R08-27-2009
20090214630Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides - Provided herein is a method of treating or preventing inflammatory bowel disease (IBD) in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an NF-κB decoy polynucleotide.08-27-2009
20090214629GENE TRANSFER METHOD - A method for efficiently transferring a gene to a target cell is provided. A method of transferring a gene to a target cell, including adding or administering a positively charged complex (A) composed of the gene and a cationic substance and gas-filled microparticles (B) to a target cell-containing composition or a living body and then exposing the target cell-containing composition or the living body to a low-frequency ultrasound.08-27-2009
20110250266LIPOSOMAL SYSTEMS COMPRISING SPHINGOMYELIN - The present disclosure provides a liposomal system comprising an aqueous medium having dispersed therein liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the aqueous medium being in iso-osmotic equilibrium with said intraliposomal aqueous compartment, the liposomes having a membrane comprising a liposome forming lipids, at least one of which being sphingomyelin (SPM), the liposomal system having increased stability as compared to the same liposomes free of SPM, and in one embodiment being stable during long-term storage, said stability being characterized in that no more than 30% of the at least one active agent is present in the aqueous medium after said storage. Further provided by the present disclosure are a method for storage of liposomes making use of the liposomal system; use of the liposomal system for the treatment of a medical condition or for the diagnostic of a medical condition; a pharmaceutical or diagnostic composition comprising the liposomal system, and a method of treating or diagnosing of a medical condition comprising administering to a subject an amount of the liposomal system.10-13-2011
20110250265Vaccine Preparation for Neospora Caninum Infection - A vaccine preparation characterized in that 10-13-2011
20110250264METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.10-13-2011
20110250263PROTEIN AND NUCLEIC ACID DELIVERY VEHICLES, COMPONENTS AND MECHANISMS THEREOF - Complex viruses are assembled from simple protein subunits by sequential and irreversible assembly. During genome packaging in bacteriophages, a powerful molecular motor assembles at the special portal vertex of an empty prohead to initiate packaging. An aspect of the invention relates to the phage T4 packaging machine being highly promiscuous, translocating DNA into finished phage heads as well as into proheads. Single motors can force exogenous DNA into phage heads at the same rate as into proheads and phage heads undergo repeated initiations, packaging multiple DNA molecules into the same head. This shows that the phage DNA packaging machine has unusual conformational plasticity, powering DNA into an apparently passive capsid receptacle, including the highly stable virus shell, until it is full. These features allow for the design of a novel class of nanocapsid delivery vehicles.10-13-2011
20090214628METHODS AND COMPOSITIONS FOR TREATMENT OF SKIN - The present invention relates to compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or determatologic skin conditions. The invention relates to compositions for treating and ameliorating skin conditions including acne, rosacea and wrinkling caused by photodamage or conditions related to aging, hormonal imbalances, hyper-pigmentation, melasma, keratosis or the like. The invention can also be used to treat conditions of the scalp such as dandruff. The present invention also relates to compositions that can be used to remove biofilms from contact lenses. More particularly, this invention relates to a composition comprising (a) one or more metasilicate; (b) one or more carbonate; (c) one or more glyconate; and (d) one or more sulfate. The composition may also contain (e) salts, e.g., sea salts and other additives or active agents.08-27-2009
20090214627METHODS OF MODIFYING INSULIN SIGNALING USING BILIVERDIN REDUCTASE - The present invention relates to a method of modulating insulin signaling in a cell. This method involves modifying the nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, in a cell, whereby a change in nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, modulates insulin signaling in the cell via biliverdin reductase interaction with one or both of insulin receptor kinase domain and insulin receptor substrate. Also disclosed are methods of treating a condition associated with insulin signaling and treating a patient for a condition associated with insulin-mediated glucose uptake.08-27-2009
20110250258TUMOR-SPECIFIC DELIVERY OF THERAPEUTIC AGENTS VIA LIPOSOMASE - is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with 10-13-2011
20090214626Platinum Complexes For Targeted Drug Delivery - The subject invention concerns biotin-conjugated platinum complexes that exhibit direct and indirect (immunological) antitumor cell activity. The subject invention also concerns the biotin-platinum complexes of the invention that have another molecule, such as an antibody, a ligand, a receptor, etc., bound to the biotin moiety. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.08-27-2009
20110097385Delivery System for Drug and Cell Therapy - A method of lowering blood glucose in a mammal includes administering orally or by injection or inhalation a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin or other therapeutic agents.04-28-2011
20110097387PARTICULATE DRUG CARRIERS AS DESENSITIZING AGENTS - The present invention provides methods for desensitization for prevention or diminishing hypersensitivity reactions including C activation-related pseudoallergy (CARPA) and other reactions to particulate medicines. The desensitization is performed via pretreatment using a drug-free vehicle or carrier to eliminate or diminish the clinical symptoms of hypersensitivity.04-28-2011
20110104258TECHNIQUE FOR DRUG AND GENE DELIVERY TO THE CELL CYTOSOL - Provided herein is a composition, a method, and a system for delivering a functional molecule to the cytosol of a cell, comprising a liposome configured to be taken into a cell, including by a process selected from the group consisting of endocytosis, pinocytosis or phagocytosis, the liposome comprising a phase transforming liquid with vapor pressure capable of forming a gas at low pressure, said liquid being associated with the liposome, and the liposome further comprising at least one functional molecule selected from the group consisting of a therapeutic molecule, a detectable label, and a targeting molecule.05-05-2011
20110104252ANTI-APOPTOTIC GENE SCC-S2 AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF - A gene that is a positive mediator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of SCC-S2 such as renal, ovarian, head and neck, breast, prostate, brain, chronic myelogenous leukemia, lung, lymphoblastic leukemia, and colorectal adenocarcinoma cells.05-05-2011
20110070298Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance - The invention provides a composition comprising: an antigen; liposomes; a polyI:C polynucleotide; and a carrier comprising a continuous phase of a hydrophobic substance. Methods for making and using the compositions are also provided.03-24-2011
20110070295METHODS FOR THE PREPARATION OF LIPOSOMES COMPRISING DOCETAXEL - Provided herein are methods for preparing liposomes comprising docetaxel and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders.03-24-2011
20110070290VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.03-24-2011
20110070294Methods for the Administration of Drugs Using Liposomes - Provided herein are methods for the administration of drugs using liposomes. In particular, provided herein is the use of liposomes as diluents for lyophilized or liquid drugs to deliver the drug safely, reduce the toxicity of the drug or the excipients used to solubilize or stabilize the drug.03-24-2011
20110070293Methods for the Preparation of Liposomes Comprising Docetaxel - Provided herein are methods for preparing liposomes comprising docetaxel and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders.03-24-2011
20110070292Methods For The Preparation Of Liposomes - Provided herein are methods for preparing liposomes and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparation contains one or more active agents. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders.03-24-2011
20110059157ANIONIC LIPIDS AND LIPID NANO-STRUCTURES AND METHODS OF PRODUCING AND USING SAME - Anionic non-phospholipids, as well as lipid nanostructures formed therefrom, are disclosed herein. Also disclosed are methods of producing and using same.03-10-2011
20100178326AMINOPHOSPHONATE CARRIERS FOR LIPOSOME-BASED DRUG RELEASE SYSTEMS - A novel class of carriers for liposome-based drug delivery and release systems is provided. Such carriers exhibit excellent compatibility with hydrophilic drug compounds as well as effective release upon transport through phospholipid bilayers of cell membranes. Furthermore, such carriers are non-cytotoxic, particularly in terms of contact with cell membranes themselves. As such, these carriers accord an excellent manner of transporting pharmaceutical and other like compounds and materials to a user's individual cells for delayed release thereof at the site necessary to effectuate proper treatment. Drug delivery materials including such carriers are encompassed within this invention, as well as the overall method of drug delivery and delayed release provided thereby.07-15-2010
20090202625TRYPANOSOME MICROSOME SYSTEM AND USES THEREOF - The present invention provides cell free preparations of protozoan microsomes, wherein the cell free preparation of protozoan microsomes demonstrate the ability to translocate a protozoan polypeptide into the microsome, methods of preparing cell free preparations of protozoan microsomes, and methods of using cell free preparations of protozoan microsomes.08-13-2009
20120148668INTRACORONARY DEVICE AND METHOD OF USE THEREOF - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems.06-14-2012
20120148666ANTI-RSV IMMUNOGENS AND METHODS OF IMMUNIZATION - Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof.06-14-2012
20120148662Formulation - The present invention relates to a novel stable S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate liposomal composition, a process for the preparation thereof and its use in the treatment of diseases.06-14-2012
20120148661HIGH BIOAVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY - The invention provides a method of treatment of cancer, wherein a individual doses of picoplatin, each of less than about 200 mg picoplatin content, the individual doses having high oral bioavailability, are administered to a patient in need thereof. The oral bioavailability can be greater than about 50%, or greater than about 75%, or greater than about 90%, depending upon the particular dosage form and dosing regimen used. The invention provides a quasi-metronomic dosing schedule including drug dosing intervals and drug intermission intervals, optionally including fasting periods prior to and following administration of each individual dose of picoplatin.06-14-2012
20120148660CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR - The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.06-14-2012
20110059163LYOPHILISED ANTIGEN COMPOSITION - The present invention provides lyophilised compositions comprising an antigen and a Toll-like receptor (TLR) 9 agonist. Such compositions may be reconstituted into immunogenic compositions for use in vaccination with a carrier selected from the group of particulate carriers consisting of liposomes, mineral salts, emulsions, polymers and ISCOMs. Methods of making immunogenic compositions from the lyophilised compositions of the invention and use of the same in immunisation are also herein provided.03-10-2011
20110059160METHODS AND COMPOSITIONS FOR TARGETED GENE MODIFICATION - Disclosed herein are methods and compositions for gene targeting utilizing fusion molecules comprising a recombinase domain and a sequence-specific DNA-binding domain.03-10-2011
20110059156Nanostructures Suitable for Sequestering Cholesterol and Other Molecules - Articles, compositions, kits, and methods relating to nanostructures, including those that can sequester molecules such as cholesterol, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanoparticle core may be surrounded by a shell including a material, such as a lipid bilayer, that can interact with cholesterol and/or other lipids. In some embodiments, the structures, when introduced into a subject, can sequester cholesterol and/or other lipids and remove them from circulation. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions, especially those associated with abnormal lipid levels.03-10-2011
20110150979METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF PRIMARY AND METASTATIC BASAL-LIKE BREAST CANCER AND OTHER CANCER TYPES - In one embodiment, a method of theranostic classification of a breast cancer tumor is provided, comprising obtaining a breast cancer tumor sample from a subject, detecting an expression level of FOXC1, comparing the expression level of FOXC1 to a predetermined cutoff level, and classifying the breast cancer tumor sample as belonging to a theranostic basal-like breast cancer tumor subtype or a theranostic hybrid basal-like breast cancer tumor subtype when the expression level of FOXC1 is higher than the predetermined cutoff level. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided,06-23-2011
20110150983CONCENTRATED, INHALABLE CIPROFLOXACIN FORMULATION - A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposomes which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.06-23-2011
20110150981Compounds for Use in Therapy - A compound of formula (I) for use in the treatment of a disease of the immune system; wherein R is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 50 carbon atoms; R06-23-2011
20110008421Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye - The invention provides a liposome for delivery to the posterior segment of the eye, comprising (A) a phospholipid, (B) a charged substance, and/or (C) a membrane-reinforcing substance; the liposome having a rigidity that provides the liposome with cell membrane permeability, and having a mean particle diameter of 1 μm or less; and a pharmaceutical composition for a disease in the posterior segment of an eye, comprising a drug encapsulated in the liposome. The liposome is delivered to the posterior segment of the eye by instillation, and is non-cytotoxic; and the pharmaceutical composition for a disease in the posterior segment of the eye comprises the liposome.01-13-2011
20110250261CIRCULAR DUMBBELL DECOY OLIGODEOXYNUCLEOTIDES (CDODN) CONTAINING DNA BINDINGS SITES OF TRANSCRIPTION - The present invention provides a circular dumbbell oligodeoxynucleotide (CDODN) comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of a transcriptional factor. The present invention further provides a pharmaceutical composition comprising said CDODN. The pharmaceutical composition can be used for treating and/or preventing a disease or disorder related to such a transcriptional factor. The present invention also provides a method for treating and/or preventing a disease or disorder related to such a transcriptional factor, comprising administering to the subject a therapeutically effective amount of a CDODN comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of the transcriptional factor.10-13-2011
20100303895FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS - Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.12-02-2010
20110212164POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF - The present invention relates to polynucleotides encoding immunogenic HIV type C Pol, Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Pol, Gag- and/or Env-containing proteins are also described.09-01-2011
20090087476PROSAPOSIN AS A NEUROTROPHIC FACTOR - Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.04-02-2009
20100310640HLA-DR BINDING PEPTIDES AND THEIR USES - The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines.12-09-2010
20100310644ANTI-DANDRUFF COMPOSITIONS CONTAINING PEPTIDES - The present invention relates to the use of special peptides in composition which can be used in particular in hair and skin cosmetics, and to such peptide-containing compositions. In particular, the present invention relates to the use of such peptides as active ingredient for inhibition or treatment of dandruff which does not accumulate in the body or in the environment. Furthermore, the invention relates to the production of such compositions, to the peptides used themselves, to their production and to coding nucleotide sequences for such peptides, to dispensing systems for such peptides and to screening methods for identifying suitable further peptides.12-09-2010
20100303898COLLAGEN DISPERSION AND METHOD OF PRODUCING SAME - A stable dispersion of insoluble collagen is provided by a microfluidization process. The dispersions of insoluble collagen protein remain in stable suspension under long term storage conditions, with minimal or no settling or precipitation. More specifically the invention provides a stable dispersion of insoluble collagen comprising collagen particles wherein 50% by volume of said particles are less than 30 micrometers in width. These dispersions provide collagen in an aqueous form, which enables ease of incorporation into food and beverages and ease of administration to people or other mammals in need of collagen.12-02-2010
20100247624VACCINE COMPOSITIONS AND METHODS CONTAINING AN IMMUNOGEN DERIVED FROM EQUINE ARTERITIS VIRUS - The present invention relates to vaccine compositions comprising a nucleic acid encoded by an equine arterivirus virus (EAV) open reading frame (ORF) 2 nucleic acid, and a nucleic vector comprising said EAV ORF 2. The invention further relates to the methods and kits encompassing the use of EAV ORF 2 containing vaccine compositions and nucleic acid vectors for the prevention and/or treatment of EAV infections.09-30-2010
20110256214SINGLE-TIME VACCINES - The invention is related to the field of vaccines. The technical objective is to obtain novel unitemporal therapeutic and prophylactic vaccines (single time vaccination strategy) using simultaneously one or more mucosal doses and one parenteral dose where the use of potent mucosal adjuvants are essential, preferable the Cochleate (AFCo I, Adjuvant Finlay Cochleate 1). The incorporation or co-administration by parenteral and mucosal routes of non-related PL antigens (heterologous), and/or the additional use of delivery systems like Aluminum, Chitosan or oil/water emulsions by parenteral application is also included in this invention. The induction of cellular immune responses than including systemic specific IgG and secretory specific IgA is obtained with at least two simultaneously doses. So, this unitemporal strategy is applicable to obtaining new unique or multiples vaccines (several mucosal vaccine antigens with the corresponding parenteral combine vaccine) in the pharmaceutical industry which permit to increase vaccine coverage and reduce the time-cost of vaccine campaigns.10-20-2011
20120034295CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS - The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.02-09-2012
20090022784SYSTEMS, DEVICES, AND METHODS FOR IONTOPHORETIC DELIVERY OF COMPOSITIONS INCLUDING LIPOSOME-ENCAPSULATED INSULIN - Systems, devices, and methods for delivering one or more active ingredients to intradermal tissues, deep regions of pores, and intradermal tissues in the vicinity of pores. In some embodiments, a composition is provided including a plurality of liposomes including a cationic lipid, and an amphiphilic glycerophospholipid having a saturated fatty acid moiety and an unsaturated fatty acid moiety, and at least one insulin, insulin analog, or insulin derivative.01-22-2009
20090022782Blood Retainable Device Exhibiting Selective Degradability in Tumor Tissue - A phospholipid derivative useful for the preparation of liposomes for efficient uptake of an antitumor agent or a gene intracellularly by a target tumor cell, which comprises a residue of an alcohol compound and a residue of a phospholipid, and comprising a peptide between the residue of an alcohol compound and the residue of a phospholipid, and wherein (a) the alcohol compound is an alcohol compound selected from poly(alkylene glycols) and the like, (b) the phospholipid is a phospholipid selected from phosphatidylethanolamines, phosphatidylcholines, phosphatidylserines and the like, and (c) the peptide is a peptide comprising a substrate peptide that can serve as a substrate of a matrix metalloproteinase, provided that one amino acid residue or an oligopeptide containing 2 to 8 amino acid residues may bind to one or both ends of the substrate peptide.01-22-2009
20090022783siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES - The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.01-22-2009
20100003314METHOD AND COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS - The present invention relates to a method and composition for the treatment of skin conditions such as acne. Either natural or artificial sea water is enhanced by the addition of magnesium until it is at least about double the normal natural concentration of magnesium and then used as an application to the skin such as the face for treating acne and improving the appearance of the skin.01-07-2010
20100003316METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS USING PLASMONICS ENHANCED PHOTOSPECTRAL THERAPY (PEPST) AND EXCITON-PLASMON ENHANCED PHOTOTHERAPY (EPEP) - The use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes used therein.01-07-2010
20080248091Charge Gradient Inhibition of Trypanosoma Cruzi and Other Parasite's Invasive Action - Methods for delaying and/or preventing the binding of parasites to host cells (especially mammalian host cells) are provided. The methods delay or prevent infection of host cells and the development of disease symptoms. The methods delay or prevent the parasites from locating and binding to host cells, thereby reducing the infectivity of the parasite, and allow for adjuvant drug therapy to have a longer treatment time period before infection sets in. The methods involve modifying the charge field sensed by the parasite in the vicinity of potential host cells. Such modifications may be made by exposing the parasite and/or the host cell to charge-altering agents such as charged nanoparticles.10-09-2008
20080248093pH sensitive prodrugs of 2,6-diisopropylphenol - The present invention is directed to water-soluble derivatives of 2,6-diisopropylphenol (Propofol). The compounds act as prodrugs of 2,6-diisopropylphenol and metabolize rapidly to Propofol thereby providing an alternative to the water-insoluble 2,6-diisopropylphenol. Pharmaceutical compositions comprising these compounds, methods of induction and maintenance of anesthesia or sedation as well as methods of treating neurodegenerative diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.10-09-2008
20080248097POLYMERIC MICELLES FOR COMBINATION DRUG DELIVERY - The invention provides block polymers, micelles, and micelle formulations for combination drug therapy. Polyamide block polymers, such as those of formulas I and II are useful, for example, for preparation of mixed drug micelles, including simply mixed micelles, physically mixed micelles, and chemically mixed micelles. The invention further provides methods of treating cancer, and inhibiting and killing cancer cells. Also provided are methods for the preparation of polymer drug conjugates and intermediates for their synthesis.10-09-2008
20110150980CGRP ANALOG - Sequence modified calcitonin gene related peptide (CGRP) compounds are useful for treating heart failure, stroke, hemorrhagic shock, or migraine, improving renal function, preventing or delaying the advancement of heart failure into advanced stages, treating angina, controlling pulmonary hypertension, counteracting ischemia due to a myocardial infarction, preventing vasospasms during angioplasty, preventing reocclusion of blood vessels during and/or after angioplasty, stent insertion, or the implantation of a vascular grafts, and for treating male impotence and female sexual arousal disorder.06-23-2011
20110150978PH-SENSITIVE BLOCK COPOLYMER FORMING POLYIONIC COMPLEX MICELLES AND DRUG OR PROTEIN CARRIER USING THE SAME - Disclosed is a pH-sensitive block copolymer that forms polyionic complex micelles. The block copolymer is prepared by copolymerization of (a) a polyethylene glycol compound, (b) a poly(amino acid) compound, and (c) a heterocyclic alkyl amine compound having the ability to induce the formation of ionic complexes. Further disclosed is a drug or protein carrier using the block copolymer.06-23-2011
20110150977ANTIMICROBIAL POLYMERS AND METHODS OF MANUFACTURE THEREOF - Biodegradable cationic block copolymers are disclosed, comprising a hydrophilic block comprising first repeat units derived from a first cyclic carbonyl monomer by ring-opening polymerization, wherein more than 0% of the first repeat units comprise a side chain moiety comprising a quaternary amine group; a hydrophobic block comprising second repeat units derived from a second cyclic carbonyl monomer by ring-opening polymerization; an optional endcap group; and a chain fragment derived from an initiator for the ring opening polymerization. The cationic block copolymers form aqueous micelle mixtures suitable for antimicrobial applications.06-23-2011
20110212167LIPID BASED PHARMACEUTICAL PREPARATIONS FOR ORAL AND TOPICAL APPLICATION; THEIR COMPOSITIONS, METHODS, AND USES THEREOF - The present invention relates to the topical and oral delivery of a composition comprising one or more active agents for treating a disease or symptoms in a subject. In some embodiments, the present invention comprises a composition comprising at least one active compound, e.g., finasteride or minoxidil, and one or more lipids. In some embodiments, the present invention relates to composition and method of preparation for treating androgenic alopecia (AGA), prevention of hair loss and female hirsutism. In some embodiment, the present invention comprises finasteride and at least one lipid component for the treatment of benign prostatic hyperplasia. In some embodiment, the present invention comprises tacrolimus or amphotericin B and at least one lipid component for the treatment of skin or eye related diseases. The present invention provides a method of preparation of a composition comprising at least one active compound and at least one lipid and administering the composition to a subject by oral or topical delivery. In certain embodiments the subject is a mammal. In certain preferred embodiment, the subject is human.09-01-2011
20090317457ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN B-4 - The invention relates to a method of treating inflammatory conditions in a subject comprising administering to a subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also provides a method of promoting wound healing in a subject comprising administering to the subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also relates to methods of treating the above mentioned conditions in a subject comprising administering to the subject a nucleic acid encoding a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also relates to pharmaceutical compositions comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant, or salt thereof, and a pharmaceutically acceptable carrier.12-24-2009
20090317456USE OF ONCOLYTIC VIRUSES AND ANTIANGIOGENIC AGENTS IN THE TREATMENT OF CANCER - The present invention relates to a combination of at least one oncolytic virus and at least one antiangiogenic agent and to the use of this combination in tumor therapy.12-24-2009
20090317455REVERSE TARGETING LIPID VESICLE - The present invention provides an immunomodulating agent and a therapeutic agent for a immune disease, which comprise a lipid vesicle encapsulating a drug capable of suppressing or damaging an immunocyte that expresses or binds to an antibody, the lipid vesicle having an antigen for the antibody bound to the outer surface thereof. Hence, there is provided means for effectively treating an immune disease such as an allergic diseases or an autoimmune disease.12-24-2009
20090291132Enhanced delivery of antifungal agents - Tetrahydrofuran antibiotics formulated with certain diacylglycerol-poltethyleneglycol (DAG-PEG) lipids have increased water solubility and bioavailability. PEG-12 GDO, PEG-12 GDLO, PEG-12 GDM and PEG-12 GDP are particularly suitable for forming liposomes that incorporate tetrahydrofurans in the bilayer.11-26-2009
20090285884Platinum Complexes and Methods of Use - The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.11-19-2009
20090246270Use of Iontophoresis or Electrotherapy and Ultrasound to Deliver Agents for Skin Rejuvenation. - The method disclosed includes the combining of iontophoresis or electrotherapy and ultrasound to deliver the appropriate chromophores to the skin for cosmetic or therapeutic treatment of the skin and skin conditions by the use of a laser, Intense Pulsed Light (IPL), a combination of laser and Radio Frequency (RF) energy, or a combination of IPL and RF.10-01-2009
20110150984METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS - This invention pertains to methods of increasing the bioavailability and/or cellular uptake of an amphiphilic drug when administered parenterally, which method comprises the step of parenterally co-administering the drug with a short-chain sphingolipid as described herein.06-23-2011
20090220586PROTEOMIMETIC COMPOUNDS AS INHIBITORS OF THE INTERACTION OF NUCLEAR RECEPTOR WITH COACTIVATOR PEPTIDES - The present invention relates to compounds, pharmaceutical compositions and methods which inhibit the binding of coactivator proteins in nuclear receptors, including estrogen receptors (alpha and/or beta), androgen receptors, thyroid receptors and peroxisome proliferators-activated receptors, among others. Compounds according to the present invention may be useful in the treatment of a variety of disease states or conditions which are mediated through nuclear receptors.09-03-2009
20120201874Liposome Having Inner Water Phase Containing Sulfobutyl Ether Cyclodextrin Salt - A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase contains sulfobutyl ether cyclodextrin and active compound. Said sulfobutyl ether cyclodextrin is sulfobutyl ether α-cyclodextrin, sulfobutyl ether β-cyclodextrin, or sulfobutyl ether γ-cyclodextrin.08-09-2012
20120201873CONTROLLED RELEASE FORMULATIONS OF LIPOCALIN MUTEINS - The present invention relates to pharmaceutical compositions for the controlled release of lipocalin muteins and conjugates thereof with a moiety selected from the group consisting of a protein, protein domain, peptide, lipid, fatty acid, polysaccharide and/or an organic polymer that comprise said lipocalin mutein of conjugate thereof in combination with a biodegradable polymer. The invention further relates to a method for the controlled delivery of the lipocalin muteins or conjugates thereof, methods for the production of a controlled release formulation and the thus produced formulation. Finally, the invention is directed to the use of the formulations of the invention for the controlled delivery of the lipocalin mutein, for extending the in vivo half-life of the lipocalin mutein, for increasing the bioavailability of the lipocalin mutein, or for decreasing the immunogenic-ity of the lipocalin mutein upon administration to a subject as well as methods for the treatment of a disease or disorder comprising the administration of the formulations of the invention to a subject in need thereof.08-09-2012
20120201871PERMEATION ENHANCERS WITH LIPOSOMES FOR TOPICAL FORMULATIONS - Method for producing liposomes in a composition for skin permeation are provided. A composition that includes water, skin lipids, butters having linoleic acid and linolenic acid, Pracaxi oil, Plukenetia Volubilis seed oil, and phospholipids is provided. The composition is dispersed in a vessel using a high shear homogenizer. Negative pressure is created in the vessel such that liposomes of 5-20 microns are produced thereby providing for increased skin permeation of active ingredients added to the composition.08-09-2012
20110256213PHOSPHOLIPID MICELLAR AND LIPOSOMAL COMPOSITIONS AND USES THEREOF - The invention generally relates to compositions and methods for the reduction or neutralization of toxins associated with a bacterial, mycobacterial, fungal, viral, or protozoal agent. More particularly, the invention is directed to sterically stabilized phospholipid micellar and liposomal compositions, which interact with the toxins to decrease or neutralize their toxicity. Additionally, the invention includes the use of sterically stabilized phospholipid micellar compositions comprising one or more water-insoluble antibiotic, antifungal, antiviral, antiprotozoal, or anti-inflammatory agent(s), wherein the micellar or liposomal composition inhibits the formation of aggregates. The invention further includes the use of sterically stabilized micelle and liposomal compositions to deliver compounds to the site of action, and in some cases targets the compound to the site of action, for the treatment of inflammation and infection. The invention includes the use of combinations of such micellar and liposomal compositions to improve the effectiveness of treatment.10-20-2011
20090214635IDENTIFICATION OF A CONSERVED REGION OF PLASMODIUM FALCIPARUM MSP3 TARGETED BY BIOLOGICALLY ACTIVE ANTIBODIES - Antigenic and immunogenic determinants of Merozoite surface protein 3 (MSP3). Antigenicity and functional assays identified a 68-amino acid conserved domain of MSP3 as a target of biologically active antibodies. A peptide comprising amino acid residues 184-251 of SEQ ID NO: 2, may also be employed as may peptides consisting of different combinations of the MSP3 a, b, c, d, e and f peptides. Particular non-overlapping or overlapping segments of MSP3 a, b, c, d, e and f peptides may also be used. The various overlapping segments and nonoverlapping segments among the different MSP3 peptides are shown in FIG. 08-27-2009
20090162422Single-domain brain-targeting antibody fragments derived from LLAMA antibodies - A phage-displayed library of llama single heavy domain antibodies (sdAbs) was enriched for species that selectively bind to and are internalized by human cerebromicrovascular endothelial cells (HCEC). From the enriched library, two sdAbs were selected, sequenced, subcloned, and expressed as fusion proteins with c-myc-His06-25-2009
20100143453ANTI-INFLAMMATORY COMPOUNDS CONTAINING COMPOSITIONS FOR TREATMENT OF CANCER - The present invention relates to compositions comprising non-steroidal anti-inflammatory compounds, and especially to the use of such compositions in the treatment of cancer or in the inhibition of cancer growth. More specifically, the invention relates to a method for targeting an anti-inflammatory compound to tumor tissue.06-10-2010
20090117176Anticancer Treatments - A method of treating the human body for cancer comprises administering an effective therapeutic amount of a Pegylated Liposomal form of the anthracycline Doxorubicin (“PLD”), in combination with an effective therapeutic amount of ET-74305-07-2009
20110212160CONFIGURABLE MICROSCOPIC MEDICAL PAYLOAD DELIVERY DEVICE TO DELIVER NUCLEAR SIGNALING PROTEINS TO SPECIFIC CELLS TO MANAGE DIABETES MELLITUS AND GENETIC DEFICIENCY DISORDERS - The innovative treatment strategy described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver nuclear signaling proteins to specific cell types in the body. Utilizing probes on the exterior of the transport device, transport device locate specific target cell types in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery device inserts its payload of nuclear signaling proteins into the target cell type. By delivering nuclear signaling proteins to specific cell types, genes can be activated or inactivated in those specific cell types. These medically therapeutic nuclear signaling proteins are intended to improve cell function or the longevity of the cell or eliminate cells that pose a hazard to the general health of the body.09-01-2011
20110212166CARNITINE CONJUGATES OF ADAMANTANAMINES DERIVATIVES AS DUAL PRODRUGS FOR VARIOUS USES - This invention concerns compounds of adamantanamines and neramexane, including their pharmaceutically-acceptable salts, diesterioisomers, and formulations for treating Alzheimer's related dementias, depression, AIDS related dementias, as antivirals, inflammatory diseases such as rheumatoid arthritis, and cerebral ischemia, hyperlipidemia, and diabetes.09-01-2011
20080317834Compounds and methods for modulating cerebral amyloid angiopathy - The invention provides methods of inhibiting cerebral amyloid angiopathy. The invention further provides methods of treating a disease state characterized by cerebral amyloid angiopathy in a subject.12-25-2008
20110256215NON-PEGYLATED LIPOSOMAL DOXORUBICIN TRIPLE COMBINATION THERAPY - The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.10-20-2011
20110256212Use of 8-Quinolinol and its Analogs to Target Cancer Stem Cells - 8-quinolinol (8Q) and derivatives thereof for use in the treatment of proliferative diseases such as cancer, in particular slow metabolizing quiescent cancer stem cells.10-20-2011
20080279924HLA class I A2 tumor associated antigen peptides and vaccine compositions - A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.11-13-2008
20080274170PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.11-06-2008
20080268029PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.10-30-2008
20080268028Lyophilization of virosomes - The present invention relates to biologically active compositions and methods for the lyophilization and reconstruction of virosomes comprising special membrane compositions. These compositions are essential to the invention and provide superior freeze-drying stress-resistance for the virosomes of the invention.10-30-2008
20120201872LIPOSOMES COMPRISING A CALCIUM PHOSPHATE-CONTAINING PRECIPITATE - Provided herein are methods and compositions for the delivery of bioactive compounds to a cell, tissue, or physiological site. The compositions comprise delivery system complexes comprising liposomes encapsulating a biodegradable ionic precipitate having incorporated therein a bioactive compound and delivery system complexes comprising a biodegradable ionic precipitate ionically bound to a surrounding lipid bilayer, wherein the biodegradable ionic precipitate comprises a bioactive compound. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes comprising bioactive compounds that have therapeutic activity against the disease or unwanted condition to the subject.08-09-2012
20120148663LIPOPHILIC DRUG CARRIER - Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their pay-load upon exposure to acoustic energy.06-14-2012
201003038965BETA, 14BETA-ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF RESTENOSIS AFTER ANGIOPLASTIC OR ENDOARTHERECTOMY AND DISEASES DUE TO ORGAN FIBROSIS - Compound of formula (I), wherein the symbol have the meaning reported in the text; for preparing a medicament for the prevention and/or treatment of obstructive vascular lesions following vascular surgery and for the prevention and/or treatment of diseases due to organ fibrosis.12-02-2010
20080254108Formulations and Methods for Modulating Satiety - This disclosure relates to formulations and methods of suppressing appetite and eliciting satiety (sense of being filled) in mammals through the oral administration of an effective amount of an appetite suppressing moiety.10-16-2008
20110165231Treatment of Fructose Malabsorption - The present invention relates to the composition comprising crystalline xylose-isomerase (EC 5.3.1.5) and at least one salt of a metal and/or alkaline earth metal.07-07-2011
20110165226INFLUENZA CAP-LEADER SEQUENCE - The invention comprises a viral cap-leader sequence which comprises at least three bases complementary to the 3′-ultimate residues of a (−)ssRNA virus template sequence. Preferably said consensus sequence is represented by the general formula 07-07-2011
20110165224VACCINES FOR INCLUSION BODY HEPATITIS - A composition comprising an isolated fowl adenovirus (FAdV), wherein the FAdV is a strain selected from FAdV-2, FAdV-7, FAdv-8a, FAdV-8b, FAdV-8a/8b or FAdV-11 serotype strains; and a suitable carrier and methods for inducing protective immunity in a subject and/or its progeny.07-07-2011
20120121696Terpene Glycosides and Their Combinations as Solubilizing Agents - Several terpene glycosides (e.g., mogroside V, paenoiflorin, geniposide, rubusoside, rebaudioside A, steviol mono-side and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including but not limited to, paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole, celecoxib, clofazimine, digoxin, oleandrin, nifedipine, and amiodarone. The use of the diterpene glycoside rubusoside and monoterpene glycoside paenoiflorin increased solubility in all tested compounds. The terpene glycosides are a naturally occurring class of water solubility-enhancing compounds that are non-toxic and that will be useful as new complexing agents or excipients in the pharmaceutical, agricultural (e.g., solubilizing pesticides), cosmetic and food industries.05-17-2012
20110165232Use of Opioid Antagonists for the Preparation of a Medicament in the Treatment of Retinal Degenerative Diseases - Retinal degenerative diseases affect the delicate layer of retina tissue that lines the inside back of the eye leading to gradual vision loss. The use of opioid anatgonists for the preparation of a medicament for the selective blocking of the body's opioid receptors sites is a method of treating this human suffering by daily administration to the patient of from about 0.5 to about 10 mg of drugs such as naltrexone, naloxone or nalmefene. They act primarily by normalizing derangements in the human complement system that may occur in the disease etiology. Therapeutical approach for macular degeneration and retinitis pigmentosa is primarily intended. Oral, parenteral uses as well as topical applications may all be considered. They may be administered in one or divided doses daily for the best receptor blocking activity, preferably in the evening hours. Low Dose Naltrexone suitable for oral administration is most preferred regimen at about 4.5 mg/day.07-07-2011
20110165230ATTENUATED LIVE VACCINES - Disclosed is an attenuated flavivirus live vaccine comprising a flavivirus mutant, characterised in that the flavivirus mutant has a deletion in the capsid protein of at least more than 4 successive amino acids, wherein the carboxy-terminal hydrophobic region is not affected by the deletion.07-07-2011
20110165225Modified Drugs for Use in Liposomal Nanoparticles - Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.07-07-2011
20110262527CATIONIC LIPIDS AND METHODS OF USE - The present invention provides compositions comprising cationic lipids, liposomes and nucleic acid-lipid particles comprising the cationic lipids, and methods of using such compositions, liposomes, and nucleic acid-lipid particles.10-27-2011
20120121690METHOD TO ENHANCE AN IMMUNE RESPONSE OF NUCLEIC ACID VACCINATION - A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The composition provides an improved immune response compared to mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein.05-17-2012
20120121688PREVENTATIVE OR THERAPEUTIC AGENT AND METHOD FOR IMMUNE DISEASE - The present invention provides a method of selectively augmenting an immunosuppressive function in various functions of NKT cells, and a method of efficiently inducing an antigen specific immunosuppression in vivo, as well as a pharmaceutical obtained by applying the same.05-17-2012
20110165223Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen - The present invention relates to methods for preventing, reducing or treating a variety of conditions, including cancer, and vaccines, compositions and liposomes used to elicit or amplify an immune response specific to the condition by delivering to the spleen of an individual a pegylated liposome construct having a diameter of greater than about 300 nm and including a therapeutic agent and an adjuvant for eliciting or amplifying the immune response.07-07-2011
20110020430Novel mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy - Methods for treating neuroblastoma in a subject are provided. The methods include administering to the subject nucleic acid that is capable of causing a significant reduction of the amount of doublecortin like protein (DCL) in the subject. The nucleic acids include antisense oligonucleotides and small interfering RNA.01-27-2011
20110027347POLYMERSOMES AND METHODS OF MAKING AND USING THEREOF - Described herein is the synthesis and pharmacology of polymersomes containing one or more bioactive agents. The polymersome is generally derived from a polymer having the formula XY02-03-2011
20110027351LIPOSOMAL FORMULATIONS COMPRISING AN AMPHIPATHIC WEAK BASE LIKE TEMPAMINE FOR TREATMENT OF NEURODEGENERATIVE CONDITIONS - Provided is the use of an amphipathic weak base having defined characteristics for the preparation of a pharmaceutical formulation for the treatment or prevention of neurodegenerative conditions. The amphipathic weak base can be encapsulated in a liposome. Also provided are pharmaceutical formulations and methods of use thereof for the treatment or prevention of neurodegenerative conditions. A specific and amphipathic weak base is tempamine (TMN). Further, tempamine can be loaded in sterically stabilized liposomes (SSL-TMN).02-03-2011
20100285112METHODS OF DELIVERING OLIGONUCLEOTIDES TO IMMUNE CELLS - The invention relates to the field of delivery of nucleic acid-based agents to immune cells.11-11-2010
20100285104COMPOSITIONS AND METHODS FOR THE DELIVERY OF OXYGEN - H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O11-11-2010
20100285107SHORT NUCLEIC ACID MOLECULE-MEDIATED MODULATION OF AURORA B KINASE EXPRESSION AND COMBINATIONS FOR USE IN ANTICANCER THERAPY - This invention relates to the use of short nucleic acid molecules that modulate Aurora-B kinase (AurkB) expression. The invention includes compounds, compositions and methods useful for the modulation of expression and activity of genes involved in the AurkB pathway. In one embodiment, the present invention provides short nucleic acid molecules, such as siRNA, which can be used in treating, preventing, or inhibiting cancer, and any other proliferative disease, trait or condition, which respond to a reduction in AurkB expression in a cell or tissue. Such short nucleic acid molecules can be used alone or in combination with other treatments or therapies, including short nucleic acid molecules that modulate expression of EGFR.11-11-2010
20100285111SELF-ASSEMBLING MICELLE-LIKE NANOPARTICLES FOR SYSTEMIC GENE DELIVERY - Nanoparticles containing nucleic acid and suitable for use as in vivo delivery agents for nucleic acids are provided. The nanoparticles use a covalent conjugate of a polycation such as polyethylenimine and phospholipids. The final DNA-containing nanoparticle has a vesicular structure with a polyplex core surrounded by a mixed lipid/PEG-lipid monolayer envelope and offers simple preparation, high loading capacity, and in vivo stability. The nanoparticles have good in vivo stability and a prolonged blood circulation time and can effectively deliver a gene to a biological target such as a tumor.11-11-2010
20100285108Method for therapeutic use - The present invention is related to methods for the therapeutic use in the treatment of diseases and disorders where T-helper independent antibody responses are beneficial. In particular, the present invention relates to a method wherein these diseases and disorders above are treated in immunocompromised or autoimmune diseased animals or humans. Even more particular the present invention relates to the treatment of Alzheimer's disease in immunocompromised or autoimmune diseased animals or humans or where inflammatory reactions need to be specifically avoided.11-11-2010
20100285103MEDICAMENT FOR TREATMENT OF TUMORS AND THE USE THEREOF - The present invention discloses an anti-tumor conjugate and pharmaceutical composition or kits comprising the conjugate, as well as a method of producing the anti-tumor conjugate. The anti-tumor conjugate of the present invention is metabolically stable in vivo, and is ultimately available for the treatment of tumors and production of anti-tumor medicaments.11-11-2010
20100285106MULTICOMPONENT VACCINE - The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to a multicomponent vaccine and method of using same to protect against HTV-I infection.11-11-2010
20110059159NANOSCALE BOUND BILAYERS, METHODS OF USE AND PRODUCTION - Methods for rapidly obtaining a nanoscale apolipoprotein bound phospholipid bilayer (NABB) associated with at least one membrane protein are provided. Also disclosed are methods for rapidly obtaining a NABB not associated with membrane proteins. Immunogenic compositions comprising NABBs with native conformational epitopes are also provided along with their methods of use.03-10-2011
20100330161Oral delivery of tetanus toxoid - Orally active vitamin B12-30-2010
20100330163Compositions and Methods for Enhancing Metal Ion Dependent Drug Therapies - Methods and compositions are provided for increasing responsiveness to therapeutic metalloproteases including increasing and/or maximizing responsiveness and preventing botulinum and tetanus toxin resistance due to a functional deficiency of zinc. Also provided are methods for zinc replacement or supplement in lacking individuals comprising the administration of a zinc supplement for a loading period and/or administration of a phytase supplement together with the zinc supplement. Also provided are methods for standardization of botulinum toxin potency assays that provide for greater certainty and margins of safety in the use of products from different manufacturers.12-30-2010
20100330162Spray freeze dry of compositions for pulmonary adminstration - This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles.12-30-2010
20100330166AGENT FOR ENHANCING ANTI-TUMOR EFFECT COMPRISING OXALIPLATIN LIPOSOME PREPARATION, AND ANTI-TUMOR AGENT COMPRISING THE LIPOSOME PREPARATION - An object of the present invention is to further enhance the antitumor effect when oxaliplatin is administered in combination with a combination drug containing tegafur, gimeracil and oteracil potassium. According to the present invention, by using oxaliplatin encapsulated in a liposome preparation, combination therapy of oxaliplatin plus a combination drug containing tegafur, gimeracil and oteracil potassium, is revealed to show remarkably enhanced antitumor effect without increasing side effects.12-30-2010
20100330157BIOMATERIAL FOR THE CONTROLLED DELIVERY OF INGREDIENTS - The disclosure relates to a biomaterial that comprises an aqueous phase, polymer network, a second polymer included in said disclosure invention more particularly relates to a biomaterial including an aqueous phase and a first polymer network made of a first proteic or saccharidic polymer or a mixture of first proteic and saccharidic polymers, wherein the first polymer network and the aqueous phase define a first gel (A), the biomaterial including: a second proteic or saccharidic polymer or a mixture of the second proteic and saccharidic polymers, either in solution in the aqueous phase of the gel (A) or in the form of a gel (B), and a first enzyme for degrading said second polymer or second polymer network. The disclosure also relates to a method for making biomaterials, and to the uses of the biomaterial particularly for releasing active substances, and to a device for the controlled release of active substances that include the biomaterial. The disclosure can particularly be used in the field of cosmetics and pharmaceuticals.12-30-2010
20100330153METHOD FOR PRODUCING BIOLOGICALLY INGESTIBLE MATERIAL AND BIOLOGICALLY INGESTIBLE MATERIAL OBTAINED THEREFROM - The present invention provides a production method for obtaining a biologically ingestible material having an intended diameter with low energy as compared with conventional methods, the method includes mixing a fluid to be processed in a dispersed phase containing a pharmacologically active substance and a fluid to be processed in a continuous phase including at least a disperse solvent, while each of the fluids are retained in an independent state, in a thin film fluid formed between two processing surfaces arranged to be opposite to each other to be able to approach to and separate from each other, at least one of which rotates relative to the other, through independent pathways corresponding to the respective phases, whereby the components contained in the fluid to be processed in a dispersed phase are formed into microparticles having a desired diameter.12-30-2010
20100330152METHODS AND COMPOSITONS FOR ANTISENSE VEGF OLIGONUCLEOTIDES - This invention relates to compositions and methods for inhibition of abnormal proliferation of cells or angiogenesis. More particularly this invention provides VEGF antisense oligonucleotides capable of inhibiting proliferation of cancer cells or angiogenesis or combinations thereof. also provided are screening and prognostic assays, as well kits comprising the VEGF antisense oligonucleotides.12-30-2010
20110070289ADAPTABLE MODIFIED VIRUS VECTOR TO DELIVER MODIFIED MESSENGER RIBONUCLEIC ACID AS A MEDICAL TREATMENT DEVICE TO MANAGE DIABETES MELLITUS AND OTHER PROTEIN DEFICIENT DISEASES - Diabetes mellitus is a disease of elevated blood glucose, often directly related to a deficiency in insulin production or insulin receptor production. The innovative strategy of treatment described here utilizes modified viruses and virus-like vehicles to act as a transport mechanism to deliver modified messenger RNA molecules to target cells in the body. Delivering to the Beta cells in the body the modified messenger RNA needed to construction of insulin or insulin receptors will lead to enhanced production of biologically active insulin or insulin receptors by Beta cells as necessary, which will lead to correcting deficiencies in insulin or insulin receptors the result of which will help properly regulate blood glucose levels throughout the body utilizing innate regulatory mechanisms.03-24-2011
20110104254Medicament for treatment of tumors wherein hedgehog/smoothened signaling is employed for inhibition of apoptosis of the tumor cells - This invention concerns the use of cyclopamine in vivo on basal cell carcinomas (BCC's) to achieve therapeutic effect by causing differentiation of the tumor cells and, at the same time, apoptotic death and removal of these tumor cells while preserving the normal tissue cells, including the undifferentiated cells of the normal epidermal basal layer and hair follicles. Causation of apoptosis by cyclopamine is by a non-genotoxic mechanism and thus unlike the radiation therapy and most of the currently used cancer chemotherapeutics which act by causing DNA-damage. These novel effects, previously unachieved by a cancer chemotherapeutic, make the use of cyclopamine highly desirable in cancer therapy, in the treatment of BCC's and other tumors that use the hedgehog/smoothened signal transduction pathway for proliferation and prevention of apoptosis.05-05-2011
20110111014METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROLOGICAL DISORDERS - Methods and compositions are provided for preventing and treating neurological disorders, in particular Parkinson's disease.05-12-2011
20110111017USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOGEN INFECTIONS - The invention provides compositions featuring cationic liposome nucleic acid molecules complexed with pathogen derived antigen and methods of using such compositions for the treatment or prevention of an infectious disease. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.05-12-2011
20110135715DEFENSIN-ANTIGEN FUSION PROTEINS - The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.06-09-2011
20110135712Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration - The present invention relates to a novel chemical compound of formula S-(1):06-09-2011
20110135716DELIVERY OF H2 ANTAGONISTS - The present invention provides improved systems and methods for the local delivery of H2 antagonists. The inventive methods include topical administration of an effective amount of a H2 antagonist encapsulated in liposomes. In certain embodiments, the H2 antagonist, for example, Cimetidine, is encapsulated into paucilamellar liposomes, such as NOVASOME® microvesicles. Also provided are pharmaceutical compositions comprising liposome-encapsulated H2 antagonists. The methods and compositions of the present invention may be used to treat any disease state or condition where local administration of H2 antagonists is beneficial.06-09-2011
20110135714COMPOSITIONS FOR EXTERNAL APPLICATION, CONTAINING ADENOSYL COBALAMIN FOR IMPROVEMENT OF SKIN DISEASES - The present invention relates to a composition for external application for improving a skin disease (e.g. psoriasis). The composition contains adenosyl cobalamin (coenzyme B12), optionally in admixture with other cobalamins. The composition can be present in the form of liposomal preparations, which are made of a phospholipid and cholesterol.06-09-2011
20110135713Antimicrobial and Antiviral Compounds and Methods for Their Use - The present invention provides protonated compounds having antiviral and antimicrobial activity. The invention also provides antimicrobial compositions comprising protonated compounds of the invention. The protonated compounds of the invention provide efficacious antimicrobial activity against resistant strains of bacteria and opportunistic fungi. The invention also provides antiviral compositions comprising compounds of the invention. Viruses that may be treated by compositions of the invention include, but are not limited to, HIV, HSV, CMV, HBV, HCV and influenza virus.06-09-2011
20110135711Methods and Compositions for Delivery of Catecholic Butanes for Treatment of Tumors - The present invention provides kits, methods and compositions for the treatment of diseases such as cancers. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered to one or more subjects in need of treatment by a route other than direct injection into the affected tissues or topical application on affected tissues.06-09-2011
20110135710Methods and Compositions for the Inhibition of Gene Expression - The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.06-09-2011
20110262526METHOD OF INDUCING AN ANTI-VIRAL IMMUNE RESPONSE - The present invention relates to a method of inducing an anti-viral immune response. The method comprises administering to a patient in need thereof an antigen that induces the production of antibodies that, upon binding to a cell surface target, result in the production of chemokines that inhibit viral infection.10-27-2011
20110262524LIPOSOMES WITH IMPROVED DRUG RETENTION FOR TREATMENT OF CANCER - The present invention relates to the use of copper ions to achieve enhanced retention of a therapeutic agent within a liposome. The invention may be employed to more effectively deliver a liposomally encapsulated therapeutic agent to a target site in vitro and in vivo for anti-cancer or other therapy. The liposome may comprise an interior buffer solution containing the therapeutic agent, the solution having a pH less than 6.5 and most preferably approximating pH 3.5. At least some of the copper ions are retained within the interior solution. In a particular embodiment the therapeutic agent may be a chemotherapeutic drug, such as irinotecan. The invention may also comprise an ionophore to facilitate loading of drug into the liposome. In one particular embodiment the combination of the ionophore A23187 and encapsulated divalent copper (Cu2+) resulted in an irinotecan formulation that exhibited surprisingly improved drug retention attributes.10-27-2011
20110262530SUSTAINED RELEASE OF APO A-I MIMETIC PEPTIDES AND METHODS OF TREATMENT - A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (Apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (Apo A-I) synthetic peptide, or combination of an Apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various Apo A-I mimetic peptides, or endogenous Apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous Apo A-I.10-27-2011
20110052678METHOD FOR TREATING AGE RELATED MACULAR DEGENERATION - A method for treating age related macular degeneration uses insulin preparation applied topically in a therapeutically effective amount to an affected conjunctival sac of the eye. The topically effective dose is delivered to the fovea centralis and macula lutea. In other embodiments, additional therapeutic, pharmaceutical, biochemical, nutriceutical, biological (monoclonal antibodies and others) agent or compound, and organic and inorganic agents are also applied to the afflicted site through the conjunctival sac and choroidal vascular system of the eye. IGF-1 may be applied as well with or without insulin to treat ARMD.03-03-2011
20110052677MODULATION OF SRPX2-MEDIATED ANGIOGENESIS - The present invention relates to nucleic acids and antibodies against SRPX2 and SRPX2 protein function in angiogenesis. Angiogenesis-related conditions, such as cancer or wound healing, can be treated by the composition comprising the SRPX2 antagonists or agonists, respectively.03-03-2011
20110052676Composition For Delaying Cellular Senescence - Disclosed herein is a composition for delaying cellular senescence comprising from about 0.01 wt % to about 5 wt % of Hexapeptide-11(Phe-Val-Ala-Pro-Phe-Pro), based on the total weight of the composition, and a dermatologically-acceptable carrier for the peptide selected from the group consisting of water, oil, alcohol, silicone, and combinations thereof.03-03-2011
20110052675Orally Disintegrting Forms for Sustained Release and Controlled Release - Orally disintegrating forms with sustained release capability and a method of making thereof are provided.03-03-2011
20110052674ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES - New angiotensin II receptor blocker nitroderivatives of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof: and their use for treating cardiovascular, renal and chronic liver diseases, inflammatory processes and metabolic syndromes.03-03-2011
20110052673THERAPEUTIC COMPOSITIONS - Therapeutic compositions containing therapeutic agents and nitrogen-containing lipids are described. These tertiary amine-containing polymers are preferably biodegradable and biocompatible. Nanoparticles, microparticles, and complexes containing lipid/therapeutic agent complexes are also described.03-03-2011
20110052672TREATMENTS OF DISEASE OR DISORDERS USING NANOPARTICLES FOR FOCUSED HYPERTHERMIA TO INCREASE THERAPY EFFICACY - Methods are provided for the treatment of diseases and disorders using systematically-introduced nanoparticles to create a focused localized hyperthermia in a target area to enhance the effect of additional treatment therapies such as ionizing radiation. Advantages include an enhancement of the therapeutic effect of other therapies by increasing perfusion or reducing hypoxia in the treatment area, further, the methods herein may also result in the disruption of the vasculature, which provide further impetus for such treatments, singly and in combination with conventional therapies such as chemotherapy and radiation therapy. Methods for treating a target area may comprise systemically introducing nanoparticles into an organism; allowing the nanoparticles to preferentially accumulate in the target area, applying an external energy where the nanoparticles are adapted to transduce at least a portion of the external energy into a heal energy so as to create a focused localized hyperthermia; and applying a subsequent additional therapy.03-03-2011
20110052671NEAR INFRA-RED PULSED LASER TRIGGERED DRUG RELEASE FROM HOLLOW NANOSHELL DISRUPTED VESICLES AND VESOSOMES - The disclosure provides drug delivery methods and compositions. More particularly, the application provides liposomal delivery compositions comprising a nanostructure.03-03-2011
20110052670IDENTIFICATION OF A PLURIPOTENT PRE-MESENCHYMAL, PRE-HEMATOPOIETIC PROGENITOR CELL - The present invention provides a molecular marker for the identification of pluripotent pre-mesenchymal, pre-hematopoietic stem cells. The invention further provides primitive progenitor cells identified by the molecular marker. Such cells have the potential to differentiate into both mesenchymal and hematopoietic phenotypes, as determined by a proliferative response to inductive growth factors and cytokines, and by their morphologic and cytochemical features.03-03-2011
20110052669METHODS FOR MODULATING DE NOVO HEPATIC LIPOGENESIS BY MODULATING XBP-1 ACTIVITY - The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-I protein or a molecule in a signal transduction pathway involving XBP-1.03-03-2011
20110052668Identification and Characterization of a Specific CCK-C Receptor Antibody for Human Pancreatic Cancer and Its Use for Early Detection and Staging of Pancreatic Cancer - Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer.03-03-2011
20110052667COMPOSITIONS AND METHODS FOR INHIBITING ANGIOGENESIS AND TUMORIGENESIS - The present invention relates to the regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, such as small organic molecules, antibodies, peptides and nucleic acids (e.g., antisense molecules, RNAi molecules and ribozymes), that modulate angiogenesis and tumorigenesis via modulation of IGF-II and, in turn, EphB4, as well as to the use of expression profiles and compositions in the diagnosis and therapy of angiogenesis and cancer.03-03-2011
20110052666Compositions, Methods, and Systems for SIRNA Delivery - The instant invention provides silencer expression cassettes for delivery of RNAi therapy. The silencer cassettes of the instant invention encode an RNAi agent and lack means for replication within a host cell, inverted terminal repeats and further lacking one or more selectable markers. Optionally, the silencer cassettes lack CpG dinucleotides and/or the RNAi agent is within a scaffold of a naturally occurring miRNA. The composition comprising the silencer cassettes of the instant invention, as well as methods of use and suitable systems are also provided.03-03-2011
20100196461RESUSCITATION FLUID - A method for treating conditions related to lack of blood supply with a resuscitation fluid is disclosed. The resuscitation fluid contains a lipophilic component and a polar liquid carrier. The lipophilic component forms an emulsion with the polar liquid carrier. The resuscitation fluid can be used to increase the blood pressure and to carry oxygen and other lipophilic gases to tissues. The resuscitation fluid can also be used for preserving the biological integrity of donor organs for transplantation.08-05-2010
20100303899TOCOPHEROLS, TOCOTRIENOLS, OTHER CHROMAN AND SIDE CHAIN DERIVATIVES AND USES THEREOF - The present invention provides an antiproliferative compound having a structural formula12-02-2010
20100183708Antigen Delivery Vectors and Constructs - The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.07-22-2010
20100323003Flaviviridae Mutants Comprising a Deletion in the Capsid Protein for Use as Vaccines - The present invention relates to a mutant virus of the family flaviviridae, comprising a deletion in the capsid protein of at least 20 successive amino acids, without any further deletion, substitution or insertion mutation except of the amino acids next to the deletion, which may be substituted.12-23-2010
20100323001In Vivo Delivery Of Double Stranded RNA To a Target Cell - The invention encompasses methods of delivering nucleic acids, including dsRNA, to mammalian target cells in vivo via intercellular transfer, wherein the dsRNA is delivered to or expressed in a first cell different from the target cell, wherein the first cell facilitates delivery of the dsRNA to the target cell.12-23-2010
20100323004NON-PEGYLATED LIPOSOMAL DOXORUBICIN TRIPLE COMBINATION THERAPY - The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.12-23-2010
20100330159System for transporting active substances in a biological system - A stabilizer-free system for transporting active substances in a biological system of one or more active substances and magnetic particles, which is characterized in that the particles are provided with active substance(s) on at least part of their surface, is claimed. Modification of the magnetic particles is not absolutely required in this system. It can be incorporated both into aqueous and oily suspensions and into microemulsions, oil-in-water emulsions, water-in-oil emulsions and also water-in-oil-in-water emulsions.12-30-2010
20100178324COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS - The present invention includes methods of making and methods of using peptidomimetics compositions that mimic α-helical BH3 sequences in cells. The peptidomimetics can be used to mimic α-helical BH3 sequences and kill cancer cells.07-15-2010
20110142913COMPOSITION AND METHOD FOR TREATING ATHEROSCLEROSIS, METHOD FOR DETERMINING IF A SUBJECT HAS ATHEROSCLEROSIS AND METHOD OF SCREENING AN ANTI-ATHEROSCLEROTIC DRUG - The invention provides a method for determining if a subject has atherosclerosis, including: determining an endogenous microRNA-195 expression level of a subject suspected of having atherosclerosis; and comparing the endogenous microRNA-195 expression level of the subject with an endogenous microRNA-195 expression level of a normal group, wherein an increase in the endogenous microRNA-195 expression level of the subject as compared to the endogenous microRNA-195 expression level of the normal group indicates that the subject has atherosclerosis.06-16-2011
20110150982ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.06-23-2011
20110165227Compositions and Methods Using siRNA Molecules for Treatment of Gliomas - The present invention provides small interfering RNA (siRNA) molecules, compositions containing the molecules, and methods of using the compositions to treat gliomas.07-07-2011
20100119588PEPTIDE FOR INHIBITION OF INFLUENZA INFECTION, INHIBITOR OF INFLUENZA INFECTION, LIPOSOME, AND PROPHYLACTIC/THERAPEUTIC AGENT FOR INFLUENZA - To provide peptides having high affinity for hemagglutinin and peptides having high inhibitory activity against influenza virus infection, as well as pharmaceutical compositions containing the peptides, the polypeptides having any one of SEQ ID NOs: 2 to 7, 9 to 10, and 12 to 18 are obtained by introducing mutation into a peptide having the sequence of ARLSPTMVHPNGAQP (peptide A-1: SEQ ID NO: 1) and screening for peptides having higher affinity for hemagglutinin. Further, the inhibitory activity of the peptide of SEQ ID NO: 3 against influenza virus infection can be enhanced by truncating SEQ ID NO: 3 in its C-terminus region with leaving ARLPR or ARLP. In addition, an influenza virus-infection inhibitor and an influenza preventive/therapeutic agent can be prepared by formulating these influenza virus receptor-binding peptides.05-13-2010
20090202624METHOD FOR DETECTING CARCINOMA AND AGENT FOR SUPPRESSING CARCINOMA - An object of the present invention is to identify genes exhibiting characteristic behavior in the cases of carcinoma such as oral squamous-cell carcinoma using a change of expression level of micro RNA in oral squamous-cell carcinoma as an indicator, so as to provide a method for detecting carcinoma and an agent for suppressing carcinoma. The present invention A method for detecting oral squamous-cell carcinoma, which comprises detecting malignant transformation of specimens by employing a change of expression level of micro RNA as an indicator, and an agent for suppressing oral squamous-cell carcinoma using micro RNA.08-13-2009
20090202619POLYOXYALKYLENE CHAIN-CONTAINING LIPID DERIVATIVE AND LIPID FILM STRUCTURE CONTAINING SUCH DERIVATIVE - A polyoxyalkylene chain-containing lipid derivative, which is represented by the following formula (1):08-13-2009
20110135717Composition for Prevention or Treatment of Hyperlipidemia, Fatty Liver or Obesity - Disclosed is a composition for prophylaxis or treatment of hyperlipidemia, fatty liver, cardiovascular disease or obesity including a compound represented by General Formula I as an effective ingredient:06-09-2011
20110097392ANTIBODY BOUND SYNTHETIC VESICLE CONTAINING MOLECULES FOR DELIVER TO CENTRAL AND PERIPHERAL NERVOUS SYSTEM CELLS - A process is provided of delivering at least one active agent cargo molecule into an neuronal cell whereby a cargo molecule is placed within a synthetic vesicle such as a liposome and a biotinylated protein such as an antibody is bound to the synthetic vesicle to form a protein bound synthetic vesicle whereby the protein recognizes a receptor expressed on the surface of a neuronal cell, and exposing the protein bound synthetic vesicle to the cell until the cargo molecule is delivered into the neuronal cell. Numerous cargo molecules are delivered by the inventive synthetic vesicle including a calpain inhibitor and a caspase inhibitor. The protein illustratively targets a cellular receptor for a ligand such as glutamate, glycine, dopamine, nicotine, muscarine, acetylcholine, or serotonin, and the like.04-28-2011
20110097389P53 BIOMARKERS - The present invention relates to the identification of p04-28-2011
20110097390Ultra-Small RNAs as Toll-Like Receptor-3 Antagonists - Provided are methods and compositions for the treatment or prevention of macular degeneration or other diseases or disorders associated with activation of TLR04-28-2011
20110097391Phospholipid Emulsion Containing Dihydroquercetin, and Method of Producing Thereof - This present invention relates generally to the field of chemistry, food industry, cosmetics, and pharmaceutical industry. More specifically, the present invention relates to liposomal biologically active forms and methods of producing thereof. The present invention provides a stable phospholipid emulsion based on dihydroquercetin (DHQ), its compounds and derivatives. The invention further provides a method a quite simple and economic method for the preparation of disclosed emulsion. The disclosed emulsion is characterized by the improved bioavailabilty and selectivity of the effect of active compounds and by the increased stability and prolonged storage terms. The claimed result is achieved using a phospholipid emulsion containing DHQ, its compounds and/or derivatives, at least one membrane-forming phospholipid, at least one zwitter-ion amino acid base, aminoacetic ether, and aqueous ethanol in the following ratio of components (wt %): Dihydroquercetin, 0.01-3; Phospholipid, 0.15-10; Zwitter-ion amino acid base, 0-8; Aminoacetic ether, 0-4; Aqueous ethanol solution (with ethanol concentration within 0.05-20%), 75-98.84.04-28-2011
20100260827Methods of diagnosing, preventing and treating cancer metastasis - The invention relates to methods and compositions for inhibiting metastasis, such as by inhibiting FOXC2 expression or activity. The invention further relates to methods of prognosticating, diagnosing, and assisting in the diagnosis of metastasis in an individual, or of determining the metastatic potential of a tumor. The invention further relates to methods of identifying agents which inhibit metastasis.10-14-2010
20100166846MANAGEMENT OF MYOCLONUS WITH ORAL LIPOSOMAL REDUCED GLUTATHIONE - The invention relates to a composition and method for the management of myoclonus and myoclonus and other illnesses related to mold toxin exposure.07-01-2010
20100166840LIPOSOME HAVING LIPID MEMBRANE CONTAINING BACTERIAL CELL COMPONENT - The object is to provide a liposome by which a bacterial cell component insoluble in water and an organic solvent (e.g., BCG-CW) can be pharmaceutically prepared in a form applicable to a living body (i.e., a form in which the bacterial cell component can be dispersed in an aqueous solvent and has a controlled size) without using any surfactant. Disclosed is a liposome having a lipid membrane containing a bacterial cell component insoluble in water and an organic solvent (e.g., BCG-CW).07-01-2010
20100166847Method for coating fine particles with lipid membrane - An object of the present invention is to provide a safe, convenient and efficient method for coating fine particles with lipid membrane.07-01-2010
20100166849GLUTATHIONE BASED DELIVERY SYSTEM - A delivery system. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative.07-01-2010
20100166841Prostaglandin Based Compositions and Method of Use Thereof - The present disclosure sets forth particular prostaglandin based compounds that are relatively more stable in aqueous environments than other such compounds; and further that by complexing such a prostaglandin based compound of the disclosure with an agent, such as cyclodextrin, the prostaglandin based compound may be stabilized and provided in a cosmetic composition that can be used to enhance the appearance of hair.07-01-2010
20100166839NON PEPTIDIC RENIN INHIBITORS NITRODERIVATIVES - Non-peptidic renin inhibitors nitroderivatives of general formula (I):07-01-2010
20100166843PHARMACEUTICAL COMPOSITION COMPRISING A CAMPOTHECIN DERIVATIVE - The present invention relates to pharmaceutical compositions comprising a topoisomerase I inhibitor including, but not limited to, a camptothecin derivative.07-01-2010
20100166842AMPHIPHILIC SUBSTANCES AND FUNCTIONALIZED LIPID VESICLES INCLUDING THE SAME - An amphiphilic substance includes a hydrophobic group, and a polynucleotide group attached to the hydrophobic group. The polynucleotide group includes a first polynucleotide segment and a second polynucleotide segment. The first and second polynucleotide segments are at least partially complementary and are bound together by interactions including base pairing. At least one of the first and second segments includes at least one of an aptamer and a nucleic acid-based enzyme. A lipid vesicle may include the amphiphilic substance, a first polar lipid that is an unstable vesicle former, and a polar liquid. Upon exposure to a rupture agent, the vesicle may rupture, releasing the contents of the vesicle. Substances that may be released from the vesicle include bioactive agents, such as drug agents.07-01-2010
20100166838Methods And Compositions For Modulating Keratinocyte Function - The disclosure is generally directed to methods and compositions for modulating keratinocyte function, more particularly, to compositions and methods for normalizing keratinocyte proliferation and differentiation, compositions and methods for modulating levels of phosphatidylglycerol (PG) in keratinocyes, and compositions and methods for treating skin conditions by modulating keratinocyte proliferation.07-01-2010
20110182978ACTIVATED NITRIC OXIDE DONORS AND METHODS OF MAKING AND USING THEREOF - Described herein are compositions useful in anticancer treatment and prevention. The compositions are composed of (a) an O07-28-2011
20100196454DRESSING FORMULATIONS TO PREVENT AND REDUCE SCARRING - Provided herein is a scar dressing formulation comprising a blend of a high molecular weight silicone elastomer crosspolymer and a silicone oil, wherein said silicone elastomer crosspolymer is in a volatile fluid. The formulation has a soft, silky feel without being greasy and dries quickly to form a durable, flexible scar dressing.08-05-2010
20100196456EMULSION PRECONCENTRATES AND MICELLAR FORMULATIONS CONTAINING WOOD RESINS - The invention relates to micelles and emulsion preconcentrates comprising i) one or more active ingredients and ii) wood resin, optionally in combination with gum arabic, and iii) optionally additional adjuvants; products containing said micelles and/or emulsion preconcentrates, method for the production of micelles, emulsion preconcentrates, and products.08-05-2010
20100196457AGENT, PHARMACEUTICAL COMPOSITION, AND METHOD FOR TREATING THE ETHYL ALCOHOL AND/OR NARCOTIC DEPENDENCE - The invention relates to the area of the chemical-pharmaceutical industry and medicine, in particular, to an agent for treatment of dependence on ethyl alcohol and/or drugs, treatment of psychosomatic and neurological complications in such patients; to pharmaceutical compositions containing this agent; and to treatment methods for psychosomatic and neurological complications with this agent.08-05-2010
20100196460Integrated Photoactive Agents for Real-Time Monitoring of Hemostasis - The present invention discloses a number of photoactive compounds designed to bind and inhibit serine proteases. Compounds disclosed herein may be utilized in a number of appropriate medical diagnostic and/or therapeutic procedures such as the monitoring of hemostasis, imaging and/or treatment of vulnerable plaques, and/or tumor imaging and/or treatment.08-05-2010
20100196452PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING ERECTILE DYSFUNCTION - The present invention relates to the use of Ang-(1-7) and/or Ang-(1-7) receptor agonist and/or Ang (1-7) analogue in treating/restoring erectile dysfunction.08-05-2010
20100196458MODIFIED CYTOKINES FOR USE IN CANCER THERAPY - Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.08-05-2010
20100196453BIPHASIC LIPID-VESICLE COMPOSITION AND METHOD FOR TREATING CERVICAL DYSPLASIA BY INTRAVAGINAL DELIVERY - A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks.08-05-2010
20100068255Immunoliposomes that Optimize Internationalization into Target Cells - The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab′ domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides for growth-inhibiting immunoliposomes that lack growth-inhibiting therapeutic agents and yet are capable of inhibiting the growth and proliferation of target cells.03-18-2010
20100068263Method and Compositions for Stimulation of an Immune Response to TRP2 using a Xenogeneic TRP2 Antigen - Tolerance of the immune system for endogenous TRP2 can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed TRP2 antigen. For example, mouse TRP2, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against TRP2 expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of cancers expressing TRP2, such as melanoma.03-18-2010
20100068254Modifying a medicament availability state of a final dosage form - Provided embodiments include a final dosage form, an article of manufacture, and method. A method of modifying a medicament availability state of a final dosage form is provided. The method includes initiating an exposure of a particle or polymeric material of the final dosage form to a stimulus. The initiated stimulus is selected to transform the particle or polymeric material from a medicament-retention state to a medicament-release state.03-18-2010
20100068264NIOSOME-HYDROGEL DRUG DELIVERY SYSTEM - Localized drug delivery systems are effective means to administer therapeutic concentrations and controlled release of drugs. A delivery system consisting of non-ionic surfactant vesicles (niosomes) packaged within a biodegradable, temperature and pH sensitive hydrogel network was developed. Drug behaviors were modeled using a fluorescent dye with similar physical properties as therapeutic drugs for cancer. The niosomes were embedded into a biodegradable hydrogel providing a stable niosome environment. A cross linked chitosan was used as the hydrogel, which is a liquid at room temperature, and gels inside the body. Depending on the conditions to which individual niosomes are exposed, the release rate can be controlled to last from 24 hours to more than 3 months.03-18-2010
20100068256Ex vivo modifiable medicament release-substance - A described final dosage form includes a substance carrying a medicament in a first medicament-release state having a first bioavailability. The substance is modifiable ex vivo by an exposure to a first stimulus to carry the medicament in a second medicament-release state having a second bioavailability. The substance is modifiable ex vivo by an exposure to a second stimulus to carry the medicament in a third medicament-release state having a third bioavailability. The final dosage form includes another substance carrying another medicament in another first medicament-release state having another first bioavailability. The another substance is modifiable ex vivo by an exposure to another first stimulus to carry the another medicament in another second medicament-release state having another second bioavailability. The another substance is modifiable ex vivo by an exposure to another second stimulus to carry the another medicament in another third medicament-release state having another third bioavailability.03-18-2010
20100068252METHOD FOR PREPARING POLYMERIC MATRICES BY RADIATION IN THE PRESENCE OF SENSITIVE PHARMACEUTICAL COMPOUNDS - The present invention relates to a method for the preparation of a drug loaded matrix with a pharmaceutical compound by polymerizing a polymerisation mixture by radiation in the presence of at least one sensitive pharmaceutical compound, wherein the polymerisation mixture comprises a) at least one polymerisable compound b) optionally at least one photoinitiator c) optionally at least one additive which are chosen such that the sensitive pharmaceutical compound is degraded less than 2%, or which are chosen such that the sensitive pharmaceutical compound is protected against degradation such that the degradation is about 50% or less when compared to radiation with a constituent that produce radical.03-18-2010
20100068253BLEOMYCIN PREPARATION FOR USE AGAINST SKIN TUMOURS - A preparation for use against skin tumours, which preparation has a semi-solid consistency for enabling the preparation to be applied to and remain on a patient's skin during treatment of a tumour on the patient's skin; which preparation comprises bleomycin which acts against the tumour, an elastic liposome which entraps the bleomycin; and a bleomycin containing carrier which contains the bleomycin in the elastic liposome; and which preparation is such that: (i) the concentration of the bleomycin in the bleomycin containing carrier is not less than the concentration of the bleomycin in the elastic liposome; (ii) the concentration of the bleomycin in the bleomycin containing carrier is not so great as to cause the bleomycin in the bleomycin containing carrier to leak into the elastic liposome and cause the elastic liposome to burst; and (iii) the external concentration of the bleomycin in the bleomycin containing carrier is such that it maintains an osmotic balance between internal and external environments of the elastic liposome whereby the internal concentration of the bleomycin in the elastic liposome is kept constant.03-18-2010
20110262529CYTOTOXIC T CELL EPITOPE PEPTIDE FOR SARS CORONAVIRUS, AND USE THEREOF - The present invention aims to provide a novel CTL epitope peptide of the SARS coronavirus. The present invention provides a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 11, 12, 13, 15, 17, 18, 23 and 24.10-27-2011
20090285881CATIONIC LIPIDS AND USES THEREOF - Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.11-19-2009
20090175932MICELLE ASSEMBLIES - The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. Also, the invention encompasses compounds of the formula: A-X-Y-Z-R07-09-2009
20090175931COMPOSITIONS AND METHODS FOR MODULATING HEMOSTASIS - Factor Xa variants and methods of use thereof are disclosed.07-09-2009
20110189268Inhibition of Placenta Growth Factor (PLGF) Mediated Metastasis and/or Angiogenesis - The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PlGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and/or tumor survival. In certain embodiments, PlGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PlGF expression levels may be determined by any known method to select those patients most likely to respond to PlGF targeted therapies.08-04-2011
20110189267MULTIPLE CpG OLIGODEOXYNUCLEOTIDE AND THEIR USE TO INDUCE AN IMMUNE RESPONSE - Compositions including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compositions can include either D or K type oligodeoxynucleotides. These compositions are of use in inducing an immune response in a large percentage of the individuals in a population.08-04-2011
20110189265THERAPEUTIC USE OF NEW PHARMACEUTICAL PREPARATIONS CONTAINING ANTITUMORAL DRUGS BOUND TO HYALURONIC ACID IN THE TREATMENT OF NEOPLASIAS - The present invention describes the new use in the oncologic field of bioconjugates as differentiating agents obtained by the conjugation between hyaluronic acid (HA) and a chemotherapeutic product (identified hereafter with the trade-name ONCOFID®) among which, in particular, Irinotecan, Doxorubicin, Paclitaxel, Cis-platinum and 5-Fluorouracyl (5-FU) for treating primary tumors and metastasis. In particular, the biological behaviour is described in terms of action mechanism, efficacy and tolerability of pharmaceutical preparations of derivative of ONCOFID® soluble in water. More specifically, the invention relates to the surprising biological and pharmacological effect demonstrated by formulations based on ONCOFID-S (HA-SN38 conjugates) and ONCOFID-D (HA-Doxorubicin conjugates) in promoting the differentiation of tumoral cells towards a untransformed phenotype, compared with the reference drug Irinotecan (or CPT11 whose active form is represented by SN38) and Doxorubicin.08-04-2011
20110189263PEPTIDES THAT TARGET DORSAL ROOT GANGLION NEURONS - The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.08-04-2011
20110189262Methods and Compositions for Reducing Systemic Toxicity of Vectors - A method for reducing leakage of a delivery formulation from a target tissue via a damaged blood vessel during and after administration of the delivery formulation is provided. The method includes the steps of: (a) providing a delivery formulation comprising a blocking agent and one or more vectors encoding one or more polypeptides, wherein the delivery formulation is in a liquid form; and (b) administering the delivery formulation to a target tissue in a subject, wherein the administering results in the viscosity of the blocking agent increasing to at least about 100 cP, whereby leakage of the delivery formulation from the target tissue either during or after administration of the delivery formulation is reduced.08-04-2011
20110189266CORTICOSTEROID MICROVESICLES FOR TREATMENT OF CARDIOVASCULAR DISEASES - The invention provides a use of a long-circulating microvesicle comprising a sterol, partially synthetic or wholly synthetic vesicle-forming phospholipids, and a corticosteroid in water soluble form, which microvesicle has a mean particle diameter size range of between about 75 and 150 nm and which microvesicle is non-charged or negatively charged at physiological conditions, for the preparation of a medicament for the treatment of atherosclerosis and/or cardiovascular disease. A method for treating a subject suffering from, or at risk of suffering from, atherosclerosis and/or cardiovascular disease, comprising administering to said subject a therapeutically effective amount of such long-circulating microvesicles is also provided.08-04-2011
20110171286HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE - The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional constituent selected from the group consisting of vitamin B, C and vitamin E, wherein the formulation exhibits greater stability than an HA gel formulation without the additional constituent. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.07-14-2011
20100055163FORMULATION OF NATURAL TRITERPENES AND BIOPHENOLS OBTAINED FROM THE GENUS OLEA IN LIPOSOMES - The present invention relates to compositions of natural biophenols and, optionally, of natural biophenols and triterpenes obtained from the genus 03-04-2010
20100028414COMBINATION OF TYROSINE KINASE INHIBITOR AND HER-2/NEU FOR CANCER THERAPY - A method of treating cancer is described comprising administration of a 4-quinazolineamine and a vaccine targeting the HER-2/neu molecule, as well as a pharmaceutical combination comprising 4-quinazolineamines and a vaccine targeting the HER-2/neu molecule.02-04-2010
20100028417USE OF SUBSTITUTED GLYCERIN DERIVATIVES FOR PRODUCING A PHARMACEUTICAL PREPARATION - A compound of the formula (1) or pharmaceutically acceptable salts thereof can be used for producing a pharmaceutical preparation for preventing or treating cancerous diseases, pathological sequelae of alcohol abuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal disorders, hepatic insulin resistance in diabetes mellitus, liver damage associated with Wilson's disease and/or sideroses, ischemic reperfusion damage, for use as an antidote to environmental toxins and prescription drug intoxication, for prolonging the retention time of drugs in the organism, and/or for combating toxic side effects on administration of chemotherapeutic agents. B02-04-2010
20100028416DRUG CARRIERS - Compositions that can include a carrier, targeting agent, and therapeutic agent are disclosed herein. The therapeutic agent may have a therapeutic activity such as inhibiting fibrosis within a target organ or tissue or inhibiting the growth of a cancer cell.02-04-2010
20100028415Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.02-04-2010
20120308648METHODS OF TREATING HOT FLASHES WITH FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION - The present invention relates generally to methods for treating hot flashes by administering formulations for transdermal or transmucosal administration of estrogen. The formulations of the invention are effective at treating hot flashes at surprisingly low daily doses, preferably the lowest effective dose of estrogen to treat hot flashes, e.g., about 0.45 to about 0.6 mg of estrogen per day. The amount of estrogen which is administered produces an estimated nominal daily estrogen dose in a subject undergoing treatment of from about 10 to about 15 micrograms, and a serum estradiol level of between about 25 pg/ml to about 50 pg/ml. The preferred formulations are substantially free of malodorous, and irritation causing long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.12-06-2012
20120308647USE OF MIR-30E TO TREAT VASCULAR LESIONS - MicroRNA molecules are directed to the treatment of diseases associated with plaque formation, cardiovascular diseases, inflammation, stroke, and disorders associated with aging.12-06-2012
20120308646TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES - Aminoside tetracyclic anthraquinones represented by formula (I) and (II). Peptides are introduced to connect tetracyclic anthraquinones and fatty acid to enable selective absorption and release of the anticancer agents. In addition, aminosaccharide and tetracyclic moieties are introduced into the branched chain to improve water-solubility. The compounds of formula (I) and (II) are pharmaceutically active components useful for treating diseases that are cured by aminoside tetracyclic anthraquinones, including cancer.12-06-2012
20120308645COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF HIF-1 ALPHA - RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.12-06-2012
20120308644Compositions for mucosal delivery of agents - Compositions and methods for mucosal delivery of agents are provided. The compositions are intended for administration to mucosal surface, such as oral, gastrointestinal and nasal mucosa. The compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.12-06-2012
20120308643LIPOSOMAL MITIGATION OF DRUG-INDUCED LONG QT SYNDROME AND POTASSIUM DELAYED-RECTIFIER CURRENT - Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.12-06-2012
20120308641Compositions and Methods for Enhancing Coagulation Factor VIII Function - Factor VIII variants and methods of use thereof are disclosed.12-06-2012
20120308640AMPHIPHILIC JANUS-DENDRIMERS - The invention concerns compounds of the formula: X—(Y)12-06-2012
20100021532Personal care composition containing yeast/polyphenol ferment extract - Disclosed is a yeast/polyphenol ferment extract, and a personal care composition including the yeast/polyphenol ferment extract. Also disclosed is a method for preparing and using the yeast/polyphenol extract and the personal care composition.01-28-2010
20100021531METHOD FOR PRODUCTION OF LIPOSOME PREPARATION - Disclosed is a method which permits simple and easy production of a stable, high-quality liposome preparation suppressed in lipid degradation. This method can significantly shorten production time and can achieve a substantial cost cut-down in medium- to large-scale production, and can also attain the incorporation of a drug in uniform amounts. Specifically disclosed is a method for producing a liposome preparation by using a remote loading method. This method includes a drug incorporation step that heats a mixture of a suspension of liposomes and a drug, the mixture having been prepared beforehand, by rapid heating means to a temperature from not lower than a phase transition point of membranes of the liposomes to not higher than 80° C. to incorporate the drug into the liposomes.01-28-2010
20110104257POLYMORPHISMS PREDICTIVE OF PLATINUM-COORDINATING COMPOUND-INDUCED OTOTOXICITY - Methods of determining a subjects ototoxicity risk from administration of platinum-coordinating compounds having an ototoxicity risk, methods of administering a platinum-coordinating compound having an ototoxicity risk and oligonucleotides, peptide nucleic acids, arrays and addressable collections for performing embodiments of the methods are provided herein.05-05-2011
20100104627STABLE AQUEOUS G-CSF FORMULATIONS - The invention relates to stable glutamate-buffered G-CSF formulations having a pH of from 3.5 to 4.8. The invention further concerns lyophilisates and powders obtainable from such formulations, and to pharmaceutical kits containing such lyophilisates and powders.04-29-2010
20100151002Guggulphospholipid Methods and Compositions - The present invention relates to the methods for preparing synthetic guggulphospholipids, their fatty acid analogues and other bioactive molecules. The present invention relates to E-guggulsterone and Z-guggulsterone or mixture of E- and Z-guggulsterones. The present invention also provides a novel method for the preparation of E-guggulsterol and Z-guggulsterol or mixture of E- and Z-guggulsterols from a mixture of E- and Z-guggulsterones. The present invention further relates to guggulphospholipids and other bioactive molecules incorporated into complexes such as liposomes, complexes, emulsions, vesicles, micelles, and mixed micelles, which can include other active agents, such as hydrophobic or hydrophilic drugs for use, e.g., in treatment of human and animal diseases.06-17-2010
20090104257Liposomal Vancomycin Formulations - The present disclosure relates in part to liposomal vancomycin compositions having low lipid to drug ratios and high concentration of vancomycin. The present disclosure also relates in part to methods of making such compositions.04-23-2009
20120034296PROLONGED DURATION LOCAL ANESTHESIA WITH MINIMAL TOXICITY - Compositions containing site 1 sodium channel blockers for use as local anesthetics with rapid nerve block, improved potency and efficacy, and no local toxicity have been developed. Liposomes were employed for increased loading of the site 1 sodium channel blocker, producing prolonged duration of block without systemic toxicity. In one embodiment, the compositions contain a site 1 sodium channel blocker alone. In another embodiment, the compositions contain a site 1 sodium channel blocker in combination with a corticosteroid. As demonstrated by the examples, encapsulating site 1 sodium channel blockers in liposomes results in rapid and prolonged nerve block without systemic toxicity, which is enhanced by the addition of a corticosteroid. Fluid liposomes showed more rapid release of STX than did solid ones, and dexamethasone accelerated STX release.02-09-2012
20120034294METHOD OF MAKING SMALL LIPOSOMES - Liposomes of constrained particle size are prepared by substantially continuously mixing substantially continuously flowing streams of water, and of an organic solvent contain lipid(s) capable of forming liposomes, and cooling the mixture so liposomes form, the ratio of the flow rate of the stream of water to the flow rate of the stream of organic solvent, and the rate of cooling of said mixture, being controlled so as to obtain a preparation of liposomes such that at least about 90% of the liposomes are of a particle size less than about 200 nm.02-09-2012
20110014277Smoking Cessation With Body Weight Maintenance And Nutritional Supplement - Disclosed is a compound and methods for use by an individual attempting to reduce or cease tobacco smoking or one exposed to environmental tobacco smoke. The compound includes a first component blocking nicotine receptor sites to reduce nicotine cravings or withdrawal symptoms, a second component increasing serotonin levels and acting synergistically with the first component to reduce nicotine cravings or withdrawal symptoms, assisting in maintaining body weight and reducing increased stress and anxiety, and a third component acting synergistically with the first and/or second component to reduce nicotine cravings or withdrawal symptoms, maintain body weight, and/or reduce increased stress and anxiety. The third component comprises a supplement that replenishes depleted body substance(s), repairs damaged body substance(s), and/or ameliorates the impaired function of body substance(s). Some combination of the first, second, and third component alters the perceived taste of tobacco smoke.01-20-2011
20110070291FOOD OR BEVERAGE COMPOSITION FORTIFIED WITH THYRONAMINES AND/OR THYRONAMINE PRECURSORS - Food or beverage compositions fortified with thyronines and/or thyronamines, processes for increasing T2, T1AM, and/or T0AM in a subject by administering a food or beverage composition that is fortified with at least one thyronine and/or thyronamine compound, and processes for promoting a healthy state by administering a food or beverage composition to a subject that is fortified with at least one thyronine and/or thyronamine compound. Increased levels of T2, T1AM, and/or T0AM in a subject can be associated with at least one of healthy cholesterol levels, healthy triglyceride levels, healthy blood sugar levels, cardiovascular health, healthy sleep patterns, healthy mood, healthy skin, healthy nails, or healthy endocrine function and/or a number of other markers of associated with general health and well-being.03-24-2011
20090053301SILICONE VESICLES CONTAINING ACTIVES - A process is disclosed for preparing a hydrophobic active loaded vesicle composition by admixing a hydrophobic active to a pre-formed silicone vesicle dispersion. The silicone vesicle compositions are useful in a variety of personal and healthcare compositions.02-26-2009
20090041833Composition comprising gas-filled microcapsules for ultrasound mediated delivery - Composition comprising gas filled microcapsules and a bioactive agent, useful for an ultrasound-mediated delivery of said bioactive agent. The microcapsules comprise a relatively stiff shell of polymeric or lipid material and have in particular a resistance to a mechanical index of at least 0.15, while the bioactive agent is substantially unbound to the shell of the microcapsules. The composition of the invention is particularly suitable for effectively delivering a genetic material into a cell, upon exposure of the composition to a level of acoustic pressure capable of destroying a portion of the microcapsules and releasing the gas contained therein.02-12-2009
20090087481METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOEITIC GROWTH FACTORS - The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.04-02-2009
20100196459THERAPEUTIC FORMULATIONS CONTAINING VENOM OR VENOM ANTI-SERUM EITHER ALONE OR IN COMBINATION FOR THE THERAPEUTIC PROPHYLAXIS AND THERAPY OF NEOPLASMS - A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method optionally further comprises administering to the mammal at least one other therapeutically effective agent, e.g., an anti-inflammatory agent.08-05-2010
20090186079Oral and overall health by negating the biological effects of bacterial lipids - A method of treating an oral cavity condition, a topical composition for use in treating an oral cavity condition and a method of testing a potential agent for its ability to do the same are disclosed. When present in the oral cavity of an individual or animal, bacterial lipids cause various health conditions, such as periodontal disease. Conditions can be treated by any one or more of removal, reduction and/or antagonism of the biological effects of bacterial lipids; solubilizing and removing bacterial lipids; covering, diluting or masking bacterial lipids; antagonizing the cellular signaling of bacterial lipids; and promoting decomposition of bacterial lipids. Conditions can be treated by applying topical compositions containing a safe and effective amount of agents disclosed herein.07-23-2009
20100285105OIL PRODUCING MICROBES ADN METHOD OF MODIFICATION THEREOF - Disclosed are compositions and methods related to a eukaryote of the order Thraustochytriales and family Thraustochytriaceae which when cultured produce quantities of unsaturated fatty acids, such as omega 3 (n-3) and/or omega 6 (n-6) oils, such as DHA, EPA and DPA, capable of being purified and used as all such compositions are used and more, because of their means of production.11-11-2010
20110086087Process and Formulation for Immunizing Fish in Aquaculture Systems - Process, use, method and formulation of inclusion of Deoxyribonucleic acid (DNA) in food compositions for livestock animals, in particular in aquacultural systems.04-14-2011
20110033525Diterpene Glycosides as Natural Solubilizers - Several diterpene glycosides (e.g., rubusoside, rebaudioside, steviol monoside and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including but not limited to, paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole, and celecoxib. The use of the diterpene glycoside rubusoside increased solubility in all tested compounds. The diterpene glycosides are a naturally occurring class of water solubility-enhancing compounds that are non-toxic and that will be useful as new complexing agents or excipients in the pharmaceutical, agricultural (e.g., solubilizing pesticides), cosmetic and food industries. Aqueous solutions by using rubusoside to increase the solubility of otherwise insoluble drugs will have several new routes of administration. In addition, aqueous solutions of therapeutic compounds with rubusoside were shown to retain the known pharmacological activity of the compounds.02-10-2011
20100310643CD133 EPITOPES - An immunogen includes an isolated peptide that includes the amino sequence of any one of SEQ ID NOs:1-21 with four or fewer amino acid substitutions.12-09-2010
20100068251Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof - The present invention relates to a methods of preparing active compounds complexed with lipids using aqueous systems that are free of organic solvents, and methods of using the complexes, e.g., in treating a disease in a subject. In some embodiments, the present invention comprises a composition comprising a complex comprising at least one active compound, e.g., a polyene antibiotic, an immunosuppressant agent such as tacrolimus or a taxane or taxane derivative, and one or more lipids. In some embodiments, the present invention provides a method comprising preparing a composition comprising a lipid complex comprising at least one active compound and at least one lipid and administering the composition to a subject. In certain embodiments the subject is a mammal. In certain preferred embodiments, the subject is human.03-18-2010
20100226975Compositions and Methods for Stabilizing Lipid Based Adjuvant Formulations Using Glycolipids - The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.09-09-2010
20090104258Use of tocopheryl phosphate as an agent for preventing or slowing down the appearance of the effects of skin ageing - The invention relates to a cosmetic composition of a tocopheryl phosphate, especially in its dl or d form, or in the form of a cosmetically acceptable salt or ester thereof, as a cosmetic agent for preventing or slowing down the appearance of the effects of skin ageing, in particular of photoageing of the skin, said tocopheryl phosphate being at least partially encapsulated in lipid vesicles, in particular liposomes. It relates most particularly to the use of alpha-tocopheryl phosphate. It also relates to cosmetic compositions containing a tocopheryl phosphate, in particular an alpha-tocopheryl phosphate, at least partially incorporated into lipid vesicles, in particular liposomes, these compositions being in particular in the form of a serum or of a stable emulsion. The invention also relates to a cosmetic skincare process.04-23-2009
20090047336 NOVEL FORMULATION OF DEHYDRATED LIPID VESICLES FOR CONTROLLED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT VIA INHALATION - A new formulation of dehydrated lipid vesicles employs a vesicle preserver and permits the control of release and delivery of active pharmaceutical ingredients into the respiratory system for treatment in particular of asthma. The typical formulation provides controlled release of the active pharmaceutical ingredient from 0% to 100% from 0 to 72 hours after inhalation, changes the systemic administration to topical administration, allows prolonged therapeutic period for one administration, increased stability, with reduced dose, reduced systemic side effects, reduced toxicity.02-19-2009
20090246272MDA-7 PROTEINS AND METHODS OF USE THEREOF - This invention provides a method of generating a subtracted cDNA library of a cell comprising: a) generating a cDNA library of the cell; b) isolating double-stranded DNAs from the cDNA library; c) releasing the double-stranded cDNA inserts from the double-stranded DNAs; d) denaturing the isolated double-stranded cDNA inserts; e) hybridizing the denatured double-stranded cDNA inserts with a labelled single-stranded nucleic acid molecules which are to be subtracted from the cDNA library; and f) separating the hybridized labeled single-stranded nucleic acid molecule from the double-stranded cDNA inserts, thereby generating a subtracted cDNA library of a cell. This invention also provides different uses of the subtracted library.10-01-2009
20100310641THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS - The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders. More particularly, the invention relates to combined therapies for treating said disease by affecting PMP22 expression in a subject.12-09-2010
20090148511COMPOSITION AND METHOD FOR DERMATOLOGICAL TREATMENT - A topical composition for the treatment of acne and other dermatological conditions comprises a liposomal formulation of a retinoid and an antibiotic in which the retinoid is disposed in the lipid phase of the formulation, and the antibiotic is disposed in the aqueous phase. Lincosamides, such as clindamycin, are one group of antibiotics which may be used in the composition. Tretinoin is one preferred retinoid. Also disclosed are methods for making the compositions and methods for using the composition.06-11-2009
20110027350GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS - A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.02-03-2011
20100260828Modulation of Platelet Aggregation - Methods and compositions for inhibition of platelet cell aggregation are described. In particular, compositions comprising cell permeant RGT peptides, such as RGT bound to a lipid moiety are provided. Compositions may be used in the treatment and prevention of clot related diseases such as stroke and myocardial infarction.10-14-2010
20080248096SMALL PARTICLE LIPOSOME AEROSOLS FOR DELIVERY OF ANTI-CANCER DRUGS - Provided herein is a method of treating primary lung cancer or metastatic cancer to the lung in an individual by delivering at least once to the respiratory tract of the individual via inhalation a nebulized liposomal aerosol comprising a dilauroylphosphatidylcholine liposome containing camptothecin or a derivative thereof in an amount sufficient to deliver a pharmacologically effective dose of the camptothecin or its derivative to treat the cancer. Also provided is a nebulized liposomal aerosol comprising the DLPC containing the camptothecin or its derivative and a method of making the liposome-drug comprising the aerosol.10-09-2008
20110020428GEL-STABILIZED LIPOSOME COMPOSITIONS, METHODS FOR THEIR PREPARATION AND USES THEREOF - Compositions, preparation methods and potential applications of gel-stabilized liposomes with high degree of entrapment efficiency and stability are described. In particular, the novel liposome system comprises liposomes that each encapsulate an internal thermo-transformable hydrogel, dispersed and suspended in a continuous external thermo-reversible hydrogel phase. Agents, such as active agents, are encapsulated in the internal hydrogel core or in the lipid bilayer, or multilayers, depending on whether the active agent is water or lipid soluble, respectively.01-27-2011
20090074847Transport System In Biological Systems - The invention relates to a transport system (03-19-2009
20110117186INTRAVENOUS INFUSION OF CURCUMIN AND A CALCIUM CHANNEL BLOCKER - Compositions and methods for treating systemic diseases by intravenous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly a calcium channel blocker to human subjects with neoplastic and neurodegenerative diseases are disclosed herein. The diseases are treated by prolonged administration of sub-optimal doses of liposomal curcumin or polymeric nanocurcumin or the sustained release curcumin from PLGA nanocurcumin at dosages below systemic hemolytic thresholds concomitantly with or without calcium channel blockers.05-19-2011
20110117185METHODS FOR TREATING OR PREVENTING HEART DAMAGE WITH INTEGRIN-LINKED KINASE (ILK) COMPOSITIONS - The present invention generally provides methods for administering a composition having an ILK-based protein or peptide having a sequence that is at least 90% homologous to wild-type human integrin-linked kinase (ILK) protein for use in treating or administering to cardiac cells in vitro or in vivo. The ILK-based protein or peptide may further have a mutation or substitution at a position corresponding to amino acid position 211 of wild-type human ILK replacing the arginine (R) with an alanine (A). The present invention further provides compositions having polynucleotides encoding such proteins or peptides. Various vectors, delivery reagents and the like are also provided for use in delivering the compositions to cells. The compositions administered to cells in vitro or in vivo according to present methods may be used to treat, prevent, etc., heart failure, ischemic disease, cardiomyopathy, etc.05-19-2011
20110117181TREATING HEPATITIS C VIRUS INFECTION WITH OVER-EXPRESSION OF MICRORNA-196 - The present invention is directed to methods of treating cells infected with HCV and mammals suffering from HCV infection by transfecting the infected cells with miRNA-196 mimic. miRNA-196 mimic significantly down-regulates Bach1 protein and HCV gene expression, while also up-regulating HMOX1 gene expression. miRNA-196 binds with the 3′-UTR of Bach1 mRNA to reduce the expression of Bach1. As such, miRNA-196 can play an important role in the regulation of HCV replication and HMOX1/Bach1 expression in hepatocytes. The present invention also provides a formulation for the treatment of cells expressing HCV comprising a therapeutically effective amount of miRNA-196 such that Bach1 and HCV gene expression are down-regulated while HMOX1 expression is increased. The formulations are adapted to enable the transfection of miRNA-196 mimic into hepatocytes expressing HCV proteins.05-19-2011
20110117188Group of Nucleic Acid Fragments for Prevention of HIV Infection or AIDS and the Usage Thereof - The invention provides a group of nucleic acid fragments, shown in the sequence listing, for prevention of HIV infection or AIDS and the usage thereof. In the invention, a series of RNA fragments, which are highly homogenous to all the published HIV gene sequences, were obtained by homology compare. The double-stranded RNA (dsRNA) derived from these fragments can effectively inhibit the expression of the HIV genes. The RNA transcribed by plasmid, also can suppress the expression of the HIV in the cell. After the adenovirus or associated virus which carry DNA corresponding above RNA infect the cell, the transcription dsRNA can inhibit the expression of the HIV genes.05-19-2011
20110117182COMBINATION OF DAPSONE WITH OTHER ANTI-ACNE AGENTS - A composition suitable for topical application that contains at least two active ingredients, one of these being dapsone and one selected from the group consisting of adapalene, tazarotene and treinion for the effective treatment of acne and other dermatological conditions.05-19-2011
20110070297GLUCOKINASE ACTIVATORS - Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of:03-24-2011
20100330154 AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS - An amphoteric liposome comprising neutral lipids wherein said neutral lipids are selected from the group comprising cholesterol or mixtures of cholesterol and at least one neutral or zwitterionic lipid and wherein K (neutral) of said mixtures is 0.3 or less. Said amphoteric liposome may encapsulate an active agent, such as nucleic acid therapeutics. Also disclosed are pharmaceutical compositions comprising said amphoteric liposomes as a carrier for the delivery or targeted delivery of active agents or ingredients.12-30-2010
20120039991USE OF APOPTOSIS INHIBITING COMPOUNDS IN DEGENERATIVE NEUROLOGICAL DISORDERS - The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases that is characterized by an excess buildup of buildup of intracellular protein aggregates. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding an inhibitor of apoptosis protein (IAP) to cells in the region.02-16-2012
20090047337Method of administering a cationic liposomal preparation - The present invention relates to the use of pharmaceutical preparations comprising paclitaxel for administration to a human patient in need thereof.02-19-2009
20100291195TOPICAL DELIVERY OF L-ARGININE TO CAUSE BENEFICIAL EFFECTS - A preparation is disclosed for producing enhanced blood flow in tissue thus causing beneficial effects such as promoting hair growth on scalp tissue lacking sufficient hair, restoring normal sexual function in males with erectile dysfunction. Specifically, this is a preparation which provides local delivery of the amino acid L-arginine, an important biological precursor to the main substance which is responsible for relaxation of blood vessels permitting enhancement of blood flow. In the preferred embodiments, the L-arginine is provided so that it can be topically applied to the scalp or penis. The preparation also contains an agent which aids in the transfer of L-arginine into the tissue. In the preferred embodiments this agent overcomes the resistance to transfer caused by the high charge density of L-arginine. In the preferred embodiments this means is high ionic strength created by addition of choline chloride, magnesium chloride and sodium chloride. This preparation when applied nightly to scalp tissue lacking sufficient hair for a period of time causes substantial growth of hair on the scalp. Further, when applied to the penis of a subject with erectile dysfunction causes restoration of normal sexual function.11-18-2010
20100068258PROPHYLACTIC TUBERCULOSIS VACCINE - The invention relates to the use of an immunotherapeutic agent containing cell wall fragments of a virulent strain of 03-18-2010
20100215726Compositions for Diminishing the Appearance of Wrinkles - Topical skin care compositions are provided for the improvement of the appearance of the skin, namely of the skin comprising the face, surrounding the eyes, mouth, and hands, as well as the skin of the body. The skin care compositions include synergistic combinations of active peptide ingredients that are specially formulated to enhance the natural appearance of the face, hands, and/or body. Specifically, the synergistic skin care compositions may be applied to one or more of the skin surrounding the eyes, mouth, nose, forehead, ears, neck, hands, feed, and overall body to give the skin thereof a cleaner, smoother and more wrinkle free appearance.08-26-2010
20110305752LIPOSOME-ENCAPSULATED GLUTATHIONE FOR ORAL ADMINISTRATION - The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.12-15-2011
20120039986COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2 - RNA interference using small interfering RNAs which are specific for mRNA produced from the Ang1, Ang2 or Tie2 genes inhibits expression of these genes. Diseases which involve Ang1, Ang2 or Tie2 mediated angiogenesis, such as inflammatory and autoimmune diseases, diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.02-16-2012
20110305748Vaccines for Pandemic Influenza - Pharmaceutical and vaccine compositions comprise recombinant hemagglutinin from a pre-pandemic or pandemic influenza virus and an adjuvant comprising GLA. A particularly relevant pre-pandemic influenza virus is H5N1. Kits and methods of using the compositions are also provided.12-15-2011
20110305750MEMBRANE TYPE-1 MATRIX METALLOPROTEIN INHIBITORS AND USES THEREOF - Based on the discovery that a soluble polypeptide including a nonphosphorylatable form of the cytoplasmic domain is capable of inhibiting in a dominant negative manner, the present invention provides compositions including MT1-MMP inhibitors such as peptide inhibitors, and methods for treating diseases associated with MT1-MMP activity. Such diseases include cancer, arthritis, and heart disease, and vascular disease.12-15-2011
20110305749HIV-1 Envelope Polypeptides for HIV Vaccine - Immunogenic HIV-1 envelope polypeptides are provided, wherein specific amino acid residues are mutated to repress immunosuppression in GP41, thereby boosting the immune response against HIV-1. Specifically, mutation of those specific residues does not affect the fusogenic properties of the viral particle and/or the overall protein structure of the viral envelope protein. The invention further provides peptides and antigens based on the immunogenic HIV-1 envelopes as well as nucleic acid sequences and vectors encoding those. Moreover, biological entities such as viral particles are provided, as well as use of the provided components for preparation of a vaccine against HIV-1/AIDS.12-15-2011
20110305747COMBINATION OF DAPSONE WITH OTHER ANTI-ACNE AGENTS - A composition suitable for topical application that contains at least two active ingredients, one of these being dapsone and one selected from the group consisting of adapalene, tazarotene and treinion for the effective treatment of acne and other dermatological conditions.12-15-2011
20100189772Compositions of TLR ligands and antivirals - The invention relates to methods and products for the treatment of viral infection using a combination of anti-viral agents and TLR ligands. The invention also relates to screening assays, associated products, kits, and in vitro methods.07-29-2010
20110305751GLUTATHIONE-BASED DRUG DELIVERY SYSTEM - The invention relates to methods of targeted drug delivery of compounds, including, chemical agents, (poly)peptides and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of compounds to extravascular and intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (CNS), into and across the blood-brain barrier, by targeting to glutathione transporters present on these cells, tissues and organs. Thereto, the compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to glutathione-based ligands that facilitate the specific binding to and internalization by these glutathione transporters.12-15-2011
20090291129FORMULATION OF INSOLUBLE SMALL MOLECULE THERAPEUTICS IN LIPID-BASED CARRIERS - The present invention provides formulations containing at least one unsaturated amphiphilic lipid and an amphipathic or hydrophobic drug and methods of making these formulations. In particular, the present invention provides formulations of at least one unsaturated phospholipid and an amphipathic or hydrophobic pyrimidine drug, methods of making these formulations and the use of such formulations in a variety of contexts, including, for example, the treatment of proliferative disorders, such as tumors and cancers.11-26-2009
20100124567STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF - The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.05-20-2010
20100226972TRANSDERMAL PAIN GEL - A transdermal gel including a complementary array of medicinal components has beneficial effects for pain relief in muscular and connective tissues. The medicinal components include active ingredients having a synergistic effect for permitting musculoskeletal movement by countering the symptoms of musculoskeletal pain and being non-narcotic for avoiding dependency, and are combined in a liposomal base with a wetting agent to form a gel consistency suitable for skin application. The transdermal gel allows topical application of greater quantities and concentrations of the active ingredients than could safely be obtained via conventional oral administration.09-09-2010
20090081284THERAPEUTIC AGENT FOR ALLERGY CONTAINING LIPOSOME HAVING OLIGOSACCHARIDE ON ITS SURFACE - An object of the present invention is to provide a therapeutic agent for allergy which realizes enhancement of therapeutic efficacy and improvement in side effects such as anaphylaxis in a method for treating allergy by allergen administration (hyposensitization therapy).03-26-2009
20100062048TOPICAL CO-ENZYME Q10 FORMULATIONS AND TREATMENT OF PAIN, FATIGUE AND WOUNDS - CoQ1O has a stimulatory effect on fibroblasts and keratinocytes, increases ATP production, decreases pain. The formulations are useful for promoting acute wound healing, fatigue and treatment of acute and chronic pain.03-11-2010
20080274172Liposome Preparation Method - The invention relates to a method for preparing liposomes with at least two uniformly distributed phospholipids without using organic solvents.11-06-2008
20120039992COMPOSITIONS OF POLYMERIC MYRCENE - The invention relates to compositions and formulations comprising polymeric myrcene. More particularly, the invention relates to compositions comprising an isolated fraction of polymeric myrcene in a hydrophobic carrier and formulations which maintain the biological activity of the active polymer.02-16-2012
20120039989ERYTHROCYTE-BINDING THERAPEUTICS - Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.02-16-2012
20120039984GLYCOPEPTIDE AND USES THEREOF - A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.02-16-2012
20090035363Photoactive Compounds and Compositions and Uses Thereof - Photoactive compounds and compositions, as well as methods of using the same. For example, compositions of the invention may be used in Type 1 phototherapy, Type 2 phototherapy, or a combination of Types 1 and 2 phototherapy.02-05-2009
20120039995ARSENIC COMPOUNDS, THEIR PREPARATION METHODS AND USES THEREOF - Arsenic compounds of general formula (I), their preparation methods, the pharmaceutical compositions containing the compounds, and their uses in the manufacture of medicaments for treating cancer, particularly leukemia, are disclosed.02-16-2012
20120039994VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.02-16-2012
20120039990Liposome Compositions and Methods of Use Thereof - The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide.02-16-2012
20120039988CANCER-TARGETING PEPTIDES AND USES THEREOF IN CANCER THERAPY - Cancer-targeting peptides and uses thereof in cancer therapy.02-16-2012
20120039987NIOSOME HAVING METAL PORPHYRIN COMPLEX EMBEDDED THEREIN, PROCESS FOR PRODUCING THE SAME AND DRUG WITH THE USE THEREOF - A niosome having a metalloporphyrin complex embedded therein comprising a cationized metalloporphyrin complex and a niosome-forming substance. The niosome having a metalloporphyrin complex embedded therein has an SOD activity, can interact with superoxide anionic radicals (O02-16-2012
20120039985DENDRITIC CELL MODULATION IN POST-ISCHEMIC WOUNDS - Compositions and methods useful for targeted depletion or modulation of dendritic cells are provided. The compositions and methods can be used to promote healing of ischemia-related injury, including ischemia-reperfusion injury. Disclosed are a variety of dendritic cell-targeted toxins, bone morphogenetic protein 7 (BMP7) agonists, and dendritic cell-targeted transforming growth factor beta 1 (TGF-β1) antagonists, all useful in practicing methods of the invention. The inventive compositions and methods can be used in the treatment of various conditions including myocardial infarction, stroke, and critical limb ischemia.02-16-2012
20120039983AMPHIPHILIC MACROMOLECULE-LIPID COMPLEXES - The invention provides amphiphilic macromolecule (AM)-lipid complexes, methods of making the complexes, and methods of using the complexes.02-16-2012
20090068257BETULONIC AND BETULINIC ACID DERIVATIVES - The present invention relates to betulonic and betulinic acid derivatives and, in particular, to C-28 and C-3 derivatives. The present invention relates to betulonic acid esters, dihydro-betulonic acid esters, PAG-modified betulinic acid derivatives, and PAG-modified dihydro-betulinic acid derivatives. Betulinic acid and derivatives thereof may be bound to a poly(alkylene glycol) (PAG) such as poly(ethylene glycol). Binding may be via a linker, such as a diamine, an amino acid, a peptide, an ester or a carbonate.03-12-2009
20120148667BIORESORBABLE FILLERS CONSTITUTED BY PHOSPHOLIPID LIPOSOMES AND HYALURONIC ACID AND/OR THE DERIVATIVES THEREOF - The present invention describes a new bioresorbable filler constituted by hyaluronic acid and/or the derivatives thereof structured with/in phospholipid liposomes, which increase the residence time of the starting polymer in situ. Said fillers described herein are substantially intended to increase the soft tissues in aesthetic surgery and dermocosmetics for the correction of mild to medium defects, but because of their special characteristics they can also be used in other fields of application.06-14-2012
20120301539METHOD OF PRODUCING COATED FINE PARTICLES - An object of the present invention is to provide a method for easily producing coated fine particles in which core fine particles are coated with a coating layer component, etc. There are provided a method of producing coated fine particles comprising core fine particles coated with a coating layer component, comprising the steps of dispersing the core fine particles and the coating layer component(s) in a liquid and the process of coating the core fine particles with the coating layer component, wherein the liquid contains a polar organic solvent in which the coating layer component(s) is soluble, and the concentration of the polar organic solvent is such that the core fine particles is not dissolved and the coating layer component (s) can be in the dispersed state in the liquid, and the like.11-29-2012
20120301538PHARMACEUTICAL COMPOSITIONS FOR THE STIMULATION OF STEM CELLS - The invention relates to a human or veterinary pharmaceutical composition (B) for the stimulation of stem cells, comprising at least two stem-cells-stimulating-agents and at least one pharmaceutically acceptable excipient.11-29-2012
20120301537LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF - This method provides a method for delivering shRNA targeting TS in vivo. In addition, the following is provided: an antitumor agent, which comprises short hairpin RNA (shRNA) capable of inhibiting expression of thymidylate synthase by RNAi action and a PEG-modified cationic liposome, wherein the shRNA is bound to the surface of the PEG-modified cationic liposome and has an overhang comprising at least two nucleotides at the 3′ end.11-29-2012
20110008416ACOUSTICALLY SENSITIVE DRUG DELIVERY PARTICLES COMPRISING NON-LAMELLAR FORMING LIPIDS - Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon exposure to acoustic energy.01-13-2011
20080220057THERAPEUTIC COMPOUNDS AND METHODS OF USE - Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.09-11-2008
20080220055Therapeutic composition with enhanced endothelium targeting - A composition that includes nanoparticles with binding affinity for platelets, and methods for using this composition to treat vascular disease are disclosed.09-11-2008
20120039993 Detection of Gene Expression - An oligonucleotide, primer or probe comprises the nucleotide sequence of any of SEQ ID NO. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 44, 61, 62 or 63. The oligonucleotide, primer or probe is useful for the detection of the methylation status of a gene. The oligonucleotides find application in the diagnosis and treatment of cancer.02-16-2012
20090011002Nano - and Mesosized Particles Comprising an Inorganic Core, Process and Applications Thereof - Method for the preparation of nano- and mesosized particles consisting of a lipid layer comprising at least one amphiphile and a core of an inorganic compound and/or a metal, comprising: (i) dissolving in a common solvent at least one self-aggregating amphiphile with at least one inorganic, organometallic or metallorganic precursor of said inorganic compound or metal; and (ii) either injecting the resulting solution into an aqueous solution or drying the resulting solution and re-hydrating it, so as to form particles in which the precursor is encapsulated by the amphiphile(s) and is converted therein to said inorganic compound and/or metallic solid form.01-08-2009
20090087477METHODS FOR PREPARING REVERSE MICELLES BASED ON STEROLS AND ACYLGLYCEROLS FOR THE DELIVERY OF METAL IONS - The present invention relates to a method for the preparation of reverse micelles based on sterols, acylglycerols and metal salt and to reverse micelles obtained thereby. They are advantageously useful in the pharmaceutical and dietetic fields.04-02-2009
20090068258Caveolin-mimetic peptide for prevention and treatment of pulmonary hypertension and right ventricular hypertrophy - Methods are provided for preventing and treating pulmonary hypertension and right ventricular hypertrophy involving administering to a patient a caveolin peptide coupled to a cell permeating compound such as a cell permeating peptide.03-12-2009
20090214633NANOPARTICLES WITH LIPID CORE AND POLYMER SHELL STRUCTURES FOR PROTEIN DRUG DELIVERY PREPARED BY NANOENCAPSULATION - The present invention relates to an application of stabilized nanoparticles with a lipid core and shell structures as protein drug carriers, wherein the nanoparticles are prepared by producing nano-sized particles from lecithin obtained from natural soybean, and then adsorbing polaxamer thereon. Here, lecithin is used as an ingredient of core structure, polaxamer is used as an ingredient of shell structure, and both ingredients are applicable to a human body. Thus-obtained nanoparticles having a lipid core and shell structures are applicable in the clinical application. Moreover, said nanoparticles are suitable for use as a drug carrier or a diagnostic agent because they are produced in an aqueous solution without organic solvents.08-27-2009
20110064795Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers - The invention relates to an immunogenic composition which comprises, firstly, a carrier and, secondly, as antigenic structure, conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein, each peptide being combined with several molecules of fatty acid containing a carbon chain of between C12 and C24 so as to allow, under suitable administration conditions, the induction of anti-P-170 antibodies.03-17-2011
20110064792Method for Opening Tight Junctions - The present invention is directed to a method and use of RNA interference (RNAi) for the transient, reversible and controlled opening of the tight junctions of the blood brain barrier and/or the blood retinal barrier. This method may be used in the treatment of many diseases and disorders which require the opening of the blood brain barrier and/or blood retinal barrier. Such methods generally involve the use of an RNAi-inducing agent, such as siRNA, miRNA, shRNA or an RNAi-inducing vector whose presence within a cell results in production of an siRNA or shRNA, targeting tight junction proteins to open the blood brain barrier and/or blood retinal barrier.03-17-2011
20110064791Self forming, thermodynamically stable liposomes and their applications - Certain diacylglycerol-polyethyleneglycol (DAG-PEG) lipids are especially useful for forming thermodynamically stable liposomes. Such liposomes are useful for a variety of purposes, including the delivery of therapeutic agents.03-17-2011
20110064789DOCOSAHEXANOIC ACID AS INHIBITOR OF H. PYLORI - The present invention concerns a method for preventing, modulating or curing in a mammal, the infections with 03-17-2011
20110064794Drug Delivery System, its Preparation Process and Use - A protein-phospholipid dispersion preparation in a drug delivery system is provided, in which the weight ratio of protein to phospholipid is 1:300-300:1 and the particle size is between 5 nm and 1000 nm. The preparation process of the said preparation contains the mixture of protein phase and phospholipid phase and the homogenization process. The said drug delivery system can be used in many different pharmaceutical agents.03-17-2011
20110064796CONCENTRATED, INHALABLE ANTIBIOTIC FORMULATION - A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.03-17-2011
20120156284ENHANCED BIOLOGICAL AUTOLOGOUS TISSUE ADHESIVE COMPOSITION AND METHODS OF PREPARATION AND USE - The invention includes a composition useful for preparing a tissue sealant for use on a patient, comprising: autologous fibrinogen, an activating agent and at least one supplement. The invention includes a method of treating a disc having at least one defect, comprising: introducing a composition into the disc, wherein the composition comprises autologous fibrinogen and an activating agent, and wherein the composition forms fibrin.06-21-2012
20090269396DUAL ACTION, INHALED FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE - Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.10-29-2009
20100196451Vaccines Containing Non-Live Antigenic Vectors - The present invention provides a vaccine composition comprising a non-live vector which targets the MHC class I pathway derived from a bacterial toxin or an immunologically functional derivative thereof but excluding those which bind the Gb3 receptor complexed with at least one first antigen and further comprising at least one second antigen (which may be the same or different as the first antigen) and an adjuvant.08-05-2010
20110318408HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINE COMPOSITIONS - A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.12-29-2011
20110318407INACTIVATED DENGUE VIRUS VACCINE WITH ALUMINIUM-FREE ADJUVANT - The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus.12-29-2011
20110318406Lecithin carrier vesicles and methods of making the same - A hydrated lecithin carrier vesicle composition includes a lecithin-derived membrane-forming lipid vesicle in conditioned water for incorporation of an active ingredient to form a dispersed composition. A method of making the hydrated lecithin carrier vesicle includes using lecithin having not more than about 80% w/w phosphatidylcholine in the presence of conditioned water.12-29-2011
20130195962LIPID MEMBRANE STRUCTURE - A lipid membrane structure for delivering a substance to a target cell having satisfactory cell permeability, selectivity for target cell, and in vivo stability, wherein lipid membrane is modified with (a) a polyalkylene glycol bound with a target cell-selective ligand; and (b) a polypeptide comprising a plurality of arginine residues.08-01-2013
20130195963MESOPOROUS SILICON PARTICLES FOR THE PRESENTATION OF TUMOR ANTIGENS AND ADJUVANT FOR ANTI-CANCER IMMUNITY - Disclosed are mesoporous silicon multi-stage vehicles that comprise liposomal-based second-stage particles, as well as pharmaceutical compositions and formulations including such vectors for use in a variety of diagnostic and therapeutic indications. In particular embodiments, MSV comprising ligand decorated second-stage particles are provided for therapeutic methods including, for example, treatment of mammalian cancers, including those of the human breast.08-01-2013
20130011466LIPOSOME ENCAPSULATING AMMINE-PLATINUM COMPLEX AT HIGH CONCENTRATION, AND METHOD FOR PRODUCTION OF THE LIPOSOME - The present invention provides a method of producing a liposome encapsulating an ammine platinum complex. The method includes A) providing a water-soluble ammine platinum complex, platinum complex raw materials or the combination thereof; B) providing a liposome, liposome raw materials or the combination; and C) preparing a mixture of the water-soluble ammine platinum complex, platinum complex raw materials or the combination thereof and the liposome, liposome raw materials or the combination thereof and subjecting it to a liposome-forming/maintaining condition, wherein the salt of the platinum complex forms when the liposome is in a water-soluble form.01-10-2013
20080311182MULTISTAGE DELIVERY OF ACTIVE AGENTS - Multistage delivery vehicles are disclosed which include a first stage particle and a second stage particle. The first stage particle is a micro or nanoparticle that contains the second stage particle. The second stage particle includes an active agent, such as a therapeutic agent or an imaging agent. The multistage delivery vehicle allows sequential overcoming or bypassing of biological barriers. The multistage delivery vehicle is administered as a part of a composition that includes a plurality of the vehicles. Methods of making the multistage delivery vehicles are also provided.12-18-2008
20090162426Use of a Compound with RANKL Activity - The present invention relates to the use of a compound with receptor activator of nuclear factor-kB ligand (RANKL) activity for the manufacture of a topical pharmaceutical formulation for the modulation of local or systemic Treg numbers and the treatment or the prevention of skin-associated or systemic diseases.06-25-2009
20120207821Liposomal formulation and use thereof - Cationic liposome encapsulated antimonial drugs formulations are provided. The drug-loaded liposome have enhanced efficacy as antileismanial agents and provide improved therapeutic index as compared to the minimal dose of free drug.08-16-2012
20120045501CONNEXIN ENHANCES CHEMOTHERAPY-INCLUDED APOPTOSIS IN HUMAN CANCER CELLS INHIBITING TUMOR CELL PROLIFERATION - The present invention provides methods and compositions for the inhibition of proliferation rate of target cells, for example tumor cells. In particular, a nucleic acid encoding a connexin protein, fragment, derivative or analog thereof can be incorporated into a target cell. Expression of the nucleic acid sequence encoding the connexin protein, fragment, derivative or analog thereof, particularly connexin 43 and non-phosphorylated connexin 43, reduces the level of bc1-2 expression in the cells thereby inducing the cells to enter apoptosis. Connexin protein, fragments, derivatives, or analogs thereof can also be administered to the cell population to reduce bc1-2 expression inducing apoptosis in the cell population. It has further been found that the addition of an antagonist of MCP-1 activity can enhance the effects of connexin on tumor cell proliferation. Also, the prognosis of a subject undergoing standard chemotherapy can be assessed by correlating the expression levels of connexin and bc1-2.02-23-2012
20120003302PHARMACEUTICAL COMPOSITION CONTAINING A FERMENTED, DEHYDRATED MATERIAL WITH AMORPHOUS CRYSTALLINE STRUCTURE - The invention concerns a high water soluble product, containing a dehydrated material, obtained by fermenting wheat germ in aqueous medium in the presence of microorganisms of the Saccharomyces genus, forming amorphous crystal structure with inert auxiliary materials), commonly used in preparation of drugs. The invention also relates to the production process of said products, to immunostimulatory, immunomodulatory, antitumor and cardiovaskular pharmaceutical preparations containing them, and to the therapeutic methods for their use.01-05-2012
20120003299NOVEL HSP90-TARGETED ANTI-CANCER CHIMERIC PEPTIDE - Disclosed is a substance which is not accumulated stably in cells, does not cause the dysfunction of normal cells, and so on, and therefore can be used as an anti-cancer agent or in a DDS without having any adverse side effects. It is found that Hsp90 alone cannot exhibit its function as a chaperone in assisting the refolding of a protein such as survivin, but can exhibit this function when Hop (which is one of the partner proteins of Hsp90) binds to Hsp90. Thus, specifically disclosed herein is a chimeric peptide comprising of an Hsp90 TPR domain binding peptide and a cell-penetrating peptide.01-05-2012
20120003297COMPOSITIONS AND METHODS FOR TREATING LYMPHOMA - This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.01-05-2012
20120003296NEW METHODS OF TREATING DRY EYE SYNDROME - The invention relates to a method of insulin eye drops for treating dry eye syndrome due to any and all etiological factors (Keratoconjunctivitis sicca), including Sjogren's syndrome, Meibomian gland dysfunction (MGD) and other glandular malfunction in the eye lids, lacrimal glands, cornea, conjunctiva, and exposed scleral surface of the eye. It is treated with Insulin and/or IGF-I with or without known anti-dry eye syndrome therapeutic, pharmaceutical, biochemical and biological agents or compounds.01-05-2012
20120003294FIXED RATIO CAMPTOTHECENS/PLATINUM AGENTS - Compositions which comprise liposomes having controlled release of a platinum agent are useful in achieving enhanced therapeutic effects particularly when these drugs are administered in combination with other therapeutic agents.01-05-2012
20120003300Composition Comprising Vascular Endothelial Growth Factor (VEGF) for the Treatment of Hair Loss - A composition to treat hair loss and enhance hair growth and condition. The composition comprises: i) one or more of VEGF, a VEGF biomimetic peptide, and/or a VEGFR2 receptor agonist; ii) ciclopirox olamine; and iii) a pharmaceutically acceptable carrier.01-05-2012
20120003298METHODS FOR INDUCING AN IMMUNE RESPONSE - Provided in some embodiments are methods for inducing an antigen-specific immune response in a subject, comprising administering a compound having a structure according to Formula A or Formula B:01-05-2012
20100055168CATIONIC LIPIDS AND USES THEREOF - Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.03-04-2010
20090053295REGULATABLE FUSION PROMOTERS - Fusion promoters are described that combine a RNA polymerase III basal promoter and regulatory elements from RNA polymerase II regulatory regions, and which provide specific regulation of expression from the promoter. Such fusion promoters are useful, for example, for expressing RNAi agents in vivo.02-26-2009
20100183703PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING A DOUBLE STRANDED RNA OLIGONUCLEOTIDE AND ITS USE AS AN ACTIVE PHARMACEUTICAL INGREDIENT IN THE TREATMENT OF ANDROGEN RELATED DISEASES - This invention refers to new double stranded oligonucleotides having specific antiandrogenic activity and particularly to their use in the treatment of androgen-related diseases. Oligonucleotides may preferably be formulated with an acceptable pharmaceutical support in pharmaceutical or cosmetic formulations which are related to androgen metabolism or aimed at providing a beneficial effect on skin and/or hair.07-22-2010
20120207819COMPOSITIONS AND METHODS FOR WOUND HEALING - The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked α-gal epitopes for induction of recruitment of macrophages localized within or surrounding damaged tissue. The recruited macrophages recruit stem cells and promote the repair and regeneration of the treated injured tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. In some embodiments, the present invention provides treatments for injured tissues such as brain, peripheral nerve, heart muscle, skeletal muscle, cartilage, bone, gastrointestinal tract and dysfunctional endocrine tissues.08-16-2012
20120207820COMPOSITION FOR TREATMENT OF MULTIPLE SCLEROSIS - Novel oligopeptides, combinations thereof and fusion proteins composed of the above-mentioned oligopeptides are disclosed. Oligopeptides are homologous in amino acid sequence to the selected parts of the amino acid sequence of human myelin basic protein (MBP) and are capable to ameliorate the progression of multiple sclerosis by means of binding to and inactivation of epitope-specific anti MBP catalytic auto antibodies (ESAMBPCAA) involved into binding and catalytic degradation of MBP in course of progression of Multiple Sclerosis.08-16-2012
20120207818COMPOSITION FOR SUPPRESSING EXPRESSION OF TARGET GENE - The present invention provides a composition that comprises a liposome encapsulating a double-stranded nucleic acid molecule, 08-16-2012
20120009247PHOSPHOLIPID DRUG ANALOGS - Provided in some embodiments are compositions comprising a compound having a structure according to Formula A or Formula B:01-12-2012
20120009246PHOSPHOLIPID-ANALOGOUS COMPOUNDS - Phospholipid-analogous compounds of the general formula (I)01-12-2012
20120009249CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATION OF NEUROTRANSMITTERS - This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.01-12-2012
20120009253PREPARATIONS FOR THE APPLICATION OF ANTI-INFLAMMATORY, ESPECIALLY ANTISEPTIC AGENTS AND/OR AGENTS PROMOTING THE HEALING OF WOUNDS OF THE LOWER RESPIRATORY TRACT - Use of an anti-inflammatory agent such as povidone iodine for the preparation of a pharmaceutical composition for the treatment of diseases of the lower respiratory tract which are susceptible to the administration of such agents.01-12-2012
20120009250CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS - This invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action.01-12-2012
20120009248Preservation of Bioactive Materials By Spray Drying - This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials.01-12-2012
20120009245Administration of Growth Factors for the Treatment of CNS Disorders - A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described.01-12-2012
20120009243LIPOSOMES FOR DRUG DELIVERY AND METHODS FOR PREPARATION THEREOF - The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.01-12-2012
20120009244NEUROD1 GENE EXPRESSION IN NON-ENDOCRINE PANCREATIC EPITHELIAL CELLS (NEPECs) - The introduction of the human NeuroD1 gene into human non-endocrine pancreatic epithelial cells (NEPECs) for producing insulin producing cells in vitro is described herein. Cytokeratin19 (CK19) positive NEPECs were transfected with plasmids encoding human NeuroD1 gene under human CK19 promoter. On characterization following the induction it was found that NEPEC+ND strongly expressed NeuroD1 and insulin mRNA. The ratio of NeuroD1 and human insulin positive cells in NEPEC+ND was significantly higher than NEPEC. Human insulin and C-peptide levels in culture media in NEPEC+ND were significantly higher than NEPEC. The findings demonstrate that human NeuroD1 under control of the CK19 promoter induces the differentiation of CK19 positive NEPECs into insulin producing cells.01-12-2012
20120009252LIPOSOMAL FORMULATIONS OF ANTHRACYCLINE AGENTS AND CYTIDINE ANALOGS - Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.01-12-2012
20100015215Use of Glycolipids as Adjuvants - The present invention relates to adjuvants of the glycolipid type and their uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new uses of compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours and allergies. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants.01-21-2010
20100247623Cancer Stem Cell Vaccine - The invention provides a method of making a vaccine for treating or preventing cancer in a patient or individual which comprises preparing the vaccine from cancer stem cells, from fractions, extracts, shed material or purified antigens derived from these cells, or from DNA or RNA coding for cancer stem cell associated antigens. In one embodiment of this invention, cancer stem cells are separated from unrelated cancer cell populations and then expended and cultured under conditions in which the cancer stem cells shed or release tumor antigens, and using the shed material or cancer stem cell antigens isolated from it as the vaccine. The invention further provides a vaccine and methods of treatment using the vaccine for any cancer is disclosed. Also disclosed are specific applications of this method to prepare such vaccines from antigens released or shed by cancer stem cells, and a particular application to make a shed, cancer stem cell, vaccine for breast cancer.09-30-2010
20120128762Sphingomyelin Liposomes for the Treatment of Hyperactive Bladder Disorders - The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysfunction.05-24-2012
20090324699Antihistamine-and corticosteroid-containing lipsome composition and its use for the manufacture of medicament for treating rhinitis and related disorders - There is provided homogeneous pharmaceutical compositions for the treatment of, for example, rhinitis, asthma and/or chronic obstructive pulmonary disease comprising a corticosteroid and an antihistamine, a polar lipid liposome and a pharmaceutical-acceptable aqueous carrier.12-31-2009
20100196455Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof - The present invention relates, in part, to a composition comprising a multicationic drug and an organic multianion. In some embodiments, the multicationic drug is enclosed within a carrier. In some embodiments, the carrier is a liposome. In some embodiments, the multicationic drug and organic multianion are enclosed within a carrier, while in other embodiments, the multicationic drug is enclosed within the carrier and the organic multianion is outside the carrier. The present invention also relates, in part, to a method of treating a subject for pulmonary distress comprising administering to a subject in need thereof the aforementioned composition.08-05-2010
20120045503Compositions And Methods For Wound Healing - The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osteoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked α-gal epitopes for induction of recruitment of macrophages localized within or surrounding damaged tissue. The recruited macrophages and stem cells promote the repair and regeneration of the treated injured tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. In some embodiments, the present invention provides treatments for injured tissues such as brain, peripheral nerve, muscle, cartilage, bone, gastrointestinal tract and dysfunctional endocrine tissues.02-23-2012
20120045502ANTAGONISTS OF MUC1 - The present invention is directed to improved compositions for cellular delivery of peptides. Using segments of only 3-5 positively-charged residues, one can effectively transfer peptides, including therapeutic peptides, into cells. Also provided are modified peptides such as those include stapled and cyclized peptide technology, as well as peptoids/peptidomimetics.02-23-2012
20120015025CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy.01-19-2012
20120015024METHODS FOR TREATING TWEAK-RELATED CONDITIONS - The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.01-19-2012
20120015026PHARMACEUTICAL COMPOSITION CONTAINING A DRUG AND SIRNA - The present invention relates generally to the fields of molecular biology, medicine, oncology, and delivery of therapeutic compounds. In particular, the present invention relates to pharmaceutical compositions containing a hydrophobic drug substance and an inhibitory nucleic acid molecule, such as short interfering RNA (siRNA), in a single drug delivery system, as well as a process for making and a process for administering the same.01-19-2012
20120015023Treatment of tumors prostate with arsonoliposomes - The invention provides a method for treating a prostate proliferative disorder, such a prostate carcinoma or a begnin prostatic hyperplasia, in a patient, which method comprises administering arsonoliposomes comprising arsonolipids, wherein the arsonolipids are 2,3-diacyloxypropylarsonic acids, to a patient in need thereof.01-19-2012
20110081404NOVEL LIPOSOME COMPOSITIONS - The present disclosure provides lipid-containing compositions, including targeted liposomes encapsulating drug, and pharmaceutical formulations thereof, as well as methods for the making and using the lipid-containing compositions, including the use of the targeted liposomes in the treatment of cancer and other diseases.04-07-2011
20090186076Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent - The combined use of a TGF-β signaling inhibitor and an antitumor active substance or an imaging agent modified by a drug-encapsulating macromolecular micelle, or the like, is provided. The selective delivery capability of the antitumor active substance or the imaging agent to the target is improved, increasing the antitumoral activity in the target.07-23-2009
20120064148PH-RESPONSIVE LIPOSOME - The present invention provides pH-responsive liposomes which are capable of holding a desired substance in an acidic pH environment and releasing the desired substance in a basic pH environment.03-15-2012
20120064147AGENT FOR IMPROVING TISSUE PENETRATION - The invention concerns a pharmaceutical preparation which improves penetration of active substances through the tissue membrane or barrier of the target organ.03-15-2012
20120064151ENHANCED IMMUNE RESPONSE IN AVIAN SPECIES - The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the avian species. The method is particularly effective for protecting a member of the avian species from infectious disease and treating animals inflicted with infectious disease.03-15-2012
20120064150BIOCOMPATIBLE MATERIALS CONTAINING STABLE COMPLEXES OF TSG-6 AND HYALURONAN AND METHOD OF USING SAME - The present invention provides a biocompatible material in the form of a solid, a water insoluble cross-linked gel or a liposome, which contains a stable comples of TNF-stimulated gene 6 protein (TSG-6) and hyaluronan.03-15-2012
20120058178Liposome Composition - The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture.03-08-2012
20120058177NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY - The present invention provides an aqueous tumor-targeting liposome nanoparticle composition comprising an aqueous dispersion of liposome nanoparticles. The nanoparticles preferably encapsulate an anti-cancer chemotherapeutic agent, which can be added to a pre-formed liposome composition or can be incorporated in the liposomes during the formation of the liposomes. The liposome nanoparticles comprise a legumain-targeting lipid admixed with one or more other micelle or vesicle-forming lipid materials in the form of nanoparticulate liposomes dispersed in an aqueous carrier. A preferred tumor-targeting liposome nanoparticle composition comprises (a) a legumain-targeting lipid component, (b) a zwitterionic lipid component; (c) an amino-substituted lipid component; (d) a neutral lipid component; and (e) polyethylene glycol-conjugated lipid component. The legumain-targeting lipid component comprising a hydrophobic lipid portion covalenetly attached to a legumain-binding moiety.03-08-2012
20120058176CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS AND METHOD OF TREATMENT - This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.03-08-2012
20100158995SYSTEMS FOR DELIVERY AND RELEASE OF ANGIOTENSIN-(1-7) - The prior art lacks a formulation, application or product of D-Ala7-Angiotensin-(1-7) (A-06-24-2010
20120156280MYELOID DERIVED SUPPRESSOR CELL INHIBITING AGENTS - Myeloid derived suppressor cell (MDSC) inhibitory agents and vaccine and/or adjuvant enhancers are provided. Improved vaccine treatment regimens employing these agents are also provided. Cancer vaccines and methods for inhibiting tumor growth and cancer metastases are also presented. The myeloid derived suppressor cell (MDSC) inhibiting agents are described as bisphosphonates (such as liposomal clodronate) and CCR2 inhibitors and/or CCR2 antagonists. Methods for enhancing antibody titer levels in response to an antigen of interest are also provided.06-21-2012
20120207817SMALL INTERFERING RNAS AND METHODS FOR PREVENTION, INHIBITION AND/OR TREATMENT OF MALIGNANT PROGRESSION OF BREAST CANCER - The invention found that overexpression and activation of α9-nAChR are associated with tumorigenesis of breast cancer and create a number of small interfering RNAs to inhibit the expression of α9-nAChR so as to inhibit breast cancer. Therefore, the invention provides small interfering RNAs (siRNAs) for inhibiting expression of α9-nAChR so as to inhibit breast cancer, methods to prevent/inhibit/treat malignant progression of nicotine-derived-compound-induced breast cancer and method of determining malignant level of such breast cancer.08-16-2012
20100166844POLYMER PARTICLE DISPERSION, COMPOSITION CONTAINING THE SAME AND COSMETIC TREATMENT METHOD - The present patent application relates to novel dispersions of particles of polymer stabilized at the surface in a nonaqueous medium, in which dispersions the polymer comprises mainly hydrophilic cationic monomers.07-01-2010
20120064149HIGH-CLARITY AQUEOUS CONCENTRATES OF 4-HEXYLRESORCINOL - The present invention relates to hexylresorcinol/water concentrates that are high in clarity, easily handled, and readily blended with other ingredients to form skin care compositions.03-15-2012
20100278904NUCLEOTIDE VACCINE - The present invention relates to a vaccine comprising a nucleic acid construct such as a DNA construct especially a nucleic acid construct comprising sequences encoding invariant chain operatively linked to antigenic protein or peptide encoding sequences. The vaccine stimulates an immune response, especially an immune response in an MHC-I dependent, but CD411-04-2010
20110097386STABILIZED GLUCAGON SOLUTIONS - A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so as not to induce or to minimize site irritation. The combination of a simple sugar and an surfactant stabilizes the glucagon molecule in an aqueous solution for seven days at 37° C.04-28-2011
20120107389AMPHOTERIC LIPOSOMAL COMPOSITIONS FOR CELLULAR DELIVERY OF SMALL RNA MOLECULES FOR USE IN RNA INTERFERENCE - The present invention provides method and pharmaceutical composition for efficient delivery of siRNA (small interfering ribonucleic acids) into cultured mammalian cells. In addition, the present invention provides methods and compositions for knocking down the expression of a specific target gene by treating cells with the formulations comprising cationic amphiphile, a neutral colipid and a small RNA molecule. We demonstrate that our method delivers siRNA efficaciously into animal cells for the purpose of RNA interference. The area of medical science that is likely to benefit most from the present invention is RNAi therapeutics.05-03-2012
20120156283Methods and Compositions for Wound Treatment - The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.06-21-2012
20120156282EXPANDING THE T CELL REPERTOIRE TO INCLUDE SUBDOMINANT EPITOPES BY VACCINATION WITH ANTIGENS DELIVERED AS PROTEIN FRAGMENTS OR PEPTIDE COCKTAILS - A convenient way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease is provided. The method involves immunizing with pools of overlapping fragments (synthetic peptides, e.g., 10-30 mers with 2-20 aa overlap) of the desired antigen in appropriate adjuvants. The T cell repertoire is primed to include not only the immunodominant epitope recognized when the intact molecule is used for immunization and induced by the chronic infection itself, but induce a much broader and balanced response to a number of the subdominant epitopes as well. The vaccination with peptide mix induces a T-cell response that includes response to subdominant epitopes is important for protection against chronic disease that on their own induces a response focused only on immunodominant epitopes.06-21-2012
20110081407ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.04-07-2011
20120107391THERAPY OF PLATINUM-RESISTANT CANCER - The present invention concerns a method for treating platinum-resistant, ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma with the combination of a HER2 antibody that effectively inhibits HER dimerization as well as gemcitabine.05-03-2012
20110091532COMPOSITION FOR THE TREATMENT OF ARTHRITIS CONTAINING A DIBENZO-P-DIOXIN DERIVATIVE AS THE ACTIVE INGREDIENT - Disclosed is a composition for treating arthritis containing a dibenzo-p-dioxin derivative as an active ingredient. This dibenzo-p-dioxin derivative is very effective in inhibiting NF-kB and AP-1 activity, alleviates the symptoms of degenerative arthritis and rheumatoid arthritis without irritating the skin or causing side effects, and can continue to exhibit improvement effects for a considerable period of time after discontinuation of treatment. Additionally, when the dibenzo-p-dioxin derivative is contained in liposomes, the composition of the invention exhibits much greater effects on treating arthritis by absorption through skin, and thus is useful for the treatment of degenerative arthritis and rheumatoid arthritis.04-21-2011
20110091531Cooling Composition - A liquid cooling composition, which is a mixture of at least one primary cooling compound, at least one different secondary cooling compound and at least one ingestible non-polar solvent for the primary cooling compound, the weight ratios of primary cooling compound:secondary cooling compound:solvent being 1:1.5-2.25:2-4.4.04-21-2011
20110091530OLIGOPEPTIDE TYROSINASE INHIBITORS AND USES THEREOF - Disclosed are peptides that inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Peptide sequences disclosed include KFEKKFEK (SEQ ID NO: 1) and YRSRKYSSWY (SEQ ID NO: 2).04-21-2011
20110091529ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.04-21-2011
20110091528ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.04-21-2011
20110091525POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF - The present invention provides compositions comprising polytheylyene-dialkyloxypropyl conjugates (PEG-DAA), liposomes, SNALP, and SPLP comprising such compositions, and methods of using such compositions, liposomes, SNALP, and SPLP.04-21-2011
20110091524BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY - The present invention provides, for example, methods for conveniently determining if a cancerous condition in a subject will be responsive to an IGF1R inhibitor. The invention includes patient selection methods and methods of treatment.04-21-2011
20110091523Cochleate compositions directed against expression of proteins - Disclosed herein are novel siRNA-cochleate and morpholino-cochleate compositions. Also disclosed are methods of making and using siRNA-cochleate and morpholino-cochleate compositions.04-21-2011
20100008977LIPOSOMALLY ENCAPSULATED HYBRID ADENOVIRUS-SEMLIKI FOREST VIRUS (SFV) VECTORS CARRYING RNAI CONSTRUCTS AND THERAPEUTIC GENES FOR USE AGAINST CANCER TARGETS AND OTHER DISEASES - A hybrid adenovirus Semliki Forest Virus (SFV) vector includes 3′ and 5′ inverted terminal repeat (ITR) of adenovirus, the packaging signal of adenovirus, the structural genes encoding the adenovirus hexon and penton proteins, fiber and knob proteins and that may be deleted in the E4 region, E2 region or in the both the E2 and E4 regions. The adenovirus vector may not require a helper virus coinfection for propagation in producer cell lines. A hybrid vector includes a eukaryotic promoter controlling expression of the 42S genome of SFV comprising the nonstructural genes 1-4 or two point mutations thereof, and the therapeutic mRNA, in the cytoplasm. In use, the hybrid vector further comprises cDNA encoding for microRNA (miRNA) and hairpin loops of short interfering RNA (siRNA) or cDNA encoding for double-stranded RNA (dsRNA).01-14-2010
20090011004IMPROVED CARRIERS FOR DELIVERY OF NUCLEIC ACID AGENTS TO CELLS AND TISSUES - This invention relates to drug delivery and specifically to the preparation and use of functionalized carriers such as nanopolymers and nanovesicles for improved delivery of nucleic acid agents (NAA) to tissues and cells. These compounds have broad applicability for treating numerous diseases and disorders, including neurodegenerative and neuromuscular disorders. The concept encompasses preferably polymeric carriers for delivery of a class of oligonucleotides that modulate RNA splicing.01-08-2009
20110020429USE OF PARTICLES COMPRISING AN ALCOHOL - Novel use of ultrasound sensitive drug carrying particles comprising an alcohol is disclosed, as well as products and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon ultrasound exposure.01-27-2011
20100291194Compositions and Methods for Inhibiting Expression of a Mutant Gene - The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a complementary RNA strand having a complementary region that is substantially complementary to a portion of the mutant gene, and which is partially complementary to the corresponding wild-type gene. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.11-18-2010
20100291191TUNABLE SUSTAINED RELEASE OF A SPARINGLY SOLUBLE HYDROPHOBIC THERAPEUTIC AGENT FROM A HYDROGEL MATRIX - The incorporation of polymeric excipients into an injectable hydrogel matrix, for example, methyl cellulose in the case of a hydrogel matrix comprising hyaluronan and methylcellulose (HAMC) has been found to increase the solubility of sparingly soluble hydrophobic drugs and tune their rate of release. The hydrogel matrix may also include other sparingly soluble hydrophobic food or cosmetic agents.11-18-2010
20100291188Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same - We claim the compositions of matter and methods described herein.11-18-2010
20120128757Method of Manufacture of Liposome Composition - The present invention provides a method of manufacture of a liposome composition including a step in which: a liposome dispersion liquid containing a liposome, and further containing cyclodextrin in the liposome internal phase is provided and a step in which an active compound is introduced into said liposome internal phase, and the liposome composition.05-24-2012
20110104261REMOTE DETECTION OF SUBSTANCE DELIVERY TO CELLS - The present invention provides for the development of endocytosis-sensitive probes, and a remote method for measuring cellular endocytosis. These probes are based on the reduced water permeability of a nanoparticle or liposomal delivery system, and inherent degradability or disruption of barrier integrity upon endocytosis. The invention also provides for liposomes having combined therapeutic and diagnostic utilities by co-encapsulating ionically coupled diagnostic and therapeutic agents, in one embodiment, by a method using anionic chelators to prepare electrochemical gradients for loading of amphipathic therapeutic bases into liposomes already encapsulating an imaging agent. The invention provides for imaging of therapeutic liposomes by inserting a lipopolymer anchored, remotely sensing reporter molecules into liposomal lipid layer. The invention allows for an integrated delivery system capable of imaging molecular fingerprints in diseased tissues, treatment, and treatment monitoring.05-05-2011
20110104263CLAUDIN-4 BINDING PEPTIDES, COMPOSITIONS AND METHODS OF USE - The disclosure provides methods and compositions useful for treating claudin-4 associated disorders including cell proliferative disorders. The disclosure also provide claudin-family binding peptides useful in the methods of the disclosure. 05-05-2011
20110104259PROCESSES FOR TASTE-MASKING OF INHALED FORMULATIONS - The present invention provides novel processes and methodologies to minimize the bitter or otherwise unpleasant taste, to minimize the tendency to stimulate the cough reflex, or to minimize oropharyngeal deposition of medically-active compounds administered by the pulmonary/inhalation route and to deliver hydroxychloroquine (HCQ) either singularly or in combination with an antimalarial and aminoquinolone by the pulmonary/inhalation route in a sustained release or other formulation that minimizes the bitter or otherwise unpleasant taste of HCQ or any potential to stimulate the cough reflex, and to deliver a dopaminergic compound or its prodrug, including ABT-431 by the pulmonary/inhalation route in a sustained release or other formulation that minimizes the unpleasant taste of the drug or any potential to stimulate the cough reflex, and to deliver a lantibiotic, including duramycin by the pulmonary/inhalation route in a sustained release or other formulation that minimizes the unpleasant taste of the drug or any potential to stimulate throat irritation.05-05-2011
20110104253AGENT FOR INTRA-ARTICULAR INJECTION - The present invention relates to agents for intra-articular injection that contain a mixture of alpha-tocopherol, phospholipids, proteoglycans, and a cortisone crystal suspension or a cortisone crystal solution. The agents are suitable for therapy of rheumatic diseases, in particular of arthrosis.05-05-2011
20110104260VACCINE AGAINST VARICELLA ZOSTER VIRUS - Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen and an adjuvant containing QS21, cholesterol and 3D MPL are also claimed05-05-2011
20110104255THERAPEUTIC AGENT FOR FIBROID LUNG - Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent.05-05-2011
20110104251Cosmetic Composition And Method For Retarding Hair Growth - The present invention comprises cosmetic compositions and methods for retarding hair growth comprising a combination of an ornithine decarboxylase inhibitor, an anti-angiogenic active and an anti-inflammatory.05-05-2011
20110104250Redox-gated Liposomes - The present invention provides lipid compounds for delivering therapeutic amounts of active agents in response to enzymatic activities of cancer tissues. Lipid compositions may include one or more drugs, or a biologically-active agent, encapsulated within liposomes.05-05-2011
20110104249Oncotherapeutic Application of Inhibitors of High-Affinity Glucose Transporters - The subject invention concerns materials and methods for treating oncological disorders in a person or animal using any agent or compound that inhibits uptake of glucose into a cell. The subject invention also concerns methods for inducing apoptosis and inhibiting the proliferation or survival of a cell. In one embodiment, the methods comprise administering an effective amount of an agent or compound that inhibits the activity of one or more glucose transporter proteins, such as Glut-1. An antibody that binds to and inhibits a glucose transporter protein can be used in the present methods.05-05-2011
20110104248LIPOSOMES AND IMMUNOPOTENTIATING COMPOSITIONS CONTAINING THE SAME - It is an object to enhance immunopotentiating activity of a glycosphingolipid.05-05-2011
20120251618DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS - Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.10-04-2012
20120251617BI-FUNCTIONAL SHRNA TARGETING STATHMIN 1 AND USES THEREOF - The present invention includes bifunctional shRNAs capable of reducing an expression of a Stathmin 1 gene; wherein at least one target site sequence of the bifunctional RNA molecule is located within the Stathmin 1 gene, wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of Stathmin 1.10-04-2012
20120251613METHOD FOR TREATING VITILIGO WITH A PROSTAGLANDIN ANALOGUE - A method of stimulating melanogenesis in a skin surface of a patient, by treating the skin surface with a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier. The topical formulation may be a cream, a gel, a lotion, a spray, an ointment, an aqueous solution, a nonaqueous solution, or a transdermal patch. The dermatologically acceptable carrier may contain an oily carrier or an aqueous carrier.10-04-2012
20110033524TREATMENT OF TUMORS - The invention provides for innovative improvements in tumour therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity.02-10-2011
20120121694Compositions and Kits for Ocular Treatment - Embodiments of the invention provide eyelid preparations, methods, and kits, for treating ocular conditions. The eyelid preparations comprise a mixture of tea tree oil and sea buckthorn oil in a pharmaceutically acceptable carrier.05-17-2012
20120121693METHODS FOR GENERATING NEW HAIR FOLLICLES, TREATING BALDNESS, AND HAIR REMOVAL - The present invention provides methods of treating baldness in a subject and generating new hair follicles, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell. The present invention also provides methods for hair removal and inducing hair pigmentation.05-17-2012
20120121697Compositions and Methods for the Diagnosis and Treatment of Inflammatory Disorders and Fibrotic Disease - Compositions and methods are disclosed for the treatment and diagnosis of inflammatory diseases and disorders, including pulmonary diseases and fibrotic disorders, including COPD.05-17-2012
20120121695ACOUSTICALLY SENSITIVE DRUG DELIVERY PARTICLES COMPRISING NON-LAMELLAR FORMING PHOSPHATIDYLETHANOLAMINE - Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their pay-load upon exposure to acoustic energy.05-17-2012
20120121691Method for Increasing the Production of a Specific ACYL-Chain Dihydroceramide(s) for Improving the Effectiveness of Cancer Treatments - A method to improve the effectiveness of cancer treatments by increasing the production of specific ACYL-chain dihydroceramide(s). Increase of native chain-length dihydroceramides is directly cytotoxic to human acute lymphoblastic leukemia cell line MOLT-4 ALL cells with a cytotoxic potency that is dependent upon the specific fatty acid acyl-chain length and saturation of the dihydroceramides. The combination of sphinganine and GT-11 lead to cell death in the absence of an increase of reactive oxygen species, suggesting that the ability of fenretinide to increase cytotoxic ROS is mechanistically independent of dihydroceramides increase and related cytotoxicity. Most unexpectedly, supplementing the exposure of cancer cells to a dihydroceramide-increasing anti-hyperproliferative agent(s), such as fenretinide, with specifically-chosen fatty acids can increase the cytotoxicity of the anti-hyperproliferative agent to the cancer cells to a beneficial effect.05-17-2012
20120121689SMALL INTERFERING RNA DELIVERY - A liposomal siRNA composition is described. The liposomes are formed of neutral liposome forming components, and the composition comprising additionally sugar. The composition provides reduced expression of target gene, without causing systemic toxicity. The composition is produced by a dehydration-rehydration technique to provide high yields and good control of liposome size.05-17-2012
20110129523Liposomally Encapsulated Reduced Glutathione, including with Other Pharmacologic Preparation, Capable of Administration as an Oral, Topical, Intraoral or Transmucosal, Prepartion, for Reversal and Prevention of Oxidation of Cholesterol and of Low Density Lipoprotein - The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy.06-02-2011
20100255074TRANSMEMBRANE PROSTATIC ACID PHOSPHATASE - The present invention relates to a novel transmembrane prostatic acid phosphatase (TM-PAP) protein or the C-terminal part thereof, nucleic acid molecules encoding said protein, vectors containing said nucleic acid molecules and host cells expressing said proteins. The present invention relates also to pharmaceutical compositions containing TM-PAP or the C-terminal part thereof and methods for using thereof in therapy and diagnostics. The present invention also relates to methods utilizing a transmembrane prostatic acid phosphatase knockout/knockdown non-human animal model and uses thereof.10-07-2010
20120315322NANOPARTICLE MEDIATED GENE THERAPY AND THERAPEUTIC PRODUCTS FOR ALZHEIMERS - The present disclosure provides compositions and methods of treating Alzheimers Disease. In an aspect, a nanoparticle is paired to one or more genetic materials that regulates inflammation in a microenvironment. Such nanoparticles can be used to target predefined target cell types in connection with treatment of at least one of the following Alzheimer's disease, Pick's disease, Lewy Body disease, or Idiopathic dementia.12-13-2012
20100247625Orally Bioavailable Lipid-Based Constructs - The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.09-30-2010
20100247626PEGYLATED COMPOUNDS FOR AGE-RELATED MACULAR DEGENERATION - A special photosensitizer formulation and Photodynamic Therapy method for treating choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) is provided. CNV is a major cause for vision loss in elderly patients. A special drug delivery formulation is used to encapsulate the hydrophobic photosensitizer, preferably a pegylated liposome. This improves the solubility and therapeutic index of the photosensitizers. In one preferred embodiment, a pegylated photoactive agent remains confined in the intravascular compartment of neovasculature for a longer duration. Thus efficient elimination of neovascular proliferation and minimal damage to extravascular tissue and normal vessels is ensured. In this method, a hydrophobic photosensitizer, that is able to photochemically destroy neovessels, is injected into the patient. CNV irradiation with a non-thermal laser follows after a predefined time interval. The excited photosensitizer photocoagulates newly formed blood vessels thereby improving the vision and preventing further loss of vision.09-30-2010
20100247627FOXN1 AND PIGMENTATION - The present invention provides methods and compositions for modulating skin pigmentation.09-30-2010
20100247630Skin Treatment Compositions Containing Copper-Pigment Complexes - A therapeutic method is described in which copper is delivered into the skin as a complex with sodium chlorophyllin. Sodium copper chlorophyllin is encapsulated in suitable lecithin-type liposomes, containing a high concentration of linoleic acid and having diameters in the range 150-350 nanometers. The method provides therapeutic benefits in the treatment of environmentally-induce premature skin aging, excessively oily skin, acne and acne-related skin disorders, acne-rosacea, and also stimulates the natural tanning response of skin to sunlight and other ultraviolet-containing radiation.09-30-2010
20100247629Method for drug loading in liposomes - A liposome composition having a protonatable therapeutic agent entrapped in the form of a salt with a glucuronate anion is disclosed. Methods for preparing the composition using an ammonium ion transmembrane gradient having glucuronate as the counterion are also disclosed. In one embodiment where the protonatable agent is doxorubicin, the method of the invention has comparable loading efficiency, faster release rate, without compromising the therapeutic efficacy compared to loading with an ammonium ion gradient having sulfate as the counterion.09-30-2010
20100247628Skin Treatment Compositions Containing Copper-Pigment Complexes - This invention discloses compositions and method for treating various types of skin disorders, based on topical cutaneous delivery of copper chemically bound with botanical pigments. Sodium-copper-chlorophyllin is used as an example, showing benefits in the treatment of rosacea, acne, oily skin, enlarged pores, and in relieving skin inflammation. Benefits are also disclosed in treatment of environmentally caused premature skin aging, via reductions in fine facial lines and wrinkles, increased tensile strength of the skin, and increased protection against sunlight via increased production of melanin. Therapeutic outcomes are improved when the copper-pigment complex is enclosed within submicron liposomes.09-30-2010
20100247620Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product - This invention is for an improved process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid liposomes. Non-toxic supercritical or near-critical fluids with/without polar cosolvents are utilized to solubilize phospholipid materials and hydrophobic drugs, and form uniform liposomes to encapsulate hydrophobic drugs and hydrophilic drugs.09-30-2010
20100247622TREATMENT REGIME FOR PROLIFERATIVE DISORDERS - Provided herein are methods for treating or ameliorating a proliferative disorder in a subject. The method contains the steps of administering to the subject one dose of an immunosuppressive agent followed by administering to the subject one to five doses of a reovirus. The immunosuppressive agent is administered to the subject at least about 72 hours prior to administration of the reovirus. Also provided herein are methods for treating or ameliorating a proliferative disorder in a subject including the steps of administering to the subject an oncolytic virus and a B-cell modulating agent. Also provided are kits and pharmaceutical compositions containing an oncolytic virus and at least one B-cell modulating agent.09-30-2010
20100247618Novel synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV - The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit protective immune response against HIV infection. Compositions, pharmaceutical compositions and vaccines comprising these antigenic peptides are also encompassed by the present invention, as well as neutralizing antibodies which inhibit infection of primary CD4+ T lymphocytes by various HIV isolates. Methods for diagnosis of HIV are also disclosed.09-30-2010
20100247631PREPARATIONS FOR THE EXTERNAL APPLICATION OF ANTISEPTIC AGENTS AND/OR AGENTS PROMOTING THE HEALING OF WOUNDS - The present invention relates to liposomal pharmaceutical preparations which include active agents such as antiseptic agents, wound-healing agents, or combinations thereof, useful in the treatment of external wounds. The active agents are encapsulated in liposomes, and the liposomes are incorporated in pharmaceutical preparations such as liquids, ointments, gels, lotions, or creams capable of delivering the active agents to external wound sites. The invention further relates to methods of preparation of the liposomes and the pharmaceutical preparations, and to methods of treatment of external wounds and ophthalmic infections.09-30-2010
20100247619Nanostructured Lipid Carriers Containing Riluzole And Phamaceutical Formulations Containing Said Particles - This invention relates to nanoparticles consisting of riluzole trapped in lipids, and their use to prepare medicinal products for the treatment of Amyotrophic Lateral Sclerosis and Multiple Sclerosis.09-30-2010
20090130195PROSTATE CARCINOGENESIS PREDICTOR - A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-ι and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-ι, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-ι levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-ι. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-ι. The compound can be a small interfering RNA (siRNA) molecule.05-21-2009
20090130194Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously - In one aspect, the present invention relates to methods of treating cancer in a patient comprising administering intravenously to a patient in need thereof a cancer treating effective amount of a lipid-complexed platinum compound composition wherein the concentration of the platinum compound of the lipid-complexed platinum compound composition is greater than about 1.2 mg/ml.05-21-2009
20090130191Osteoclast Growth Inhibitor, Oral Composition, and Preventive or Therapeutic Agent for Bone Diseases, Containing Liposome-Encapsulated Lactoferrin - A growth of osteoclasts is inhibited by orally administering a liposomal lactoferrin. Thus a bone disease in which the osteoclast is involved is effectively prevented or treated by orally administering the liposomal lactoferrin. The present invention provides an osteoclast growth inhibitor, an oral composition and a preventive and therapeutic agent for bone diseases (osteoporosis, rheumatoid, periodontal diseases with alveolar bone resorption, which contain the liposomal lactoferrin, and a preventive or therapeutic method for the bone diseases. According to the present invention, the growth of the osteoclasts can be inhibited and the bone diseases due to promotion of the osteoclast growth can be prevented or treated.05-21-2009
20120282324Methods for Promoting the Revascularization and Reenervation of CNS Lesions - The present invention provides methods of promoting the revascularization and/or reenervation of central nervous system lesions using an in-situ crosslinkable hydrogel. The present invention also provides methods of treating a spinal cord injury by topically delivering to the spinal cord injury site a vehicle comprising a neurotrophic factor and/or anti-inflammatory agent. Also provided are methods of treating a spinal cord injury by topically administering or delivering a hydrogel to the injury site.11-08-2012
20120282325LIPOSOME OF IRINOTECAN OR ITS HYDROCHLORIDE AND PREPARATION METHOD THEREOF - A liposome of irinotecan or irinotecan hydrochloride and its preparation method are disclosed. The liposome contains irinotecan or irinotecan hydrochloride, neutral phospholipid and cholesterol, wherein the weight ratio of the cholesterol to the neutral phospholipid is 1:3 to 1:5. The liposome is prepared by an ion gradient method.11-08-2012
20120164214LIPOSOMAL COMPOSITIONS AND USES OF SAME - Compositions comprising liposomes composed of whole cell membrane fraction are provided. The liposomes may be attached to, or encapsulate a pharmaceutical agent. Also provided are methods of generating and using these lipospmes.06-28-2012
20120164212STEM CELL BEACON - The invention relates to methods and compositions for selectively directing stem cells to a target tissue within a subject using a system that employs one or more vectors that contain a gene switch/biosensor, a tissue-specific promoter, a gene encoding a stem cell-attracting chemokine, and a gene amplification system. In one embodiment, a stem cell-attracting chemokine is expressed in damaged tissue using a stimulus-responsive vector system. The stimulus can be a physiological stimulus associated with cell injury, such as hypoxia or elevated glucose levels, for example. Expression of the chemokine increases the trafficking of stem cells to the damaged tissue.06-28-2012
20120128763LUBRICANT FOR THE OCULAR SURFACE - A formulation has been developed for treatment of the symptoms of dry eye which incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear and eyedrop as well as stabilize the eyedrop. The improved performance of the jojoba wax supplemented tear relieves irritation and discomfort as well as sharpens the blurred vision.05-24-2012
20120128761Lipophilic Polynucleotide Conjugates - Disclosed are lipophilic polynucleotide conjugates including polynucleotide-cholesterol conjugates and methods of delivering therapeutic polynucleotides to a mammalian cell or patient in need of treatment using said conjugates. The disclosure further provides methods of synthesizing the lipophilic polynucleotide conjugates. The conjugates are designed to mimic or target cellular miRNAs. The lipophilic moiety, such as cholesterol or cholesterol derivative, is spaced from the polynucleotide by a substantially linear hydrocarbon group. Due to an absence of significantly polar groups and/or exchangeable protons in the vicinity of the lipophilic moiety, the interaction between the lipophilic moiety and cell membranes is enhanced to provide for efficient entry into cells.05-24-2012
20120128755Personal Care Composition Containing Yeast Extract And Hexapeptide - A personal care composition comprising (a) a yeast extract, (b) Hexapeptide-11 (Phe-Val-Ala-Pro-Phe-Pro) (SEQ ID NO:1), and (c) a determatologically-acceptable carrier, wherein the total amount of components (a) and (b) is from about 2 wt % to about 6 wt %, preferably from 4-6% based on the total weight of the personal care composition. Also disclosed is a method for regulating skin conditions by using this composition.05-24-2012
20120128758FORMULATION FOR INDUCING BROADLY REACTIVE NEUTRALIZING ANTI-HIV ANTIBODIES - The present invention relates in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies, and, in particular, to a formulation comprising Toll Like Receptor (TLR) agonists with HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to methods of inducing neutralizing anti-HIV-1 antibodies using such formulations.05-24-2012
20120128759METHOD TO INHIBIT AIRWAY HYPERRESPONSIVENESS USING AEROSOLIZED T CELL RECEPTOR ANTIBODIES - Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system.05-24-2012
20120128756Skin Permeating And Cell Entering (SPACE) Peptides and Methods of Use Thereof - The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.05-24-2012
20120164215TOPICAL CO-ENZYME Q10 FORMULATIONS AND METHODS OF USE - Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.06-28-2012
20120164211COMPOSITIONS AND METHODS FOR TREATING LYMPHOMA - The present invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of leukemias, including acute lymphoblastic leukemia (ALL). The methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, in combination with dexamethasone to a mammal with a leukemia.06-28-2012
20120164210PHOTODYNAMIC THERAPEUTIC AGENT HAVING CELL-SPECIFIC ACTIVE ACCUMULATION PROPERTIES - The present invention relates to a cancer-cell-specific polymer compound containing a photosensitizer for photodynamic therapy and having a surface to which an antibody against a cancer-cell-specific antigen binds. An object of the present invention is to provide a photodynamic therapeutic agent that can reach the cancer tissue at a low concentration via active targeting and makes complications (e.g., sunlight hypersensitivity) associated with photodynamic therapy unlikely to occur.06-28-2012
20120128760LIPID COMPOSITIONS - Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is (F). Also disclosed are methods of producing the cationic lipid of formula (I).05-24-2012
20100209489Formulations of desvenlafaxine - Controlled release formulations of active compounds with pH-dependent solubility are provided. The formulations comprise solubility modulators which minimize the influence of environment on the solubility of the active compounds.08-19-2010
20100209490IMMUNOLIPOSOME INDUCING APOPTOSIS INTO CELL EXPRESSING DEATH DOMAIN-CONTAINING RECEPTOR - The present invention relates to an immunoliposome preparation having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor.08-19-2010
20110182982LIPOSOME TREATMENT OF VIRAL INFECTIONS - One can treat a viral infection such as hepatitis B (HBV), hepatitis C(HCV), and bovine viral diarrhea virus (BVDV) infections via the delivery of pH sensitive liposomes directly into the endoplasmic reticulum (ER) membrane. Two exemplary liposome formulations are DOPE/CHEMS (DC liposomes) and DOPE/CHEMS/PEG-PE (DCPP liposomes). DC and DCPP liposomes can optimize the intracellular delivery of N-butyl deoxynojirimycin (NB-DNJ), and consequently increase the in vivo activity of this iminosugar several orders of magnitude, and could be used in combination with other therapeutic agents such as interferon and/or ribavirin. The optimized release of NB-DNJ directly into the ER can be also applied for the treatment of other viruses, for which NB-DNJ is known to be an effective antiviral, such as human immunodeficiency virus (HIV).07-28-2011
20110182980COMPOSITION FOR SUPPRESSING EXPRESSION OF TARGET GENE - An object of the present invention is to provide a composition for suppressing expression of a target gene, and the like. A composition comprising an RNA-encapsulated liposome, wherein the RNA contains a sequence consisting of 15 to 30 contiguous bases of a target gene mRNA (hereinafter, sequence X) and a base sequence (hereinafter, complementary sequence X′) complementary to the sequence X, 1 to 90% of all sugars binding to the bases of the sequence X and the complementary sequence X′ being ribose substituted by a modifying group at 2′ position, and the lipid particle being capable of reaching a tissue or an organ containing an expression site of the target gene is provide.07-28-2011
20110182981GONOCOCCAL VACCINES - The present invention relates to immunogenic compositions comprising a recombinant 07-28-2011
20110182979In-Vivo Non-Viral Gene Delivery of Human Vascular Endothelial Growth Factor Following Islet Transplantation - An ultrasound-mediated gene transfer method named Ultrasound Targeted Microbubble Destruction (UTMD) for the delivery of human vascular endothelial growth factor (hVEGF) gene to transplanted islets and the surrounding tissue is described herein. The delivery of hVEGF promotes islet revascularization and survival. The inventors, first transplanted human islets were transplanted into diabetic nude mice liver followed by the induction of non-viral plasmid vectors encoding hVEGF or Green Fluorescent Protein (GFP) gene in the host liver by UTMD. Transplantation without gene delivery was also performed as a control. Blood glucose, serum human insulin, C-peptide levels and the revascularization in graft islets were evaluated. The findings of the method of the present invention indicated that hVEGF gene delivery to host liver using UTMD promoted islet revascularization after islet transplantation and improved the restoration of euglycemia.07-28-2011
20110182977TOPICAL COMPOSITION CONTAINING IBUPROFEN - The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and optionally, a hostile biophysical environment. In some cases, the composition may be stabilized using a stabilization polymer such as xanthan gum, KELTROL® BT and/or KELTROL® RD; propylene glycol; and a polysorbate surfactant such as Polysorbate 20, which unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.07-28-2011
20110182976LIPOPLEX-PATCH BASED DNA VACCINE - This invention relates to a DNA vaccine preparation in a patch against virus infection comprising a DNA construct incorporated in a liposome, wherein the ratio of DNA to liposome is from 1:1 to 1:10; wherein the DNA vaccine preparation is preferably administrated after a pretreatment with alpha hydroxyl acids.07-28-2011
20110182975METHOD OF CONFERRING A PROTECTIVE IMMUNE RESPONSE TO NOROVIRUS - The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.07-28-2011
20110182974MULTIMERIC MULTIEPITOPE INFLUENZA VACCINES - The present invention relates to multimeric multi-epitope peptide-based vaccines. In particular, the present invention relates to the use of multimeric multi-epitope peptide-based vaccines eliciting protective immunity to influenza.07-28-2011
20110182973POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS - The invention relates to polymerase inhibitors, particularly polymerase alpha inhibitors, and the use thereof in the treatment of cell growth disorders, particularly tumor disorders, preferably actinic keratoses, basal cell carcinomas, and/or spinocellular carcinomas.07-28-2011
20120164213TIME-RELEASE AND MICRO-DOSE FORMULATIONS FOR TOPICAL APPLICATION OF ESTROGEN AND ESTROGEN ANALOGS OR OTHER ESTROGEN RECEPTOR MODULATORS IN THE TREATMENT OF DRY EYE SYNDROME, AND METHODS OF PREPARATION AND APPLICATION - A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-β-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.06-28-2012
20100068257Sustained Release of Antiinfectives - Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.03-18-2010
20120213845SKIN COMPOSITION COMPRISING AN EXFOLIATE, A BRIGHTENER AND A COLLAGEN BOOSTER, AND METHOD OF USING THE SAME - There is disclosed a composition that provides improved anti-aging benefits and creates a healthier skin using the combination of skin exfoliation, brightening, and collagen synthesis. In one embodiment, the composition comprises, a skin exfoliation ingredient such as citric acid and gluconolactone, at least one skin brightening ingredient, such licorice extract, and at least one collagen enhancing ingredient, such as hydroxyproline, bioactive polypeptides or combinations thereof. Depending on the end-use, various optional ingredients, such as moisturizers, anti-inflammatory agents, UVA/UVB protectants, and cleansers, may be added to the composition, which may take various forms, such as a cream, mousse, serum, or gel.08-23-2012
20120135064CONJUGATED NANODELIVERY VEHICLES - Anti-angiogenesis agent-linked liposomes and micelles, methods of making such liposomes and micelles, and methods of using such liposomes and micelles, such as for delivery of therapeutic and detection agents to tumor cells, are described.05-31-2012
20120135068LIPOSOME-ENCAPSULATED GLUTATHIONE FOR ORAL ADMINISTRATION - The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.05-31-2012
20120135067VACCINE FOR MYCOPLASMA INFECTION - Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, 05-31-2012
20120135066REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO - The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.05-31-2012
20120135063GLUCURONIC ACID-CONTAINING GLUCAN, PROCESS FOR PRODUCTION OF SAME, AND USE OF SAME - An object of the present invention is to provide a uronic acid-containing glucan or a modified product thereof. The glucuronic acid-containing glucan of the present invention is a glucuronic acid-containing glucan in which a glucuronic acid residue is bound to at least one non-reducing end of a glucan, and the glucan is a branched α-1,4 glucan or a linear α-1,4 glucan. The glucuronic acid-containing glucan of the present invention can be provided by allowing α-glucan phosphorylase derived from 05-31-2012
20120219618SPLA2 HYDROLYSABLE LIPOSOMES WITH IMPROVED STORAGE STABILITY - The present invention provides a composition comprising a sPLA2 hydrolysable liposome, an exterior solution, and an interior solution within the liposome, -wherein the concentration of osmolytes is higher in the interior solution than in the exterior solution. The composition improves storage stability of sPLA2 hydrolysable liposomes, in particular at when stored at 2-8 degrees Celsius. The liposome preferably encapsulates cisplatin. The invention also provides methods of preparing the composition of the invention.08-30-2012
20120219615Therapeutic Use of a TLR Agonist and Combination Therapy - The present invention is directed generally to formulations of a TLR agonist preferably a TLR8 agonist, and its use in the treatment of various diseases, including combination therapies for treating cancer.08-30-2012
20120219616LIPOSOMAL REDUCED GLUTATHIONE AND l-ARGININE, INCLUDING WITH OTHER INGREDIENT(S), CAPABLE OF MULTIPATH ADMINISTRATION FOR REVERSAL AND PREVENTION OF OBESITY AND FOR MITOCHONDRIAL BIOGENESIS - The invention enables management of mammalian disease related to decreased energy production in the mitochondria by a combination of liposomal reduced glutathione and 1-arginine. For individuals whose inability to lose weight is related to inefficiency of the biochemical pathways facilitating mitochondrial function and energy production, the invention proposes to assist in weight loss by improving the inefficient production of energy by the respiratory transport chain of mitochondria. The invention is useful for the management of the metabolic syndrome, a group of metabolic factors associated with an increased risk of vascular disease problems. The invention is also useful for the resolution of fatigue that accompanies both weight gain and illnesses. The ability of the invention to increase the production of the biochemical agmatine in the central nervous system as well as generally in the body is part of the benefit of the combination of liposomal reduced glutathione and 1-arginine.08-30-2012
20120219613Novel Antiviral Agents for Enveloped Viruses - Provided herein are a series of arylmethylidene rhodanine derivatives having broad-spectrum antiviral activity against enveloped viruses, including but not limited to filoviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses, influenza A, and HIV-1. The compounds act via a novel mechanism to disrupt viral membranes and inhibit viral attachment, fusion, and/or entry into host cells. The membrane disrupting activity of the compounds is selective for viral membranes relative to other biological membranes, making the compounds non-toxic to cells and host subjects.08-30-2012
20120219614METHODS AND COMPOSITIONS FOR PREVENTING A CONDITION - Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can comprise a nucleic acid sequence encoding an antigen fused to an immune cell product, e.g., MIP-3α, and an adjuvant. The antigen can be from a bacteria, virus, fungus, parasite, or cancer. The antigen can be an Alzheimer's disease antigen.08-30-2012
20120135065Amphoteric Liposomes, A Method Of Formulating An Amphoteric Liposome And A Method Of Loading An Amphoteric Liposome - An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there is a stoichiometric excess of positively charged cationic amphiphile at a first lower pH, a stoichiometric excess of negatively charged anionic amphiphile at a second higher pH and said mixture has an isoelectric point intermediate said first and second pHs; characterised in that said positively charged cationic and negatively charged anionic amphiphiles are adapted to form a lipid salt with one another at said isoelectric point. Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety.05-31-2012
20120213844LIPOSOME COMPOSITION FOR TARGETING EGFR RECEPTOR - Short oligopeptides are provide which are capable of binding to the epidermal growth factor receptor on the surface of human tumor cells. Methods for using the peptides as targeting moieties in more complex compositions, such as conjugates of cytoxins, and/or structures, such as liposomal structures, for the purposes of drug delivery are also provided.08-23-2012
20100330158PROTEIN-ASSISTED DRUG DELIVERY SYSTEM FOR THE TARGETED ADMINISTRATION OF ACTIVE AGENTS - The present invention provides a composition and prodrug for targeted drug delivery to the central nervous system of a patient. The inventive composition and prodrug include a pharmaceutically acceptable active agent and at least one protein selected from the group consisting of a fimbrial adhesin protein, a membrane protein, and combinations thereof. The inventive compositions and prodrugs of the present invention selectively target the blood-brain barrier and deliver hydrophilic and lipophilic active agents of varying sizes to the central nervous system.12-30-2010
20100172967COMPOUND MODIFIED WITH GLYCEROL DERIVATIVE - Objects of the present invention are to provide a compound which is useful as a surface modifier for producing a drug carrier or the like, or a salt thereof; a fine particle comprising the same; and the like. The present invention provides a compound in which a substance to be modified, which is selected from the group consisting of an amphiphilic substance and a hydrophobic substance, is modified with a glycerol derivative represented by the following formula (1):07-08-2010
20100172965ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES - Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.07-08-2010
20100172962THERAPEUTIC TARGETING OF INTERLEUKINS USING SIRNA IN NEUTRAL LIPOSOMES - The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides compositions that include an siRNA targeted to an interleukin and a neutral lipid, and methods of treating a human subject with cancer involving administering to the subject a pharmaceutically effective amount of an interleukin-8 antagonist or a composition as set forth herein.07-08-2010
20100172966Methods and compositions for cellular reprogramming - Compositions and methods useful for the treatment of aberrant programming diseases, particularly those associated with aberrant apoptosis are disclosed07-08-2010
20120219617MUC1 Based Glycolipopeptide Vaccine with Adjuvant - Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.08-30-2012
20120251620Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof - Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.10-04-2012
20120251616Tocopherols, Tocotrienols, Other Chroman and Side Chain Derivatives and Uses Thereof - The present invention provides an antiproliferative compound having a structural formula10-04-2012
20120251614PROCESSED FEEDS, FOODS AND BIOFUELS AND METHODS OF MAKING AND USING THEM - In one aspect, the invention provides methods for manufacturing, processing and recovering organic matter from a biomass, e.g., a biofluid or biosemisolid comprising a protein and a lipid, for example, from a dairy-based material. In one aspect, the invention provides methods for encapsulating oils with proteins for, e.g., making foods, food supplements or additives and feeds or feed supplements or additives. Compositions made by processes of this invention can be used for foods, food supplements or additives, feeds or feed supplements or additives, and/or biofuels.10-04-2012
20120171283Liposomes Useful for Drug Delivery - The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provides methods of making the liposome compositions provided by the present invention.07-05-2012
20120171281Novel Formulations of Volatile Anesthetics and Methods of Use for Reducing Inflammation - The present invention provides methods for treating inflammation or a wound in a subject in need of such wound treatment or inflammation treatment by delivering a volatile anesthetic to the wound or the inflammation site.07-05-2012
20120171280METHOD OF MAKING LIPOSOMES, LIPOSOME COMPOSITIONS MADE BY THE METHODS, AND METHODS OF USING THE SAME - A method of preparing liposomes, liposome compositions formed by the process, and methods of using the liposome composition are provided herein.07-05-2012
20120171279STRONGLY BOUND BASE-MODIFIED OLIGONUCLEOTIDES - The present invention provides compounds having a chelating moiety and an oligonucleotide sequence wherein the oligonucleotide includes one or more modified nucleobases, such as hydroxynucleobases. The disclosed compounds are suitable for antisense therapy. The chelating moiety can be complexed to an ion of a lanthanide metal. These compounds are efficient translation inhibitors of nucleic acids and have increased binding affinity for target nucleic acids. The invention also includes compositions and methods of using these compositions as antisense therapy.07-05-2012
20120251615AGENT FOR INTRA-ARTICULAR INJECTION - The present invention relates to agents for intra-articular injection that contain a mixture of alpha-tocopherol, phospholipids or poloxamers, proteoglycans, and a cortisone crystal suspension or a cortisone crystal solution. The agents are suitable for therapy of rheumatic diseases, in particular of arthrosis.10-04-2012
20100062055LIPID-BASED NITRIC OXIDE DONORS - Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglyerols, (d) diacylglycerols, (e) glycosylacylglycerols, and (f) sterol compounds of the formula:03-11-2010
20090074849Cancer-suppressing agents - It is an object of the present invention to provide a cancer-suppressing agent comprising a novel cancer-suppressing gene based on the discovery of such cancer-suppressing gene. The present invention provides a cancer-suppressing agent which comprises NR1I2 gene or a homologous gene thereof; and a cancer-suppressing agent which comprises NR1I2 protein or a homologous protein thereof.03-19-2009
20120076853COMPOSITION FOR USE IN GENE THERAPY - A composition useful in gene therapy and a method of treatment to effect gene therapy is provided. In particular, a parenteral pharmaceutical gene therapy composition comprising a non-immunogenic net polyanionic oligosaccharide associated with a particulate complex of an anionic nucleic acid material and a cationic macromolecule, optionally together with at least one pharmaceutical carrier or excipient, is provided.03-29-2012
20120076852DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS - An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.03-29-2012
20120076851CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS - Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.03-29-2012
20100255076COMPOSITION AND METHOD FOR DERMAL REGENERATION - The present invention relates to glucommannan oligosaccharides and polysaccharides that possess one or more properties selected from skin regeneration, wound healing and skin augmentation. More particularly, the invention relates to the use of glucomannan oligosaccharides and polysaccharides for one or more of skin regeneration, wound healing and skin augmentation agents in a mammal. The invention also relates to a pharmaceutical formulation for treating skin of a subject comprising an active component comprising glucomannan in a suitable diluent, excipient or physical form such as dermal scaffold or sponge, the active component being capable of promoting an accumulation of fibroblasts in the skin and stimulating production of collagen in the skin.10-07-2010
20100047330TREATMENT FOR DARK ADAPTATION - The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.02-25-2010
20100047336INHIBITION OF BRAIN ENZYMES INVOLVED IN CEREBRAL AMYLOID ANGIOPATHY AND MACULAR DEGENERATION - A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the macula of the patient.02-25-2010
20100047334PH SENSITIVE LIPOSOME COMPOSITIONS FOR CONTROLLING SURFACE TOPOGRAPHY AND BINDING REACTIVITY IN FUNCTIONALIZED LIPOSOMES - Methods for controlling surface topography and binding reactivity in functionalized lipid layers, including in the form of liposomes, using pH-dependent processes. During direct cell-to-cell communication, lipids on the extracellular side of plasma membranes reorganize, and membrane associated communication-related molecules co-localize. At co-localization sites, sometimes identified as rafts, the local cell surface topography and reactivity are altered. Integration of these processes on nanometer-sized lipid vesicles used as drug delivery carriers would precisely control their interactions with diseased cells minimizing toxicities. Included are pH-dependent processes on functionalized lipid bilayers demonstrating reversible sharp changes in binding reactivity within a narrow pH window. Cholesterol enables tuning of the membrane reorganization to occur at pH values not necessarily close to the reported pKa's of the constituent titratable lipids. One illustrative function of the invention is to use liposomes to deliver bioactive agents to cancer or tumor cells and compositions of specific lipids that form liposomes to deliver a biologically active agent.02-25-2010
20100047333Modified Peptides and Their Use for the Treatment of Autoimmune Diseases - Disclosed herein are a modified peptide, compositions containing the same and their use in the treatment of autoimmune diseases. The modified peptide is provided by a chemical modification of at least one of the several amino acid residues comprising the peptide. The modification is carried out by phosphorylation, acetylation or methylation, or as a combination thereof.02-25-2010
20100047331METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.02-25-2010
20100047329Novel Vaccination Carrier - An object of the present invention is to prepare novel vaccine carriers that can be used to produce vaccines that are capable of efficient induction of humoral and cellular immune responses. Another object of the present invention is to provide vaccines that are capable of efficient induction of humoral and cellular immune responses.02-25-2010
20100278907Immunogenic Compositions Containing Ceramide and Methods of Use Thereof - Immunogenic compositions containing ceramide or ceramide analogs for treating or reducing the risk of developing one or more symptoms of a disease or disorder associated with ceramide-induced cell death are provided. The immunogenic compositions contain immunogenic ceramide, and, optionally, pharmaceutically acceptable excipients and one or more additional adjuvants. Methods of using the disclosed immunogenic ceramide compositions for reducing ceramide-induced cell death are provided. Methods of using the disclosed immunogenic ceramide compositions therapeutically or prophylactically for treating or reducing the risk of developing one or more symptoms of a disease or disorder associated with ceramide-induced cell death are also provided.11-04-2010
20120177723SiRNA PHOSPHOLIPID CONJUGATE - siRNA-conjugated liposomes and micelles, methods of making such conjugates, and methods of using such conjugates, such as for the delivery of siRNA to cells to reduce expression of target polypeptides in such cells, are described.07-12-2012
20120177726MEDICAL USE OF SPLA2 HYDROLYSABLE LIPOSOMES - The present invention relates to medical use of liposomes, more particular the first medical use of sPLA2 hydrolysable liposomes. Such liposomes may be used for targeted delivery of therapeutic agents to cancerous tissue and in such embodiments; the therapeutic agents are typically small molecule antitumor agents. Other aspects of the inventions relates to methods of reducing the side effects of therapeutic agents, e.g. reducing nephrotoxicity, neurotoxicity and gastrointestinal toxicity of a therapeutic agent. Yet another aspect of the present invention relate to methods of prolonging the therapeutic effect of a therapeutic agent.07-12-2012
20120177725PREPARATIONS FOR THE EXTERNAL APPLICATION OF ANTISEPTIC AGENTS AND/OR AGENTS PROMOTING THE HEALING OF WOUNDS - The present invention relates to liposomal pharmaceutical preparations which include active agents such as antiseptic agents, wound-healing agents, or combinations thereof, useful in the treatment of external wounds. The active agents are encapsulated in liposomes, and the liposomes are incorporated in pharmaceutical preparations such as liquids, ointments, gels, lotions, or creams capable of delivering the active agents to external wound sites. The invention further relates to methods of preparation of the liposomes and the pharmaceutical preparations, and to methods of treatment of external wounds and ophthalmic infections.07-12-2012
20120177724LIPID VESICLE COMPOSITIONS AND METHODS OF USE - The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles comprise terminal-cysteine-bearing antigens or cysteine-modified antigens, at their surface and/or internally.07-12-2012
20120177722Lyaseenzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them - This invention provides polypeptides having lyase activity, polynucleotides encoding these polypeptides, and meth-°ds of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having ammonia lyase activity, e.g., phenylalanine ammonia lyase, tyrosine ammonia lyase and/or histidine ammonia lyase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.07-12-2012
20120177721FORMULATION - The present invention relates, in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies and, in particular, to a formulation comprising a prehairpin intermediate form of HIV-1 envelope gp41 linked to a liposome. The invention also relates to methods of inducing broadly neutralizing anti-HIV-1 antibodies using such a formulation.07-12-2012
20120315320USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS - Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.12-13-2012
20100272789EXTERNAL MEDICINE FOR TREATMENT OR PREVENTION - An external medicine includes an active hydrogen generating agent, which generates active hydrogen by bringing multiple agents into contact, and/ or an active hydrogen generating agent, which activates generated hydrogen molecules.10-28-2010
20100272788VACCINES FOR MALARIA - The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. Furthermore, particles with the specific ratio can be prepared by employing yeast, 10-28-2010
20100272787AMETHOD OF TREATING NEURODEGENERATIVE DISEASES - This invention provides compositions and methods for treating a subject suffering from a disease or disorder of the nervous system, associated with an inflammatory response. This invention further provides a pharmaceutical composition comprising, inter alia, an agent which increases brain levels of interferon-γ; and an agent which reduces the number of brain T regulatory (Treg) cells, and optionally further comprising an agent which suppresses neurotoxic inflammatory brain responses.10-28-2010
20100272785RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES - Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated cytokine IFN-α.10-28-2010
20100028418GAINAC SPECIFIC BINDING MOLECULES AND USES THEREOF - The present invention provides among others means and methods for detecting terminal GalNAc containing molecules. A preferred molecule for detecting said structures is a molecule comprising a carbohydrate binding part of MGL.02-04-2010
20100008981METHODS AND SEQUENCES TO SUPPRESS PRIMATE HUNTINGTON GENE EXPRESSION - Disclosed herein are sequences, molecules and methods used to suppress the expression of HD genes encoding for huntingtin protein in primates including 01-14-2010
20100008980Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with Surgery, Chemotherapy or Radiotherapy for the Treatment of Cancer - A combination therapy comprising an immunotherapy based on a tumour antigen or an immunological derivative thereof, and at least one other treatment for cancer such as chemotherapy, radiotherapy and/or surgery.01-14-2010
20100008979DELIVERY OF THERAPEUTIC AGENTS TO THE BONE - This invention relates to compositions and methods of delivering therapeutic agents to bone. More specifically, the invention relates to endowing a large molecule vectors i.e., adeno virus, retrovirus, liposomes, micelles, natural and synthetic polymers, or combinations thereof, with the ability to target bone tissue in vivo and with improved stability in the blood, by attaching multiple copies of acid amino acid peptides. One preferred embodiment of the invention relates to endowing an adeno-associated virus (AAV) vector with the ability to target bone-tissue in vivo and improve its stability, by the addition of multiple acidic amino acid peptides attached to the capsid of the viral vector.01-14-2010
20100008978NANOPARTICLES EFFECTIVE FOR INTERNALIZATION INTO CELLS - This invention provides antibodies that have improved affinity for the epidermal growth factor receptor (EGFR). In addition, this invention provides microparticles and nanoparticles comprising a plurality of EGFR affinity moieties that are effectively internalized by cells expressing an EGFR.01-14-2010
20100008975Predicting response to a HER inhibitor - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab.01-14-2010
20090068256Encapsulation of Bioactive Complexes in Liposomes - This invention provides a method to prepare liposome-encapsulated bioactive agents, such as nucleic acids, comprising complexation of the bioactive agents to reverse micelles prior to forming liposomes, as well as methods of using the liposomes so formed and formulations to deliver nucleic acids to cells.03-12-2009
20090232884Composition and method for treatment of the side-effects associated with administration of cancer chemotherapeutic agents - A composition and method for the treatment of the side-effects associated with the administration of cancer chemotherapeutic agents involves the oral ingestion of cationic liposomes containing the substrates orotate, UMP and AMP. The cationic liposomes bind to the cells lining the mucosa of the intestinal tract and then the contents of the cationic liposome are then taken up in the interior of the cells to prevent the metabolism or anabolism of the cancer treatment drug 5-FU into a toxic species.09-17-2009
20090060992Preparation of magneto-vesicles with DOPE/DDAB layers - Magneto-vesicles with two different surfactants, i.e., Dioleoyl phosphatidylethanolamine (DOPE) and dimethyl dioctadecylammonium bromide (DDAB), were synthesized using size controllable magnetite nanoparticles (D03-05-2009
20090060991GLUTATHIONE BASED DELIVERY SYSTEM - A delivery system. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative.03-05-2009
20090060990NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY - The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDS) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the other system component with such activity being typically a surfactant. In contrast, the remaining amongst said at least three amphipatic components typically forms a stable lipid membrane on it's own. An essential characteristics of the resulting, relatively large, aggregates is an improved ability to penetrate pores, in a semi-permeable barrier, at least 30%, and often much smaller than the average diameter of the complex aggregate. This enables said aggregates to mediate NSAID transport through semi-permeable barriers including mammalian skin. As a result of the skin penetration by NSAID loaded large aggregates, the drug delivered transcutaneously with such carriers gets deeper into the tissue than the corresponding NSAID from a solution on the skin surface. This is believed to be due to the special ability of suitable large carriers to bypass the local sink of blood capillaries at the epidermal-dermal junction in the skin. The carrier-mediated delivery of locally applied NSAIDs thus allows therapy of deep tissues under the drug administration site, which is medically highly desirable.03-05-2009
20090060988Nell-1 enhanced bone mineralization - The present invention provides Nell-1 genes and gene products and pharmaceutical compositions comprising the same that promote bone mineralization and osteoblast differentiation. The Nell-1 genes and gene products also represent targets for screening for modulators of bone mineralization and osteoblast differentiation. In addition, Nell-1-associated compounds and compositions can be used to increase bone density and facilitate repair of bone fractures.03-05-2009
20090060987DEVICES, SYSTEMS AND METHODS FOR IMPROVING MEMORY AND/OR COGNITIVE FUNCTION THROUGH BRAIN DELIVERY OF SIRNA - The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions to the brain, or using devices, systems, methods of delivery, and compositions that deliver small interfering RNA or vectors containing the DNA encoding the small interfering RNA across the blood-brain barrier. The present invention also provides valuable small interfering RNA vectors, and methods for reduction of BACE1 levels in the hippocampus, cerebral cortex, or other regions of the brain that have beneficial effects on improving memory and/or cognitive function in a subject.03-05-2009
20120315321IMMUNOLOGICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to immunogenic compositions and peptides comprising residues 4-10 (FRHDSGY) of the amyloid peptide Abeta12-13-2012
20120315324EXOSOMAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE - An exosomal composition is provided that comprises a therapeutic agent encapsulated by an exosome. The therapeutic agent can be a phytochemical agent, a chemotherapeutic agent, or a Stat3 inhibitor. Pharmaceutical compositions comprising the exosomal compositions are also provided. Methods for treating an inflammatory disease or a cancer are further provided and include administering an effective amount of an exosomal composition to a subject in need thereof to thereby treat the inflammatory disorder or the cancer.12-13-2012
20120315323INFLUENZA HEMAGGLUTININ ANTIBODIES, COMPOSITIONS AND RELATED METHODS - Antibodies against influenza hemagglutinin, compositions containing the antibodies, and methods of using the antibodies are provided herein.12-13-2012
20090324698LIPOSOMAL COMPOSITION COMPRISING AN ACTIVE INGREDIENT FOR RELAXING SMOOTH MUSCLE, THE PRODUCTION OF THIS COMPOSITION AND THE THERAPEUTIC USE THEREOF - The invention relates to a pharmaceutical composition made from an active ingredient included in liposomes for topical application, whereby the liposomes have an aqueous medium in the interior thereof and contain at least one active ingredient therein which exerts a direct or indirect relaxing effect on smooth musculature and is preferably selected from the group of prostaglandins, adenylate cyclases, cAMP, AMP, ATP, NO-synthetases, nitrogen monoxide (NO), NO compounds, nitrates, guanylate cyclases, cGMP, GMP, GTP and phosphodiesterases, in particular, Sildenafil. The invention further relates to a method for production of said composition, optionally, in sterile form and the use of the liposomes supporting the active ingredient in various galenic forms for external application in the genital region, for prophylaxis and/or therapy of sexual disorders in men or women and/or for increase of sexual sensitivity.12-31-2009
20100266675LIPOPROTEINS, LIPOPEPTIDES AND ANALOGS, AND METHODS FOR MAKING AND USING THEM - The invention provides novel compositions—lipopeptides and analogs, including somocystinamide A, and somocystinamide A variants and analogs, and pharmaceutical compositions, liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these lipopeptides and analogs are used to induce apoptosis in a cell, which can be a normal cell, a dysfunctional cell and/or a cancer (tumor) cell. In alternative embodiments, the compositions of the invention, including the lipopeptides and analogs of the invention, and the pharmaceutical compositions comprising them, are used to treat or ameliorate (including slowing the progression of) normal, dysfunctional (e.g., abnormally proliferating) and/or tumor associated blood vessels, including endothelial and/or capillary cell growth; including neovasculature related to (within, providing a blood supply to) a tumor.10-21-2010
20120263781METHODS AND COMPOSITIONS FOR TREATING RHINITIS - Improved efficacy in treatment of rhinitis with botulinum toxin is obtained using liposomal encapsulated botulinum formulations for administration of the botulinum toxin. The liposomes are typically administered in a physiologically acceptable carrier such as saline or phosphate buffered saline by instillation into the nasal passages.10-18-2012
20120263782METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION - A method for treating latent HIV infection is disclosed. The method includes administering to a subject in need of such treatment an effective amount of an anti-IκBα agent, an anti-IκBε agent or both; and administering to the subject an effective amount of an antiviral agent. A pharmaceutical composition for treating latent HIV infection is also disclosed.10-18-2012
20120263784EMERGENCY CONTRACEPTIVE - The present invention discloses an emergency contraceptive formulation for nasal and/or pulmonary administration comprising of levonorgestrel optionally in combination with ethylestradiol. The said formulation can be in form of solution, suspension or carrier based systems selected from microemulsion and liposomes.10-18-2012
20130017247TREATMENT AND/OR PREVENTION OF ORAL ALLERGIC SYMPTOMS CAUSED BY ORAL CONTACT WITH FRUITS AND/OR VEGETABLES - Treatment or prevention of oral allergy syndrome, or other allergy-related oral inflammatory processes using a topical preparation of at least one of a mast cell stabilizer and an antihistamine is disclosed. For example, the topical administration of Cromolyn Sodium prior to ingestion of raw fruits and raw vegetables may be used to prevent oral allergy symptoms. The topical administration can be performed by use of a solution, a powder, an aerosol, a tablet, a chewable tablet, a gel, a melting strip, a mouth rinse, a mouth swab, or a piece of candy, and may be combined with carrier molecules and/or mucoadhesive molecules to enhance efficacy.01-17-2013
20120263783SINGLE MOLECULE NUCLEIC ACID NANOPARTICLES - The present technology relates to a nanoparticle platform based on the unique and varied properties of DNA. Circular DNA can be replicated using a strand displacing polymerase to generate long linear concatamers of controllable length that spontaneously fold into a ball conformation due to internal base-pairing. These balls of DNA are discreet particles that can be made in variable sizes on a nanometer size scale in a scalable manner. The particles can be used in a variety of manners, discussed herein, including specific targeting, drug delivery to cancer cells, and diagnostics. Nanoparticles may also serve as multifunctional platforms for the integration of many currently used cancer therapeutic techniques.10-18-2012
20120258165PHOSPHOLIPID DERIVATIVE AND PH-RESPONSIVE LIPOSOMES - A phospholipid derivative represented by the following formula (1)10-11-2012
20120082717COMPLEX, MULTILAYER USING THE SAME, AND DEVICE COATED WITH THE MULTILAYER - Disclosed herein is a complex, wherein micelles and/or liposomes dispersed in hyaluronic acids and/or hyaluronic acid derivatives, with a drug and/or functional material loaded in the micelles and/or the liposomes. The complex can release the drug and/or functional material in a controlled manner. Also, a multilayer using the complex, and a device coated with the multilayer are disclosed herein.04-05-2012
20120082716Cytotoxic agents - A method of killing a cell that is lacking in effective p53 protein activity, particularly as compared to wild type, is provided characterised in that it comprises delivering to the cell a single stranded DNA including a portion with at least one base, internally located with respect to any 3′ and 5′ ends of the DNA, that is unbasepaired with another base in a form that is capable of being internalised by the cell.04-05-2012
20120189691DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS - An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.07-26-2012
20120189690Liposomes covered with the Extracellular Domain of the APO2L/Trail Protein - The invention relates to the field of biotechnology and medicine. The invention specifically relates to a compound comprising a liposome covered or decorated at least with the extracellular domain of the APO2L/TRAIL protein, and to the use thereof far developing a medicament preferably for the treatment of a cancer or inflammatory or autoimmune diseases, such as rheumatoid arthritis.07-26-2012
20120189689ACOUSTICALLY SENSITIVE DRUG DELIVERY PARTICLES COMPRISING NON-LAMELLAR FORMING PHOSPHATIDYLCHOLINE - Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon exposure to acoustic energy.07-26-2012
20120189687Compositions and Methods for Topical Application of Growth Factors and Cytokines - A composition for therapeutically enhancing skin health by allowing growth factors derived from stem cells or fibroblasts to penetrate within the epidermis to increase the proliferation, growth and differentiation of skin cells. The composition includes at least one and preferably plural growth factors that are encapsulated within liposomes. Cytokines may also be encapsulated as well. The liposomally encapsulated growth factors and/or cytokines are able to penetrate into the basal skin cell layer to attach to the skin cells or penetrate through the follicles to reach the dermis.07-26-2012
20090017108Liposome compositions for treatment of hepatitis C - In the present invention compositions and methods are described for treating patients with a hepatitis C viral infection typically using interferon-alpha and/or ribavirin which are incorporated into liposomes, wherein the liposomes typically contain at least one carbohydrate moiety on the surface, such as a mono-, di-, oligo-, or polysaccharide moiety or any combination thereof, for targeting to hepatocytes. Other liposome surface modifications are provided to enhance effectiveness of the compound(s) therein.01-15-2009
20090017103Antisense oligonucleotides for prevention of metastasis formation of cancer cells - Described are antisense oligonucleotides targeted to the gene encoding osteopontin, bone sialoprotein II and/or osteonectin, wherein said oligonucleotides inhibit the expression of said gene(s). Moreover, the therapeutic use of said antisense oligonucleotides is described, e.g., for the treatment or prevention of cancer/metastasis, preferably osteolytic metastasis or metastasis of breast cancer cells.01-15-2009
20090017106ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS - The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new conjugates of the bisacyloxycysteine type useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.01-15-2009
20090017105PROLIPOSOMAL AND LIPOSOMAL COMPOSITIONS OF POORLY WATER SOLUBLE DRUGS - Concentrates or proliposomal compositions of poorly water-soluble drugs and compounds, comprising of one or more membrane forming lipids, a membrane stabilizing agent, in a suitable vehicle, and optionally containing a Polyethylene Glycol (PEG)-coupled phospholipid or a mixture thereof and further, optionally containing pharmaceutically acceptable excipients such as antioxidants, buffering agents, acidifying agents etc. are provided, which have superior long term stability. The concentrates of proliposomal compositions instantly form liposomes of the said poorly water-soluble drugs and compounds on rapid injection to a diluting fluid, the liposomal composition so obtained, characterized by a physical stability more than 24 hours, ≧95% drug encapsulation and having a particle size diameter of less than 100 nm. The liposomal compositions so obtained can further be directly administered to patients in need of treatment of the poorly water-soluble drugs and compounds.01-15-2009
20090017104COMPOSITIONS CONTAINING RETINOID AND BETA-AMINOISOBUTYIC ACID DERIVATIVES - The present invention relates to a composition including at least one retinoid and at least one beta-aminoisobutyric acid derivative and the use thereof for the preparation of an article to be used for the topical application to skin, hair or nails.01-15-2009
20110123603ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.05-26-2011
20110123602MOLECULAR LYMPHATIC MAPPING OF SENTINEL LYMPH NODES - The present invention describes a method for identification and labeling of sentinel lymph nodes (SLNs) and the presence or absence of lymph node metastases as an important diagnostic and prognostic factor in early stage cancers of all types. The method, know as Molecular Lymphatic Mapping, uses traditional dye/radioactive tracer based techniques in conjunction with a nucleic acid marker to identify and label the SLN, not only for current diagnostic methods, but for archival purposes. In addition, MLM can be used to deliver a therapeutic gene or genes to the SLN to activate tumor immunity to tumor cells, and/or to inhibit tumor metastases. The methods may be combined with therapeutic intervention including chemotherapy and radiotherapy.05-26-2011
20110123600Use of alkylureas for treating acne - Methods of treating acne are provided. The methods involve applying to the acne an alkyl urea in a pharmaceutically acceptable carrier. The use of an alkyl urea in the manufacture of a medicament for the treatment of acne is also provided. Compositions of alkyl ureas in a pharmaceutically acceptable carrier are additionally provided.05-26-2011
20120231071NATURAL PRODUCT INHIBITORS OF 3DG - Compositions are disclosed which have as a component thereof an inhibitor of the enzymatic production of 3-deoxyglucosone (3DG) from fructoselysine and/or an inactivator of 3DG, and which are useful for the treatment or prophylaxis of a condition or disease state that is alleviated by inhibiting such 3DG production. Methods of using such compositions, e.g., for improving the appearance, texture and/or elasticity of aging skin, are also disclosed.09-13-2012
20120231070SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS - The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multi vesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.09-13-2012
20120231069Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes - Disclosed herein are nanoparticle, micelle and/or liposome compositions, each comprising a therapeutic agent encapsulated in one or more polymer(s), wherein a vitamin B12 or a derivative thereof is attached to the one or more polymer(s) via a linker group, as well as methods for making and using same.09-13-2012
20120231068VIRUCIDAL PROPERTIES OF VARIOUS FORMS OF SOPHOROLIPIDS - A method for neutralizing or inactivating a virus, and neutralizing or inactivating HIV using sophorolipids having antiviral properties produced by synthesizing the sophorolipid by fermentation of 09-13-2012
20120231066Multi-drug liposomes to treat tumors - A process for treating tumors by administering a mixture of cancer fighting drugs incorporated into a stabilized liposomal formulation. Each cancer drug is selected to target a different phase of the cell-cycle of the cancer cell thus expanding the number of cancer cells that can be killed at one time without compromising the safety of the patient. The stabilized multi-drug liposomes are designed to extravasate thru “leaky” blood capillaries supplying the tumor and enter the tumor tissue where they will accumulate over time and ultimately released to kill surrounding tumor cells. The multi-drug liposomes are likewise unable to extravasate thru normal blood capillaries and will thus be less toxic to normal tissues.09-13-2012
20120231067VESICLE COMPOSITIONS - Vesicle compositions are provided that comprise a therapeutic compound. The vesicle compositions may be capable of releasing the therapeutic compound in response to the presence of an external trigger. The vesicle compositions may comprise a plurality of biocompatible vesicles. The biocompatible vesicles may comprise a therapeutic compound for treatment of a patient in need thereof, and one or more cross-linkages between two or more of the biocompatible vesicles, each cross-linkage comprising a chemical sensing moiety and a sensed moiety. In some embodiments, the therapeutic compound may be any compound that provides palliative, curative, or otherwise beneficial effects to a patent.09-13-2012
20120231065METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOEITIC GROWTH FACTORS - The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.09-13-2012
20110002983COMPOUND - The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein R01-06-2011
20110002982LIPID CARRIER COMPOSITIONS WITH ENHANCED BLOOD STABILITY - Liposomes that contain at least 10 mol % of a negatively charged lipid coupled to a non-zwitterionic moiety are stable in the blood. Liposomes containing at least 1 mol % of such lipids may be frozen safely.01-06-2011
20110002981MCPIP Protection Against Cardiac Dysfunction - Disclosed herein are methods and compositions of treating a patient at risk of experiencing sepsis induced cardiac dysfunction. In exemplary examples, the method involves elevating MCPIP levels in a patient in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP).01-06-2011
20110002980VACCINES USING NUCLEIC ACID-LIPID COMPLEXES - This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.01-06-2011
20110002979STYRENE MALEIC ANHYDRIDE BASED FORMULATION FOR MALE CONTRACEPTION AND PROSTATE CANCER - The invention provides a styrene maleic anhydride based synergistic formulation comprising styrene maleic anhydride [SMA] having lower molecular weight and styrene maleic anhydride [SMA] having higher molecular weight dissolved in DMSO, and being capable of preventing the prostate cancer as well as causing male contraception even when administered in smaller doses for one or two administrations in the life time and predominantly causing no or minimal side effects, and still being reasonably affordable by common man, and the formulation being capable of traveling along the vas deferens after causing male contraception in the vas deferens to the prostate gland and getting absorbed into the epithelial zone of the prostate gland.01-06-2011
20110002977LIPOSOMAL PHARMACEUTICAL PREPARATION AND METHOD FOR MANUFACTURING THE SAME - The present invention relates to a liposomal pharmaceutical preparation containing a multivalent ionic drug, a process for the preparation of the liposomal pharmaceutical preparation, and a use thereof in the treatment of diseases, in which the liposome has a size of about 30-80 nm, and the phospholipid bilayer has a phospholipid with a Tm higher than body temperature, so that the phase transition temperature of the liposome is higher than the body temperature.01-06-2011
20120237592ENDOPLASMIC RETICULUM TARGETING LIPOSOMES - Provided are compositions that include lipid particles, such as liposomes, that can fuse with the ER membrane of a cell. The lipid particles can also deliver a cargo, such as a therapeutic or an imaging agent, encapsulated inside the particles inside the ER lumen of the cell. The compositions can be useful for treating and/or preventing diseases or conditions caused by or associated with a virus, such as viral infections, including HIV and HCV infections.09-20-2012
20120328694THERAPEUTIC AGENT FOR FIBROID LUNG - Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent.12-27-2012
20120328693METHOD FOR ENHANCING IMMUNE RESPONSE IN THE TREATMENT OF INFECTIOUS AND MALIGNANT DISEASES - The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new DNA and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response.12-27-2012
20120328691ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.12-27-2012
20120328692POTENT D-PEPTIDE ANTAGONISTS OF MDM2 AND MDMX FOR ANTICANCER THERAPY - The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.12-27-2012
20110038924OSTEOARTHRITIS GENE THERAPY - The present invention relates to methods and compositions for protecting joint cartilage from degradation by inserting transgenes that increase Kras-2b expression or an effector thereof within one or more tissues of the joint. The present invention can thus be used in the treatment and/or prevention of joint diseases and disorders, including but not limited to osteoarthritis.02-17-2011
20110038923ADIPOCYTE-SPECIFIC CONSTRUCTS AND METHODS FOR INHIBITING PLATELET-TYPE 12 LIPOXYGENASE EXPRESSION - The present invention is directed to constructs, compositions and methods for modulating platelet-type 12 lipoxygenase (12-LO) in adipose tissue in vivo. Specifically, the invention provides constructs encoding expression-inhibiting oligonucleic acids, e.g., antisense and RNA interfering (RNAi) molecules, targeted to a platelet-type 12-LO gene or a transcript thereof, which are capable of reducing or silencing platelet-type 12-LO expression specifically in adipocytes and pre-adipocytes. Vectors of these constructs (including, but not limited to, viral vectors), compositions of them and methods of using same for the treatment and amelioration of conditions associated with excess fat cell mass and obesity are also provided.02-17-2011
20090162424COMPOSITIONS AND METHODS FOR MAKING AND USING MULTIFUNCTIONAL POLYMERIZED LIPOSOMES - According to some embodiments, the present invention provides compositions and methods for making and using multifunctional polymerized liposomes finding relevant application in medical sciences, particularly in bioimaging, diagnostics, drug delivery, and drug formulation. The compositions and methods involve lipids that are both polymerizable and have a “clickable” group that provides the ability to functionalize via a click reaction with various functional moieties useful for the above-listed applications.06-25-2009
20110045061GENE THERAPY FOR DIABETIC ISCHEMIC DISEASE - It is possible to stimulate the angiogenesis of an ischemic site declined by diabetes and to recuperate ischemic disease by administering HGF (hepatocyte growth factor) gene to the diabetic ischemic.02-24-2011
20110045060KIT FOR DETECTING CANCER CELLS METASTASIZING INTO SENTINEL LYMPH NODE - A kit for detecting cancer cells metastasizing into a sentinel lymph node which comprises a human lymph channel-origin endothelial cell line attached to a base material. A drug delivery agent toward to sentinel lymph node wherein an antibody against an adhesive molecule, which mediates the adhesion of metastatic cancer cells from a primary cancer lesion to lymph channel endothelial cells in the sentinel lymph node, is exposed on the surface of colloidal particles.02-24-2011
20110045059VACCINE AGAINST VARICELLA ZOSTER VIRUS - Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen and an adjuvant containing QS21, cholesterol and 3D MPL are also claimed02-24-2011
20110045058TRANSFECTION REAGENT - The invention described herein features methods, compositions, and kits for introducing a nucleic acid molecule or biologically active molecule into a eukaryotic cell in vitro or in vivo utilizing a reagent containing energy-rich additives.02-24-2011
20110045057Virosomes Comprising Hemagglutinin Derived from an Influenza Virus Produced in a Cell Line, Compositions, Methods of Manufacturing, Use Thereof - The present invention relates to virosomes comprising hemagglutinin (HA) with improved fusion activity. Preferably, the HA comprised in said virosomes was derived from influenza virus produced in a cell line. The present invention also relates to compositions and a kit comprising the virosomes according to the invention. Further, the present invention relates to uses and methods involving said virosomes, as well as to a method for preparing same.02-24-2011
20120148665TOPICAL COMPOSITION CONTAINING NAPROXEN - The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and optionally, a hostile biophysical environment. In some cases, the composition may be stabilized using a stabilization polymer such as xanthan gum, KELTROL® BT and/or KELTROL® RD; propylene glycol; and a polysorbate surfactant such as Polysorbate 20, which unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.06-14-2012
20120148664CHEMICAL MODIFICATIONS MOTIFS FOR MIRNA INHIBITORS AND MIMETICS - The present invention provides polynucleotides having chemistry patterns that provide for improved stability, potency, and/or toxicity relative to their use as miRNA inhibitors or miRNA mimetics. The invention further provides pharmaceutical compositions and formulations comprising the polynucleotides, and methods for treating patients having a condition associated with miRNA or mRNA expression.06-14-2012
20100183702Therapies For Cancer Using RLIP76 - The present invention is a composition identified as a region of ralA binding protein 1, wherein the region neighbors a membrane-associated portion of the ralA binding protein 1, reduces transport activity and membrane association of the ralA binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells. Medicines may be in the form of antibodies, si-RNA and small molecules that recognize the region.07-22-2010
20120269883MicroRNA-140-5P as a Tumor Suppressor and Sensitizing Agent for Chemotherapy - The present invention provides a method of improving a therapeutic response to a cancer treatment, in a subject, the method comprising administering an effective amount of an agent that enhances the expression of microRNA-140-5p or an agent that mimics the effects of microRNA-140-5p. Further provided is a method of treating a cancer in a subject in need of such treatment comprising the step of administering an effective amount of a microRNA-140-5p or an agent that enhances the expression of microRNA-140-5p.10-25-2012
20120269885Vaccine for Modulating Between T1 and T2 Immune Responses - The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.10-25-2012
20080317835Personalized Nutrient Deficiency Assay Methods - Assays are preformed to determine nutrient deficiency levels in an individual to address the deficiencies and improve health and longevity. Nutraceutical and cosmeceutical products containing nanoencapsulated active ingredients are provided, in addition to dietary, exercise, sleep, and other lifestyle recommendations.12-25-2008
20120321701ANG-(1-7) RECEPTOR AGONIST - The application provides Ang-(1-7) receptor agonist peptides and their use for treating acute lung injury.12-20-2012
20120321697BPB-BASED CARGO DELIVERY SYSTEM - Disclosed are bipodal peptide binder (BPB) based cargo delivery systems wherein cargo is linked to a BPB for delivery into cells or to cell surfaces using target binding ability and specificity of the BPB. The BPB has a structure stabilizing region of parallel or antiparallel amino acid strands or a combination of these strands to induce interstrand non-covalent bonds. The BPB also has target binding regions I and II, each binding to each of both termini of the structure stabilizing region. The number of amino acid residues of regions I and II, respectively, are n and m. The BPB exhibits the K12-20-2012
20120321694COMPOSITIONS AND USES - Compositions and methods comprising or using a combination of an adjuvant such as AS01B and an antigen such as a β-amyloid antigen are provided. The compositions and methods provided are particularly useful for prevention or treatment of Alzheimer's disease. Suitable β-amyloid antigens are Aβ1-5, Aβ1-6, Aβ1-7, Aβ1-10, Aβ1-14, Aβ1-15, Aβ2-7, Aβ2-8, Aβ3-7, Aβ3-8, Aβ11-16, Aβ11-17, Aβp(E)3-7, Aβp(E)3-8, Aβp(E)3-40, Aβp(E)3-42, Aβp(E)11-16, Aβp(E)11-17, Aβp(E)11-40 or Aβp(E)11-42, optionally with a protein carrier. Suitable adjuvants comprise QS21, 3D-MPL or an AGP, optionally in combination with a liposome.12-20-2012
20110229554INTRAVENOUS FORMULATIONS OF COENZYME Q10 (CoQ10) AND METHODS OF USE THEREOF - Disclosed herein are formulations suitable for parenteral administration of certain hydrophobic active agents such as Coenzyme Q10. Methods of preparing the same and methods of treatment of oncological disorders using the same are also provided herein. The formulations comprise an aqueous solution; a hydrophobic active agent dispersed to form a colloidal nano-dispersion of particles; and at least one of a dispersion stabilizing agent and an opsonization reducer wherein the colloidal nano-dispersion of the active agent is dispersed into nano-dispersion particles having a mean size of less than 200-nm. Methods of preparing the parenteral formulations comprise dispersing the hydrophobic active agent by high pressure homogenization by (1) adding hydrophobic active agent to a 65° C. bath of water and mixing to form a hydrophobic active agent/water mixture; (2) adding a dispersion stabilizing agent to the hydrophobic active agent/water mixture and mix at 65° C. to form a hydrophobic active agent/water/stabilizer mixture; (3) adding an opsonization reducer to form a hydrophobic active agent/water/stabilizer/reducer mixture; (4) pre-heating a Microfluidizer to 65° C.; and (5) processing by mixing the hydrophobic active agent/water/stabilizer/reducer mixture in the Microfluidizer at 65° C. such that a hydrophobic active agent colloidal nano-dispersion having a mean particle size less than 200-nm is formed. Provided herein are also methods of treating oncological disorders by administering formulations described herein to a subject such that treatment or prevention of the oncological disorder occurs.09-22-2011
20110236469POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF - The present invention relates to polynucleotides encoding immunogenic HIV type C Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Gag- and/or Env-containing proteins are also described.09-29-2011
20100233249CONTRACEPTIVE METHODS AND COMPOSITIONS RELATED TO PROTEASOMAL INTERFERENCE - The present invention concerns the use of compositions and methods of regulating or evaluating fertility in an animal, in particular a mammal. In various embodiments of the invention, methods of contraception include inhibiting proteasome activity of a gamete, in particular spermatozoon. Proteasomal activity may be inhibited in vitro or in vivo. Inhibitors of the proteasome pathway include, but are not limited to small molecules, peptides, polypeptides (e.g., antibodies and the like) and affinity reagents that bind various components of the proteasome pathway (e.g., aptamers, etc.). In some embodiments, the activity of the proteasome pathway or the activity of a component in the proteasome pathway is inhibited by antibodies that bind and inhibit one or more components of the proteasome pathway.09-16-2010
20130183368P97-ANTIBODY CONJUGATES AND METHODS OF USE - The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.07-18-2013
20130183369Means of inducing cellular exocytosis and uses thereof - Means, compositions, and uses for triggering exocytosis of lysosomes in living cells. During exocytosis, lysosomes travel to the plasma membrane of the cell and dump their contents outside of the cells, thus removing accumulations of harmful, reactive metabolic by-products, such as lipofuscin. Consequently, cells function better, thus improving their vitality and the vitality of people, animals, and cell cultures. Degenerative diseases can be prevented or reversed. Embodied methods include electrical pulses, sonic vibrations, mechanical pressure, and mixtures of substances, which may include drugs, proteins, antibodies, or liposomes, which can be combined, injected, or administered transdermally or orally. Other embodiments are described and shown.07-18-2013
20130183370SUSTAINED RELEASE FORMULATION OF METHOTREXATE AS A DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD) AND AN ANTI-CANCER AGENT - Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a C07-18-2013
20110250267USE OF DIINDOLYLMETHANE-RELATED INDOLES FOR THE TREATMENT AND PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS ASSOCIATED CONDITIONS - The present invention includes compositions and methods for the treatment and prevention of conditions associated with Respiratory Syncytial Virus (RSV) infection. RSV-associated conditions include acute infections in mammals, typically bronchiolitis and pneumonia, and post-infectious chronic respiratory conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3′-diindolylmethane (DIM), or a DIM-related indole, alone or in combination with an inhibitor of a membrane bound Epidermal Growth Factor Receptor (EGFR) inhibitors, to treat conditions associated with exposure to RSV.10-13-2011
20100068262Method and Compositions for Stimulation of an Immune Response to PSMA using a Xenogeneic PSMA Antigen - Tolerance of the immune system for endogenous PSMA can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed PSMA antigen. For example, mouse PSMA, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against PSMA expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of cancers expressing PSMA, such as prostate cancer.03-18-2010
20120321700Compositions And Methods For Inhibiting Expression Of The HAMP Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition.12-20-2012
20120321696Accelerating Thrombus Resolution Through Augmentation of p53 Activity - A novel function for the p53 gene related to resolution of deep venous thrombosis is disclosed herein. Lack of the p53 gene results in impaired thrombus resolution in a clinically relevant in vivo model of deep venous thrombus resolution. It is further shown that augmentation of p53 activity with quinacrine accelerates thrombus resolution in vivo, and that this beneficial effect is completely dependent on p53. p53-based therapy is therefore provided to accelerate thrombus resolution in patients, and to prevent or ameliorate the debilitating long-tem complications of deep venous thrombosis such as post-thrombotic syndrome.12-20-2012
20120321698INHALABLE PHARMACEUTICAL COMPOSITIONS - Inhalable pharmaceutical compositions can include an aqueous dispersion of particles including a hydrophobic bioactive agent (e.g., CoQ10) suitable for continuous aerosolization. Due to their chemical composition and methods of manufacture, the pharmaceutical compositions exhibit distinctive physicochemical properties that provide advantageous aerosol transmission and output.12-20-2012
20120321695Use of PVP-Iodine Liposomes for Treatment of Herpes - The invention concerns a method for the production of a pharmaceutical preparation for the treatment of 12-20-2012
20120321699METHOD OF INDUCING THE PRODUCTION OF PROTECTIVE ANTI-HIV-1 ANTIBODIES - The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method.12-20-2012
20120321693PRG4 TREATMENT FOR INTERSTITIAL CYSTITIS - The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients via administration of a therapeutically effective concentration of PRG4.12-20-2012
20120321692Methods and Dressings for Sealing Internal Injuries - Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings.12-20-2012
20120087976ADJUVANT COMPOSITIONS COMPRISING A NON-IONIC ISOTONICITY AGENT - The present invention relates to an aqueous adjuvant composition comprising a TLR-4 agonist and a saponin in a liposomal formulation and a non-ionic isotonicity agent having low salt concentrations.04-12-2012
20120087975Method of Producing A Cationic Liposomal Preparation Comprising A Lipophilic Compound - A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.04-12-2012
20120087974INCREASED EFFECTIVENESS OF ALLYLAMINE DRUG COMPOUNDS FOR TOPICAL TREATMENT OF FUNGAL INFECTIONS OF THE SKIN AND SKIN APPENDAGES - The present invention provides compositions comprising allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages. In some embodiments a positive charge and enhancers are used in the compositions to allow for increased penetration of the active ingredient through skin and skin appendages. In some embodiments the positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle. The present invention also provides methods for making compositions comprising an allylamine drug compound, and methods of using such compositions for the treatment of fungal infections of the skin and skin appendages.04-12-2012
20130183373METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.07-18-2013
20120282326COMPOSITIONS AND METHODS RELATED TO MIRNA IN DIABETIC CONDITIONS - The present invention relates to methods of treating a disorder associated with glucose mediated cell damage in a subject comprising administering to the subject an agent that modulates the expression of one or more miRNAs in a damaged cell or cells of the subject. The present invention also relates to compositions for treating a disorder associated with glucose mediated cell damage comprising an agent that modulates the expression of one or more miRNAs in a damaged cell or cells. The invention also relates to methods of diagnosing a disorder associated with glucose mediated cell damage in a subject, including diagnosis of diabetic retinopathy.11-08-2012
20120282328DUAL ACTION, INHALED FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE - Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.11-08-2012
20120282323Dry Liposomal PVP-iodine Compositions - The present invention is directed to a storage stable package of a iodophor containing particulate pharmaceutically acceptable carrier compositions. The invention is particularly directed to a storage stable package of a PVP-iodine liposome compositions. The packaging material is generally plastic, paper or cardboard.11-08-2012
20120282322COCHLEATE COMPOSITIONS DIRECTED AGAINST EXPRESSION OF PROTEINS - Disclosed herein are novel siRNA-cochleate and morpholino-cochleate compositions. Also disclosed are methods of making and using siRNA-cochleate and morpholino-cochleate compositions.11-08-2012
20120282329MUC1 Based Glycolipopeptide Vaccine with Adjuvant - Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.11-08-2012
20110280929SIRNA OF NF-KB P105 FOR INHIBITING CELL PROLIFERATION AND MIGRATION AND A COMPOSITION COMPRISING SAME - The present invention relates to a siRNA which targets mRNA of the NF-Kappa B p105 gene to cause its degradation by RNAi induction. In addition, the present invention provides a pharmaceutical composition for the treatment of diseases associated with aberrant cell proliferation and migration, comprising the siRNA and delivery vehicle capable of intracellular delivery of the same.11-17-2011
20110287089USE OF A SACCHAROMYCES CEREVISIAE MITOCHONDRIAL NUCLEIC ACIDS FRACTION FOR IMMUNE STIMULATION - The present invention relates to the use of a 11-24-2011
20110293704PRIMING OF AN IMMUNE RESPONSE - The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.12-01-2011
20100215725PHARMACEUTICAL COMPOSITION CONTAINING IDEBENONE FOR THE TREATMENT OF LIVER DISORDERS - The invention describes the use of an injectable form of Idebenone to protect against hepatic damage, improve recovery from liver trauma, poisoning, vapor intoxication, degenerative diseases, hepatocyte function loss and pathology associated with inflammation or infection. The use of injectable Idebenone restores liver function, suppresses elevated enzyme levels, decreases alcoholic and drug abuse associated syndromes, symptoms of acute hepatitis of various origins, the consequences of liver reperfusion and other signs of liver damage.08-26-2010
20100215728Skincare Methods - Disclosed are compositions and methods for skincare, e.g., reducing skin wrinkles and for treating skin disorders.08-26-2010
20120100207PROCESS FOR PRODUCING LIPOSOMES BY TWO-STEP EMULSIFICATION METHOD UTILIZING OUTER AQUEOUS PHASE CONTAINING SPECIFIC DISPERSING AGENT, PROCESS FOR PRODUCING LIPOSOME DISPERSION OR DRY POWDER THEREOF USING THE PROCESS FOR PRODUCING LIPOSOMES, AND LIPOSOME DISPERSION OR DRY POWDER THEREOF PRODUCED THEREBY - [Problem] To provide a process for producing liposomes, a liposome dispersion or a dry powder of the dispersion by a two-step emulsification method using an additive (dispersing agent) by which a liposome dispersion and a dry powder thereof which can inhibit leakage of an encapsulated drug or the like from liposomes even in the long-term storage and can be stably used over a long period of time are obtained. [Solution to problem] A process for producing liposomes by a two-step emulsification method characterized by using, in the secondary emulsification step, an outer aqueous phase containing a dispersing agent which forms no molecular self-aggregate or a dispersing agent which exclusively forms molecular self-aggregates having a volume mean particle diameter of not more than 10 nm (said dispersing agent being referred to as a “specific dispersing agent” hereinafter), and a process for producing a liposome dispersion or a dry powder thereof utilizing the process for producing liposomes. The specific dispersing agent preferably contains at least one of gelatin, albumin, dextran and a polyalkylene oxide-based compound.04-26-2012
20120100206TARGETED LIPOSOMES COMPRISING N-CONTAINING BISPHOSPHONATES AND USES THEREOF - The present is based on the finding that folate targeted liposomal alendronate (FT-AL-L) was significantly more potent against two tested cancer cell lines than the free alendronate (AL) or the non-targeted liposomal alendronate (AL-L), as observed by the increased cytotoxicity of the folate targeted liposomal alendronate. Thus, the present disclosure provides targeted liposomes comprising a membrane and an intraliposomal core, the membrane comprising at least one liposome forming lipid and a targeting moiety, such as folate, exposed at the membrane's outer surface; and the intraliposomal core comprising encapsulated therein least one N-containing bisphosphonate. Also provided by the present disclosure are methods of use of the targeted liposomes such as for the treatment of a disease or disorder.04-26-2012
20120100205COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES - The invention suggests amphoteric lipids wherein one or more amphoteric groups having an isoelectric point between 4 and 9 are substituted on a membranous or membrane-forming amphiphilic substance, as well as liposomes containing such compounds.04-26-2012
20120100204TGF-Beta Stimulating Agent Compositions and Combinations - Compositions and methods for preventing, inhibiting or treating a disorder associated with the loss of normal adult tissue architecture are provided.04-26-2012
20120288558METHOD FOR ADMINISTRATION OF PEGYLATED LIPOSOMAL DOXORUBICIN - An embodiment of the present invention comprises a method of treating malignancies in a subject in need of treatment comprising administering to the subject a high loading dose of a pegylated liposomal doxorubicin (PLD) in an initial cycle, followed by a reduced dose in a second cycle, wherein the second cycle reduced dose is in the range of 20% to 50%, preferably 50%, of the initial loading dose, and thereafter one or more maintenance doses in further cycles. The interval between dose cycles is in the range of about three-to-four weeks, preferably about four weeks. The initial loading dose is in the range of between the maximum tolerated dose (MTD) and the recommended dose, preferably the MTD (for instance, in the range of about 70 mg/m2 to 50 mg/m2, preferably 60 mg/m2). The one or more maintenance doses are in the range of about 40 mg/m2 to 50 mg/m2, preferably 45 mg/m2).11-15-2012
20120288555ANTIPROLIFERATIVE COMPOSITIONS COMPRISING CURCUMIN ANALOGS AND METHODS OF PRODUCING AND USING SAME - Antiproliferative compositions that include CLEFMA, as well as liposomal compositions containing said antiproliferative compositions, are disclosed. Also disclosed are methods of making and using the antiproliferative compositions and liposomal compositions.11-15-2012
20120288557ACOUSTICALLY SENSITIVE DRUG DELIVERY PARTICLES COMPRISING LOW CONCENTRATIONS OF PHOSPHATIDYLETHANOLAMINE - Novel acoustically sensitive drug carrying particles comprising low concentrations of phosphatidylethanolamine are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon exposure to acoustic energy.11-15-2012
20120288554CANFOSFAMIDE MONOTHERAPY FOR TREATING MULTIPLE MYELOMA - Provided herein are methods for treating multiple myeloma by administering canfosfamide or a pharmaceutically acceptable salt thereof as a monotherapy, and also by administering canfosfamide or a pharmaceutically acceptable salt thereof as part of novel combination therapies further comprising one or more of bortezomib, lenalidomide, vorinostat, carfilzomib, pomalidomide, and elotuzumab.11-15-2012
20100209485STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF - The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example insulin and Peptide T or analog thereof.08-19-2010
20100203116USE OF LIPOSOMES IN A CARRIER COMPRISING A CONTINUOUS HYDROPHOBIC PHASE FOR DELIVERY OF POLYNUCLEOTIDES IN VIVO - The invention provides compositions comprising a carrier comprising a continuous phase of a hydrophobic substance, liposomes, and a polynucleotide, and methods for using such compositions for delivering a polynucleotide to a subject.08-12-2010
20090297593Use of Liposomes in a Carrier Comprising a Continuous Hydrophobic Phase as a Vehicle for Cancer Treatment - The invention compositions comprising a continuous hydrophobic phase and liposomes as a vehicle for delivery of an antigen capable of inducing a cytotoxic T lymphocyte (CTL) response and methods for their use in the treatment of cancer.12-03-2009
20090110720Use of compounds for the prevention of drug-induced cell toxicity - The present invention relates to the use of compounds for the manufacture of a medicament for the prophylaxis and/or treatment of induced cell toxicity, such as nephewrotoxicity and ototoxicity, in particular where the cell toxicity is induced by a medical treatment. In a preferred embodiment, the compounds have at least two nitrogen atoms, more preferably at least two amino groups. The compounds according to the invention are capable of docking binding of cell toxic compounds to the megalin receptor, and thereby inhibiting uptake of the cell toxic compounds into cells. The invention further relates to novel compounds for use in said treatment, as well as a method for reducing the cell toxicity of cell toxic compounds.04-30-2009
20100189778OPIOID DELIVERY SYSTEM - An opioid formulation for pulmonary administration in the treatment or management of pain, a pulmonary drug delivery device containing, method of administering, kit containing, and uses of same. The formulation contains at least one rapid-onset opioid and preferably also contains a sustained-effect opioid to reduce the frequency of administration. The invention employs the side effects of the opioid formulation to permit patients to self-limit drug intake, thereby avoiding toxicity while achieving analgesia. A pharmacokinetic and pharmacodynamic model is employed to determine optimum drug formulations and optimum parameters for administration.07-29-2010
20130011465COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS - The present invention includes methods of making and methods of using peptidomimetics compositions that mimic α-helical BH3 sequences in cells. The peptidomimetics can be used to mimic α-helical BH3 sequences and kill cancer cells.01-10-2013
20130011467METHOD OF TREATING MALIGNANT SOLID TUMORS USING TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) - This invention is directed to methods of treating solid tumor cancers, particularly refractory cancers by administration of two pluralities of microparticles, one comprising drug-carrying microparticles sized to lodge at the tumor preferably in the capillary bed of the tumor and the other comprising non-drug-carrying microparticles sized to lodge in the arterial system servicing the tumor so as to embolize the tumor.01-10-2013
20100166845INDIVIDUALIZED CANCER THERAPY - In certain embodiments, the invention provides methods for treating cancer, comprising: (a) obtaining a specimen of cancer tissue and normal tissue from a patient; (b) extracting total protein and RNA from the cancer tissue and normal tissue; (c) obtaining a protein expression profile of the cancer tissue and normal tissue; (d) identifying over-expressed proteins in the cancer tissue; (e) comparing the protein expression profile to a gene expression profile; (f) identifying at least one prioritized protein target by assessing connectivity of each said over-expressed protein to other cancer-related or stimulatory proteins; (g) designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding the prioritized target protein; (h): designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding a protein of higher priority in the signaling pathway in which the first protein is a component; (i) incorporating the first cassette into a first delivery vehicle; (j) providing a patient with an effective amount of the first delivery vehicle; (k) extracting total protein and RNA from the treated cancer tissue; (l) identifying over-expressed proteins in the treated cancer tissue; (m) designing a second RNA interference expression cassette to modulate the expression of a second prioritized protein in the treated tissue; (n) incorporating the second cassette into a second delivery vehicle; (o) providing the previously treated patient with an effective amount of the second delivery vehicle; (p) identifying a novel protein signal following prior treatment with protein specific knockdown; (q) identifying a gene mutation provided by gene sequencing/microarray on assessment of other protein signals; and (r) identifying of a novel protein signal as a result of determination of the gene mutation and assessment of other protein signals to, directly or indirectly, modify the expression (i.e., production) of such proteins.07-01-2010
20130017248Cationic Liposomes And Method of Use - Highly efficient cationic liposomes are provided as a system for the delivery to cells of agents or compounds, such as, compounds capable of silencing a target protein and enzyme stubstrates. The cationic liposomes can be used in methods of detecting the inhibition activity or apparent activity of a target protein in a cell, and methods of identifying a protein associated with a pathway, such as, a signal transduction pathway in a cell.01-17-2013
20130017249COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY - Here described are compounds consisting of the structure01-17-2013
20130017250Methods For High Density Lipoprotein Cholesterol Regulation - It was discovered that insulin binding to insulin receptors signals the upregulation of expression of the liver enzyme deiodinase 1 (Dio1), which in turn activates the ApoA-1 promoter, thereby thereby increasing ApoA-1 expression (primarily in the liver), that in turn raises the levels of plasma ApoA-1, the major and necessary protein in HDLC. Certain embodiments of the invention are directed to methods for increasing circulating HDLC levels in an animal by administering therapeutically effective amounts of Dio1, or by increasing the level of Dio1 through gene therapy.01-17-2013
20130017251Antibody Specific for Apolipoprotein and Methods of Use Thereof - The present disclosure provides synthetic antibodies specific for an epitope present on an apolipoprotein E polypeptide. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.01-17-2013
20130017252Method for Selectively Inhibiting the Activity of ACAT1 in the Treatment of Alzheimer's Disease - The present invention features methods for decreasing the size and density of amyloid plaques, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.01-17-2013
20130017253Inducing Cellular Immune Responses to Human Papillomavirus Using Peptide and Nucleic Acid Compositions - This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.01-17-2013
20100129433Proteoliposome, Production Method Thereof, and Biochip - A proteoliposome, which is obtained by removing a surfactant from a mixed solution including lipid, membrane proteins and the surfactant, wherein the content of the surfactant in the mixed solution is equal to or more than 1.5 times of the sum of a maximum amount of the surfactant associating with the lipid and a maximum amount of the surfactant associating with the membrane protein. A biochip wherein the above-described proteoliposome is spread on a substrate. A method for producing a proteoliposome by removing a surfactant from a mixed solution including lipid, membrane proteins and the surfactant, wherein the content of the surfactant in the mixed solution is made equal to or more than the sum of a maximum amount of the surfactant associating with the lipid and a maximum amount of the surfactant associating with the membrane protein.05-27-2010
20110142915COMPOSITIONS AND METHODS FOR INHIBITION OF VEGF - Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.06-16-2011
20110159081VACCINE - The present invention provides an immunogenic composition comprising at least one antigen delivery particle and at least one antigen, wherein the antigen and antigen delivery particle are linked using an intermediate linker.06-30-2011
20110159080COMPOSITION COMPRISING LIPOSOME-ENTRAPPED DOXORUBICIN AND METHODS OF ADMINISTRATION - Patients suffering from cancer, such as ovarian cancer, may be treated by administering an effective combined amount of a liposomal-entrappeddoxorubicin, an alkylating antineoplastic agent, and a vascular endothelial growth factor inhibitor. In one embodiment, patients suffering from ovarian cancer are treated by administering an effective combined amount of the liposome-entrapped doxorubicin product DOXIL, carboplatin and bevacizumab.06-30-2011
20110159079High Delivery Rates for Lipid Based Drug Formulations, and Methods of Treatment Thereof - Provided is a method of preparing lipid based drug formulations with low lipid/drug ratios using coacervation techniques. Also provided are methods of delivering such lipid based drug formulations at high delivery rates, and methods of treating patients with pulmonary diseases comprising administering such lipid based drug formulations.06-30-2011
20110159078Volatile Anesthetic Compositions and Methods of Use - The present invention provides methods for reducing pain in a subject in need thereof by delivering a volatile anesthetic in a solution or an emulsion that can additionally include an extractive solvent in an amount effective to reduce pain without substantially interfering with motor function. Chronic or acute pain may be treated, or the volatile anesthetic may be delivered as a regional anesthetic to a subject to anesthetize a portion of the subject prior to surgery. Dosing regimes including a one-time administration, continuous and/or periodic administration are contemplated.06-30-2011
20110159077PENTOXIFILIN-BASED DERMATOLOGICAL PHARMACEUTICAL COMPOSITION, FOR TOPICAL APPLICATION, IN CREAM, GEL, SOLUTION, EMULSION, LIPOSOME AND MICROCAPSULE FORM - A pharmaceutical dermatological composition based on Pentoxifylline, to be applied on the skin in the form of a cream, gel, unguent, solution, in an emulsion, in liposomes and in microcapsules, being selective for the vascular disorders of rosacea and disorders with photosensitivity, reducing the blood vessels and the reactions of reddening of the skin, CHARACTERIZED in that said composition consists of: from 1% to 99% of Pentoxifylline, from 0.1% to 80% of base cream and from 0.1% to 75% of liposomes.06-30-2011
20130022663Method of making and using a topical medicated formula and delivery system to use to prevent and treat breast diseases and breast cancer as well as use as skin wellness and anti-wrinkle formula - Breast cancer and breast disease are common in women and becoming more frequent in men. Early treatment is vital for better outcomes. This formula consists of a liquid anti-disease topical and/or intraductal anti-breast-disease and anti-cancer—including against precursors to cancer and atypical cells—formula that can be delivered to the source where breast cancer begins by use of a number of bio-available components and multiple diffusion and delivery systems, preventing and/or treating maladies that include, but are not limited to degenerative diseases and accumulation of toxins in the breast tissue.01-24-2013
20130022667FIDGETIN-LIKE 2 AS A TARGET TO ENHANCE WOUND HEALING - Methods of treating a wound in a subject are provided comprising administering to the subject an amount of an inhibitor of Fidgetin-like 2. Compositions and pharmaceutical compositions comprising an amount of an inhibitor of Fidgetin-like 2 are also provided. Methods are also provided for identifying an inhibitor of Fidgetin-like 2.01-24-2013
20130022669BRANCHED, COMPACT POLYETHYLENEGLYCOL DERIVATIVES - The present invention relates to branched polyethyleneglycol (PEG) derivatives consisting of a molecule with a quaternary carbon connected to three PEG chains, wherein all three PEG chains are of equal length and each comprises 1-30 —OCH01-24-2013
20130022668Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration - The present invention relates to a novel chemical compound of formula S-(1):01-24-2013
20130022664E.COLI LPFA ANTIGEN FOR PREVENTION AND TREATMENT OF INFECTIOUS DISEASES - The present disclosure relates to methods and compositions for the treatment and prevention of microbial infections and for the enhancement of resistance to infection. The disclosure includes administration of an effective amount of an 01-24-2013
20080254109LOCALIZED MYOCARDIAL INJECTION METHOD FOR TREATING ISCHEMIC MYOCARDIUM - This invention relates to a method of treating ischemic or diseased myocardium by injecting a therapeutic agent, such as a gene, protein, cell or drug, into normal myocardium, preferably adjacent to an ischemic zone in the heart of a subject. The method is useful for inducing angiogenesis and collateral blood vessel formation to improve cardiac function in subjects with ischemic heart disease. The method can also be used to promote tissue regeneration in such subjects.10-16-2008
20080286353CATIONIC LIPOSOMES CONTAINING IMMUNE RESPONSE GENERATING MOIETIES - Cationic liposomes with entrapped polynucleotide in the intravesicular space are described. The liposomes include cationic components such as cationic lipids such as DOTAP. Preferably the method of forming liposomes uses the dehydration-rehydration method in the presence of the polynucleotide. The polynucleotide preferably operatively encodes an antigen capable of eliciting a desired immune response, that is, is a gene vaccine.11-20-2008
20080248099Method for Treating Disease or Disorder of Adult Central Nervous System Associated with Tissue Shrinkage or Atrophy by Administration of Insulin - The present invention provides a use of an insulin for the manufacture of a medicament for treating or preventing diseases or disorders of adult brain. Also provided is a method for treating or preventing diseases or disorders of adult brain by administering an effective amount of an insulin to the brain. The diseases or disorders of adult brain are associated with tissue shrinkage or atrophy. The amount of the insulin administered is preferably from 0.001 Units per kg body weight per day up to 10 Units per kg body weight per day.10-09-2008
20080248098Polysaccharide Microparticles Containing Biological Agents: Their Preparation and Applications - A method of preparing polysaccharide glassy microparticles which are less than 10 μum in diameter and contain structurally delicate agents, such as proteins, peptides, gene materials, vaccines, antibodies, viruses and liposomes using low-temperature aqueous-aqueous emulsification (free of polyelectrolytes) and freezing-induced phase separation. When delicate agents are added to a polysaccharide-PEG two phase system followed by homogenization (or other shear adding process), the agents partition into the polysaccharide dispersed phase preferentially. These processes help to avoid aggregation of proteins caused by interaction with charged polyelectrolytes used for stabilizing the polysaccharide dispersed phase in our previously reported aqueous-aqueous emulsion. When this system is frozen and lyophilized, glassy particles less than 10 μm in diameter containing delicate agents can be formed. These fine polysaccharide particles protect proteins within their hydrophilic glassy matrix, and can therefore be easily suspended in hydrophobic polymer solutions and formulated to various forms of sustained release devices such microsphere, sheets, fibers, coating layers, and scaffolds. The particles can also be dispersed in hydrophilic gels to improve releasing kinetics and to deliver vaccines and antibodies for immune therapy.10-09-2008
20080248095SMALL PARTICLE LIPOSOME AEROSOLS FOR DELIVERY OF ANTI-CANCER DRUGS - The small particle liposome aerosol compounds and methods of treatment of the present invention involve lipid- or water soluble anti-cancer drugs incorporated into liposomes. The liposomes are administered in aqueous dispersions from a jet nebulizer to the respiratory tract of an individual. Various anti-cancer drugs may be used, including 20-S-Camptothecin, 9-Nitro-camptothecin, 9-Amino-camptothecin, 10, 11-methylenedioxy-camptothecin and taxol or its derivatives. Administration of these drugs by inhalation provides faster and more efficient absorption of the anticancer drug than does intramuscular administration or oral administration.10-09-2008
20080248094VACCINE ADJUVANT PROPERTIES OF LIPSOMES FORMED AT ELEVATED TEMPERATURES FROM THE POLAR CHLOROFORM EXTRACTABLE LIPIDS FROM MYCOBACTERIUM BOVIS - The invention relates to a liposome comprising a chloroform soluble and extractable total polar lipid of Mycobacterium spp, particularly a chloroform soluble extractable total polar lipid of Mycobacterium bovis BCG. The chloroform soluble and extractable polar lipid may comprise at least one of phosphatidylinositol (PI), phosphatidylinositol mannoside (PIM10-09-2008
20080248092Formulations of Water Insoluble or Poorly Water Soluble Drugs in Lipidated Glycosaminoglycan Particles and Their Use for Diagnostic and Therapy - The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery.10-09-2008
20130171237ARIPIPRAZOLE COMPOSITIONS AND METHODS FOR ITS TRANSDERMAL DELIVERY - The present invention discloses compositions of liquid and gel formulation containing aripiprazole in the form of a patch for transdermal delivery.07-04-2013
20130171239METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS - The instant invention provides preparations comprising an oxidizing antimicrobial agent such as chlorine dioxide and a heterocyclic compound that improves the antibacterial effect of the oxidizing antimicrobial agent preparation. The invention has particular use as an eye care preparation such as an eye drop. The invention further provides methods for reducing bacterial colonization and treating infection.07-04-2013
20080233183TOPICAL FORMULATIONS HAVING ENHANCED BIOAVAILABILITY - The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent.09-25-2008
20080233182ORGANIC COMPOUNDS - The present invention relates to a method of protecting copper-sensitive compounds and/or compositions from decomposition.09-25-2008
20080233181NANOPARTICLE ADJUVANTS FOR SUB-UNIT VACCINES - The present invention relates to nanoparticle vaccine adjuvants comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in order to direct it to a specific site or cell type to optimize a desired immune response. The present invention also relates to encapsulating an antigen or combinations of different antigens within such nanoparticles, with or without a targeting molecule displayed on its surface. The antigens used in this invention are effective to produce an immune response against a variety of pathological conditions.09-25-2008
20080226709Phospholipid membrane preparation - The present invention aims at providing a phospholipid membrane preparation wherein an antigen or an allergen is bound onto the surface of a phospholipid membrane comprising a phospholipid containing an acyl group or a hydrocarbon group having 10 to 12 carbon atoms, and a stabilizer of a phospholipid membrane. The present invention provides a phospholipid membrane preparation having an immune response controlling function that suppresses production of IgE antibody to increases production of practically sufficient IgG antibody and usable as a vaccine that does not easily cause an allergic response.09-18-2008
20080226708Silicone Vesicles Containing Actives - Processes are disclosed for preparing silicone vesicle compositions and emulsions containing silicone vesicles, the compositions prepared therefrom, and formulated personal and healthcare products containing the silicone vesicles and emulsions compositions.09-18-2008
20080226706Use of Repeat Sequence Protein Polymers in Personal Care Compositions - The present invention provides personal care compositions, and more particularly, personal care compositions comprising a bioactively effective amount of a repeat sequence protein polymer. In some particularly preferred embodiments, the present invention provides personal care compositions comprising an effective amount of at least one fragment of a repeat sequence protein polymer having bioactivity.09-18-2008
20080226705GEL DELIVERY SYSTEM FOR ORAL ADMINISTRATION OF MEDICAMENTS - The invention relates to a swallowable delivery device fabricated from a composition including a hydrated polymeric matrix with gelatinous consistency, one or more active ingredients, and optionally one or more stiffening agent. The delivery device is of a size and shape amenable to swallowing with enhanced solubility and controlled release of the active ingredients.09-18-2008
20080226704Method of Producing Coated Fine Particles - The present invention provides a method of producing coated fine particles in which core fine particles is coated with a coating layer, which comprises the steps of preparing a liquid (liquid A) containing a polar organic solvent in which core fine particles are dispersed and a component constituting a coating layer is dissolved; preparing a liquid (liquid B) which is miscible with the liquid A and does not contain a polar organic solvent or contains a polar organic solvent in a ratio lower than that in the liquid A; and letting the liquid A flow from at least one inlet of a device for producing coated fine particles equipped with an in-line mixing means having two or more inlets and one or more outlet(s) and letting the liquid B flow from at least one remaining inlet to mix the liquids thereby coating the core fine particles with the coating layer.09-18-2008
20130177625IMMUNOGENIC COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA - The invention provides provides immunogenic compositions comprising neoplastic cells expressing a cytokine (GM-CSF) formulated with at least one TLR agonist and methods of using the composition to induce or enhance an immune response.07-11-2013
20130177626PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLOSPORIN - The invention relates to liquid pharmaceutical compositions containing: a) a therapeutically effective dose of a cyclosporin; b) an aqueous carrier liquid; c) a first solubilizing substance selected among the group of phospholipids; and d) a second solubilizing substance selected among the group of non-ionic surfactants. Preferably, the cyclosporin is liposome solubilized. The inventive composition is suitable for oral, parenteral, nasal, mucosal, topical, and particularly pulmonary application in the form of an aerosol.07-11-2013
20130177640DELIVERY OF RNA TO DIFFERENT CELL TYPES - RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.07-11-2013
20130177624MIRNA EXPRESSION IN ALLERGIC DISEASE - Disclosed are methods for detecting an allergic lung disease that involve assessing the level of one or more microRNAs (miRNAs) in a biological sample, wherein the level of the one or more miRNAs in the biological sample compared to a reference level of the one or more miRNAs is indicative of allergic lung disease. Also disclosed are methods for the treatment or prevention of inflammatory or allergic lung disease that involve administration of a let-7 miRNA inhibitor as set forth herein, as well as biochips and kits that can be applied in the methods of the present invention.07-11-2013
20130177629LIPOSOMAL COMPOSITIONS - The present application includes liposomes and liposomal compositions that comprise chlorite, chlorate or a mixture thereof entrapped inside the liposome core, methods for their preparation and methods of use, in particular as medicaments.07-11-2013
20130177627Growth inhibitory effects of nanoparticles containing triterpene glycosides or triterpenes - The present invention relates to pharmaceutical composition containing a physiologically effective dose of a nanoparticle triterpene glycoside or nanoparticle triterpene complex, wherein said complex is a liposome encapsulated compound, or exosome-encapsulated compound.07-11-2013
20130177628COMPOSITIONS AND METHODS FOR PROMOTING WOUND HEALING AND TISSUE REGENERATION - Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.07-11-2013
20130177630ANTI-CANCER COMPOSITION AND METHOD UTILIZING 3-BP AND LIPOSOMAL REDUCED GLUTATHIONE - The invention proposes a method of treatment of cancers exhibiting a CD163 characteristic by a liposomally formulated reduced glutathione.07-11-2013
20130177631Method and medicament for inhibiting the expression of a given gene - The invention relates to an oligoribonucleotide of double-stranded structure (dsRNA) for inhibiting the expression of a given target gene in mammalian cells and a method of mediating RNA interference of an mRNA of a gene in mammalian cells using the dsRNA.07-11-2013
201301776322,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS - The present invention provides therapeutically effective 2,4,5-trisubstituted imidazole compounds, methods of preparing the same, and compositions comprising the compounds alone or in combination with other agents. The present invention further provides for the use of the compounds as anti-microbial agents. The anti-microbial properties of the compounds include anti-bacterial and/or anti-fungal activity.07-11-2013
20130177633METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.07-11-2013
20130177634METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.07-11-2013
20130177635METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.07-11-2013
20130177636METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.07-11-2013
20130177637METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.07-11-2013
20130177638METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.07-11-2013
20130177639DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS - RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.07-11-2013
20130202682SYNTHETIC MATRIX VESICLES FOR BIOMIMETIC MINERALIZATION - Compositions of synthetic matrix vesicles with mineralization relevant ions which direct mineralization of a biomimetic mineral phase and methods for use thereof are provided.08-08-2013
20130202683TOPICAL FORMULATIONS HAVING ENHANCED BIOAVAILABILITY - The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent.08-08-2013
20130202684PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING RNA - Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass of between 1 kDa and 3 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1 kDa and 3 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.08-08-2013
20120251619MicroRNA-29a,b,c as a Tumor Suppressor and Sensitizing Agent for Chemotherapy - The present invention provides a method of improving a therapeutic response to a cancer treatment, in a subject, the method comprising administering an effective amount of an agent that enhances the expression of microRNA 29 or an agent that mimics the effects of microRNA 29. Further provided is a method of treating a cancer in a subject in need of such treatment comprising the step of administering an effective amount of a microRNA 29 or an agent that enhances the expression of microRNA 29.10-04-2012
20080213353Method for preparing liposome formulations with a predefined release profile - The present invention provides a novel tool for designing a release profile of an active agent from a liposome in to which it is loaded. According to the invention, a method is provided for preparing a liposomal formulation for delivery of an active agent to a target, the release of said active agent from the liposome being designed to have a release profile in which the release is sustained for a time period to achieve an optimal effect of the active agent at said target, the method comprising preparing a liposomal formulation, wherein the liposome is loaded with said active agent and with a selected counter ion, the counter ion and the active agent interacting together to aggregate and/or to form a precipitate within the liposome, the counter ion being selected such that the release of the active agent from the liposome has said release profile.09-04-2008
20080213352Liposome carriers for in vivo delivery of fullerenes - Described herein are pharmaceutically acceptable compositions comprising fullerene molecules dispersed in vesicles comprising phosphatidylcholine (PC) phospholipid molecules and non-PC phospholipid molecules suspended in aqueous solution. In preferred embodiments, the phospholipid molecules are substantially uniformly organized into vesicles composed of one or more lipid bilayers and the fullerene molecules are substantially uniformly distributed within the lipid bilayers of the vesicles. Methods of forming these fullerene containing liposomes are also described. Such fullerene containing liposomes provide carriers for delivery of fullerenes for cosmetic, therapeutic, and imaging applications among other uses.09-04-2008
20080213351Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease - The present invention relates to pharmaceutical compositions comprising liposomes and methods of using such liposomes to prevent, treat, or manage a variety of diseases and/or bodily conditions. The liposomes may comprise large unilamellar vesicles (LUVs) alone or in combination with multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or other therapeutics. The invention relates to liposomes having certain diameters administered to patients using specific doses and/or dosing regimens.09-04-2008
20080213350Encapsulation of nucleic acids in liposomes - Complexes of nucleic acid and cationic polymer, which are encapsulated in liposomes for the purpose of delivering nucleic acid and methods for producing encapsulated complexes.09-04-2008
20080213349Liposome Complexes Containing Pharmaceutical Agents and Methods - Liposome complexes are provided for site-specific delivery of pharmaceutical agents with improved targeting efficiency. The liposome complexes include a pharmaceutical agent associated with the liposome; a sialic acid-containing molecule associated with the liposome; and optionally a targeting agent attached to the sialic acid-containing molecule. The invention also provides methods of making liposome complexes and their in vivo administration.09-04-2008
20080213348Agents for gene therapy of cerebrovascular disorders - The present invention provides novel methods for treating cerebrovascular disorders, in which HGF is overexpressed by introducing an HGF gene. The methods of this invention using an HGF gene enable active treatment of cerebrovascular disorders, such as cerebral infarction, by gene transfer, and enable the maintenance of neuronal function and the suppression of infarcted areas in patients for whom appropriate treatment methods were unavailable until now.09-04-2008
20080213347Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof - Novel ligand antagonists of the RAR receptors have the following structural formula (I):09-04-2008
20080213346Preparation of Nanoliposome-Encapsulating Proteins and Protein-Encapsulated Nanoliposome - Preparing a nanoliposome for encapsulating a protein includes preparing a dispersion by dispersing a phospholipid in an aqueous solution containing the protein, applying a shearing force to the dispersion; adding an additional amount of the phospholipid to the result of the step of applying the shearing force to the dispersion and then applying a shearing force higher than that of the step of applying the shearing force to the dispersion, and repeating the step of adding the additional amount of the phospholipid and applying the higher shearing force with an additional amount of the phospholipid and a shearing force higher than the prior step to obtain a nanoliposome having a desired diameter and encapsulation efficiency.09-04-2008
20080213345Delivering Iron to an Animal - The invention provides a method for delivery iron to an animal. This invention further provides a method for treating iron deficiency in an animal.09-04-2008
20110268790Snake Factor V and Methods of Use Thereof as a Procoagulant - Compositions and Methods for the treatment of coagulation disorders using Factor V variants are provided. Preferred disorders include hemophilia A and B.11-03-2011
20110268788IMMUNOTHERAPEUTIC AGENT SUITABLE FOR THE PRIMARY PROPHYLAXIS OF TUBERCULOSIS - The present invention relates to the use of an immunotherapeutic agent having cell wall fragments of a virulent strain of 11-03-2011
20110268787Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof - The present invention provides a method of treating a corneal disorder comprising administering to a patient in need thereof a composition containing pharmaceutically effective amount of dioleoylphosphatidylglycerol and/or palmitoyloleoylphosphatidylglycerol and a pharmaceutically acceptable carrier.11-03-2011
20130136789AGENT FOR TREATING RENAL FIBROSIS - The present invention relates to a substance delivery carrier for extracellular matrix-producing cells in the kidney, the carrier including a retinoid as a targeting agent, an agent for treating renal fibrosis utilizing the carrier, a process for producing them, a production kit, a method for treating renal fibrosis using the agent for treating renal fibrosis, etc.05-30-2013
20130115279CD133 EPITOPES - An immunogen includes an isolated peptide that includes the amino sequence of any one of SEQ ID NOs:1-21 with four or fewer amino acid substitutions.05-09-2013
20130115278Peptide Epitopes of Apolipoprotein B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.05-09-2013
20130115277Peptide Epitopes of Apolipoprotein B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.05-09-2013
20130095171HERBAL COMPOSITION AND METHOD FOR TREATMENT OF AIRWAY INFLAMMATION USING THE SAME - An herbal composition includes 04-18-2013
20130095172USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB - The present application describes uses for and articles of manufacture including Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; treating early-stage HER2-positive breast cancer; treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag; treating HER2-positive metastatic gastric cancer; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and Vinorelbine; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and aromatase inhibitor; and treating low HER3 ovarian, primary peritoneal, or fallopian tube cancer. It also describes an article of manufacture comprising a vial with Pertuzumab therein and a package insert providing safety and/or efficacy data thereon; a method of making the article of manufacture; and a method of ensuring safe and effective use of Pertuzumab related thereto. In addition the application describes an intravenous (IV) bag containing a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient.04-18-2013
20130095169Compositions and Methods for Reduced Scarring and for Treatment of Fibrosis - Methods of treating, reducing or preventing fibrosis or scarring including administering a therapeutic molecular agent selected from the group consisting of an agent that inhibits chaperonin containing Tcomplex polypeptide subunit eta polypeptide (“CCT-eta”), an agent that inhibits a-Smooth Muscle Actin (“a-SMA”), or a combination thereof, are presented. The fibrosis may include Dupuytren's contracture, Peyronie's disease, pulmonary fibrosis, cirrhosis, interstitial lung disease or scarring alopecia.04-18-2013
20130095170METHODS AND SYSTEMS FOR IDENTIFYING AND TREATING ANTI-PROGESTIN SENSITIVE TUMORS - Methods and systems for identifying and treating a patient suspected of having a tumor susceptible to growth inhibition by anti-progestins are provided. The degree of focal distribution of the progesterone receptor can be used to identify tumors susceptible to treatment with anti-progestin therapy.04-18-2013
20130095173MULTIVALENT GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF - Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.04-18-2013
20130095175TREATING NEUROLOGICAL DISORDERS - Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented.04-18-2013
20130095174Compositions and Methods for Transmucosal Delivery of Lofexidine - The present invention provides for compositions and methods for accelerating the rate of delivery of lofexidine to the systemic circulation by transmucosal administration through the nasal, sublingual, or buccal routes to provide rapid response in the treatment of opiate addicts, migraine, neuropathic pain, and other therapeutic indications related to lofexidine, to a patient in need of such treatment. Compositions of lofexidine formulated for transmucosal delivery are provided. Also provided are methods for the treatment of opiate addicts, migraine, neuropathic pain, and other therapeutic indications related to lofexidine. The methods utilize lofexidine compositions formulated for transmucosal delivery through nasal, sublingual, or buccal routes of administration in an amount effective for the treatment of the drug indications.04-18-2013
20130115273Combinational Liposome Compositions for Cancer Therapy - The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.05-09-2013
20130115272MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF - The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.05-09-2013
20130101666LIPOSOME INCLUDING ELASTIN-LIKE POLYPEPTIDE CONJUGATED TO MOIETY CONTAINING HYDROPHOBIC GROUP, CHEMOSENSITIZER AND ANTICANCER AGENT AND USE THEREOF - A liposome including a lipid bilayer, an elastin-like polypeptide (ELP) conjugated to a hydrophobic moiety; a chemosensitizer; and an anticancer agent, a pharmaceutical composition including the same, and a method of delivering a chemosensitizer and an anticancer agent to a target site of a subject by using the liposome.04-25-2013
20130101662PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN, MUCOUS MEMBRANES AND/OR HAIR AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS - Peptides of general formula (I): R04-25-2013
20130101664MUC1 LIGAND TRAPS FOR USE IN TREATING CANCERS - The present invention is directed to improved compositions for the disruption of signaling through the external domain (ED) of MUC1, Ligand traps—molecules that include MUC1 ED sequences and immunoglobulin Fc domains—effectively “trap” molecules that interact with the native MUC1 ED. Given the involvement of MUC1 in a variety of disease states, disrupting the interaction of other molecules with MUC1 ED is useful in treating these disease, in particular cancer.04-25-2013
20130101663Soluble tumor necrosis factor receptor (sTNF-R) used as a targeting agent to treat arthritis and other diseases - This invention describes the use of sTNF-R as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the sTNF-R coated liposomes. The sTNF-R coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with sTNF-R and used to deliver the drug to the site of inflammation.04-25-2013
20130171243OCTREOTIDE-MODIFIED NANOMEDICINE FOR CANCER TREATMENT OR CANCER PALLIATIVE CARE - The present invention relates to a medical composition for treatment, palliative care or prevention of cancer, such as medullary thyroid carcinoma. Specifically, the invention relates to a medical composition for treatment, palliative care or prevention of medullary thyroid carcinoma, which comprises liposomes modified with octreotide.07-04-2013
20130202686LIPOSOME COMPOSITION AND PROCESS FOR PRODUCTION THEREOF - A liposome composition into which a drug can be introduced in a high encapsulation amount, which has sustained release properties to such an extent that an effective concentration can be maintained at a clinically satisfactory level, and which is suitable for subcutaneous administration or the like. The liposome composition includes: a first liposome which has an outer membrane composed of a multilayered lipid bilayer; and a plurality of second liposomes which are accommodated in a first liposome inner region defined by the outer membrane and each of which has an outer membrane composed of a lipid bilayer. The lipid bilayer of the second liposomes can be multilayered. The liposome composition has second liposome inner regions each defined by the outer membrane of each of the second liposomes. An ion gradient is formed at least between each of the second liposome inner regions and the outside of the first liposome.08-08-2013
20130101665SELF-ASSEMBLING HALF-ANTIBODIES - Novel chimeric molecules, termed “half-antibodies”, which are capable of self-assembling to form an epitope recognition site. Using these half-antibodies or a vesicle, a viral particle, a composition or a kit thereof, for therapeutic applications, such as the prevention or treatment of cancers, genetic diseases, infectious diseases, and for in vitro diagnostic applications and detecting biological molecules. The half-antibodies include at least two chimeric molecules A and B, each has a polypeptide domain characteristic of a variable domain of a heavy chain or of a light chain of an antibody, and a nucleotide domain, the nucleotide domain of A and that of B being capable of pairing into a double stranded structure. Biologically active nucleic sequences can be grafted onto these chimeric molecules to prevent the expression of target genes in the interior of a human or non-human mammalian cell.04-25-2013
20130101667Cyclohexylamines - The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.04-25-2013
20130115271PREDICTORS OF PHARMACOKINETIC AND PHARMACODYNAMIC DISPOSITION OF CARRIER-MEDIATED AGENTS - The invention provides a method of predicting the clearance rate of a carrier-mediated agent and/or the release of an agent from a carrier in a subject comprising measuring the number and/or activity of phagocytic cells and/or the amount and/or activity of opsonins and/or the amount and/or activity of complement within a biological sample obtained from a subject, and predicting the clearance rate of the carrier-mediated agent and/or the release of the agent from the carrier based upon the number and/or activity of the phagocytic cells and/or the amount and/or activity of opsonins and/or the amount and/or activity of complement.05-09-2013
20130115270Anti-interleukin-1 (IL-1) antibody used as a targeting agent to treat arthritis and other diseases - This invention describes the use of anti-IL-1 antibody as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the anti-IL-1 antibody coated liposomes. The anti-IL-1 antibody coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with anti-IL-1 antibody and used to deliver the drug to the site of inflammation. Also in lieu of the anti-IL-1 antibody other IL-1 binding agents such as anti-IL-1 aptamers and anti-IL-1 binding peptides may be used to coat various nanosized drug delivery vehicles in order to deliver the drug to the site of inflammation.05-09-2013
20130115269Anti-tumor necrosis factor alpha (TNF-a) antibody used as a targeting agent to treat arthritis and other diseases - This invention describes the use of anti-TNF-a antibody as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the anti-TNF-a coated liposomes. The anti-TNF-a coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with anti-TNF-a antibody and used to deliver the drug to the site of inflammation. Also in lieu of the anti-TNF-a antibody other TNF-a binding agents such as aptamers and binding peptides may be used to coat the various nanosized drug delivery vehicles such as micelles, dendrimers, nanocapsules and nanoparticles in order to deliver the drug to the site of inflammation.05-09-2013
20130115274METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY - What is described is a method for preparing a liposome that efficiently encapsulates a negatively charged therapeutic polymer, e.g., siRNA. The process involves preparing a lipid mixture comprising a cationic lipid in a water miscible organic solvent, such as ethanol, at a concentration of 2.3 mg/ml, and adding this solution to the polymer dissolved in water to a final concentration of 35% ethanol in water. The final charge ratio of drug:lipid is 1:2.5. The resulting nanoparticles have a mean size of 50 to 150 nm.05-09-2013
20130115275Peptide Epitopes of Apolipoprotein B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.05-09-2013
20130115276Peptide Epitopes of Apolipoprotein B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.05-09-2013
20130171242Single-Stranded RNAi Agents Containing an Internal, Non-Nucleic Acid Spacer - Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.07-04-2013
20130171241LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA-VALUE FOR RNA DELIVERY - RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.07-04-2013
20130171240DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS - Disclosed is a stellate cell-specific drug carrier comprising a stellate cell-specific amount of a retinoid derivative and/or a vitamin A analogue, and a drug carrier component other than the retinoid derivative and/or a vitamin A analogue. Also disclosed in a medicine comprising the stellate cell-specific drug carrier, and a drug in an amount effective for controlling the activity or growth of stellate cells.07-04-2013
20130171238IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA TRACHOMATIS - The invention relates to immunogenic compositions comprising combinations of 07-04-2013
20130171236Prevention and Treatment of Ischemia-Reperfusion Injury and Related Conditions - Disclosed are lipids, annexin, and lipid-annexin complexes for use in the prevention and/or treatment of ischemia-reperfusion injury and reperfusion injury associated with a variety of diseases and conditions. Also disclosed are therapeutic targets and compositions for the prevention and treatment of ischemia-reperfusion injury and diseases and conditions associated with ischemia-reperfusion injury.07-04-2013
20130171235USE OF PTEN-LONG LEADER SEQUENCE FOR TRANSMEMBRANE DELIVERY OF MOLECULES - A composition for delivering cargo molecules across biological membranes is provided comprising (i) a peptide comprising consecutive amino acid residues having the sequence set forth in SEQ ID NO 1 for the transport of a cargo molecule across a biological membrane and (ii) the cargo molecule, wherein the cargo molecule is not a peptide comprising amino acid residues having the sequence set forth in SEQ ID NO 4. Methods of delivering cargo molecules across biological membranes are also provided. Methods of treating a tumor, cancer, a metabolic disorder, and a cardiovascular disorder are also provided.07-04-2013
20130171234Subunit Vaccines for Herpes Viruses and Methods of Use - The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.07-04-2013
20130171233COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE - The present invention provides liposomal compositions for inducing immune tolerance. The compounds typically comprise a liposome displaying a specific antigen and also a binding moiety for a sialic acid binding Ig-like lectin (Siglec) expressed on B cells. The invention also provides methods for inducing tolerance to a protein or polypeptide antigen (e.g., a protein antigen) in a subject. The methods involve administering to the subject a pharmaceutical composition that co-presents both the antigen and a glycan ligand for a Siglec expressed on B lymphocytes.07-04-2013
20130122081LIPOSOMES USEFUL FOR DRUG DELIVERY - The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provides methods of making the liposome compositions provided by the present invention.05-16-2013
20130122084HYDROGEL - The invention is related to gel preparations capable of absorbing as well as releasing liquid, and the use of such gel preparations in the treatment of wounds.05-16-2013
20130129813TARGETED DELIVERY USING TISSUE-SPECIFIC PEPTIDOMIMETIC LIGANDS - Compositions and methods for tissue-specific targeted delivery of therapeutic agents through the use of tissue-specific peptidomimetic ligands are disclosed herein. The ligand comprises a composition of formula A-scaffold-A′ and one or more hydrophobic anchors covalently linked to the scaffold. The A and A′ compounds linked to the scaffold comprise monovalent peptidomimetic compounds wherein each monovalent peptidomimetic compound is selected from the group consisting of fragments IKs, GKs, IDs, GSs, GTs, VSs, TKs, KTs, ARs, KIs, KEs, AEs, GRs, YSs, IRs, and morpholino.05-23-2013
20130129815LIPOSOMAL FORMULATION FOR ORAL ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA GEL CAPSULE - The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation in a gel cap. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.05-23-2013
20130129814Regional Delivery Of Therapeutic Agents For The Treatment Of Vascular Diseases - The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.05-23-2013
20130129811CATIONIC LIPID - The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I)05-23-2013
20130129809COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER BY TARGETING AND INHIBITING CANCER STEM CELLS - The invention relates to compositions and methods for treating cancer comprising administering to a subject in need a pharmaceutically effective dose of a cancer stem cell inhibitor, methods of inhibiting the growth of cancer stem cells or tumor initiating cell comprising administering to a subject in need a pharmaceutically effective dose of a cancer stem cell inhibitor, and methods of enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells comprising administering to a subject in need a pharmaceutically effective dose of a chemotherapeutic drug and a pharmaceutically effective dose of a cancer stem cell inhibitor.05-23-2013
20130129812NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER - Provided herein are methods and compositions inter alia for treating diseases, including hyperproliferative diseases, migraine headaches, and depression.05-23-2013
20130129810IRON OXIDE NANOPARTICLES FOR USE IN TREATING NON-INFECTIOUS INFLAMMATORY DISORDERS - In accordance with the present disclosure there are provided iron oxide nanoparticles for use in the treatment of non-infectious inflammatory disorders. Also provided by the present disclosure is a method of treatment of non-infectious inflammatory disorders making use of such particles, pharmaceutical compositions and kits comprising such particles05-23-2013
20130129817METHOD OF TREATING MALIGNANT SOLID TUMORS - This invention is directed to methods of treating solid tumor cancers, particularly refractory cancers by administration of a drug capable of inhibiting mTOR and/or inhibiting an efflux pump and/or inhibiting HIF-1α and VEGF, the drug in particular being selected from the group consisting of sirolimus, everolimus, zotarolimus, tacrolimus, iolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, novolimus, 40-O-(3-hydroxypropyl), 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin and 40-O-tetrazolylrapamycin, the drug being administered along with a chemotherapeutic agent and/or radiation therapy.05-23-2013
20130129816THERAPEUTIC COMPOSITION WITH ENHANCED ENDOTHELIUM TARGETING - A composition that includes nanoparticles with binding affinity for platelets, and methods for using this composition to treat vascular disease are disclosed.05-23-2013
20130142861Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis - Novel compositions and methods for detecting and preventing and/or treating abnormal liver homeostasis and hepatocarcinoma as well as conditions that may be regulated by microRNA-122 are provided. A transgenic knockout non-human animal comprising a disruption in the endogenous mir-122 gene is also provided.06-06-2013
20130142862Tumor-Specific Delivery of Therapeutic Agents Via Liposomase - is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with 06-06-2013
20130142863PHOSPHATIDYLCHOLINE LIPID LIPOSOMES AS BOUNDRY LUBRICANTS IN AQUEOUS MEDIA - The invention provides a method for lubricating one or more surfaces, comprising applying gel-phase liposomes onto said one or more surfaces, wherein the temperature of said surface(s) at the time of lubrication is below the phase transition temperature Tm of said liposomes. The method can be used for lubricating non-biological surfaces, and also for lubricating the surfaces of a biological tissue in a mammalian subject, e.g., for treating joint dysfunction.06-06-2013
20130142864IN VIVO TARGETING OF DENDRITIC CELLS - The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the dendritic cells, the ligand being linked to a metal chelating group via a metal affinity tag on the ligand. The composition further includes an immunomodulatory factor. A process for preparing the composition is also provided. The invention further provides a method of modulating an immune disorder, and methods of treating tumours and infections.06-06-2013
20130142865FIXED DOSING OF HER ANTIBODIES - The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.06-06-2013
20130142866COMPOSITIONS AND METHODS FOR IMPROVED ORGAN TRANSPLANT PRESERVATION AND ACCEPTANCE - The invention provides a novel aqueous composition for the storage and preservation of transplants, such as organ or tissue allografts. The composition comprises the compound N-octanoyl dopamine in solubilised form. The composition may also be administered as a pre-treatment of transplant donors. Moreover, it may be used in transplant recipients, optionally in combination with immunosuppressants.06-06-2013
20130142867CANCER-TARGETING PEPTIDES AND USES THEREOF IN CANCER TREATMENT AND DIAGNOSIS - Cancer-targeting peptides having a PX06-06-2013
20130142868Circumferential Aerosol Device for Delivering Drugs to Olfactory Epithelium and Brain - Methods of delivering a pharmaceutical compounds directly to the olfactory epithelium of a mammal by providing a pharmaceutical aerosol suspension comprising an aerosol and the pharmaceutical compound; aerosolizing the suspension to generate a stream of droplets, the stream having a rotational component, and, delivering the droplets directly to the olfactory epithelium, wherein at least 15% of the droplets are delivered directly to the olfactory deposition. The pharmaceutical compound may be encapsulated within a liposome nanoparticle.06-06-2013
20090297592Lipid Vesicle Composition - It is an object of the present invention to provide an enzyme preparation which is excellent in stability in blood (blood residence) and in transfer to a target organ (targeting property), and can be used effectively in enzyme replacement therapy or the like.12-03-2009
20100278905STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER - An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.11-04-2010
20080206316Chromium-Fatty Acid Compounds and Methods of Making and Using Thereof - Disclosed are compounds comprising one or more chromium atoms bonded to one or more fatty acids. Also disclosed are nutritional supplements, pharmaceutical formulations, delivery devices, and foodstuffs comprising the disclosed compounds. Methods of using the disclosed compounds and compositions to improve health are also disclosed.08-28-2008
20110217361Group of Nucleic Acid Fragments for Prevention of HIV Infection or AIDS and the Usage Thereof - The invention provides a group of nucleic acid fragments, shown in the sequence listing, for prevention of HIV infection or AIDS and the usage thereof. In the invention, a series of RNA fragments, which are highly homogenous to all the published HIV gene sequences, were obtained by homology compare. The double-stranded RNA (dsRNA) derived from these fragments can effectively inhibit the expression of the HIV genes. The RNA transcribed by plasmid, also can suppress the expression of the HIV in the cell. After the adenovirus or associated virus which carry DNA corresponding above RNA infect the cell, the transcription dsRNA can inhibit the expression of the HIV genes.09-08-2011
20110212165PHARMACEUTICAL COMPOSITIONS OF THE ISOLATED D-ENANTIOMER OF THE QUINAZOLINONE DERIVATIVE HALOFUGINONE - The present invention relates to pharmaceutical compositions comprising as an active ingredient an isolated, chirally pure D-enantiomer of the quinazolinone derivative halofuginone having increased therapeutic activity and decreased side effects compared to the corresponding racemic mixtures, the composition being substantially free of the L-enantiomer and useful in the treatment of diseases and disorders associated with fibrotic conditions or cell proliferation.09-01-2011
20110212162LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS - Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.09-01-2011
20110212161TREATMENT SKIN DISORDERS - Disclosed are a composition and a method for treating skin disorders, including rosacea, pityriasis rosea, erythema, rhinophyma, and rosacea-associated disorders including pimples, papules, pustules, and telangiectasia.09-01-2011
20080199515FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS - Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.08-21-2008
20080199514Functional Variant of Lymphoid Tyrosine Phosphatase is Associated with Autoimmune Disorders - The invention is the discovery of a single nucleotide polymorphism in the gene coding for lymphoid tyrosine phosphatase. This SNP leads to a mutation in the lymphoid tyrosine phosphatase protein that prohibits binding with the SH3 domain of Csk, and leads to a subsequent dysregulation of the T-Cell activation cascade. Such dysregulation can lead to a variety of autoimmune disorders. Thus, the invention provides a series of useful methods for diagnosing, discovering modulators, developing treatments and providing research tools. Also, the invention provides compositions of matter useful for research and useful for the diagnosis and treatment of these disorders.08-21-2008
20110223241COMBINATION METHODS AND COMPOSITIONS - Compositions which comprise a liposomal water-soluble camptothecin and optionally a liposomal fluoropyrimidine in combination with a vascular epithelial growth factor (VEGF) inhibitor such as cetuximab or an epidermal growth factor receptor (EGFR) inhibitor such as bevacizumab are useful in achieving enhanced therapeutic effects for the treatment of cancer.09-15-2011
20110223240COMPOUNDS FOR REVERSING AND INHIBITING PROTEIN AGGREGATION, AND METHODS FOR MAKING AND USING THEM - The invention provides compositions for increasing the clearance of protein aggregates, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for accelerating protein aggregate clearance in the CNS, e.g., for treating diseases that are characterized by protein aggregation—including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent, reverse (partially or completely) or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e.g., synuclein, beta-amyloid and/or tau protein aggregation. In one aspect, compositions and methods of this invention are used to treat, prevent or ameliorate (including slowing the progression of) Parkinson's disease, fronto-temporal dementia (FTD), Alzheimer's Disease (AD), Lewy body disease (LBD) and Multiple system atrophy (MSA).09-15-2011
20090053299Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery - The present invention is in the fields of drug delivery, and specifically, cationic liposome-based vaccines. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of molecules to induce immune responses against viral antigens or to treat or prevent viral diseases. The specificity of the delivery system is derived from the targeting ligands.02-26-2009
20130149373Compositions, methods and kits for modeling, diagnosing, and treating complement disorders - Systems, compositions, methods, and kits for identifying potential therapeutic agents for treatment of complement based ocular diseases are provided herein. The methods and kits include a complement component 3 (C3) protein or derivative that is contacted to ocular cells or tissue. Another embodiment of the invention herein provides for diagnosis and/or prognosis of a complement-associated ocular disease. Compositions, methods and kits for regulating or treating a complement-related condition using at least one of CD46 protein, CD55 protein, and a recombinant chimeric soluble terminator of activated complement (STAC) protein or source of the STAC protein. The STAC protein includes an amino acid sequence including at least two of an amino acid sequence of a CD59 protein, an amino acid sequence derived from a CD46 protein, and an amino acid sequence derived from a CD55 protein, optionally further comprising a linker to connect amino acid sequences.06-13-2013
20110236471PLATINUM COMPLEXES AND METHODS FOR INHIBITING TUMOR CELL PROLIFERATION - The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.09-29-2011
20110236468VACCINE COMPOSITIONS - The present invention relates, inter alia, to a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more viral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more viral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, viral vectors and adjuvants.09-29-2011
20110236467METHOD FOR ERECTILE FUNCTION POTENTIATION BY PHARMACEUTICAL COMPOSITIONS COMPRISING TOXIN TX2-6 OF THE SPIDER PHONEUTRIA NIGRIVENTER - The present invention concerns a method for male erectile function potentiating by means of toxin Tx2-6 from the spider 09-29-2011
20110236466CHEMO VECTOR THERAPY TO DELIVER CHEMOTHERAPY MOLECULES TO SPECIFIC CELLS TO MANAGE BREAST CANCER, OTHER CANCERS AND INFLAMMATORY DISORDERS - The innovative treatment strategy described here utilizes configurable microscopic medical payload delivery devices to act as a transport means to deliver chemotherapy molecules to specific cell types in the body. Utilizing probes present on the exterior of the transport device, transport device locates specific target cell types in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery device inserts its payload of chemotherapy molecules into the target cell type. By delivering chemotherapy molecules into specific cells, the growth of the specific cells can be stifled. Delivering chemotherapy molecules into specific cancer cells inhibits the rate of growth and rate of cell reproduction of the cancer cells. Utilizing configurable microscopic medical payload delivery devices to insert chemotherapy into targeted cancer cells or inflammatory cells effectively manages cancer, inflammatory arthritis and other inflammatory conditions, while preventing unwanted side effects.09-29-2011
20110250262METHOD FOR PRODUCING LIPOSOME AND METHOD FOR DISSOLVING CHOLESTEROL - Disclosed is a method for producing a liposome, which comprises: a first mixing step wherein one or more lipids are mixed with an aqueous solution containing a water-miscible organic solvent; a heating step wherein the mixture obtained by mixing the lipids with the aqueous solution is heated to a temperature at which the lipids are dissolved in the aqueous solution; and a cooling step following the heating step, wherein the resulting mixture is cooled down to a temperature at which a liposome is produced. Uniform-sized liposomes having a high encapsulation rate can be easily obtained by the method.10-13-2011
20110250260INHIBITION OF BRAIN ENZYMES INOLVED IN CEREBRAL AMYLOID ANGIOPATHY AND MACULAR DEGENERATION - A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrinan in a manner that permits access to brain sites and/or the macula of the patient.10-13-2011
20130149370HERBAL COMPOSITION FOR PREVENTING AND/OR TREATING ANXIETY RELATED CONDITIONS - The present invention relates to herbal compositions for the treatment and/or prevention of anxiety disorders or stress. These compositions comprise hawthorn fruit (Shan Zha), light wheat grain (Fu xiao mai) and Lilly Bulb (bai hi) in amounts which are effective to treat anxiety conditions. The compositions may further comprise Chinese date (Da zao).06-13-2013
20130149371MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN - A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.06-13-2013
20130149372Polypeptides for the Treatment or Prevention of Cancer and uses Thereof - Disclosed herein are polypeptides or their derivatives and their application. The polypeptides and their derivatives can treat or prevent cancer. The polypeptides of the invention have significant lethality to the cancer cells when used alone. When its clinical commonly used chemotherapy drugs such as cisplatin in combination, it can significantly increase the sensitivity of chemotherapeutic agents on cancer cells, to enhance its lethality of cancer cells, to reduce the dosage. The peptides can kill a variety of cancer cells, but without apparent toxicity enhancing effect on normal cells. The prepared peptides of the present invention can be chemically synthesized, high-purity, low molecular weight, specificity, non-immunogenic, safe and reliable.06-13-2013
20130149374Asymmetric Liposomes for the Highly Efficient Encapsulation of Nucleic Acids and Hydrophilic Anionic Compounds, and Method for Preparing Same - The present invention relates to asymmetric liposomes for high encapsulation efficiency of nucleic acids and hydrophilic anionic compounds, and to a method for preparing same, and specifically, to asymmetric liposomes consisting of a cationic lipid having a small head group as an internal lipid and a neutral or PEGylated lipid having a big head group as an external lipid, wherein nucleic acids and/or anionic compounds are encapsulated in the internal lipid. According to the present invention, asymmetric liposomes, in which nucleic acids and hydrophilic anionic compounds are encapsulated with high efficiency, may be prepared, and thus the same may be used for various purposes, such as gene therapy, and the delivery of hydrophilic anionic drugs which are difficult to prepare as prodrugs, and drug delivery, imaging, etc. can be carried out by encapsulating a fluorescent contrast agent in the liposome.06-13-2013
20130149375IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA - RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal06-13-2013
20130149376VACCINE COMPOSITION BASED ON STICHOLYSIN ENCAPSULATED INTO LIPOSOMES - The current invention relates to the field of Biotechnology applied to human health. Here it is described a vaccine vehicle wherein toxins from eukaryotic organisms are encapsulated into multilamellar vesicles obtained by the dehydration-rehydration procedure whose lipidic composition is dipalmitoylphosphatidylcholine:cholesterol in a 1:1 molar ratio for subcutaneous or intramuscular administration. These compositions do not require the use of other adjuvants.06-13-2013
20130149369COMPOSITION FOR NUCLEIC ACID TRANSFECTION - The invention provides a nucleic-acid-transfecting composition which exhibits low cytotoxicity, which facilitates an effective nucleic acid transfection into a cell, and which improves expression of the nucleic acid in the cell.06-13-2013
20120276193Agents, Uses and Methods - The present invention relates to therapeutic agents for the targeted delivery of an immunosuppressive agent to monocytes and/or monocyte-derived cells comprising a binding moiety with specificity for monocytes and/or monocyte-derived cells and an immunosuppressive agent. In one embodiment, the agent is a glucocorticoid-antibody conjugate. The invention also relates to methods, uses, kits and compositions comprising such agents.11-01-2012
20120276192COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ICAM-1 - RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy and other complications arising from type I diabetes, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.11-01-2012
20120276191Treatment and Diagnosis of Macrophage Mediated Disease - The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula11-01-2012
20120276190THERAPY WITH A CHIMERIC MOLECULE AND A PRO-APOPTOTIC AGENT - The present invention provides compositions comprising a chimeric molecule comprising a cytotoxin that inhibits protein synthesis and an agent that inactivates an anti-apoptotic BCL-2 family member protein and methods of inhibiting the growth of or promoting the apoptosis of an aberrantly proliferating cell population by co-administering the chimeric molecule and the agent that inactivates an anti-apoptotic BCL-2 family member protein.11-01-2012
20120276189Therapeutic Treatment of Dermatologic Skin Disorders - β-glucans are incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of cosmetic and dermatologic disorders. In particular, β-glucan is combined with liposomes to increase the penetration of the β-glucan into the skin, to provide hydration of the skin during treatment. The deeper penetration of the β-glucan increases macrophage activity to remove scar tissue, dead skin cells and other foreign debris as well as stimulating collagen growth to improve skin health.11-01-2012
20100285110COMPOSITION COMPRISING MUCILAGINOUS POLYSACCHARIDES DERIVED FROM ALOE BARBADENSIS COMBINED WITH LIPOSOMES, METHOD FOR OBTAINING SAME AND USE THEREOF AS A SUN PROTECTOR, AN ANTI-ACNE AGENT, AN EPIDERMAL REGENERATOR AND A MOISTURISER - Provided is a composition including mucilaginous polysaccharides of 11-11-2010
20100291196METHOD OF TREATMENT OF AUTISM SPECTRUM DISORDER WITH LIPOSOMAL REDUCED GLUTATHIONE - The invention proposes the use of reduced glutathione encapsulated in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to improve symptoms in disease states related to diminished function of the methylation pathway such as autism, other neurodegenerative diseases and abnormalities of neurotransmitter levels in urine or blood. The invention also proposes combining liposomal encapsulated methylcobalamin, and/or liposomal encapsulated Insulin Growth Factor 1 (IGF-1) with liposomal reduced glutathione to accomplish such improvement.11-18-2010
20090098196LIPID CARRIER COMPOSITIONS WITH REDUCED POLY-DISPERSITY - The invention relates to a method for reducing the polydispersity of a population of gel-phase lipid-based delivery vehicles.04-16-2009
20100310642Topical Drug Delivery Systems for Ophthalmic Use - Topical drug delivery systems for ophthalmic use including mixed nanomicellar formulations of water-insoluble drugs and methods of treating diseases affecting the posterior ocular segments are disclosed. In an embodiment, an aqueous ophthalmic solution includes nanomicelles in a physiologically acceptable buffer, having a pH of 5.0 to 8.0, wherein a corticosteroid at a concentration from about 0.01% w/v to about 1.00% w/v is solubilized through entrapment in a mixed micellar hydrophobic core with a corona composed of hydrophilic chains extending from the hydrophobic core, wherein the nanomicelles comprise vitamin E TPGS at a concentration ranging from about 3.0% w/v to about 5.0% w/v stabilized with octoxynol-40 at a concentration ranging from about 1.0% w/v to about 3.0% w/v.12-09-2010
20100310639IMMUNO-MODULATORY COMPOSITION - A composition for modulating the immune response in a mammal comprising a pharmaceutically acceptable carrier solution and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a T lymphocyte cell and/or of a vascular endothelial cell and wherein the nanoparticles further comprise leukaemia inhibitory factor (LIF). Nanoparticle-mediated targeted delivery of LIF can be used a means to guide tolerogenesis in a patient and has immediate clinical application for recipients of organ grafts and also for patients suffering from autoimmune disease.12-09-2010
20100316707METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS - A delivery-enhancing peptide comprising the amino acid sequence of SEQ ID NO:11 or salt thereof. This invention is directed towards methods and compositions to administer a double-stranded ribonucleic acid to a mammal so as to effectuate transfection of the double-stranded RNA into a desired tissue of the mammal.12-16-2010
20100316706CARBOCYCLIC AND OXACARBOCYCLIC FUMARIC ACID OLIGOMERS - The present invention relates to certain carbocyclic and oxacarbocyclic fumaric acid oligomers and the use thereof for preparing a pharmaceutical preparation as well of pharmaceutical preparations containing these compounds.12-16-2010
20100316705SYSTEM FOR EXSANGUINOUS METABOLIC SUPPORT OF AN ORGAN OR TISSUE - An exsanguinous metabolic support system for maintaining an organ or tissue at a near normal metabolic rate is disclosed. The system employs a warm perfusion solution capable of supporting the metabolism of the organ or tissue thereby preserving its functional integrity. The system also monitors parameters of the circulating perfusion solution, such as pH, temperature, osmolarity, flow rate, vascular pressure and partial pressure of respiratory gases, and regulates them to insure that the organ is maintained under near-physiologic conditions. Use of the system for long-term maintenance of organs for transplantation, for resuscitation and repair of organs having sustained warm ischemic damage, as a pharmaceutical delivery system and prognosticator of posttransplantation organ function is also disclosed.12-16-2010
20100316704PLATINUM COMPLEXES AND METHODS OF USE - The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.12-16-2010
20100316703RNA INTERFERENCE MEDIATING SMALL RNA MOLECULES - Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a 12-16-2010
20100316702COMPOSITIONS AND METHODS FOR REGULATING ERYTHROPOEITIN EXPRESSION AND AMELIORATING ANEMIA AND STIMULATING ERYTHROPOIESIS - The invention provides compositions (e.g., pharmaceuticals, formulations) and methods for ameliorating (e.g., preventing or treating) an anemia and/or stimulating erythropoiesis and/or EPO erythropoietin synthesis. The invention provides compositions comprising a chimeric protein artificial transcription factor comprising a plurality of (multiple) protein DNA-binding domains, e.g., zinc finger binding domains, specific for the promoter region of an erythropoietin (EPO) gene; a consensus nuclear localization protein sequence; a cell-penetrating peptide sequence; and a transcription activation domain.12-16-2010
20100316701COMPOSITIONS AND METHOD FOR MANIPULATING PIM-1 ACTIVITY IN CIRCULATORY SYSTEM CELLS - The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-1, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-1, and methods for enhancing the regenerative potential of stem cells in the heart.12-16-2010
20100316700SYSTEMIC ADMINISTRATION OF LIPOSOMAL REDUCED GLUTATHIONE FOR THE DECORPORATION OF RADIOACTIVE MATERIALS AND NON-RADIOACTIVE MERCURY - The invention is for the combination and related methods of liposomal reduced glutathione in oral, inhaled, or intravenous, or glutathione inhaled or intravenous, to ameliorate the effects of exposure to or ingestion of radiation or radioactive materials, as treatment to ameliorate the toxic effects of radiation exposure or ingestion and to facilitate the decorporation of radioactive materials such as Co-60. The invention may also be used in conjunction with a decorporation agent such as DTPA, EDTA, DMPS or penicillamine to ameliorate the toxic effects of exposure or ingestion of radioactive agents or other toxic metals.12-16-2010
20100316699Compositions and Methods for Inhibiting Viral Replication - The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.12-16-2010
20100316698POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF - The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described.12-16-2010
20100316697METHODS AND COMPOSITIONS FOR DRUG TARGETING - The present invention provides methods and compositions for targeting a drug to a specific desired location, such as an intracellular location in a mammalian cell, by causing said drug to migrate along a pH gradient to the specific location, where the drug preferentially accumulates at a pH range of the specific location. Accordingly, the invention described herein is based on providing a drug which is “pH matched” with that of a particular location, such that the drug preferentially migrates to and accumulates at the pH or pH range at that location. The location may be a type of tissue, a type of cell, a sub-cellular location or an intracellular location, such as an organelle. Without being bound to any theory, the drug migrates along or across a pH gradient, and stops migrating and accumulates at a location of specific pH or range of pH at which the drug is energetically neutral, or where its diffusion potential is at a minimum.12-16-2010
20110274749METHODS AND COMPOSITIONS FOR TARGETING AGENTS INTO AND ACROSS THE BLOOD-BRAIN BARRIER AND OTHER ENDOTHELIAL CELL MICROVASCULAR BARRIERS - The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain bather functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain bather properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain/retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-LPSS polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of LPSS polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.11-10-2011
20110274748CAI-Based Systems and Methods for the Localized Treatment of Ocular and Other Diseases - The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies) that are effective and are associated with little or no adverse side effects.11-10-2011
20110274747C-Terminal Fragments of Glucagon-Like Peptide-1 (GLP-1) - C-Terminal Fragments of Glucagon-Like Peptide-1 (GLP 1), and methods of use thereof, e.g., for the treatment of obesity and obesity-related disorders, e.g., diabetes and the metabolic syndrome.11-10-2011
20110274745INSTILLATION OF LIPOSOMAL FORMULATION OF SIRNA AND ANTISENSE OLIGONUCLEOTIDES - A pharmaceutically acceptable deliverable composition and methods for administration of macromolecules for sequence-specific gene-silencing in bladder to treat overactive bladder (OAB), interstitial cystitis/painful bladder syndrome (IC/PBS), lower urinary tract symptoms (LUTS) locally in the bladder, or other diseases or disorders of the bladder or LUTS, has been discovered. In the preferred embodiment, a liposome based delivery system is used to deliver an effective amount of antisense oligonucleotides (ODN) or siRNA that interact with or bind to messenger RNA (mRNA) coding for human nerve growth factor (NGF) to stop the synthesis of NGF.11-10-2011
20130156849MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS - The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.06-20-2013
20130156850APO A-I MIMETIC PEPTIDES AND METHODS OF TREATMENT - A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a synthetic apolipoprotein A-1 (Apo A-I) mimetic peptide into a wall of the blood vessel at the particular region, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including a synthetic apolipoprotein A-I (Apo A-I) mimetic peptide, or combination of an Apo A-I synthetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of an endogenous Apo A-I related peptide. A composition including an apolipoprotein A-1 (Apo A-I) synthetic peptide in a form suitable for delivery into a blood vessel, the peptide including an amino acid backbone that has less amino acid residues relative to endogenous Apo A-I and a chimera of helix 1 and helix 9 of Apo A-I.06-20-2013
20130156851LIPOMACROCYCLES AND USES THEREOF - What is described are macrocyclic compounds formed by reaction of a cyclic compound, which contains an amine, with an epoxide. The macrocyclic compound has the following structure:06-20-2013
20130156846L-SERINE COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS - L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).06-20-2013
20130156845LIPID FORMULATED SINGLE STRANDED RNA - The present invention provides compositions comprising a nucleic acid lipid particle and an oligomeric compound and uses thereof. In certain embodiments, such compositions are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.06-20-2013
20130156847METHODS OF INDUCING CELL DIFFERENTIATION WITH PLACENTAL EXTRACTS - Disclosed are methods of preparing and using placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described.06-20-2013
20130156848COMPOSITIONS AND METHODS FOR MODULATING HEMOSTASIS - Novel thrombin/prothrombin protease/zymogen variants which have anticoagulation activity and methods of use thereof are disclosed.06-20-2013
20130183376HEPATITIS C VIRUS LIPOSOME VACCINE - The present invention provides a peptide-bound liposome wherein the peptide contains a partial amino acid sequence having a length of not less than 9 amino acids in the amino acid sequence of hepatitis C virus NS3 protein, has a length of 9 to 11 amino acids, and is capable of inducing cytotoxic T lymphocytes, the liposome contains a phospholipid containing an acyl group having 14 to 24 carbon atoms and one unsaturated bond or a hydrocarbon group having 14 to 24 carbon atoms and one unsaturated bond, and a liposome stabilizer, and the peptide is bound to the surface of the liposome; a cytotoxic T lymphocyte activator containing the peptide-bound liposome; and a hepatitis C virus vaccine.07-18-2013
20130183378CD133 Epitopes - An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.07-18-2013
20130183367PEPTIDES DES-[ASP1]-[ALA1], ANGIOTENSIN-(1-7) AGONIST AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES - The present invention is related to the peptide Des-[Asp07-18-2013
20130183371SUSTAINED RELEASE FORMULATION OF METHOTREXATE AS A DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD) AND AN ANTI-CANCER AGENT - Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a C07-18-2013
20130183372METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.07-18-2013
20130183374SUSTAINED RELEASE FORMULATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG - Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.07-18-2013
20130183375METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.07-18-2013
20130183377SYNTHETIC IMMUNOGEN USEFUL FOR GENERATING LONG LASTING IMMUNITY AND PROTECTION AGAINST PATHOGENS - The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen 07-18-2013
20130183379GRAFT COPOLYMER POLYELECTROLYTE COMPLEXES FOR DRUG DELIVERY - Graft copolymer polyelectrolyte complexes are disclosed for the efficient delivery of anionic, cationic or polyelectrolyte therapeutic agents into biological cells, and for maintaining the biological activity of these molecules while in serum and other aqueous environments are provided. Such complexes comprise (1) an anionic graft copolymer containing an anionic polymer backbone, with pendent carboxylic acid groups and pendant chains containing amphipathic or hydrophilic polymers covalently bonded to a portion of the pendant carboxylic acid groups, (2) one or more anionic, cationic or polyelectrolyte therapeutic agents, and (3) optionally a liposome optionally containing an additional therapeutic agent. Also disclosed are functional nanoparticles containing the complexes.07-18-2013
20110287087MODIFIED CATIONIC LIPOSOME ADJUVANS - The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of anti-bodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and 11-24-2011
20110311616TARGETING TUMOR ASSOCIATED MACROPHAGES USING BISPHOSPHONATE-LOADED PARTICLES - Provided herein are compositions including particles that comprise a bisphosphonate compound and a tumor specific targeting peptide or peptidomimetic. Also provided herein are methods of reducing tumor associated macrophages and methods of treating cancer with said compositions.12-22-2011
20110311615NOVEL GP41 ANTIGENS - The present invention deals with a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N−L−C and comprising: a N-helix region of gp41 (N), a C-helix region of gp41 (C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593-617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutral izing and 98.6 D epitopes, but not 2F5 and 4E10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2 (IL2).12-22-2011
20110311614SPLITTING GP41 - The present invention deals with a method for therapeutic or prophylactic treatment of HIV, in particular a prophylactic vaccinal method, comprising at least: administering to a patient a first antigen comprising the broadly neutralizing epitopes of the Membrane Proximal Ectodomain Region (MPER) of gp41, and administering to the same patient a second antigen comprising a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N-L-C and comprising: a N-helix region of gp41(N), a C-helix region of gp41(C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593-617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutralizing and 98.6 D epitopes, but not 2F5 and 4E10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2.12-22-2011
20110311613TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS - Described herein, are topical formulations for treating a dermatological disease, disorder, or condition. Topical formulations disclosed herein include a therapeutically-effective amount of a FLAP inhibitor formulated for dermal administration12-22-2011
20110311612Humanized Neuraminidase Antibody and Methods of Use Thereof - Antibodies against influenza neuraminidase, compositions containing the antibodies, and methods of using the antibodies are provided herein.12-22-2011
20130189347DISEASE TREATMENT DRUG - A disease treatment drug having high pharmacological effects and no side effects is provided, the disease treatment drug being capable of intensively delivering an iron or manganese porphyrin complex capable of removing active oxygen to abnormal tissue within a living body, and effectively removing the active oxygen within the abnormal tissue. The disease treatment drug contains an iron or manganese porphyrin complex nanocapsule housing an iron or manganese porphyrin complex within a nanosized capsule. In the disease treatment drug, disease of abnormal tissue having a high concentration of active oxygen can be treated by the iron or manganese porphyrin complex delivered into the abnormal tissue as a result of the nanocapsule, without affecting normal tissue having a low concentration of active oxygen, and side effects can be suppressed.07-25-2013
20130189348SUSTAINED RELEASE FORMULATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG - Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comp